WO2024081602A2 - Ace2-targeted compositions and methods for treating co0vid-19 - Google Patents
Ace2-targeted compositions and methods for treating co0vid-19 Download PDFInfo
- Publication number
- WO2024081602A2 WO2024081602A2 PCT/US2023/076403 US2023076403W WO2024081602A2 WO 2024081602 A2 WO2024081602 A2 WO 2024081602A2 US 2023076403 W US2023076403 W US 2023076403W WO 2024081602 A2 WO2024081602 A2 WO 2024081602A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- monoclonal antibody
- amino acid
- hace2
- residues
- sars
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 14
- 238000000034 method Methods 0.000 title claims description 54
- 101000929928 Homo sapiens Angiotensin-converting enzyme 2 Proteins 0.000 claims abstract description 371
- 102000048657 human ACE2 Human genes 0.000 claims abstract description 370
- 239000002245 particle Substances 0.000 claims abstract description 78
- 241001678559 COVID-19 virus Species 0.000 claims abstract description 67
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 36
- 101800000733 Angiotensin-2 Proteins 0.000 claims abstract description 34
- 229950006323 angiotensin ii Drugs 0.000 claims abstract description 34
- 239000013607 AAV vector Substances 0.000 claims abstract description 12
- 102000005862 Angiotensin II Human genes 0.000 claims abstract 3
- 125000000539 amino acid group Chemical group 0.000 claims description 251
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 79
- 239000013598 vector Substances 0.000 claims description 20
- 208000025721 COVID-19 Diseases 0.000 claims description 19
- 150000007523 nucleic acids Chemical class 0.000 claims description 17
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 15
- 208000037847 SARS-CoV-2-infection Diseases 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 14
- 239000003085 diluting agent Substances 0.000 claims description 9
- 239000000725 suspension Substances 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 101100536371 Rattus norvegicus Taok3 gene Proteins 0.000 claims description 3
- 238000013518 transcription Methods 0.000 claims description 3
- 230000035897 transcription Effects 0.000 claims description 3
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 claims 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 abstract description 32
- 230000000069 prophylactic effect Effects 0.000 abstract description 3
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 230000035772 mutation Effects 0.000 description 65
- 210000004027 cell Anatomy 0.000 description 49
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 41
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 41
- 108090000623 proteins and genes Proteins 0.000 description 36
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 35
- 102000004169 proteins and genes Human genes 0.000 description 34
- 102400000345 Angiotensin-2 Human genes 0.000 description 31
- 241000702421 Dependoparvovirus Species 0.000 description 27
- 230000000694 effects Effects 0.000 description 23
- 239000012636 effector Substances 0.000 description 22
- 230000006870 function Effects 0.000 description 21
- 239000000758 substrate Substances 0.000 description 21
- 241001112090 Pseudovirus Species 0.000 description 19
- 238000003556 assay Methods 0.000 description 19
- 210000002966 serum Anatomy 0.000 description 19
- 241000700605 Viruses Species 0.000 description 18
- 210000005260 human cell Anatomy 0.000 description 17
- 102000005962 receptors Human genes 0.000 description 17
- 208000024891 symptom Diseases 0.000 description 17
- 230000003612 virological effect Effects 0.000 description 17
- 238000012986 modification Methods 0.000 description 16
- 230000004048 modification Effects 0.000 description 16
- 108091005609 SARS-CoV-2 Spike Subunit S1 Proteins 0.000 description 14
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 13
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- 210000004899 c-terminal region Anatomy 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 11
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 10
- 241000282567 Macaca fascicularis Species 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 101100454808 Caenorhabditis elegans lgg-2 gene Proteins 0.000 description 9
- 108091005634 SARS-CoV-2 receptor-binding domains Proteins 0.000 description 9
- 238000003776 cleavage reaction Methods 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 208000027028 long COVID Diseases 0.000 description 9
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 9
- 230000007017 scission Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- OVVIBUHLQIYUEU-IWIISZHXSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-[[(2s,3s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-5-(diaminometh Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 OVVIBUHLQIYUEU-IWIISZHXSA-N 0.000 description 7
- 102400000252 Apelin-13 Human genes 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- PVHLMTREZMEJCG-GDTLVBQBSA-N Ile(5)-angiotensin II (1-7) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 PVHLMTREZMEJCG-GDTLVBQBSA-N 0.000 description 7
- PANUJGMSOSQAAY-UHFFFAOYSA-N Kinetensin Natural products C1CCC(C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CC(C)C)C(O)=O)N1C(=O)C(NC(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(C)NC(=O)C(N)C(C)CC)CC1=CN=CN1 PANUJGMSOSQAAY-UHFFFAOYSA-N 0.000 description 7
- 102400001103 Neurotensin Human genes 0.000 description 7
- 101800001814 Neurotensin Proteins 0.000 description 7
- 102220489104 Phosphatidylinositol transfer protein beta isoform_T59E_mutation Human genes 0.000 description 7
- 241000315672 SARS coronavirus Species 0.000 description 7
- 108010021281 angiotensin I (1-7) Proteins 0.000 description 7
- XXCCRHIAIBQDPX-PEWBXTNBSA-N apelin-13 Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CCC(N)=O)C1=CN=CN1 XXCCRHIAIBQDPX-PEWBXTNBSA-N 0.000 description 7
- 108010040480 apelin-13 peptide Proteins 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 238000012377 drug delivery Methods 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 7
- 108010021792 kinetensin Proteins 0.000 description 7
- PANUJGMSOSQAAY-IHXGQVBNSA-N kinetensin Chemical compound C([C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CN=CN1 PANUJGMSOSQAAY-IHXGQVBNSA-N 0.000 description 7
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 6
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000003149 assay kit Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 102220499768 Carbonic anhydrase 2_H94Q_mutation Human genes 0.000 description 5
- 101000899004 Phasmahyla jandaia Des-Arg9-bradykinin Proteins 0.000 description 5
- 101710198474 Spike protein Proteins 0.000 description 5
- 102220615731 Superoxide dismutase [Mn], mitochondrial_Y58F_mutation Human genes 0.000 description 5
- 229960002685 biotin Drugs 0.000 description 5
- 239000011616 biotin Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000004949 mass spectrometry Methods 0.000 description 5
- 238000007423 screening assay Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000001488 sodium phosphate Substances 0.000 description 5
- 229910000162 sodium phosphate Inorganic materials 0.000 description 5
- 235000011008 sodium phosphates Nutrition 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108020004635 Complementary DNA Proteins 0.000 description 4
- 241000494545 Cordyline virus 2 Species 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 108010007859 Lisinopril Proteins 0.000 description 4
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 4
- 229960000830 captopril Drugs 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 229960002394 lisinopril Drugs 0.000 description 4
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 4
- 208000012396 long COVID-19 Diseases 0.000 description 4
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 238000013207 serial dilution Methods 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- -1 180 mM) Chemical compound 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 102220571644 Centromere protein Q_R52H_mutation Human genes 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 102220556562 Delta and Notch-like epidermal growth factor-related receptor_Y33R_mutation Human genes 0.000 description 3
- 102220535995 Dynein axonemal intermediate chain 4_R93A_mutation Human genes 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 3
- 206010015548 Euthanasia Diseases 0.000 description 3
- 102000004961 Furin Human genes 0.000 description 3
- 108090001126 Furin Proteins 0.000 description 3
- 238000010268 HPLC based assay Methods 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 description 3
- 241000482741 Human coronavirus NL63 Species 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 229940096437 Protein S Drugs 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 238000010804 cDNA synthesis Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 102000049800 human TMPRSS2 Human genes 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 229920001993 poloxamer 188 Polymers 0.000 description 3
- 229940044519 poloxamer 188 Drugs 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000013608 rAAV vector Substances 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 description 2
- GTOFKXZQQDSVFH-UHFFFAOYSA-N 2-benzylsuccinic acid Chemical compound OC(=O)CC(C(O)=O)CC1=CC=CC=C1 GTOFKXZQQDSVFH-UHFFFAOYSA-N 0.000 description 2
- 241000710929 Alphavirus Species 0.000 description 2
- 101800000734 Angiotensin-1 Proteins 0.000 description 2
- 102400000344 Angiotensin-1 Human genes 0.000 description 2
- 102220614025 Angiotensin-converting enzyme 2_N33D_mutation Human genes 0.000 description 2
- 102000015427 Angiotensins Human genes 0.000 description 2
- 108010064733 Angiotensins Proteins 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 108090000565 Capsid Proteins Proteins 0.000 description 2
- 102100023321 Ceruloplasmin Human genes 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 102220597589 Cyclin-dependent kinase 19_Y32H_mutation Human genes 0.000 description 2
- 102220501462 Cytosolic iron-sulfur assembly component 3_S26H_mutation Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102220632025 Decorin_S52D_mutation Human genes 0.000 description 2
- 102220548598 Delta and Notch-like epidermal growth factor-related receptor_Y32A_mutation Human genes 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108010066671 Enalaprilat Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 102220605905 GTPase HRas_Y32F_mutation Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102220611330 Homeobox protein MSX-2_D97W_mutation Human genes 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 102220538277 Modulator of macroautophagy TMEM150B_Y32Q_mutation Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 101100226902 Mus musculus Fcrlb gene Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 102220640678 Polyadenylate-binding protein 1_L46W_mutation Human genes 0.000 description 2
- 102220586596 Protein FAM177A1_A55L_mutation Human genes 0.000 description 2
- 102220543899 Protocadherin-10_K26R_mutation Human genes 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 101150010882 S gene Proteins 0.000 description 2
- 102220606007 Sorting nexin-10_Y32S_mutation Human genes 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000012505 Superdex™ Substances 0.000 description 2
- 102220608146 TYRO protein tyrosine kinase-binding protein_D50Q_mutation Human genes 0.000 description 2
- 102220468334 Tektin-1_F98Y_mutation Human genes 0.000 description 2
- 102220482639 Uncharacterized protein EXOC3-AS1_D57K_mutation Human genes 0.000 description 2
- 102220531209 Uncharacterized protein KIAA2012_F27R_mutation Human genes 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- LJXGOQOPNPFXFT-JWRYNVNRSA-N angiotensin (1-9) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 LJXGOQOPNPFXFT-JWRYNVNRSA-N 0.000 description 2
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 102220401484 c.164C>A Human genes 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229960002680 enalaprilat Drugs 0.000 description 2
- LZFZMUMEGBBDTC-QEJZJMRPSA-N enalaprilat (anhydrous) Chemical compound C([C@H](N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 LZFZMUMEGBBDTC-QEJZJMRPSA-N 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 108010068617 neonatal Fc receptor Proteins 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 239000013074 reference sample Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 102220279120 rs1021443408 Human genes 0.000 description 2
- 102200095585 rs118204002 Human genes 0.000 description 2
- 102220320206 rs1554431444 Human genes 0.000 description 2
- 102220280629 rs1555085496 Human genes 0.000 description 2
- 102220275250 rs1555756363 Human genes 0.000 description 2
- 102220053803 rs727504425 Human genes 0.000 description 2
- 102220058223 rs730881928 Human genes 0.000 description 2
- 102200057225 rs771170000 Human genes 0.000 description 2
- 102220165167 rs772221026 Human genes 0.000 description 2
- 102220463950 rs7782939 Human genes 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 239000008354 sodium chloride injection Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 102220542003 tRNA (guanine-N(7)-)-methyltransferase_S27E_mutation Human genes 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 229910052721 tungsten Inorganic materials 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 229910052720 vanadium Inorganic materials 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- VCEHWDBVPZFHAG-UHFFFAOYSA-N 2-[[1-[2-[[2-[[2-[[1-[1-[2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]pyrrolidine-2-carbonyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid Chemical compound NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(O)=O)CCC1 VCEHWDBVPZFHAG-UHFFFAOYSA-N 0.000 description 1
- 102220512334 26S proteasome non-ATPase regulatory subunit 5_L46A_mutation Human genes 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 102220494450 39S ribosomal protein L16, mitochondrial_T64K_mutation Human genes 0.000 description 1
- 102220639932 40S ribosomal protein S17_D98A_mutation Human genes 0.000 description 1
- 102220470040 60S acidic ribosomal protein P0-like_L47H_mutation Human genes 0.000 description 1
- 102220620489 AP-3 complex subunit beta-1_S27G_mutation Human genes 0.000 description 1
- 102220554166 APC membrane recruitment protein 1_D50A_mutation Human genes 0.000 description 1
- 102220511121 APC membrane recruitment protein 1_D50K_mutation Human genes 0.000 description 1
- 102220511116 APC membrane recruitment protein 1_D50S_mutation Human genes 0.000 description 1
- 102220554225 APC membrane recruitment protein 1_D97A_mutation Human genes 0.000 description 1
- 102220554192 APC membrane recruitment protein 1_H34A_mutation Human genes 0.000 description 1
- 102220553746 APC membrane recruitment protein 1_K54A_mutation Human genes 0.000 description 1
- 102220510697 APC membrane recruitment protein 1_T28A_mutation Human genes 0.000 description 1
- 102220554150 APC membrane recruitment protein 1_T59A_mutation Human genes 0.000 description 1
- 102220511125 APC membrane recruitment protein 1_Y58S_mutation Human genes 0.000 description 1
- 102220560681 ATP-binding cassette sub-family C member 8_F27S_mutation Human genes 0.000 description 1
- 102220588045 Acidic mammalian chitinase_I21T_mutation Human genes 0.000 description 1
- 102220604002 Actin filament-associated protein 1_Y93F_mutation Human genes 0.000 description 1
- 241001655883 Adeno-associated virus - 1 Species 0.000 description 1
- 241000702423 Adeno-associated virus - 2 Species 0.000 description 1
- 241000202702 Adeno-associated virus - 3 Species 0.000 description 1
- 241000580270 Adeno-associated virus - 4 Species 0.000 description 1
- 241001634120 Adeno-associated virus - 5 Species 0.000 description 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 description 1
- 241001164823 Adeno-associated virus - 7 Species 0.000 description 1
- 241001164825 Adeno-associated virus - 8 Species 0.000 description 1
- 241000649045 Adeno-associated virus 10 Species 0.000 description 1
- 241000649046 Adeno-associated virus 11 Species 0.000 description 1
- 241000649047 Adeno-associated virus 12 Species 0.000 description 1
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
- 102220635346 Adenylate kinase isoenzyme 6_V29K_mutation Human genes 0.000 description 1
- 102220486165 Alkaline ceramidase 1_H94A_mutation Human genes 0.000 description 1
- 102220495823 Alkaline ceramidase 1_L46Q_mutation Human genes 0.000 description 1
- 102220495789 Alkaline ceramidase 1_S28A_mutation Human genes 0.000 description 1
- 102220495837 Alkaline ceramidase 1_Y49A_mutation Human genes 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 102220569500 Androgen receptor_L54S_mutation Human genes 0.000 description 1
- 102400000347 Angiotensin 1-7 Human genes 0.000 description 1
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 1
- 102220613772 Angiotensin-converting enzyme 2_Q89P_mutation Human genes 0.000 description 1
- 102220613578 Angiotensin-converting enzyme 2_S19P_mutation Human genes 0.000 description 1
- 102220468481 Annexin A2_S26E_mutation Human genes 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 102220547881 Apoptosis-associated speck-like protein containing a CARD_D50R_mutation Human genes 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 102220533529 Baculoviral IAP repeat-containing protein 1_Y58T_mutation Human genes 0.000 description 1
- 102220520102 Barrier-to-autointegration factor_K53A_mutation Human genes 0.000 description 1
- 102220520114 Barrier-to-autointegration factor_K53E_mutation Human genes 0.000 description 1
- 102220520088 Barrier-to-autointegration factor_K54E_mutation Human genes 0.000 description 1
- 102220520193 Barrier-to-autointegration factor_L46E_mutation Human genes 0.000 description 1
- 102220608040 Beta-defensin 1_R30T_mutation Human genes 0.000 description 1
- 102220530627 Beta-galactosidase_S63I_mutation Human genes 0.000 description 1
- 102220488098 Bone morphogenetic protein receptor type-1A_Y62D_mutation Human genes 0.000 description 1
- 102220505155 Borealin_L46Y_mutation Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102220607928 C-reactive protein_K53N_mutation Human genes 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 101100217502 Caenorhabditis elegans lgg-3 gene Proteins 0.000 description 1
- 102220612254 Calcyclin-binding protein_N56Y_mutation Human genes 0.000 description 1
- 101710203402 Carboxypeptidase A inhibitor Proteins 0.000 description 1
- 102220571118 Carboxypeptidase M_V29R_mutation Human genes 0.000 description 1
- 102000000496 Carboxypeptidases A Human genes 0.000 description 1
- 108010080937 Carboxypeptidases A Proteins 0.000 description 1
- 102220572735 Cbp/p300-interacting transactivator 1_M95A_mutation Human genes 0.000 description 1
- 102220597867 Cell division cycle and apoptosis regulator protein 1_N94A_mutation Human genes 0.000 description 1
- 102220570951 Centromere protein R_L96R_mutation Human genes 0.000 description 1
- 102220579879 Ceramide-1-phosphate transfer protein_F50R_mutation Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102220591969 Chitinase domain-containing protein 1_G99W_mutation Human genes 0.000 description 1
- 102220586505 Circadian locomoter output cycles protein kaput_F50M_mutation Human genes 0.000 description 1
- 102220604032 Clathrin heavy chain 1_Q89A_mutation Human genes 0.000 description 1
- 102220568228 Collagen alpha-2(I) chain_T59P_mutation Human genes 0.000 description 1
- 102220598269 Complement decay-accelerating factor_R52L_mutation Human genes 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102220566004 Cyclic AMP-dependent transcription factor ATF-7_M33D_mutation Human genes 0.000 description 1
- 102220553650 Cyclic GMP-AMP synthase_T97E_mutation Human genes 0.000 description 1
- 102220590866 Cystatin-like 1_Y62F_mutation Human genes 0.000 description 1
- 102220586640 Cysteinyl leukotriene receptor 1_K54S_mutation Human genes 0.000 description 1
- 102220569940 Cytochrome P450 1B1_S28W_mutation Human genes 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102220503788 Cytotoxic T-lymphocyte protein 4_L47D_mutation Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102220603764 DNA damage-regulated autophagy modulator protein 1_K54R_mutation Human genes 0.000 description 1
- 102220490279 DNA mismatch repair protein Mlh3_N35A_mutation Human genes 0.000 description 1
- 102220626423 DNA polymerase eta_R93P_mutation Human genes 0.000 description 1
- 102220488661 Dimethylglycine dehydrogenase, mitochondrial_F29I_mutation Human genes 0.000 description 1
- 102220535993 Dynein axonemal intermediate chain 4_R93E_mutation Human genes 0.000 description 1
- 102220472493 EF-hand calcium-binding domain-containing protein 7_F27I_mutation Human genes 0.000 description 1
- 102220572850 ER membrane protein complex subunit 2_M95K_mutation Human genes 0.000 description 1
- 102220498105 Electron transfer flavoprotein subunit beta_N53A_mutation Human genes 0.000 description 1
- 102220468422 Elongin-A_S26M_mutation Human genes 0.000 description 1
- 102220584607 Endonuclease 8-like 1_K54L_mutation Human genes 0.000 description 1
- 102220518434 Enhancer of filamentation 1_T28S_mutation Human genes 0.000 description 1
- 102220519462 Enoyl-CoA hydratase, mitochondrial_Q90A_mutation Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical group NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102220540588 Fibroblast growth factor 10_M95V_mutation Human genes 0.000 description 1
- 102220544989 Forkhead box protein F1_F98S_mutation Human genes 0.000 description 1
- 102220621869 G-protein coupled estrogen receptor 1_K54I_mutation Human genes 0.000 description 1
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 1
- 102220606834 Gap junction beta-1 protein_F29L_mutation Human genes 0.000 description 1
- 102220590573 Gap junction beta-1 protein_H94Y_mutation Human genes 0.000 description 1
- 102220606823 Gap junction beta-1 protein_I30T_mutation Human genes 0.000 description 1
- 102220606828 Gap junction beta-1 protein_M34K_mutation Human genes 0.000 description 1
- 102220607093 Gap junction beta-1 protein_S52P_mutation Human genes 0.000 description 1
- 102220486715 Gap junction beta-2 protein_M34A_mutation Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102220483045 Glypican-2_N56G_mutation Human genes 0.000 description 1
- 102220483047 Glypican-2_N56Q_mutation Human genes 0.000 description 1
- 102220543692 Guanine nucleotide-binding protein G(s) subunit alpha isoforms XLas_N53G_mutation Human genes 0.000 description 1
- 102220576040 HLA class I histocompatibility antigen, B alpha chain_D98Y_mutation Human genes 0.000 description 1
- 102220576068 HLA class I histocompatibility antigen, B alpha chain_Y33D_mutation Human genes 0.000 description 1
- 102220541981 HLA class II histocompatibility antigen, DQ beta 1 chain_N94K_mutation Human genes 0.000 description 1
- 102220541598 HLA class II histocompatibility antigen, DQ beta 1 chain_V29L_mutation Human genes 0.000 description 1
- 102220541631 HLA class II histocompatibility antigen, DQ beta 1 chain_Y58G_mutation Human genes 0.000 description 1
- 102220541632 HLA class II histocompatibility antigen, DQ beta 1 chain_Y58L_mutation Human genes 0.000 description 1
- 102220539793 HLA class II histocompatibility antigen, DQ beta 1 chain_Y62H_mutation Human genes 0.000 description 1
- 102220539814 HLA class II histocompatibility antigen, DQ beta 1 chain_Y62S_mutation Human genes 0.000 description 1
- 102220493579 HLA class II histocompatibility antigen, DR beta 3 chain_L96F_mutation Human genes 0.000 description 1
- 102220493580 HLA class II histocompatibility antigen, DR beta 3 chain_L96I_mutation Human genes 0.000 description 1
- 102220466836 HLA class II histocompatibility antigen, DR beta 4 chain_N35H_mutation Human genes 0.000 description 1
- 102220537095 Hemoglobin subunit epsilon_N53H_mutation Human genes 0.000 description 1
- 102100030483 Histatin-1 Human genes 0.000 description 1
- 102220604087 Homeobox protein SIX3_Y49W_mutation Human genes 0.000 description 1
- 101001082500 Homo sapiens Histatin-1 Proteins 0.000 description 1
- 101001021281 Homo sapiens Protein HEXIM1 Proteins 0.000 description 1
- 101001115218 Homo sapiens Ubiquitin-40S ribosomal protein S27a Proteins 0.000 description 1
- 244000309467 Human Coronavirus Species 0.000 description 1
- 102220536578 Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial_D57G_mutation Human genes 0.000 description 1
- 102220624338 Interferon alpha-8_T51A_mutation Human genes 0.000 description 1
- 102220499975 Interferon-induced GTP-binding protein Mx2_T28L_mutation Human genes 0.000 description 1
- 102220476929 Interleukin-1 receptor-associated kinase 3_D98E_mutation Human genes 0.000 description 1
- 102220476931 Interleukin-1 receptor-associated kinase 3_D98V_mutation Human genes 0.000 description 1
- 102220525658 Keratin-associated protein 26-1_S26Y_mutation Human genes 0.000 description 1
- 102220565494 Killer cell immunoglobulin-like receptor 2DL3_H34Q_mutation Human genes 0.000 description 1
- 102220481775 Kinesin-like protein KIF20A_T60Q_mutation Human genes 0.000 description 1
- 102220508913 Kinesin-like protein KIF2C_S92E_mutation Human genes 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- NTCCRGGIJNDEAB-IRXDYDNUSA-N MLN-4760 Chemical compound CC(C)C[C@@H](C(O)=O)N[C@H](C(O)=O)CC1=CN=CN1CC1=CC(Cl)=CC(Cl)=C1 NTCCRGGIJNDEAB-IRXDYDNUSA-N 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 101710141347 Major envelope glycoprotein Proteins 0.000 description 1
- 102220595604 Major vault protein_R52C_mutation Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102220503895 Meiotic recombination protein REC8 homolog_S92V_mutation Human genes 0.000 description 1
- 102220489345 Melanoma-associated antigen 1_K53G_mutation Human genes 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102220512290 Methionine-R-sulfoxide reductase B3_L96A_mutation Human genes 0.000 description 1
- 102220608629 Methyl-CpG-binding domain protein 1_R30K_mutation Human genes 0.000 description 1
- 102220548791 Mitochondrial import inner membrane translocase subunit TIM16_Y93G_mutation Human genes 0.000 description 1
- 102220507409 Mitochondrial tRNA-specific 2-thiouridylase 1_H94K_mutation Human genes 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101000638178 Mus musculus Transmembrane protease serine 2 Proteins 0.000 description 1
- 102220485208 Myelin proteolipid protein_L46R_mutation Human genes 0.000 description 1
- 102220490875 Myeloid cell nuclear differentiation antigen_Y58D_mutation Human genes 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 102220561290 Myocardin-related transcription factor B_L96D_mutation Human genes 0.000 description 1
- 102220502064 N-acetylglutamate synthase, mitochondrial_G99S_mutation Human genes 0.000 description 1
- 102220506268 N-alpha-acetyltransferase 50_F27A_mutation Human genes 0.000 description 1
- 102220513456 NADH-ubiquinone oxidoreductase chain 6_L54I_mutation Human genes 0.000 description 1
- 102220514337 NADH-ubiquinone oxidoreductase chain 6_S26G_mutation Human genes 0.000 description 1
- 102220631334 NCK-interacting protein with SH3 domain_S92G_mutation Human genes 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 102220479647 Nephrin_M33T_mutation Human genes 0.000 description 1
- 102220572954 Netrin receptor UNC5C_S28F_mutation Human genes 0.000 description 1
- 102220594719 Neurogenic differentiation factor 6_G26H_mutation Human genes 0.000 description 1
- 102220590863 Neuroligin-3_S92Y_mutation Human genes 0.000 description 1
- 102220592550 Neuroserpin_S52R_mutation Human genes 0.000 description 1
- 102220541925 Neutrophil elastase_L47R_mutation Human genes 0.000 description 1
- 102220623366 Non-histone chromosomal protein HMG-14_K53T_mutation Human genes 0.000 description 1
- 102220580177 Non-receptor tyrosine-protein kinase TYK2_D31A_mutation Human genes 0.000 description 1
- 102220484661 Norrin_K54N_mutation Human genes 0.000 description 1
- 102220532390 Nutritionally-regulated adipose and cardiac enriched protein homolog_D98R_mutation Human genes 0.000 description 1
- 240000008881 Oenanthe javanica Species 0.000 description 1
- 102220487037 Olfactory receptor 8H3_L47I_mutation Human genes 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 102220567121 Ornithine decarboxylase antizyme 1_I48A_mutation Human genes 0.000 description 1
- 102220567115 Ornithine decarboxylase antizyme 1_Y58R_mutation Human genes 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 102220482716 Paraneoplastic antigen Ma6E_S63L_mutation Human genes 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102220535292 Peptidyl-prolyl cis-trans isomerase FKBP2_S92D_mutation Human genes 0.000 description 1
- 102220500652 Phosphatidylinositol 4-phosphate 5-kinase type-1 beta_L54M_mutation Human genes 0.000 description 1
- 102220623752 Phospholipid hydroperoxide glutathione peroxidase_Y58F_mutation Human genes 0.000 description 1
- 102220582002 Phospholipid-transporting ATPase ABCA3_N53Q_mutation Human genes 0.000 description 1
- 102220510048 Phosphomevalonate kinase_R93M_mutation Human genes 0.000 description 1
- 102220539584 Piwi-like protein 1_Y93D_mutation Human genes 0.000 description 1
- 102220466922 Podocalyxin_T60R_mutation Human genes 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102220559090 Potassium voltage-gated channel subfamily E member 1_S28T_mutation Human genes 0.000 description 1
- 102220613568 Potassium voltage-gated channel subfamily H member 2_F29A_mutation Human genes 0.000 description 1
- 102220472853 Potassium voltage-gated channel subfamily KQT member 2_S52Q_mutation Human genes 0.000 description 1
- 102220635826 Probable C-mannosyltransferase DPY19L1_S26C_mutation Human genes 0.000 description 1
- 102220474599 Probable asparagine-tRNA ligase, mitochondrial_N94D_mutation Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102220604200 Proteasomal ubiquitin receptor ADRM1_S26K_mutation Human genes 0.000 description 1
- 102220604415 Proteasomal ubiquitin receptor ADRM1_Y93A_mutation Human genes 0.000 description 1
- 102220604423 Proteasomal ubiquitin receptor ADRM1_Y93K_mutation Human genes 0.000 description 1
- 102220604355 Proteasomal ubiquitin receptor ADRM1_Y93L_mutation Human genes 0.000 description 1
- 102220470494 Proteasome subunit beta type-3_M34L_mutation Human genes 0.000 description 1
- 102220533967 Protein BEX1_E61S_mutation Human genes 0.000 description 1
- 102220564982 Protein FAM71C_R30G_mutation Human genes 0.000 description 1
- 102220580439 Protein FAM74A4/A6_D98I_mutation Human genes 0.000 description 1
- 102220470791 Protein MON2 homolog_S63D_mutation Human genes 0.000 description 1
- 102220537319 Protein NDRG2_G26K_mutation Human genes 0.000 description 1
- 102220629949 Protein amnionless_N35Q_mutation Human genes 0.000 description 1
- 102220630212 Protein amnionless_R30E_mutation Human genes 0.000 description 1
- 102220469877 Protein argonaute-3_F50A_mutation Human genes 0.000 description 1
- 102220489862 Protein ecdysoneless homolog_Y96N_mutation Human genes 0.000 description 1
- 102220520170 Protein patched homolog 1_N53K_mutation Human genes 0.000 description 1
- 102220550339 Protein unc-50 homolog_L47A_mutation Human genes 0.000 description 1
- 102220547632 Protocadherin-10_D98N_mutation Human genes 0.000 description 1
- 102220547640 Protocadherin-10_I51T_mutation Human genes 0.000 description 1
- 102220543872 Protocadherin-10_M95I_mutation Human genes 0.000 description 1
- 102220640206 Proton channel OTOP1_S26P_mutation Human genes 0.000 description 1
- 102220640029 Proton channel OTOP1_T60V_mutation Human genes 0.000 description 1
- 102220501418 Putative uncharacterized protein LINC00574_S27C_mutation Human genes 0.000 description 1
- 102220626287 RUN domain-containing protein 3B_L47M_mutation Human genes 0.000 description 1
- 102220485514 Rhodopsin_M33L_mutation Human genes 0.000 description 1
- 102220524642 Ribosomal protein S6 kinase beta-2_I30A_mutation Human genes 0.000 description 1
- 102220609055 SH2B adapter protein 1_F29R_mutation Human genes 0.000 description 1
- 102220603752 SLAM family member 5_Y62A_mutation Human genes 0.000 description 1
- 102000000185 SRCR domains Human genes 0.000 description 1
- 108050008568 SRCR domains Proteins 0.000 description 1
- 102220644281 SUMO-activating enzyme subunit 2_N56A_mutation Human genes 0.000 description 1
- 102220568394 Segment polarity protein dishevelled homolog DVL-1_L46H_mutation Human genes 0.000 description 1
- 101000629313 Severe acute respiratory syndrome coronavirus Spike glycoprotein Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 102220525770 Sodium channel subunit beta-3_Q89L_mutation Human genes 0.000 description 1
- 102220476219 Solute carrier family 22 member 7_H34I_mutation Human genes 0.000 description 1
- 102220606495 Sorting nexin-10_F29M_mutation Human genes 0.000 description 1
- 102220560184 Stromal cell-derived factor 1_N56H_mutation Human genes 0.000 description 1
- 102220560339 Stromal cell-derived factor 1_Y33A_mutation Human genes 0.000 description 1
- 102220484140 T cell receptor alpha variable 34_S63R_mutation Human genes 0.000 description 1
- 102220484143 T cell receptor alpha variable 34_S63W_mutation Human genes 0.000 description 1
- 102220585515 T cell receptor gamma constant 1_D97L_mutation Human genes 0.000 description 1
- 102220536512 THAP domain-containing protein 1_S52A_mutation Human genes 0.000 description 1
- 102220468330 Tektin-1_Y96A_mutation Human genes 0.000 description 1
- 102220483412 Tensin-2_G99E_mutation Human genes 0.000 description 1
- 102220499955 Testis-specific Y-encoded-like protein 4_R30L_mutation Human genes 0.000 description 1
- 102220484130 Testis-specific serine/threonine-protein kinase 6_K54M_mutation Human genes 0.000 description 1
- 102220598898 Thiamine transporter 1_I48F_mutation Human genes 0.000 description 1
- 102220468084 Trafficking protein particle complex subunit 3_L46M_mutation Human genes 0.000 description 1
- 102220535799 Transcription factor JunD_L54A_mutation Human genes 0.000 description 1
- 102220535931 Transcription factor JunD_R30A_mutation Human genes 0.000 description 1
- 102220604981 Transcription factor Sp2_L47Q_mutation Human genes 0.000 description 1
- 102220636841 Transforming protein RhoA_T28N_mutation Human genes 0.000 description 1
- 101710081844 Transmembrane protease serine 2 Proteins 0.000 description 1
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 description 1
- 102220501315 Transmembrane protease serine 5_D31V_mutation Human genes 0.000 description 1
- 102220579302 Transthyretin_M33I_mutation Human genes 0.000 description 1
- 102220585529 Tripartite motif-containing protein 14_L46S_mutation Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102220577898 Tyrosine-protein phosphatase non-receptor type substrate 1_L96S_mutation Human genes 0.000 description 1
- 102100023341 Ubiquitin-40S ribosomal protein S27a Human genes 0.000 description 1
- 102220642607 Ubiquitin-like protein ISG15_Y96L_mutation Human genes 0.000 description 1
- 102220480895 Uncharacterized protein EXOC3-AS1_K53D_mutation Human genes 0.000 description 1
- 102220476885 Vacuolar protein sorting-associated protein 16 homolog_K54D_mutation Human genes 0.000 description 1
- 102220640477 Vacuolar-sorting protein SNF8_R52E_mutation Human genes 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 102220472650 Vitamin K epoxide reductase complex subunit 1_S52W_mutation Human genes 0.000 description 1
- 102220506795 Vitelline membrane outer layer protein 1 homolog_F27C_mutation Human genes 0.000 description 1
- 102220533027 WW domain-containing oxidoreductase_Y33F_mutation Human genes 0.000 description 1
- 102220506286 Wiskott-Aldrich syndrome protein family member 2_L54D_mutation Human genes 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 102220495682 Zinc finger protein 324B_S63G_mutation Human genes 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- AFVLVVWMAFSXCK-VMPITWQZSA-N alpha-cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(\C#N)=C\C1=CC=C(O)C=C1 AFVLVVWMAFSXCK-VMPITWQZSA-N 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000003236 bicinchoninic acid assay Methods 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 102200153291 c.100A>G Human genes 0.000 description 1
- 102220364215 c.155G>T Human genes 0.000 description 1
- 102220354690 c.160C>G Human genes 0.000 description 1
- 102220363900 c.182A>C Human genes 0.000 description 1
- 102220359610 c.26G>A Human genes 0.000 description 1
- 102220349282 c.275C>G Human genes 0.000 description 1
- 102220355150 c.278A>G Human genes 0.000 description 1
- 102220349284 c.287A>T Human genes 0.000 description 1
- 102220393123 c.290C>G Human genes 0.000 description 1
- 102220350650 c.295G>C Human genes 0.000 description 1
- 102220361178 c.59T>C Human genes 0.000 description 1
- 102220364012 c.64T>A Human genes 0.000 description 1
- 102220393251 c.79T>C Human genes 0.000 description 1
- 102220403077 c.82A>T Human genes 0.000 description 1
- 102220364302 c.86T>C Human genes 0.000 description 1
- 102220349640 c.88C>A Human genes 0.000 description 1
- 102220347004 c.89G>A Human genes 0.000 description 1
- 102220395814 c.98T>G Human genes 0.000 description 1
- 102220365463 c.99G>C Human genes 0.000 description 1
- 102220636013 cAMP-dependent protein kinase catalytic subunit alpha_L96Q_mutation Human genes 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000003182 dose-response assay Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 102220500038 eIF5-mimic protein 2_M33A_mutation Human genes 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 108010011035 endodeoxyribonuclease DpnI Proteins 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011551 log transformation method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000007886 magnetic bead extraction Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 238000002887 multiple sequence alignment Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007030 peptide scission Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000012557 regeneration buffer Substances 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 102220281713 rs1007047958 Human genes 0.000 description 1
- 102200098671 rs1041981 Human genes 0.000 description 1
- 102220003047 rs104893857 Human genes 0.000 description 1
- 102200153433 rs104894817 Human genes 0.000 description 1
- 102220032396 rs104895235 Human genes 0.000 description 1
- 102220032360 rs104895237 Human genes 0.000 description 1
- 102220032361 rs104895237 Human genes 0.000 description 1
- 102220032393 rs104895244 Human genes 0.000 description 1
- 102220196645 rs1057518868 Human genes 0.000 description 1
- 102220198146 rs1057519886 Human genes 0.000 description 1
- 102200120948 rs1057520695 Human genes 0.000 description 1
- 102220219659 rs1060500190 Human genes 0.000 description 1
- 102200153293 rs1060500998 Human genes 0.000 description 1
- 102200153431 rs1060501000 Human genes 0.000 description 1
- 102220222791 rs1060501227 Human genes 0.000 description 1
- 102220219080 rs1060503402 Human genes 0.000 description 1
- 102220198385 rs1060503765 Human genes 0.000 description 1
- 102220227738 rs1064796459 Human genes 0.000 description 1
- 102220231834 rs1064797300 Human genes 0.000 description 1
- 102220007346 rs111033670 Human genes 0.000 description 1
- 102220104353 rs111400494 Human genes 0.000 description 1
- 102220234460 rs1114167630 Human genes 0.000 description 1
- 102220039795 rs113782655 Human genes 0.000 description 1
- 102220101984 rs115452881 Human genes 0.000 description 1
- 102220306153 rs1213881768 Human genes 0.000 description 1
- 102200081489 rs121913585 Human genes 0.000 description 1
- 102200068095 rs121913658 Human genes 0.000 description 1
- 102220001972 rs121917826 Human genes 0.000 description 1
- 102200026945 rs121918101 Human genes 0.000 description 1
- 102200133668 rs121918251 Human genes 0.000 description 1
- 102200114092 rs121965060 Human genes 0.000 description 1
- 102200007939 rs128626231 Human genes 0.000 description 1
- 102220291128 rs1300589513 Human genes 0.000 description 1
- 102220262481 rs1320351683 Human genes 0.000 description 1
- 102220003945 rs132630296 Human genes 0.000 description 1
- 102200127268 rs137853826 Human genes 0.000 description 1
- 102220313252 rs1386345719 Human genes 0.000 description 1
- 102220265335 rs139105272 Human genes 0.000 description 1
- 102220278861 rs1395998044 Human genes 0.000 description 1
- 102220278863 rs1395998044 Human genes 0.000 description 1
- 102220162304 rs140167393 Human genes 0.000 description 1
- 102220245300 rs1404795980 Human genes 0.000 description 1
- 102220272599 rs140825795 Human genes 0.000 description 1
- 102220134332 rs142032681 Human genes 0.000 description 1
- 102220272597 rs1423724305 Human genes 0.000 description 1
- 102220285822 rs1423724305 Human genes 0.000 description 1
- 102200128054 rs142986731 Human genes 0.000 description 1
- 102220050270 rs144165984 Human genes 0.000 description 1
- 102220149593 rs145337669 Human genes 0.000 description 1
- 102220065976 rs145474820 Human genes 0.000 description 1
- 102220036853 rs146480420 Human genes 0.000 description 1
- 102220083515 rs147479204 Human genes 0.000 description 1
- 102220179770 rs148409389 Human genes 0.000 description 1
- 102220202173 rs148450358 Human genes 0.000 description 1
- 102220306518 rs149808406 Human genes 0.000 description 1
- 102200042492 rs149991239 Human genes 0.000 description 1
- 102220318984 rs150326789 Human genes 0.000 description 1
- 102200096284 rs154774635 Human genes 0.000 description 1
- 102220254290 rs1553156175 Human genes 0.000 description 1
- 102220242992 rs1553178041 Human genes 0.000 description 1
- 102220277588 rs1553645950 Human genes 0.000 description 1
- 102220317537 rs1553646295 Human genes 0.000 description 1
- 102220317885 rs1554069716 Human genes 0.000 description 1
- 102220288775 rs1554193610 Human genes 0.000 description 1
- 102220320590 rs1554306309 Human genes 0.000 description 1
- 102220320593 rs1554306309 Human genes 0.000 description 1
- 102220308561 rs1554698939 Human genes 0.000 description 1
- 102220321566 rs1554780187 Human genes 0.000 description 1
- 102220279294 rs1554888320 Human genes 0.000 description 1
- 102220325068 rs1555280376 Human genes 0.000 description 1
- 102220325592 rs1555376563 Human genes 0.000 description 1
- 102200070464 rs1555568396 Human genes 0.000 description 1
- 102220287616 rs1555570422 Human genes 0.000 description 1
- 102220271531 rs1555570486 Human genes 0.000 description 1
- 102220274769 rs1555835400 Human genes 0.000 description 1
- 102220288337 rs1556370576 Human genes 0.000 description 1
- 102200086451 rs16948978 Human genes 0.000 description 1
- 102200156952 rs1799807 Human genes 0.000 description 1
- 102200149451 rs1800361 Human genes 0.000 description 1
- 102200115810 rs1800458 Human genes 0.000 description 1
- 102220220001 rs188579132 Human genes 0.000 description 1
- 102200097288 rs199472827 Human genes 0.000 description 1
- 102220024922 rs199472831 Human genes 0.000 description 1
- 102200148756 rs199476332 Human genes 0.000 description 1
- 102220025220 rs199476357 Human genes 0.000 description 1
- 102220067383 rs199960045 Human genes 0.000 description 1
- 102220219704 rs200141048 Human genes 0.000 description 1
- 102220267030 rs200141048 Human genes 0.000 description 1
- 102220046348 rs200632093 Human genes 0.000 description 1
- 102200087968 rs267608026 Human genes 0.000 description 1
- 102220036189 rs273585616 Human genes 0.000 description 1
- 102200068708 rs281865216 Human genes 0.000 description 1
- 102200063016 rs2819590 Human genes 0.000 description 1
- 102200029099 rs28756978 Human genes 0.000 description 1
- 102200145345 rs28931594 Human genes 0.000 description 1
- 102200145346 rs28931594 Human genes 0.000 description 1
- 102200052311 rs3218772 Human genes 0.000 description 1
- 102220005386 rs33991779 Human genes 0.000 description 1
- 102200087970 rs35462442 Human genes 0.000 description 1
- 102200082934 rs35474880 Human genes 0.000 description 1
- 102200158798 rs35687396 Human genes 0.000 description 1
- 102220014001 rs35887622 Human genes 0.000 description 1
- 102200101286 rs366439 Human genes 0.000 description 1
- 102220090146 rs370608001 Human genes 0.000 description 1
- 102220083620 rs371904636 Human genes 0.000 description 1
- 102220219960 rs372459649 Human genes 0.000 description 1
- 102220139813 rs372921526 Human genes 0.000 description 1
- 102220146788 rs373174008 Human genes 0.000 description 1
- 102220075284 rs374402088 Human genes 0.000 description 1
- 102220341607 rs374625633 Human genes 0.000 description 1
- 102220106779 rs377470390 Human genes 0.000 description 1
- 102200067664 rs397507595 Human genes 0.000 description 1
- 102200067662 rs397507615 Human genes 0.000 description 1
- 102200062348 rs397514725 Human genes 0.000 description 1
- 102200160323 rs397515459 Human genes 0.000 description 1
- 102220261425 rs397515459 Human genes 0.000 description 1
- 102220014009 rs397516872 Human genes 0.000 description 1
- 102220030421 rs398124134 Human genes 0.000 description 1
- 102220045402 rs41294986 Human genes 0.000 description 1
- 102220031923 rs431825393 Human genes 0.000 description 1
- 102220039979 rs431825393 Human genes 0.000 description 1
- 102220074096 rs45471099 Human genes 0.000 description 1
- 102200115585 rs539699299 Human genes 0.000 description 1
- 102220271909 rs546729596 Human genes 0.000 description 1
- 102220102325 rs564013964 Human genes 0.000 description 1
- 102220240259 rs569172233 Human genes 0.000 description 1
- 102220106470 rs569543350 Human genes 0.000 description 1
- 102220276877 rs574257684 Human genes 0.000 description 1
- 102220064512 rs577173144 Human genes 0.000 description 1
- 102220323923 rs577173144 Human genes 0.000 description 1
- 102200131343 rs57966821 Human genes 0.000 description 1
- 102200082257 rs587777590 Human genes 0.000 description 1
- 102200153447 rs587777876 Human genes 0.000 description 1
- 102200153449 rs587777876 Human genes 0.000 description 1
- 102220040203 rs587778228 Human genes 0.000 description 1
- 102220036629 rs587779920 Human genes 0.000 description 1
- 102220214485 rs587779920 Human genes 0.000 description 1
- 102220045199 rs587781908 Human genes 0.000 description 1
- 102220045670 rs587782296 Human genes 0.000 description 1
- 102220046258 rs587782776 Human genes 0.000 description 1
- 102220254686 rs60964124 Human genes 0.000 description 1
- 102220198848 rs61737971 Human genes 0.000 description 1
- 102200059959 rs61753182 Human genes 0.000 description 1
- 102200028555 rs61754448 Human genes 0.000 description 1
- 102200001738 rs72552724 Human genes 0.000 description 1
- 102200073127 rs727502808 Human genes 0.000 description 1
- 102220338716 rs746274670 Human genes 0.000 description 1
- 102220218616 rs746322193 Human genes 0.000 description 1
- 102220243151 rs749693224 Human genes 0.000 description 1
- 102220257188 rs750949635 Human genes 0.000 description 1
- 102220204476 rs751420248 Human genes 0.000 description 1
- 102220225217 rs751938777 Human genes 0.000 description 1
- 102220071194 rs752110396 Human genes 0.000 description 1
- 102220311222 rs755835349 Human genes 0.000 description 1
- 102220117226 rs757227955 Human genes 0.000 description 1
- 102220175386 rs757831590 Human genes 0.000 description 1
- 102220101981 rs758382516 Human genes 0.000 description 1
- 102220323421 rs759472787 Human genes 0.000 description 1
- 102220243517 rs760719270 Human genes 0.000 description 1
- 102220285436 rs760770847 Human genes 0.000 description 1
- 102220086127 rs763702846 Human genes 0.000 description 1
- 102220277047 rs763702846 Human genes 0.000 description 1
- 102220316120 rs763702846 Human genes 0.000 description 1
- 102220222437 rs764367878 Human genes 0.000 description 1
- 102220086575 rs766203500 Human genes 0.000 description 1
- 102220251099 rs766269417 Human genes 0.000 description 1
- 102220151539 rs768060274 Human genes 0.000 description 1
- 102220253743 rs768101924 Human genes 0.000 description 1
- 102220215701 rs769386190 Human genes 0.000 description 1
- 102200017271 rs769452 Human genes 0.000 description 1
- 102220267607 rs769996423 Human genes 0.000 description 1
- 102200081446 rs770546306 Human genes 0.000 description 1
- 102220312163 rs772475317 Human genes 0.000 description 1
- 102200001737 rs772578415 Human genes 0.000 description 1
- 102220104797 rs773204331 Human genes 0.000 description 1
- 102220083575 rs774156512 Human genes 0.000 description 1
- 102220218329 rs774156512 Human genes 0.000 description 1
- 102220081231 rs777376620 Human genes 0.000 description 1
- 102220274420 rs778838312 Human genes 0.000 description 1
- 102220274918 rs778838312 Human genes 0.000 description 1
- 102220282393 rs778973022 Human genes 0.000 description 1
- 102220236140 rs782637049 Human genes 0.000 description 1
- 102220070930 rs794728599 Human genes 0.000 description 1
- 102220071412 rs794728839 Human genes 0.000 description 1
- 102220072337 rs794728990 Human genes 0.000 description 1
- 102220072783 rs794729227 Human genes 0.000 description 1
- 102220009751 rs80358454 Human genes 0.000 description 1
- 102220082228 rs863224038 Human genes 0.000 description 1
- 102220087056 rs864622464 Human genes 0.000 description 1
- 102220086323 rs864622699 Human genes 0.000 description 1
- 102220095353 rs876659078 Human genes 0.000 description 1
- 102220100734 rs878854049 Human genes 0.000 description 1
- 102220100736 rs878854061 Human genes 0.000 description 1
- 102220098934 rs878854576 Human genes 0.000 description 1
- 102200075465 rs878855319 Human genes 0.000 description 1
- 102200074015 rs879253763 Human genes 0.000 description 1
- 102220104728 rs879253940 Human genes 0.000 description 1
- 102220105250 rs879254386 Human genes 0.000 description 1
- 102220105300 rs879254420 Human genes 0.000 description 1
- 102200012371 rs879255637 Human genes 0.000 description 1
- 102220122065 rs886042999 Human genes 0.000 description 1
- 102220122485 rs886043103 Human genes 0.000 description 1
- 102220127142 rs886044478 Human genes 0.000 description 1
- 102220127578 rs886044619 Human genes 0.000 description 1
- 102220179462 rs886057103 Human genes 0.000 description 1
- 102220147472 rs886060981 Human genes 0.000 description 1
- 102220322006 rs950054021 Human genes 0.000 description 1
- 102220102960 rs9895963 Human genes 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 229910052716 thallium Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Definitions
- the present invention relates to monoclonal antibodies and related engineered viruses useful for therapeutically and prophylactically addressing SARS-CoV-2 infection.
- This invention provides a monoclonal antibody that (i) specifically binds to the extracellular portion of human angiotensin converting enzyme 2 (hACE2); (ii) specifically inhibits binding of SARS-CoV-2 to the extracellular portion of hACE2; and (iii) does not significantly inhibit the ability of hACE2 to cleave angiotensin II and/or a synthetic MCA-based peptide.
- hACE2 human angiotensin converting enzyme 2
- This invention also provides a monoclonal antibody comprising residues 21 through 230 of the light chain amino acid sequence set forth in Figure 6 and residues 25 through 471 of the heavy chain amino acid sequence set forth in Figure 7.
- This invention further provides a monoclonal antibody comprising residues 21 through 230 of the light chain amino acid sequence set forth in Figure 6 and residues 25 through 471 of the heavy chain amino acid sequence set forth in Figure 8.
- This invention also provides an isolated nucleic acid molecule encoding (i) the complete light chain, or a portion of the light chain, of the present monoclonal antibody, and/or (ii) the complete heavy chain, or a portion of the heavy chain, of the present monoclonal antibody.
- This invention further provides a recombinant vector comprising the present nucleic acid molecule operably linked to a promoter of RNA transcription.
- This invention still further provides a host vector system comprising one or more of the present vectors in a suitable host cell.
- This invention further provides a composition comprising (i) the present monoclonal antibody, and (ii) a pharmaceutically acceptable carrier.
- This invention still further provides a method for reducing the likelihood of a human subject’s becoming infected with SARS-CoV-2 comprising administering to the subject a prophylactically effective amount of the present monoclonal antibody.
- This invention also provides a method for treating a human subject who is infected with SARS-CoV-2 comprising administering to the subject a therapeutically effective amount of the present monoclonal antibody.
- This invention provides (a) a recombinant AAV vector comprising a nucleic acid sequence encoding a heavy chain and/or a light chain of the present monoclonal antibody; (b) a recombinant AAV particle comprising the present recombinant AAV vector; and (c) a composition comprising (i) a plurality of the present AAV particles and (ii) a pharmaceutically acceptable carrier.
- This invention provides (a) a method for reducing the likelihood of a human subject’s becoming infected with SARS-CoV-2 comprising administering to the subject a prophylactically effective number of the present AAV particles; and (b) a method for treating a human subject who is infected with SARS-CoV-2 comprising administering to the subject a therapeutically effective number of the present AAV particles.
- this invention provides (a) a first kit comprising, in separate compartments, (i) a diluent and (ii) a suspension of the present monoclonal antibody; (b) a second kit comprising, in separate compartments, (i) a diluent and (ii) the present monoclonal antibody in lyophilized form; and (c) a third kit comprising, in separate compartments, (i) a diluent and (ii) a suspension of a plurality of the present recombinant AAV particles.
- This figure sets forth the nucleotide and predicted amino acid sequence of human TMPRSS2 (GenBank Accession No. U75329).
- the potential initiation methionine codon and the translation stop codon are bold and underlined.
- the trapped sequences are underlined (for example the trapped sequence HMC26A01 extending from nucleotide 740 to 955).
- the different domains of the predicted polypeptide are dotted underlined (for example the SRCR domain extends from amino acid residue 148 to 242).
- the locations of the introns are shown with arrows. ( Figure from, and text adapted from, Figure 1 of A. Paoloni-Giacobino, et al.)
- SARS-CoV-2 RBD This figure sets forth the characterization of SARS-CoV-2 RBD. It shows multiple sequence alignment of RBDs of SARS-CoV-2, SARS-CoV, and MERS-CoV spike (S) proteins.
- GenBank accession numbers are QHR63250.1 (SARS-CoV-2 S), AY278488.2 (SARS-CoV S), and AFS88936.1 (MERS-CoV S).
- Variable amino acid residues between SARS-CoV-2 and SARS-CoV are highlighted in dark grey (cyan), and conserved residues among SARS-CoV-2, SARS-CoV, and MERS-CoV are highlighted in light grey (yellow).
- Asterisks represent fully conserved residues, colons represent highly conserved residues, and periods represent lowly conserved residues.
- FIG. 5 shows a schematic diagram of an expression cassette for inclusion in an AAV-antibody vector.
- This figure shows the amino acid sequence of a human kappa light chain (H11 B11- hKappa).
- This sequence includes a leader sequence (shown in red; residues 1-20, beginning with MET... and ending with ... STG) and the light chain sequence (residues 21-230, beginning with DIQ... and ending with ... GEC).
- the variable domain is shaded.
- the C-terminal lysine residue normally present in the wild-type light chain sequence is deleted here, although its inclusion is envisioned in one embodiment of this invention.
- This figure shows the amino acid sequence of a human lgG1 (G1m17) heavy chain (H11 B11 -h IgG 1 (STR).
- This sequence includes a leader sequence (shown in red; residues 1-24, beginning with MDP... and ending with ... SYG) and the heavy chain sequence (residues 25-471 , beginning with EVQ... and ending with ... SPG).
- the variable domain is shaded.
- the constant domain sequence contains the mutation (L234S)(L235T)(G236R).
- the C-terminal lysine residue normally present in the wildtype heavy chain sequence is deleted here, although its inclusion is envisioned in one embodiment of this invention.
- This figure shows the amino acid sequence of a human lgG1 (G1m17) heavy chain (H11 B11 -h IgG 1 (STR/YTE).
- This sequence includes a leader sequence (shown in red; residues 1-24, beginning with MDP... and ending with ... SYG) and the heavy chain sequence (residues 25-471 , beginning with EVQ... and ending with ... SPG).
- the variable domain is shaded.
- the constant domain sequence contains the mutation (L234S)(L235T)(G236R)(M252Y)(S254T) (T256E).
- the C-terminal lysine residue normally present in the wild-type heavy chain sequence is deleted here, although its inclusion is envisioned in one embodiment of this invention.
- This figure shows the human kappa light chain (H11 B11 -hKappa) amino acid sequence shown in Figure 6, along with the full-length DNA sequence (pLEV123-H11 B11 -hKappa) encoding it.
- the C-terminal lysine residue normally present in the wild-type light chain sequence is deleted here, as indicated by an asterisk.
- This figure shows the human IgG 1 (G1 ml 7) heavy chain (H11 B11 -h IgG 1 (STR) amino acid sequence shown in Figure 7, along with the full-length DNA sequence (pLEV123- H11 B11 -h IgG 1 (STR)) encoding it.
- the C-terminal lysine residue normally present in the wild-type heavy chain sequence is deleted here, as indicated by an asterisk.
- This figure shows the human IgG 1 (G1 ml 7) heavy chain (H11 B11 -h IgG 1 (STR/YTE) amino acid sequence shown in Figure 8, along with the full-length DNA sequence (pLEV123-H11 B11 -hlgG1 (STR/YTE)) encoding it.
- the C-terminal lysine residue normally present in the wild-type heavy chain sequence is deleted here, as indicated by an asterisk.
- This figure shows the kappa light chain (3E8-hKappa) amino acid sequence, along with the full-length DNA sequence (pLEV123-hKappa) encoding it.
- the C-terminal lysine residue normally present in the wild-type light chain sequence is deleted here, as indicated by an asterisk.
- This figure shows the lgG1 heavy chain (3E8-hlgG1 (STR/LS)) amino acid sequence, along with the full-length DNA sequence (pLEV123-3E8-hlgG1 (STR/LS)) encoding it.
- the C-terminal lysine residue normally present in the wild-type heavy chain sequence is deleted here, as indicated by an asterisk.
- This invention provides certain antibodies and monoclonal antibody-encoding recombinant viral vectors, related viral particles, and related methods for inhibiting and treating SARS-CoV-2-infection.
- administer means to deliver the antibodies to a subject’s body via any known method suitable for that purpose.
- Specific modes of administration include, without limitation, intravenous administration, intramuscular administration, intranasal administration, and subcutaneous administration.
- administer with respect to recombinant viral particles, means to deliver the particles to a subject’s body via any known method suitable for that purpose.
- Specific modes of administration include, without limitation, intravenous administration, intramuscular administration, and subcutaneous administration.
- monoclonal antibodies can be formulated using one or more routinely used pharmaceutically acceptable carriers.
- Such carriers are well known to those skilled in the art.
- injectable drug delivery systems include solutions containing salts (e.g., sodium chloride and sodium phosphate).
- the injectable drug delivery system comprises monoclonal antibody (e.g., 100 mg, 200 mg, 300 mg, 400 mg, or 500 mg) in the form of a lyophilized powder in a multi-use vial, which is then reconstituted and diluted in, for example, 0.9% Sodium Chloride Injection, USP.
- the injectable drug delivery system comprises monoclonal antibody (e.g., 100 mg/50 ml, 200 mg/50 ml, 300 mg/50 ml, 400 mg/50 ml, or 500 mg/50 ml) in the form of a suspension in a single-use vial, which is then withdrawn and diluted in, for example, 0.9% Sodium Chloride Injection, USP.
- Injectable drug delivery systems also include suspensions, gels, microspheres and polymeric injectables, and can comprise excipients such as solubility-altering agents (e.g., ethanol, propylene glycol, and sucrose) and polymers (e.g., polycaprylactones and PLGAs).
- recombinant viral particles can be formulated using one or more routinely used pharmaceutically acceptable carriers.
- Such carriers are well known to those skilled in the art.
- injectable drug delivery systems include solutions containing salts (e.g., sodium chloride and sodium phosphate) and surfactants (e.g., a poloxamer).
- the injectable drug delivery system comprises an aqueous solution of sodium chloride (e.g., 180 mM), sodium phosphate (e.g., 10 mM), and a poloxamer (e.g., 0.001% Poloxamer 188).
- Injectable drug delivery systems also include suspensions, gels, microspheres and polymeric injectables, and can comprise excipients such as solubility-altering agents (e.g., ethanol, propylene glycol, and sucrose) and polymers (e.g., polycaprylactones and PLGAs).
- solubility-altering agents e.g., ethanol, propylene glycol, and sucrose
- polymers e.g., polycaprylactones and PLGAs.
- antibody includes, without limitation, (a) an immunoglobulin molecule comprising two heavy chains (i.e. , H chains, such as p, 5, y, a and s) and two light chains (i.e., L chains, such as A and K) and which recognizes an antigen; (b) polyclonal and monoclonal immunoglobulin molecules; (c) monovalent (e.g., Fab) and divalent fragments thereof, and (d) bispecific forms thereof.
- Immunoglobulin molecules may derive from any of the commonly known classes, including but not limited to IgA, secretory IgA, IgG and IgM.
- IgG subclasses are also well known to those in the art and include, but are not limited to, human lgG1 , lgG2, lgG3 and lgG4 (preferably, in this invention, lgG1 ).
- Antibodies can be both naturally occurring and non-naturally occurring.
- antibodies include chimeric antibodies, wholly synthetic antibodies, single chain antibodies (e.g., scFv), and fragments thereof.
- Antibodies may contain, for example, all or a portion of a constant region (e.g., an Fc region) and a variable region, or contain only a variable region (responsible for antigen binding).
- Antibodies may be human, humanized, chimeric, or nonhuman. Methods for designing and making human and humanized antibodies are well known (See, e.g., Chiu and Gilliland; Lafleur, et al.).
- Antibodies include, without limitation, the present monoclonal antibodies as defined herein.
- CDR1 shall mean complementarity-determining region 1 , which includes heavy chain CDR1 and light chain CDR1.
- CDR2 shall mean complementarity-determining region 2, which includes heavy chain CDR2 and light chain CDR2.
- CDR3 shall mean complementarity-determining region 3, which includes heavy chain CDR3 and light chain CDR3.
- effector function includes, without limitation, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement fixation.
- ADCC antibody-dependent cell-mediated cytotoxicity
- ADCP antibody-dependent cellular phagocytosis
- complement fixation includes, without limitation, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement fixation.
- the present monoclonal antibody binds to an hACE2 “epitope” comprising a given amino acid residue if, for example, that residue directly contacts (e.g., via a hydrogen bond) at least one amino acid residue in the antibody’s paratope.
- a subject who has been “exposed” to SARS-CoV-2 includes, for example, a subject who experienced a high-risk event (e.g., one in which he/she came into contact with the bodily fluids of an infected human subject, such as by inhaling droplets of virus-containing saliva or touching a virus-containing surface).
- this exposure occurs two weeks, one week, five days, four days, three days, two days, one day, six hours, two hours, one hour, or 30 minutes prior to receiving the subject prophylaxis.
- human angiotensin converting enzyme 2 also referred to herein as “hACE2”, shall mean (i) the protein having the amino acid sequence set forth in Figure 1 ; or (ii) a naturally occurring human variant thereof (e.g., the 121 T variant, the N33D variant, the D38E variant, and the K26R variant).
- hACE2 shall mean the protein having the amino acid sequence set forth in Figure 1 .
- a “human subject” can be of any age, gender, or state of co-morbidity.
- the subject is male, and in another, the subject is female.
- the subject is co-morbid (e.g., afflicted with diabetes, asthma, and/or heart disease).
- the subject is not co-morbid.
- the subject is younger than 60 years old.
- the subject is at least 60 years old, at least 65 years old, at least 70 years old, at least 75 years old, at least 80 years old, at least 85 years old, or at least 90 years old.
- human TMPRSS2 also referred to herein as “hTMPRSS2”, shall mean (i) the protein having the amino acid sequence set forth in Figure 2; or (ii) a naturally occurring human variant thereof.
- Human TMPRSS2 is also known in the art as epitheliasin, and as transmembrane protease, serine 2.
- hTMPRSS2 cleaves the SARS-CoV-2 S protein.
- hTMPRSS2 cleaves SARS-CoV-2 S protein at an “S1/S2” cleavage site (i.e., between amino acid residues R685 and S686) and an “S2”’ cleavage site (i.e., between amino acid residues R815 and S816). See, e.g., Coutard, et al.
- a subject is “infected” with a virus if the virus is present in the subject.
- Present in the subject includes, without limitation, present in at least some cells in the subject, and/or present in at least some extracellular fluid in the subject.
- the virus present in the subject ’s cells is replicating.
- a subject who is exposed to a virus may or may not become infected with it.
- Heavy chain modifications that “inhibit half antibody formation” in lgG4 are described, for example, in C. Dumet, et al. They include, without limitation, the following, with numbering according to the Ell Index: (i) S228P; (ii) the mutation combination S228P/R409K; and (iii) K447del and the mutation combination S228P/K447del.
- Related heavy chain modifications that solve the heavy chain-mispairing problem include, for example, the “knobs-into-holes” (kih) modifications described in M. Godar, et al., and WO/1996/027011.
- a “long serum half-life”, with respect to a monoclonal antibody, is a serum half-life of at least five days (preferably as measured in vivo in a human, but which may also be measured, for example, in mice, rats, rabbits, and monkeys (e.g., rhesus monkeys, cynamolgous macaques, and marmosets)).
- a monoclonal antibody has a long serum half-life if its half-life is at least 15 days, at least 20 days, at least 25 days, at least 30 days, at least 35 days, at least 40 days, at least 45 days, at least 50 days, at least 55 days, at least 60 days, at least 65 days, at least 70 days, at least 75 days, at least 80 days, at least 85 days, at least 90 days, at least 95 days, or at least 100 days.
- a monoclonal antibody has a long serum half-life if its half-life is from 15 days to 20 days, from 20 days to 25 days, from 25 days to 30 days, from 30 days to 35 days, from 35 days to 40 days, from 40 days to 45 days, from 45 days to 50 days, from 50 days to 55 days, from 55 days to 60 days, from 60 days to 65 days, from 65 days to 70 days, from 70 days to 75 days, from 75 days to 80 days, from 80 days to 85 days, from 85 days to 90 days, from 90 days to 95 days, from 95 days to 100 days, or over 100 days.
- IgG heavy chain modifications that increase half-life relative to corresponding wild-type IgG heavy chains (such as those that increase antibody binding to FcRn) are described in C. Dumet, et al. and G.J. Robbie, et al. They include, without limitation, the following, with numbering according to the Ell Index: (i) point mutations at position 252, 254, 256, 309, 311 , 433, 434, and/or 436, including the “YTE” mutation combination M252Y/S254T/T256E (U.S. Patent No.
- a monoclonal antibody having a “low effector function” includes, without limitation, (i) a monoclonal antibody that has no effector function (e.g., by virtue of having no Fc domain), and (ii) a monoclonal antibody that has a moiety (e.g., a modified Fc domain) possessing an effector function lower than that of a wild-type IgG 1 antibody.
- Monoclonal antibodies having a low effector function include, for example, a monoclonal lgG4 antibody (e.g., a monoclonal lgG4 antibody having heavy chains engineered to reduce effector function relative to wild-type lgG4 heavy chains).
- IgG 1 heavy chain modification that lowers effector function relative to wild-type lgG1 heavy chains
- L234A/L235A/P329G LALA-PG
- Another example of an IgG 1 heavy chain modification that lowers effector function relative to wild-type lgG1 heavy chains is the L234A/L235A (LALA) modification, with numbering according to the EU Index.
- LALA L234A/L235A
- Examples of lgG4 heavy chain modifications that lower effector function relative to wild-type lgG4 heavy chains are described in C. Dumet, et al.
- L235E (WO/1994/028027);
- L235A, F234A, and G237A (WO/1994/029351 and WO/1995/026403);
- D265A U.S. Patent No.
- Schlothauer, et al. and include, without limitation, S228P/L235E/P329G (SPLE P329G), with numbering according to the EU Index.
- SPLE P329G S228P/L235E/P329G
- IgG 1 heavy chain modifications that lower effector function relative to wild-type lgG1 heavy chains are described in I. Wilkinson, et al.
- L234S/L235T/G236R STR
- L234G/L235S/G236R GSR
- L234S/L235V/G236R SVR
- L234T/L235Q/G236R TQR
- L234T/L235T/G236R TRR
- the “normal function” of hACE2 includes, without limitation, at least one of the following: (i) the ability to convert angiotensin II to angiotensin-(1-7) (i.e., by enzymatically cleaving the C-terminal phenylalanine residue from angiotensin II to form angiotensin-(1-7)); (ii) the ability to cleave [des-Arg]-bradykinin (also known as [des- Arg 9 ]-bradykinin); (iii) the ability to hydrolyze A[3-43 to yield A[3-42; (iv) the ability to convert angiotensin I to angiotensin-(1-9); (v) the ability to cleave neurotensin; (vi) the ability to cleave kinetensin; (vii) the ability to cleave a synthetic MCA-based peptide; (viii) the ability to cleave apelin
- the normal function of hACE2 means (i) the ability to convert angiotensin II to angiotensin-(1-7); (ii) the ability to cleave [des-Arg]-bradykinin; (iii) the ability to hydrolyze A[3-43 to yield A[3-42; (iv) the ability to convert angiotensin I to angiotensin-(1-9); (v) the ability to cleave neurotensin; (vi) the ability to cleave kinetensin; (vii) the ability to cleave a synthetic MCA-based peptide; (viii) the ability to cleave apelin-13; and (ix) the ability to cleave dynorphin A 1-13.
- the normal function of hACE2 means the ability to convert angiotensin II to angiotensin-(1-7).
- hACE2 activity can be measured using angiotensin II as a substrate to yield angiotensin-(1-7) according to known methods using known reagents, as described in the examples below.
- hACE2 activity can also be measured using a synthetic MCA-based peptide (e.g., a Mc-Ala/Dnp fluorescence resonance energy transfer (FRET) peptide that yields Mc-Ala upon cleavage by hACE2) according to known methods using known reagents, as described in the examples below.
- FRET fluorescence resonance energy transfer
- a “prophylactically effective amount” of the present monoclonal antibodies includes, without limitation, (i) 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, 1 g, 2 g, 3 g, 4 g, 5 g, 6 g, 7 g, 8 g, 9 g, or 10 g; (ii) 5 mg to 20 mg, 20 mg to 50 mg, 50 mg to 100 mg, 100 mg to 200 mg, 200 mg to 300 mg, 300 mg to 400 mg, 400 mg to 500 mg, 500 mg to 1 g, 1 g to 2 g, 2 g to 5 g, or 5 g to 10 g; (iii) 1 mg/kg, 2 mg/kg, 3 mg/kg,
- the prophylactically effective amount of monoclonal antibodies is administered as a single, one-time-only dose.
- the prophylactically effective amount of monoclonal antibodies is administered as two or more doses over a period of days, weeks, or months (e.g., twice daily for one or two weeks; once daily for one or two weeks; every other day for two weeks; three times per week for two weeks; twice per week for two weeks; once per week for two weeks; twice with the administrations separated by two weeks; once per month; once every two months; once every three months; once every four months; twice per year; or once per year).
- a “prophylactically effective amount” of the present recombinant viral particles includes, without limitation, (i) from 1 x 10 10 to 5 x 10 10 particles (also referred to as “viral genomes” or “vg”) per kg of body weight, from 5 x 10 10 to 1 x 10 11 particles I kg, from 1 x 10 11 to 5 x 10 11 particles I kg, from 5 x 10 11 to 1 x 10 12 particles I kg, from 1 x 10 12 to 5 x 10 12 particles I kg, from 5 x 10 12 to 1 x 10 13 particles I kg, from 1 x 10 13 to 5 x 10 13 particles I kg, or from 5 x 10 13 to 1 x 10 14 particles I kg; or (ii) 1 x 10 1 ° particles / kg, 5 x 10 1 ° particles / kg, 1 x 10 11 particles I kg,
- the prophylactically effective amount of viral particles is administered as a single, one-time-only dose. In another embodiment, the prophylactically effective amount of viral particles is administered as two or more doses over a period of months or years.
- a “recombinant AAV (adeno-associated virus) particle”, also referred to as “rAAV particle”, includes, without limitation, an AAV capsid protein (e.g., VP1 , VP2 and/or VP3) and a vector comprising a nucleic acid encoding an exogenous protein (e.g., an antibody heavy chain) situated between a pair of AAV inverted terminal repeats in a manner permitting the AAV particle to infect a target cell.
- the recombinant AAV particle is incapable of replication within its target cell.
- the AAV serotype may be any AAV serotype suitable for use in gene therapy, such as AAV1 , AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAVrhIO, AAV11 , AAV12, LK01 , LK02 or LK03.
- reducing the likelihood” of a human subject’s becoming infected with a virus includes, without limitation, reducing such likelihood by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 99%.
- reducing the likelihood of a human subject’s becoming infected with a virus means preventing the subject from becoming infected with it.
- reducing the likelihood” of a human subject’s becoming symptomatic of a viral infection includes, without limitation, reducing such likelihood by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 99%.
- reducing the likelihood of a human subject’s becoming symptomatic of a viral infection means preventing the subject from becoming symptomatic.
- “Reducing the likelihood” of a human subject’s developing long COVID includes, without limitation, reducing such likelihood by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 99%.
- SARS-CoV-2 includes, without limitation, the following variants: Wuhan-1 ; F338L; A348T; N354D; N354K; V367F; R408I; Q409E; Q414E; G446V; L452R; K458N; K458R; I468T; A475V; T478I; V483A; V483I; E484K; N501Y; Y508H; H519P; H519Q; A520S; V615L; P1263L; D614G+69-70del; D614G+A262S; D614G+V341 I; D614G+Q321 L; D614G+K417N; D614G+N439K; D614G+Y453F; D614G+S477N; D614G+F486L; Delta; Omicron [B.1.1.529]
- a monoclonal antibody does not “significantly inhibit the ability of hACE2 to cleave” a substrate if (i) it inhibits the ability of intact hACE2 (i.e. , full-length hACE2 that includes the extracellular portion, transmembrane portion, and intracellular portion) to cleave the substrate by less than 90%, and/or (ii) it inhibits the ability of the extracellular portion of hACE2 (e.g., recombinant soluble hACE2) to cleave the substrate by less than 90%.
- a monoclonal antibody does not significantly inhibit the ability of hACE2 to cleave a substrate if it inhibits the ability of intact hACE2 to cleave the substrate by less than 90%. In another embodiment, a monoclonal antibody does not significantly inhibit the ability of hACE2 to cleave a substrate if it inhibits the ability of the extracellular portion of hACE2 to cleave the substrate by less than 90%.
- a monoclonal antibody does not significantly inhibit the ability of hACE2 (i.e., intact hACE2 and/or its extracellular portion) to cleave a substrate if it inhibits that ability by less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, or less than 1 %.
- a monoclonal antibody does not significantly inhibit the ability of hACE2 (i.e., intact hACE2 and/or its extracellular portion) to cleave angiotensin II if it inhibits that ability by less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, or less than 1 %.
- a monoclonal antibody does not significantly inhibit the ability of hACE2 (i.e., intact hACE2 and/or its extracellular portion) to cleave des-Arg-bradykinin if it inhibits that ability by less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, or less than 1%.
- a monoclonal antibody does not significantly inhibit the ability of hACE2 (i.e., intact hACE2 and/or its extracellular portion) to cleave neurotensin if it inhibits that ability by less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, or less than 1 %.
- a monoclonal antibody does not significantly inhibit the ability of hACE2 (i.e., intact hACE2 and/or its extracellular portion) to cleave kinetensin if it inhibits that ability by less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, or less than 1 %.
- a monoclonal antibody does not significantly inhibit the ability of hACE2 (i.e., intact hACE2 and/or its extracellular portion) to cleave kinetensin if it inhibits that ability by less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, or less than 1 %.
- a monoclonal antibody does not significantly inhibit the ability of hACE2 (i.e.
- a synthetic MCA-based peptide preferably Mca-APK(Dnp)
- a synthetic MCA-based peptide preferably Mca-APK(Dnp)
- a monoclonal antibody does not significantly inhibit the ability of hACE2 (i.e., intact hACE2 and/or its extracellular portion) to cleave apelin-13 if it inhibits that ability by less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, or less than 1 %.
- a monoclonal antibody does not significantly inhibit the ability of hACE2 (i.e., intact hACE2 and/or its extracellular portion) to cleave dynorphin A 1-13 if it inhibits that ability by less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, or less than 1 %.
- a monoclonal antibody “specifically binds” to the extracellular portion of hACE2 if it does at least one of the following: (i) binds to the extracellular portion of hACE2 with an affinity greater than that with which it binds to any other human cell surface protein; or (ii) binds to the extracellular portion of hACE2 with an affinity of at least 500 pM.
- a monoclonal antibody specifically binds to the extracellular portion of hACE2 if it performs both of items (i) and (ii) above.
- the monoclonal antibody binds to hACE2 (i.e., to its extracellular portion) with an affinity of at least 100 pM, at least 10 pM, at least 1 pM, at least 500 nM, at least 300 nM, at least 200 nM, at least 100 nM, at least 50 nM, at least 20 nM, at least 10 nM, at least 5 nM, at least 1 nM, at least 0.5 nM, at least 0.1 nM, at least 0.05 nM, or at least 0.01 nM.
- the present monoclonal antibody binds to hACE2 with an affinity greater than that with which SARS-CoV-2 RBD binds to hACE2.
- a monoclonal antibody “specifically inhibits” binding of SARS-CoV-2 to the extracellular portion of hACE2 if it does at least one of the following: (i) reduces such binding more than it reduces the binding of SARS-CoV-2 to any other human cell surface protein; or (ii) reduces such binding by a factor of at least two.
- a monoclonal antibody specifically inhibits binding of SARS-CoV-2 to the extracellular portion of hACE2 if it performs both of items (i) and (ii) above.
- the monoclonal antibody reduces binding of SARS-CoV-2 to the extracellular portion of hACE2 by a factor of at least 10, at least 20, at least 50, at least 100, at least 1 ,000, at least 10,000, at least 100,000, or at least 1 ,000,000.
- a monoclonal antibody “specifically inhibits” binding of the SARS-CoV- 2 S1 protein receptor binding domain fragment, also referred to as the RBD (e.g., the protein consisting of S amino acid residues 331 to 524) to the extracellular portion of hACE2 if it does at least one of the following: (i) reduces such binding more than it reduces the binding of SARS-CoV-2 S1 protein receptor binding domain fragment to any other human cell surface protein; or (ii) reduces such binding by a factor of at least two.
- the RBD e.g., the protein consisting of S amino acid residues 331 to 524
- a monoclonal antibody specifically inhibits binding of SARS-CoV-2 S1 protein receptor binding domain fragment to the extracellular portion of hACE2 if it performs both of items (i) and (ii) above.
- the monoclonal antibody reduces binding of SARS-CoV-2 S1 protein receptor binding domain fragment to the extracellular portion of hACE2 by a factor of at least 10, at least 20, at least 50, at least 100, at least 1 ,000, at least 10,000, at least 100,000, or at least 1 ,000,000.
- a monoclonal antibody “specifically inhibits” the entry of SARS-CoV-2 into hACE27hTMPRSS2 + human cells if it does at least one of the following: (i) reduces such entry more than it reduces the entry of SARS-CoV-2 into hACE27hTMPRSS2 _ human cells; or (ii) reduces such entry by a factor of at least two.
- a monoclonal antibody specifically inhibits the entry of SARS-CoV-2 into hACE27hTMPRSS2 + human cells if it performs both of items (i) and (ii) above.
- the monoclonal antibody reduces the entry of SARS-CoV-2 into hACE27hTMPRSS2 + human cells by a factor of at least 10, at least 20, at least 50, at least 100, at least 1 ,000, at least 10,000, at least 100,000, or at least 1 ,000,000.
- a monoclonal antibody “specifically inhibits” the entry into hACE27hTMPRSS2 + human cells of a pseudovirus (e.g., a replication-defective SARS- CoV-2 pseudovirus) bearing SARS-CoV-2 S protein if it does at least one of the following: (i) reduces such entry more than it reduces the entry into hACE2 _ /hTMPRSS2 _ human cells of a pseudovirus bearing SARS-CoV-2 S protein; or (ii) reduces such entry by a factor of at least two.
- a pseudovirus e.g., a replication-defective SARS- CoV-2 pseudovirus
- a monoclonal antibody specifically inhibits the entry into hACE27hTMPRSS2 + human cells of a pseudovirus bearing SARS-CoV-2 S protein if it performs both of items (i) and (ii) above.
- the monoclonal antibody reduces the entry into hACE27hTMPRSS2 + human cells of a pseudovirus bearing SARS-CoV-2 S protein by a factor of at least 10, at least 20, at least 50, at least 100, at least 1 ,000, at least 10,000, at least 100,000, or at least 1 ,000,000.
- the term “subject” includes, without limitation, a mammal such as a human, a non-human primate, a dog, a cat, a horse, a sheep, a goat, a cow, a rabbit, a pig, a hamster, a rat and a mouse.
- a mammal such as a human, a non-human primate, a dog, a cat, a horse, a sheep, a goat, a cow, a rabbit, a pig, a hamster, a rat and a mouse.
- the present methods are envisioned for these non- human embodiments, mutatis mutandis, as they are for human subjects in this invention.
- a human subject is “symptomatic” of a SARS-CoV-2 infection if the subject shows one or more symptoms known to appear in a SARS-CoV-2-infected human subject after a suitable incubation period.
- symptoms include, without limitation, detectable SARS-CoV-2 in the subject, and those symptoms shown by patients afflicted with COVID-19.
- COVID-19-related symptoms include, without limitation, fever, cough, shortness of breath, persistent pain or pressure in the chest, new confusion or inability to arouse, and/or bluish lips or face.
- Such symptoms also include, without limitation, those symptoms shown by patients afflicted with “long COVID”, also known as long COVID-19, post-COVID-19 syndrome, post- COVID conditions, long-haul COVID-19, and post acute sequelae of SARS COV-2 infection (PASC).
- Long COVID involves a variety of new, returning, or ongoing symptoms that patients experience more than four weeks after getting COVID-19. In some patients, long COVID lasts months or years or causes disability. Symptoms of long COVID include fatigue, symptoms that get worse after physical or mental effort, fever, and respiratory symptoms (e.g., difficulty breathing or shortness of breath and cough).
- a “synthetic MCA-based peptide” is a peptide having affixed at one end an MCA (i.e. , (7-methoxycoumarin-4-yl)acetyl) moiety and having affixed at the other end a fluorescence-quenching moiety (e.g., 2,4-dinitrophenyl, which is also referred to as DNP or Dnp).
- MCA i.e. , (7-methoxycoumarin-4-yl)acetyl
- a fluorescence-quenching moiety e.g., 2,4-dinitrophenyl, which is also referred to as DNP or Dnp.
- synthetic MCA-based peptides cleavable by hACE2 can serve as substrates permitting facile fluorescence- based measurement of hACE2 activity and its inhibition.
- the synthetic MCA-based peptide comprises the consensus sequence Pro-X ⁇ i -3 residues)- ProHydrophobic Residue (e.g., MCA-Pro-X ⁇ i -3 residues)- Pro-Hydrophobic Residue-DNP), whereby hACE2 cleaves between the proline and the hydrophobic residue.
- the synthetic MCA-based peptide is MCA-YVADAPK-DNP (also referred to as Mca-YVADAPK(Dnp)).
- the synthetic MCA-based peptide is MCA-APK-DNP (also referred to as Mca-APK(Dnp)).
- the synthetic MCA-based peptide is the Mc-Ala/Dnp fluorescence resonance energy transfer (FRET) peptide used in the SensoLyte® 390 ACE2 Activity Assay Kit *Fluorimetric* (Anaspec) described below.
- the synthetic MCA-based peptide is the ACE2 Substrate used in the Angiotensin II Converting Enzyme (ACE2) Activity Assay Kit (Fluorometric) (BioVision) described below.
- a “therapeutically effective amount” of the present monoclonal antibodies includes, without limitation, (i) 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, 1 g, 2 g, 3 g, 4 g, 5 g, 6 g, 7 g, 8 g, 9 g, or 10 g; (ii) 5 mg to 20 mg, 20 mg to 50 mg, 50 mg to 100 mg, 100 mg to 200 mg, 200 mg to 300 mg, 300 mg to 400 mg, 400 mg to 500 mg, 500 mg to 1 g, 1 g to 2 g, 2 g to 5 g, or 5 g to 10 g; (iii) 1 mg/kg, 2 mg/kg, 3 mg/kg, 4 mg/kg
- the therapeutically effective amount of monoclonal antibodies is administered as a single, one-time-only dose.
- the therapeutically effective amount of monoclonal antibodies is administered as two or more doses over a period of days, weeks, or months (e.g., twice daily for one or two weeks; once daily for one or two weeks; every other day for two weeks; three times per week for two weeks; twice per week for two weeks; once per week for two weeks; twice with the administrations separated by two weeks; once per month; once every two months; once every three months; once every four months; twice per year; or once per year).
- a “therapeutically effective amount” of the subject recombinant viral particles includes, without limitation, (i) from 1 x 1O 10 to 5 x 1O 10 particles (also referred to as “viral genomes” or “vg”) per kg of body weight, from 5 x 1O 10 to 1 x 10 11 particles I kg, from 1 x 10 11 to 5 x 10 11 particles I kg, from 5 x 10 11 to 1 x 10 12 particles I kg, from 1 x 10 12 to 5 x 10 12 particles I kg, from 5 x 10 12 to 1 x 10 13 particles I kg, from 1 x 10 13 to 5 x 10 13 particles I kg, or from 5 x 10 13 to 1 x 10 14 particles I kg; or (ii) 1 x 10 10 particles / kg, 5 x 10 10 particles / kg, 1 x 10 11 particles I kg, 5 x 10 11 particles / kg, 1 x 10 12 particles / kg, 5 x
- treating includes, without limitation, (i) slowing, stopping, or reversing the progression of one or more of the disorder’s symptoms, (ii) slowing, stopping or reversing the progression of the disorder underlying such symptoms, (iii) reducing or eliminating the likelihood of the symptoms’ recurrence, and/or (iv) slowing the progression of, lowering or eliminating the disorder.
- treating a subject afflicted with a disorder includes (i) reversing the progression of one or more of the disorder’s symptoms, (ii) reversing the progression of the disorder underlying such symptoms, (iii) preventing the symptoms’ recurrence, and/or (iv) eliminating the disorder.
- “treating” the subject also includes, without limitation, reducing the likelihood of the subject’s becoming symptomatic of the infection, and preferably, preventing the subject from becoming symptomatic of the infection.
- “treating” the subject also includes, without limitation, reducing the likelihood of the subject’s developing long COVID, and preferably, preventing the subject from developing long COVID.
- “treating” the subject also includes, without limitation, eliminating the symptoms of long COVID.
- This invention provides certain anti-hACE2 monoclonal antibodies. It also provides recombinant viral particles (preferably recombinant AAV particles) that, when introduced into a subject, cause the long-term expression of those antibodies. These antibodies and viral particles permit prophylaxis and therapy for SARS-CoV-2 infection.
- the recently published reference of Du, et al. provides in vivo evidence that an anti- hACE2 monoclonal antibody can be used to prevent and treat SARS-CoV-2 infection.
- the present recombinant viruses can be any ones suitable for viral-mediated gene therapy including, without limitation, AAV, adenovirus, alphavirus, herpesvirus, retrovirus/lentivirus, or vaccinia virus.
- this invention provides a monoclonal antibody that (i) specifically binds to the extracellular portion of human angiotensin converting enzyme 2 (hACE2); (ii) specifically inhibits binding of SARS-CoV-2 to the extracellular portion of hACE2 (e.g., binding via the SARS-CoV-2 S1 protein receptor binding domain); and (iii) does not significantly inhibit the ability of hACE2 to cleave angiotensin II and/or a synthetic MCA- based peptide.
- hACE2 human angiotensin converting enzyme 2
- This invention also provides a monoclonal antibody that (i) specifically binds to the extracellular portion of human angiotensin converting enzyme 2 (hACE2); (ii) specifically inhibits binding of SARS-CoV-2 to the extracellular portion of hACE2 (e.g., via the SARS-CoV-2 S1 protein receptor binding domain); (iii) specifically inhibits binding of the SARS-CoV-2 S1 protein receptor binding domain fragment (e.g., the protein consisting of S amino acid residues 331 to 524) to the extracellular portion of hACE2; (iv) specifically inhibits the entry of SARS-CoV-2 into hACE2 + /hTMPRSS2 + human cells; (v) specifically inhibits the entry into hACE27hTMPRSS2 + human cells of a pseudovirus (e.g., a replication-defective SARS-CoV-2 pseudovirus) bearing SARS- CoV-2 S protein; and (vi) does not significantly inhibit the ability of hACE2 to cleave an
- This invention further provides a monoclonal antibody that (i) specifically binds to the extracellular portion of human angiotensin converting enzyme 2 (hACE2); (ii) specifically inhibits binding of SARS-CoV-2 to the extracellular portion of hACE2 (e.g., via the SARS-CoV-2 S1 protein receptor binding domain); (iii) specifically inhibits binding of the SARS-CoV-2 S1 protein receptor binding domain fragment (e.g., the protein consisting of S amino acid residues 331 to 524) to the extracellular portion of hACE2; (iv) specifically inhibits the entry of SARS-CoV-2 into hACE2 + /hTMPRSS2 + human cells; and (v) does not significantly inhibit the ability of hACE2 to cleave angiotensin II and/or a synthetic MCA-based peptide.
- hACE2 human angiotensin converting enzyme 2
- This invention still further provides a monoclonal antibody that (i) specifically binds to the extracellular portion of human angiotensin converting enzyme 2 (hACE2); (ii) specifically inhibits binding of SARS-CoV-2 to the extracellular portion of hACE2 (e.g., via the SARS-CoV-2 S1 protein receptor binding domain); (iii) specifically inhibits binding of the SARS-CoV-2 S1 protein receptor binding domain fragment (e.g., the protein consisting of S amino acid residues 331 to 524) to the extracellular portion of hACE2; (iv) specifically inhibits the entry into hACE27hTMPRSS2 + human cells of a pseudovirus (e.g., a replication-defective SARS-CoV-2 pseudovirus) bearing SARS- CoV-2 S protein; and (v) does not significantly inhibit the ability of hACE2 to cleave angiotensin II and/or a synthetic MCA-based peptide.
- hACE2 human angiotensin
- This invention also provides a monoclonal antibody that (i) specifically binds to the extracellular portion of human angiotensin converting enzyme 2 (hACE2); (ii) specifically inhibits binding of SARS-CoV-2 to the extracellular portion of hACE2 (e.g., via the SARS-CoV-2 S1 protein receptor binding domain); (iii) specifically inhibits the entry of SARS-CoV-2 into hACE27hTMPRSS2 + human cells; and (iv) does not significantly inhibit the ability of hACE2 to cleave angiotensin II and/or a synthetic MCA- based peptide.
- hACE2 human angiotensin converting enzyme 2
- This invention further provides a monoclonal antibody that (i) specifically binds to the extracellular portion of human angiotensin converting enzyme 2 (hACE2); (ii) specifically inhibits binding of the SARS-CoV-2 S1 protein receptor binding domain fragment (e.g., the protein consisting of S amino acid residues 331 to 524) to the extracellular portion of hACE2; (iii) specifically inhibits the entry into hACE27hTMPRSS2 + human cells of a pseudovirus (e.g., a replication-defective SARS- CoV-2 pseudovirus) bearing SARS-CoV-2 S protein; and (iv) does not significantly inhibit the ability of hACE2 to cleave angiotensin II and/or a synthetic MCA-based peptide.
- hACE2 human angiotensin converting enzyme 2
- SARS-CoV-2 pseudoviruses and methods of making and using them are known, as are SARS-CoV-2 S1 protein receptor binding domain (RBD) fragments. See, e.g., Shang, et al., and Hoffman, et al. (Cell 2020).
- RBD protein receptor binding domain
- the present monoclonal antibody does not significantly inhibit the ability of hACE2 to cleave angiotensin II (i.e. , to convert angiotensin II to angiotensin-(1-7).
- This inhibition can be measured according to the methods in the examples section below.
- a specific example of this embodiment of the invention is a monoclonal antibody that (i) binds to the extracellular portion of hACE2 with an affinity of 50 nM; (ii) reduces binding of SARS-CoV-2 to the extracellular portion of hACE2 by a factor of 100,000; and (iii) inhibits by 20% the ability of hACE2 to cleave angiotensin II.
- the present monoclonal antibody does not significantly inhibit the ability of hACE2 to cleave des-Arg-bradykinin.
- This inhibition can be measured according to the methods in the examples section below.
- a specific example of this embodiment of the invention is a monoclonal antibody that (i) binds to the extracellular portion of hACE2 with an affinity of 50 nM; (ii) reduces binding of SARS-CoV-2 to the extracellular portion of hACE2 by a factor of 100,000; and (iii) inhibits by 20% the ability of hACE2 to cleave des-Arg-bradykinin.
- the present monoclonal antibody does not significantly inhibit the ability of hACE2 to cleave neurotensin. This inhibition can be measured according to the methods in the examples section below.
- a specific example of this embodiment of the invention is a monoclonal antibody that (i) binds to the extracellular portion of hACE2 with an affinity of 50 nM; (ii) reduces binding of SARS-CoV-2 to the extracellular portion of hACE2 by a factor of 100,000; and (iii) inhibits by 20% the ability of hACE2 to cleave neurotensin.
- the present monoclonal antibody does not significantly inhibit the ability of hACE2 to cleave kinetensin. This inhibition can be measured according to the methods in the examples section below.
- a specific example of this embodiment of the invention is a monoclonal antibody that (i) binds to the extracellular portion of hACE2 with an affinity of 50 nM; (ii) reduces binding of SARS-CoV-2 to the extracellular portion of hACE2 by a factor of 100,000; and (iii) inhibits by 20% the ability of hACE2 to cleave kinetensin.
- the present monoclonal antibody does not significantly inhibit the ability of hACE2 to cleave a synthetic MCA-based peptide.
- This inhibition can be measured according to the methods in the examples section below.
- a specific example of this embodiment of the invention is a monoclonal antibody that (i) binds to the extracellular portion of hACE2 with an affinity of 50 nM; (ii) reduces binding of SARS- CoV-2 to the extracellular portion of hACE2 by a factor of 100,000; and (iii) inhibits by 20% the ability of hACE2 to cleave a synthetic MCA-based peptide (preferably Mca- APK(Dnp), which is also referred to as Mac-APK-Dnp).
- these peptides can be used to measure the inhibition of hACE2 carboxypeptidase activity.
- the present monoclonal antibody does not significantly inhibit the ability of hACE2 to cleave apelin-13.
- This inhibition can be measured according to the methods in the examples section below.
- a specific example of this embodiment of the invention is a monoclonal antibody that (i) binds to the extracellular portion of hACE2 with an affinity of 50 nM; (ii) reduces binding of SARS-CoV-2 to the extracellular portion of hACE2 by a factor of 100,000; and (iii) inhibits by 20% the ability of hACE2 to cleave apelin-13.
- the present monoclonal antibody does not significantly inhibit the ability of hACE2 to cleave dynorphin A 1-13.
- This inhibition can be measured according to the methods in the examples section below.
- a specific example of this embodiment of the invention is a monoclonal antibody that (i) binds to the extracellular portion of hACE2 with an affinity of 50 nM; (ii) reduces binding of SARS-CoV-2 to the extracellular portion of hACE2 by a factor of 100,000; and (iii) inhibits by 20% the ability of hACE2 to cleave dynorphin A 1-13.
- the present monoclonal antibody binds to an epitope that does not include hACE2 amino acid residues required for normal function. So, in one embodiment, the present monoclonal antibody does not specifically bind to an epitope on hACE2 comprising an amino acid residue selected from the group consisting of Arg273, His345, Pro346, His374, Glu375, His378, Glu402, His505, and Tyr515.
- the following embodiments are exemplary, (i) The present monoclonal antibody does not specifically bind to an epitope on hACE2 comprising Arg273. (ii) The present monoclonal antibody does not specifically bind to an epitope on hACE2 comprising His345.
- the present monoclonal antibody does not specifically bind to an epitope on hACE2 comprising Pro346.
- the present monoclonal antibody does not specifically bind to an epitope on hACE2 comprising His374.
- the present monoclonal antibody does not specifically bind to an epitope on hACE2 comprising Glu375.
- the present monoclonal antibody does not specifically bind to an epitope on hACE2 comprising His378.
- the present monoclonal antibody does not specifically bind to an epitope on hACE2 comprising Glu402.
- the present monoclonal antibody does not specifically bind to an epitope on hACE2 comprising His505.
- the present monoclonal antibody does not specifically bind to an epitope on hACE2 comprising Tyr515.
- the present monoclonal antibody does not specifically bind to an epitope on hACE2 comprising an amino acid residue selected from the group consisting of residues 290 to 397 and residues 417 to 430.
- the following embodiments are exemplary, (i) The present monoclonal antibody does not specifically bind to an epitope on hACE2 comprising an amino acid residue within residues 290 to 397. (ii) The present monoclonal antibody does not specifically bind to an epitope on hACE2 comprising an amino acid residue within residues 417 to 430.
- the present monoclonal antibody does not specifically bind to an epitope on hACE2 comprising an amino acid residue selected from the group consisting of residues 103 to 289, residues 398 to 416, and residues 431 to 615.
- the following embodiments are exemplary, (i) The present monoclonal antibody does not specifically bind to an epitope on hACE2 comprising an amino acid residue within residues 103 to 289. (ii) The present monoclonal antibody does not specifically bind to an epitope on hACE2 comprising an amino acid residue within residues 398 to 416. (iii) The present monoclonal antibody does not specifically bind to an epitope on hACE2 comprising an amino acid residue within residues 431 to 615.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue selected from the group consisting of residues 1-18, residues 417-430, and residues 616-740.
- the following embodiments are exemplary, (i) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 1-5. (ii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 5-10. (iii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 10-15.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 15-18.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 417-420.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 420-425.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 425-430.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 616-620.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 620-625.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 625-630.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 630-635.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 635-640.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 640-645.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 645-650.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 650-655.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 655-660.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 660-665.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 665-670.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 670-675.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 675-680.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 680-685.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 685-690.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 690-695.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 695-700.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 700-705.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 705-710.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 710-715.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 715-720.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 720-725.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 725-730.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 730-735.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 735-740.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue selected from the group consisting of residues 19-416.
- the following embodiments are exemplary, (i) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 19-25. (ii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 26-30. (iii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 31-35.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 36-40.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 41-45.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 46-50.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 51-55.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 56-60.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 61-65.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 66-70.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 71-75.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 76-80.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 81-85.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 86-90.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 91-95.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 96-100.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 101-105.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 106-110.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 111-115.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 116-120.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 121-125.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 126-130.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 131-135.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 136-140.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 141-145.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 146-150.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 151-155.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 156-160.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 161-165.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 166-170.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 171-175.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 176-180.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 181-185.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 186-190.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 191-195.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 196-200.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 201-205.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 206-210.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 211-215.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 216-220.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 221-225.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 226-230.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 231-235.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 236-240.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 241-245.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 246-250.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 251-255.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 256-260.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 261-265.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 266-270.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 271-275.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 276- 280.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 281-285.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 286-290.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 291- 295.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 296-300.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 301-305.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 306-310.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 311-315.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 316-320.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 321-325.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 326-330.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 331-335.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 336-340.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 341-345.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 346-350.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 351-355.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 356-360.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 361-365.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 366-370.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 371-375.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 376-380.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 381-385.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 386-390.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 391-395.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 396-400.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 401-405.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 406-410.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 411-416.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue selected from the group consisting of residues 431-615.
- the following embodiments are exemplary, (i) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 431-435. (ii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 436- 440. (iii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 441-445.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 446-450.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 451- 455.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 456-460.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 461-465.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 466-470.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 471-475.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 476-480.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 481-485.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 486-490.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 491-495.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 496-500.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 501-505.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 506-510.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 511-515.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 516-520.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 521-525.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 526-530.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 531-535.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 536-540.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 541-545.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 546-550.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 551-555.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 556-560.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 561-565.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 566-570.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 571-575.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 576-580.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 581-585.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 586-590.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 591-595.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 596-600.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 601-605.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 606-610.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 611-615.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue selected from the group consisting of Ser19, Gln24, Ala25, Thr27, Phe28, Lys31 , His34, Glu35, Glu37, Asp38, Tyr41 , Gln42, Leu45, Leu79, Met82, Tyr83, Gln325, Glu329, Asn330, Lys353, Gly354, Asp355, and Arg357.
- the following embodiments are exemplary, (i) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Seri 9.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Gln24.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Ala25.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Thr27.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Phe28.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Lys31 .
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue His34.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Glu35.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Glu37.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Asp38.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Tyr41 .
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Gln42.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Leu45.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Leu79.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Met82.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Tyr83.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Gln325.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Glu329.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Asn330.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Lys353.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Gly354.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Asp355.
- the present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Arg357. In a preferred embodiment, the present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Lys31 . In another preferred embodiment, the present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Lys353. In yet another preferred embodiment, the present monoclonal antibody specifically binds to an epitope on hACE2 comprising the amino acid residues Gln24, Ala25, Thr27, Phe28, Lys31 , Leu79, Met82, and Tyr83.
- the present monoclonal antibody comprises the heavy and light chain variable regions identified, respectively, as humanized 11 B11 VH and humanized 11 B11 VK, and set forth in Figure 5 below (taken from Supplementary Figure 2 of Du, et al.).
- variable regions include heavy chain CDR1 (GFTFIDYYMN), CDR2 (FIRNKANDYTTEYST), and CDR3 (RHMYDDGFDF), and light chain CDR1 (ASSSVRYMH), CDR2 (LLIYDTSKLA), and CDR3 (QQWSYNPLTF).
- the present monoclonal antibody comprises the heavy chain CDR1 having the amino acid sequence GFTFIDYYMN.
- the present monoclonal antibody comprises the heavy chain CDR2 having the amino acid sequence FIRNKANDYTTEYST. In another preferred embodiment, the present monoclonal antibody comprises the heavy chain CDR3 having the amino acid sequence RHMYDDGFDF. In another preferred embodiment, the present monoclonal antibody comprises the light chain CDR1 having the amino acid sequence ASSSVRYMH. In another preferred embodiment, the present monoclonal antibody comprises the light chain CDR2 having the amino acid sequence LLIYDTSKLA. In another preferred embodiment, the present monoclonal antibody comprises the light chain CDR3 having the amino acid sequence QQWSYNPLTF.
- the present monoclonal antibody comprises the heavy chain CDR1 having the amino acid sequence GFTFIDYYMN, the heavy chain CDR2 having the amino acid sequence FIRNKANDYTTEYST, the heavy chain CDR3 having the amino acid sequence RHMYDDGFDF, the light chain CDR1 having the amino acid sequence ASSSVRYMH, the light chain CDR2 having the amino acid sequence LLIYDTSKLA, and the light chain CDR3 having the amino acid sequence QQWSYNPLTF.
- the present monoclonal antibody comprises a point mutant of the heavy chain CDR1 .
- the present monoclonal antibody comprises a point mutant of the heavy chain CDR2.
- the present monoclonal antibody comprises a point mutant of the heavy chain CDR3.
- the present monoclonal antibody comprises a point mutant of the light chain CDR1 .
- the present monoclonal antibody comprises a point mutant of the light chain CDR2.
- the present monoclonal antibody comprises a point mutant of the light chain CDR3.
- the present monoclonal antibody comprises a heavy chain CDR3 comprising an amino acid sequence selected from the group consisting of (i) CAKDRGYSSSWYGGFDYW; (ii) CARHTWWKGAGFFDHW; (iii) CARGTRFLEWSLPLDVW; (iv) CATTENPNPRW; (v) CATTEDPYPRW; (vi) CARASPNTGWHFDHW; (vii) CATTMNPNPRW; (viii) CAAIAYEEGVYR-WDW; and (ix) RHMYDDGFDF.
- a heavy chain CDR3 comprising an amino acid sequence selected from the group consisting of (i) CAKDRGYSSSWYGGFDYW; (ii) CARHTWWKGAGFFDHW; (iii) CARGTRFLEWSLPLDVW; (iv) CATTENPNPRW; (v) CATTEDPYPRW; (vi) CARASPNTGWHFDHW; (vii) CAT
- the present monoclonal antibody comprises a heavy chain CDR3 comprising the amino acid sequence CAKDRGYSSSWYGGFDYW.
- the present monoclonal antibody comprises a heavy chain CDR3 comprising the amino acid sequence CARHTWWKGAGF-FDHW.
- the present monoclonal antibody comprises a heavy chain CDR3 comprising the amino acid sequence CARGTRFLEWSLPLDVW.
- the present monoclonal antibody comprises a heavy chain CDR3 comprising the amino acid sequence CATTENPNPRW.
- the present monoclonal antibody comprises a heavy chain CDR3 comprising the amino acid sequence CATTEDP-YPRW.
- the present monoclonal antibody comprises a heavy chain CDR3 comprising the amino acid sequence CARASPNTGWHFDHW.
- the present monoclonal antibody comprises a heavy chain CDR3 comprising the amino acid sequence CATTMNPNPRW.
- the present monoclonal antibody comprises a heavy chain CDR3 comprising the amino acid sequence CAAIAYEEGVYRWDW.
- the present monoclonal antibody comprises one or more of (i) a heavy chain CDR1 comprising the amino acid sequence GFTFIDYYMN; (ii) a heavy chain CDR2 comprising the amino acid sequence FIRNKANDYTTEYST; (iii) a heavy chain CDR3 comprising the amino acid sequence RHMYDDGFDF; (iv) a light chain CDR1 comprising the amino acid sequence ASSSVRYMH; (v) a light chain CDR2 comprising the amino acid sequence LLIYDTSKLA; and (vi) a light chain CDR3 comprising the amino acid sequence QQWSYNPLTF.
- the present monoclonal antibody comprises (i) a heavy chain CDR1 comprising the amino acid sequence GFTFIDYYMN; (ii) a heavy chain CDR2 comprising the amino acid sequence FIRNKANDYTTEYST; (iii) a heavy chain CDR3 comprising the amino acid sequence RHMYDDGFDF; (iv) a light chain CDR1 comprising the amino acid sequence ASSSVRYMH; (v) a light chain CDR2 comprising the amino acid sequence LLIYDTSKLA; and (vi) a light chain CDR3 comprising the amino acid sequence QQWSYNPLTF.
- a heavy chain CDR1 comprising the amino acid sequence GFTFIDYYMN
- a heavy chain CDR2 comprising the amino acid sequence FIRNKANDYTTEYST
- a heavy chain CDR3 comprising the amino acid sequence RHMYDDGFDF
- a light chain CDR1 comprising the amino acid sequence ASSSVRYMH
- a light chain CDR2 comprising the
- the present monoclonal antibody comprises one or more of (i) a heavy chain CDR1 comprising a heavy chain CDR1 amino acid sequence set forth in Table 1 ; (ii) a heavy chain CDR2 comprising a heavy chain CDR2 amino acid sequence set forth in Table 1 ; (iii) a heavy chain CDR3 comprising a heavy chain CDR3 amino acid sequence set forth in Table 1 ; (iv) a light chain CDR1 comprising a light chain CDR1 amino acid sequence set forth in Table 2; (v) a light chain CDR2 comprising a light chain CDR2 amino acid sequence set forth in Table 2; and (vi) a light chain CDR3 comprising a light chain CDR3 amino acid sequence set forth in Table 2.
- the present monoclonal antibody comprises the heavy and light chain CDR sequences of antibody “05B04”, namely, (i) the 05B04 heavy chain CDR1 , CDR2, and CDR3 amino acid sequences set forth in Table 1 , and (ii) the 05B04 light chain CDR1 , CDR2, and CDR3 amino acid sequences set forth in Table 2.
- Tables 1 and 2 are taken from Zhang, et al.
- the present monoclonal antibody is a humanized monoclonal antibody, and preferably a human monoclonal antibody.
- the present monoclonal antibody has a low effector function.
- the present monoclonal antibody has a long serum half-life.
- the present monoclonal antibody is an lgG1 antibody.
- the present monoclonal antibody comprises a heavy chain modification that inhibits half antibody formation.
- the present monoclonal antibody (i) has a low effector function; (ii) has a long serum half-life; (iii) is an lgG4 antibody; and (iv) comprises a heavy chain modification that inhibits half antibody formation.
- the present monoclonal antibody is an antigenbinding fragment or a single chain antibody.
- the present monoclonal antibody is a humanized or human lgG4 antibody that (i) has the serum half-life-extending mutation combination M252Y/S254T/T256E (YTE) (with numbering according to the Ell Index); (ii) has the half antibody formation-inhibiting mutation S228P or K447del, or the mutation combination S228P/K447del (with numbering according to the Ell Index); and (iii) has the effector function-lowering L235E mutation (with numbering according to the Ell Index).
- YTE serum half-life-extending mutation combination M252Y/S254T/T256E
- the present monoclonal antibody is a humanized or human lgG4 antibody that (i) has the serum half-life-extending mutation combination M252Y/S254T/T256E (YTE) (with numbering according to the Ell Index);
- the present monoclonal antibody is a humanized or human lgG4 antibody that (i) has the serum half-life-extending mutation combination M252Y/S254T/T256E (YTE) (with numbering according to the Ell Index); (ii) has the half antibody formation-inhibiting mutation S228P or K447del, or the mutation combination S228P/K447del (with numbering according to the Ell Index); and (iii) has the effector function-lowering D265A mutation (with numbering according to the Ell Index).
- YTE serum half-life-extending mutation combination M252Y/S254T/T256E
- the present monoclonal antibody is a humanized or human lgG4 antibody that (i) has the serum half-life-extending mutation combination M252Y/S254T/T256E (YTE) (with numbering according to the Ell Index);
- the present monoclonal antibody is a humanized or human lgG4 antibody that (i) has the serum half-life-extending mutation combination M252Y/S254T/T256E (YTE) (with numbering according to the Ell Index); (ii) has the half antibody formation-inhibiting mutation S228P or K447del, or the mutation combination S228P/K447del (with numbering according to the Ell Index); and (iii) has the effector function-lowering lgG2/lgG4 format wherein lgG2 (up to T260) is joined to lgG4 (with numbering according to the Ell Index).
- YTE serum half-life-extending mutation combination M252Y/S254T/T256E
- the present monoclonal antibody is a humanized or human lgG4 antibody that (i) has the serum half-life-extending mutation combination M252Y/S254T/T256E (YTE) (with numbering according to the Ell Index);
- the present monoclonal antibody is a humanized or human lgG4 antibody that (i) has the serum half-life-extending mutation combination M252Y/S254T/T256E (YTE) (with numbering according to the Ell Index);
- the present monoclonal antibody is a humanized or human lgG4 antibody that (i) has the serum half-life-extending mutation combination M252Y/S254T/T256E (YTE) (with numbering according to the Ell Index);
- the present monoclonal antibody has a “knobs-into-holes” (kih) modification to prevent heavy chain mispairing.
- the present monoclonal antibody comprises two distinct heavy chains and two identical light chains.
- one of the heavy chains contains a chimeric Fc form that ablates binding to Protein A via the contact region. This technology, known as FcAAdp, is described in M. Godar, et al., and A.D. Tustian, et al.
- the present monoclonal antibody is a humanized lgG4 antibody that (i) has the serum half-life-extending mutation combination M252Y/S254T/T256E (YTE) (with numbering according to the Ell Index);
- (iii) has an effector function-lowering mutation, mutation combination, or alteration, selected from the group consisting of L235E, L235A, F234A, G237A, D265A, A330R, F243L, L328 substitution, F243AA/264A, E233P/F234A/L235A/G236del/ G237A, S228P/L235E, and an lgG2/lgG4 format wherein lgG2 (up to T260) is joined to lgG4 (with numbering according to the Ell Index).
- an effector function-lowering mutation, mutation combination, or alteration selected from the group consisting of L235E, L235A, F234A, G237A, D265A, A330R, F243L, L328 substitution, F243AA/264A, E233P/F234A/L235A/G236del/ G237A, S228P/L235E, and an lgG2/lgG
- the present monoclonal antibody is a human lgG4 antibody that (i) has the serum half-life-extending mutation combination M252Y/S254T/T256E (YTE) (with numbering according to the Ell Index); (ii) has the half antibody formation-inhibiting mutation S228P or K447del, or the mutation combination S228P/K447del (with numbering according to the Ell Index); and (iii) has an effector function-lowering mutation, mutation combination, or alteration, selected from the group consisting of L235E, L235A, F234A, G237A, D265A, A330R, F243L, L328 substitution, F243AA/264A, E233P/F234A/L235A/G236del/G237A, S228P/L235E, and an lgG2/lgG4 format wherein lgG2 (up to T260) is joined to lgG4 (with
- the present monoclonal antibody has a “knobs-into-holes” (kih) modification to prevent heavy chain mispairing.
- the present monoclonal antibody comprises two distinct heavy chains and two identical light chains.
- one of the heavy chains contains a chimeric Fc form that ablates binding to Protein A via the contact region (i.e. , FcAAdp technology).
- This invention further provides a monoclonal antibody comprising residues 21 through 230 of the light chain amino acid sequence set forth in Figure 6 and residues 25 through 471 of the heavy chain amino acid sequence set forth in Figure 7.
- This invention still further provides a monoclonal antibody comprising residues 21 through 230 of the light chain amino acid sequence set forth in Figure 6 and residues 25 through 471 of the heavy chain amino acid sequence set forth in Figure 8.
- This invention further provides the monoclonal antibody designated 3E8-hlgG1(STR) having the heavy and light chain amino acid sequences as defined herein, and 3E8- hlgG1 (STR/LS) having the heavy and light chain amino acid sequences as defined herein.
- This invention still further provides the monoclonal antibody disclosed in F.
- the antibody comprises the heavy chain modification (i) L234S/L235T/G236R (STR) or (ii) L234S/L235T/G236R/M252Y/S254T/T256E (STR/YTE).
- L234S/L235T/G236R L234S/L235T/G236R/M252Y/S254T/T256E
- STR L234S/L235T/G236R
- STR/YTE L234S/L235T/G236R/M252Y/S254T/T256E
- This invention provides an isolated nucleic acid molecule encoding (i) the complete light chain, or a portion of the light chain, of the present monoclonal antibody, and/or (ii) the complete heavy chain, or a portion of the heavy chain, of the present monoclonal antibody.
- the present nucleic acid molecule is
- This invention further provides a recombinant vector, for example a plasmid or a viral vector, comprising the present nucleic acid molecule operably linked to a promoter of RNA transcription.
- a recombinant vector for example a plasmid or a viral vector, comprising the present nucleic acid molecule operably linked to a promoter of RNA transcription.
- This invention still further provides a host vector system comprising one or more of the present vectors in a suitable host cell (e.g., a bacterial cell, an insect cell, a yeast cell, or a mammalian cell such as a hybridoma cell (See, e.g., Chiu and Gilliland; Kohler and Milstein)).
- a suitable host cell e.g., a bacterial cell, an insect cell, a yeast cell, or a mammalian cell such as a hybridoma cell (See, e.g., Chiu and Gilliland; Kohler and Milstein)).
- composition comprising (i) the present monoclonal antibody, and (ii) a pharmaceutically acceptable carrier.
- This invention also provides a method for reducing the likelihood of a human subject’s becoming infected with SARS-CoV-2 comprising administering to the subject a prophylactically effective amount of the present monoclonal antibody.
- the subject has been exposed to SARS-CoV-2.
- the present monoclonal antibody does not exhibit significant toxicity in a cynomolgus monkey when administered at a prophylactically effective amount.
- the present monoclonal antibody when administered at a prophylactically effective amount to a cynomolgus monkey, does not cause more than a 15% fluctuation in blood pressure or in the number of white blood cells, red blood cells, monocytes, or lymphocytes.
- This invention further provides a method for treating a human subject who is infected with SARS-CoV-2 comprising administering to the subject a therapeutically effective amount of the present monoclonal antibody.
- the subject is symptomatic of a SARS-CoV-2 infection.
- the subject is asymptomatic of a SARS-CoV-2 infection.
- the present monoclonal antibody does not exhibit significant toxicity in a cynomolgus monkey when administered at a therapeutically effective amount.
- the present monoclonal antibody when administered at a therapeutically effective amount to a cynomolgus monkey, does not cause more than a 15% fluctuation in blood pressure or in the number of white blood cells, red blood cells, monocytes, or lymphocytes.
- This invention provides a recombinant AAV vector comprising a nucleic acid sequence encoding a heavy chain and/or a light chain of the present monoclonal antibody.
- a nucleic acid sequence “encoding” a protein encodes it operably (i.e. , in a manner permitting its expression in a cell infected by a viral particle comprising the vector that contains the nucleic acid sequence).
- the recombinant viral vectors of this invention are not limited to any particular configuration with respect to the exogenous protein-coding sequences.
- a “one vector” approach is used wherein a singular recombinant AAV vector includes nucleic acid sequences encoding both heavy and light antibody chains.
- a “two vector” approach is used wherein one recombinant AAV vector includes a nucleic acid sequence encoding the heavy antibody chain, and a second recombinant AAV vector includes a nucleic acid sequence encoding the light antibody chain (See, e.g., S.P. Fuchs, et al. (2016)).
- This invention further provides a recombinant AAV particle comprising the present recombinant AAV vector and an AAV capsid protein.
- This invention also provides a composition comprising (i) a plurality of the present AAV particles and (ii) a pharmaceutically acceptable carrier.
- This invention provides a method for reducing the likelihood of a human subject’s becoming infected with SARS-CoV-2 comprising administering to the subject a prophylactically effective number of the present AAV particles.
- the subject has been exposed to SARS-CoV-2.
- the subject has not been exposed to SARS- CoV-2.
- This invention provides a method for treating a human subject who is infected with SARS-CoV-2 comprising administering to the subject a therapeutically effective number of the present AAV particles.
- the subject is symptomatic of a SARS-CoV-2 infection. In another embodiment, the subject is asymptomatic of a SARS-CoV-2 infection.
- This invention further provides a kit comprising, in separate compartments, (a) a diluent and (b) the present monoclonal antibody either as a suspension or in lyophilized form.
- this invention provides a kit comprising, in separate compartments, (a) a diluent and (b) a suspension of a plurality of the present recombinant AAV particles.
- the subject kit comprises (i) a single-dose vial containing a concentrated solution of the subject particles (also measured as viral genomes) in a suitable solution (e.g., a solution of sterile water, sodium chloride, sodium phosphate, and Poloxamer 188) and (ii) one or more vials of suitable diluent (e.g., a solution of sterile water, sodium chloride, sodium phosphate, and Poloxamer 188).
- a suitable solution e.g., a solution of sterile water, sodium chloride, sodium phosphate, and Poloxamer 188.
- non-AW viruses e.g., lentivirus, adenovirus, alphavirus, herpesvirus, or vaccinia virus
- mutatis mutandis as they are for recombinant AAV viruses in this invention.
- SARS-CoV-2 e.g., SARS-CoV
- SARS-CoV SARS-CoV
- mutatis mutandis SARS-CoV-2
- BioVision, Inc. sells the Angiotensin II Converting Enzyme (ACE2) Activity Assay Kit (Fluorometric) (https://www.biovision.com/angiotensin-ii-converting-enzyrne-ace2- activity-assay-kit-fluorometric.html). This kit can be used to measure the degree to which an antibody inhibits the ability of hACE2 to cleave angiotensin II.
- BioVision provides the following background information regarding its test kit, which has been edited here.
- Angiotensin II converting enzyme ACE2
- RAS renin-angiotensin system
- ACE2 is a receptor of human coronaviruses, such as SARS and HCoV-NL63. It is expressed on the vascular endothelial cells of lung, kidney, and heart.
- ACE2 is a potential therapeutic target for cardiovascular and coronavirus-induced diseases. BioVision’s kit will aid research in this field.
- BioVision also provides an ACE2- specific inhibitor that can differentiate the ACE2 activity from other proteolytic activity. This kit can detect as low as 0.4 mil, is simple, and can be used in a high- throughput format.
- Example 2 -
- SensoLyte kit 390 ACE2 Activity Assay Kit *Fluorimetric* (https://www.anaspec.com/products/product.asp7ick43987). This kit can be used to measure the degree to which an antibody inhibits the ability of hACE2 to cleave angiotensin II.
- Anaspec provides the following information regarding its SensoLyte test kit, which has been edited here.
- the kit provides a convenient assay for high throughput screening of ACE2 enzyme inhibitors and inducers using a Mc-Ala/Dnp fluorescence resonance energy transfer (FRET) peptide.
- FRET fluorescence resonance energy transfer
- Dnp quenches the fluorescence of Mc-Ala.
- This assay can detect the activity of sub-nanogram levels of ACE2. Assays are performed in a convenient 96-well microplate format.
- the Sensolyte kit also has the following specifications: (i) Cat # - AS-72086; (ii) Size - 100 assays; (iii) Storage Conditions - -20°C.
- This method can be used to quantitatively measure hACE2 activity using mass spectrometry. In particular, it can be used to measure the degree to which an antibody inhibits the ability of hACE2 to cleave angiotensin II, as well as other substrates.
- the method is adapted from the ACE2 assay described in Donoghue, et al.
- Enzymatic reactions are performed in 15 pl. To each tube at room temperature is added 10 pl of buffer (10 mmol/l Tris, pH 7.0) with or without hACE2.
- the hACE2 used in this method is recombinant soluble hACE2 prepared according to Donoghue, et al. Five microliters of purified angiotensin II (Sigma) are added to each tube for a final concentration of 5 pmol/l.
- This mass spectrometry assay can also employ peptide substrates other than angiotensin II (e.g., des-Arg-bradykinin, neurotensin, kinetensin, apelin-13, and dynorphin A 1-13).)
- Lisinopril or captopril (Sigma) is added to some reactions at final concentrations of 6.6 pmol/l. Neither lisinopril nor captopril inhibits hACE2 activity, and these compounds are thus useful as controls to ensure that the angiotensin II cleavage measured is due to hACE2 activity.
- the tubes are incubated at 37°C for 30 minutes.
- a portion (1 pl) of each reaction is quenched by the addition of 1 pl of a low-pH MALDI matrix compound (10 g/L a-cyano-4 hydroxycinnamic acid in a 1 :1 mixture of acetonitrile and water).
- a low-pH MALDI matrix compound (10 g/L a-cyano-4 hydroxycinnamic acid in a 1 :1 mixture of acetonitrile and water).
- a MALDI matrix compound 10 g/L a-cyano-4 hydroxycinnamic acid in a 1 :1 mixture of acetonitrile and water.
- One microliter of the resulting solution is applied to the surface of a MALDI plate.
- the plate is then air-dried and inserted into the sample introduction port of the Voyager Elite biospectrometry MALDI time-of-flight (TOF) mass spectrometer (PerSeptive Biosystems).
- TOF Voyager Elite biospectrometry MA
- quadrupole time-of-flight mass spectrometer (Q-TOF-MS) (Micromass UK Limited) equipped with an orthogonal electrospray source (Z-spray) is used.
- Q-TOF-MS quadrupole time-of-flight mass spectrometer
- Z-spray orthogonal electrospray source
- the quadrupole is set up to pass precursor ions of selected m/z to the hexapole collision cell (Q2), and product ion spectra are acquired with the TOF analyzer.
- Argon is introduced into the Q2 with a collision energy of 35 eV and cone energy of 25 V.
- HPLC assay can be used to quantitatively measure hACE2 activity using HPLC. In particular, it can be used to measure the degree to which an antibody inhibits the ability of hACE2 to cleave angiotensin II, as well as other substrates.
- the method is adapted from the “ACEH” assay described in Tipnis, et al.
- Protein and Enzymatic Assays Protein concentrations are determined using the bicinchoninic acid assay (Smith, et al.) with bovine serum albumin as a standard. Assays for hACE2 activity are carried out in a total volume of 100 pl, containing 100 mM Tris-HCI, pH 7.4, 20 pg of protein and 100 pM angiotensin II as a substrate.
- This HPLC assay can also employ peptide substrates other than angiotensin II (e.g., des- Arg-bradykinin, neurotensin, and kinetensin, apelin-13, and dynorphin A 1-13).) Where appropriate, inhibitors are added to give final concentrations of 10 pM lisinopril, 10 pM captopril, 10 pM enalaprilat, 100 pM benzyl succinate, or 10 mM EDTA.
- peptide substrates other than angiotensin II e.g., des- Arg-bradykinin, neurotensin, and kinetensin, apelin-13, and dynorphin A 1-13.
- EDTA inhibits hACE2 activity, but none of lisinopril, captopril, enalaprilat, and benzyl succinate (a carboxypeptidase A inhibitor) inhibits hACE2 activity. These compounds are thus useful as controls to ensure that the angiotensin II cleavage measured is due to hACE2 activity. Reactions are carried out at 37°C, for 2 hours and stopped by heating to 100°C for 5 minutes followed by centrifugation at 11 ,600 x g for 10 minutes.
- Carboxypeptidase A assays are carried out at room temperature for 30 minutes, using 0.1 units of enzyme per assay.
- measuring the interaction of soluble RBD protein (a proxy for SARS-CoV-2) with soluble hACE2 (a proxy for the extracellular portion of hACE2) can be used to indirectly measure (i) the binding of a monoclonal antibody to the extracellular portion of hACE2, and (ii) a monoclonal antibody’s ability to inhibit binding of SARS-CoV-2 to the extracellular portion of hACE2.
- the following method for analyzing hACE2-binding inhibition is taken from SuryJe, et al.
- Wells of 384-well microtiter plates are coated with 1 pg/mL purified recombinant SARS-CoV-2 S2Pecto protein at 4°C overnight. Plates are blocked with 2% non-fat dry milk and 2% normal goat serum in DPBS-T for 1 hour.
- purified monoclonal antibodies are diluted two-fold in blocking buffer starting from 10 pg/mL in triplicate, added to the wells (20 pL per well) and incubated for 1 hour at ambient temperature.
- Recombinant hACE2 with a C-terminal Flag tag peptide is added to wells at 2 pg/mL in a 5 pL per well volume (final 0.4 pg/mL concentration of hACE2) without washing of antibody and then incubated for 40 minutes at ambient temperature. Plates are washed and bound hACE2 is detected using HRP-conjugated anti-Flag antibody (Sigma-Aldrich, cat. A8592, lot SLBV3799, 1 :5,000 dilution) and TMB substrate. ACE2 binding without antibody serves as a control.
- the signal obtained for binding of the human ACE2 in the presence of each dilution of tested antibody is expressed as a percentage of the human ACE2 binding without antibody after subtracting the background signal.
- serial dilutions of purified monoclonal antibodies are applied to the wells in triplicate, and monoclonal antibody binding is detected as detailed above.
- IC50 values for inhibition by monoclonal antibody of S2Pecto protein binding to human ACE2 are determined after log transformation of antibody concentration using sigmoidal dose-response nonlinear regression analysis.
- reagents used in this example can be made according to this reference and/or purchased commercially (e.g., from LakePharma, Inc., Worcester, MA).
- related kits are commercially available.
- a SARS-CoV-2 Spike-ACE2 Interaction Inhibitor Screening Assay Kit is available from Cayman Chemical (Ann Arbor, Ml); and
- a SARS-CoV-2 Spike:ACE2 Inhibitor Screening Assay Kit, an ACE2 Inhibitor Screening Assay Kit, and a Spike RBD (SARS-CoV-2) : ACE2 Inhibitor Screening Assay Kit are all available from BPS Bioscience (San Diego, CA).
- the present monoclonal antibody s hACE2- binding ability, hACE2 carboxypeptidase-inhibiting ability, virus-neutralizing ability, and toxicity can be determined using the following methods taken from Du, et al.
- HEK293T ATCC, CRL-3216
- HEK293T-ACE2 SeoBiological, OEC001
- Vero E6 ATCC, CRL-1586
- LLC-MK2 ATCC, CRL-7 cells are cultured at 37 °C under 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM) (HyClone, South Logan, UT) supplemented with 10% fetal bovine serum (FBS) (Gibco, Carlsbad, CA, USA).
- DMEM Dulbecco’s modified Eagle’s medium
- FBS fetal bovine serum
- SARS-CoV-2 virus (BetaCoV/Wuhan/IVDC-HB-01/2020, GISAID accession ID: EPI JSL 402119) is used. Vero E6 cells are applied to the reproduction of SARS-CoV- 2 stocks. The HCoV-NL63 strain is used. LLC-MK2 cells are applied to the reproduction of HCoV-NL63 stocks.
- ACE2-blocking monoclonal antibodies To generate murine anti-hACE2 antibodies, BALB/c mice receive hACE2 (19–615) soluble antigens in a prime-boost immunization regimen with a 4-week interval. Using 5 hybridoma technology, one obtains a number of mouse anti-hACE2 cell clones. After screening hybridoma supernatants, several clones of the monoclonal antibodies that block HEK293T-hACE2 cell infection with SARS-CoV and SARS-CoV-2 spike pseudotyped virus are identified. The antibody clone exhibiting the best inhibitory activity against pseudotyped virus infection (top antibody) is identified.
- the sequences 10 of the variable regions of the top antibody are obtained through rapid amplification of complementary DNA (cDNA) ends amplification.
- Plasmid construction 15 The coding sequences of SARS-CoV-RBD (residues 306–527, accession number: NC_004718), SARS-CoV-2-RBD (residues 319–541, accession number EPI_ISL_402119), hACE2 (residues 19–615, accession number BAJ21180), and hACE2 variants (S19P, I21T, K26R, N33D, and D38E) fused with N-terminal native signal peptides and C-terminal 6 ⁇ His tag are, respectively, cloned into the pCAGGS 20 expression vector (Addgene) using the EcoRI and XhoI restriction sites.
- the signal peptides and variable regions of antibody are synthesized (GenScript) and fused with the coding sequences for the human IgG4 and kappa light chain constant region into the pCAGGS vectors.
- the pEGFP-N1-hACE2 plasmid is constructed by cloning the coding region of hACE2 into pEGFP-N1 using restriction enzymes XhoI and SmaI.
- a coding sequence of residues 19–615 is synthesized (GenScript) and cloned into pFastBac1 vector (Invitrogen), with an N- terminal gp67 signal peptide and a C-terminal 6 ⁇ His tag.
- HEK293T cells are transiently transfected with expressing plasmids containing the coding sequence for the indicated proteins. After 3 days, the supernatant is collected and soluble protein is purified by Ni affinity chromatograph ⁇ XVLQJ ⁇ D ⁇ +LV7UDS ⁇ +3 ⁇ PO ⁇ 35 column (GE Healthcare). The samples are then further purified via size-exclusion 49
- chromatography with a Superdex 200 column (GE Healthcare) in a buffer composed of ⁇ P0 ⁇ 7ULV-+&O ⁇ S+ ⁇ DQG ⁇ P0 ⁇ 1D&O.
- Preparation of the full-length protein is achieved by transfection of plasmids into HEK293T cells.
- the protein is purified from the culture supernatants using a HiTrap Protein A HP column (GE Healthcare) and 5 subsequently purified via the above size-exclusion chromatography.
- the peptidase domain of human ACE2 (19–615) with a C- terminal 6 ⁇ His tag is expressed using the baculovirus–insect cell system.
- the baculovirus is generated and amplified using the Sf21 insect cells (Invitrogen, B82101), 10 and Hi5 insect cells (Invitrogen, B85502) are used for protein expression.
- the conditioned medium is FROOHFWHG ⁇ K ⁇ SRVW ⁇ LQIHFWLRQ ⁇ DQG ⁇ H[FKDQJHG ⁇ LQWR ⁇ WKH ⁇ ELQGLQJ ⁇ EXIIHU ⁇ P0 ⁇ +(3(6 ⁇ S+ ⁇ DQG ⁇ P0 ⁇ 1D&O ⁇ .
- the ACE2 (19–615) and antibody- Fab proteins are purified as described above for HEK293T cell-derived ACE2 (19–615).
- ACE2 and antibody-Fab are incubated together, passed through a Superdex 200 increase 10/300 gel filtration column (GE Healthcare), and eluted using the binding buffer.
- Flow cytometry assay 20 To test the activity of antibodies to block the binding between ACE2 and SARS-CoV- RBD, or SARS-CoV-2-RBD.
- HEK293T cells are transiently transfected with pEGFP- N1-ACE2 plasmids.
- $IWHU ⁇ K ⁇ î ⁇ 5 cells are FROOHFWHG ⁇ DQG ⁇ LQFXEDWHG ⁇ ZLWK ⁇ J ⁇ PO ⁇ antibody SURWHLQ ⁇ RU ⁇ LVRW ⁇ SH ⁇ ,J* ⁇ DW ⁇ & ⁇ IRU ⁇ PLQ ⁇ IROORZHG ⁇ E ⁇ LQFXEDWLRQ ⁇ ZLWK ⁇ ⁇ QJ ⁇ PO ⁇ 5%' ⁇ SURWHLQV ⁇ DW ⁇ & ⁇ IRU ⁇ DQRWKHU ⁇ PLQ. After washing three times, the25 cells are incubated with APC-conjugated anti-His antibody (1:200, Miltenyi Biotec, 130- 119-782) for DQRWKHU ⁇ PLQ.
- HEK293T-hACE2 cells are LQFXEDWHG ⁇ ZLWK ⁇ GLIIHUHQW ⁇ FRQFHQWUDWLRQV ⁇ J ⁇ PO ⁇ RU ⁇ ZLWK ⁇ five-IROG ⁇ VHULDO ⁇ GLOXWLRQV ⁇ UDQJLQJ ⁇ IURP ⁇ J ⁇ PO ⁇ WR ⁇ QJ ⁇ PO ⁇ RI ⁇ DQWLERG ⁇ DW ⁇ & ⁇ LQ ⁇ '0(0 ⁇ ZLWK ⁇ )%6 ⁇ IRU ⁇ RU ⁇ K.
- the cells are washed with FACS buffer (phosphate-bufferHG ⁇ VDOLQH ⁇ 3%6 ⁇ ERYLQH ⁇ VHUXP ⁇ DOEXPLQ ⁇ DQG ⁇ P0 ⁇ ('7$ ⁇ DQG ⁇ LQFXEDWHG ⁇ ZLWK ⁇ J ⁇ PO ⁇ DQWLERG ⁇ RU ⁇ LVRW ⁇ SH ⁇ ,J* ⁇ DW ⁇ & ⁇ IRU ⁇ PLQ.
- FACS buffer phosphate-bufferHG ⁇ VDOLQH ⁇ 3%6 ⁇ ERYLQH ⁇ VHUXP ⁇ DOEXPLQ ⁇ DQG ⁇ P0 ⁇ ('7$ ⁇ DQG ⁇ LQFXEDWHG ⁇ ZLWK ⁇ J ⁇ PO ⁇ DQWLERG ⁇ RU ⁇ LVRW ⁇ SH ⁇ ,J* ⁇ DW ⁇ & ⁇ IRU ⁇ PLQ.
- the sensor is UHJHQHUDWHG ⁇ ZLWK ⁇ P0 ⁇ *O ⁇ -HCl (pH 1.5).
- the raw data and affinities are 15 collected and calculated using a 1:1 fitting model with BIAevaluation software (GE +HDOWKFDUH ⁇ %LDFRUH ⁇ . ⁇ &RQWURO ⁇ 6RIWZDUH ⁇ DQG ⁇ %LDFRUH ⁇ ,QVLJKW ⁇ (YDOXDWLRQ ⁇ 1.0.5.11069).
- hACE2 carboxypeptidase activity measurement 20 Enzymatic reactions are performed in black microtiter plates at ambient temperature ⁇ & ⁇ .
- 7R ⁇ HDFK ⁇ ZHOO ⁇ O ⁇ RI ⁇ J ⁇ PO ⁇ K$&( ⁇ –615) protein in PBS is added, respectively.
- 7KHQ ⁇ O antibody at various final concentrations of 100, 200, and ⁇ J ⁇ PO ⁇ RU ⁇ K$&( ⁇ LQKLELWRr (MLN-4760, Sigma, 5.30616) at a final concentration of 25 ⁇ 0 ⁇ are DGGHG ⁇ WR ⁇ ZHOOV ⁇ DQG ⁇ LQFXEDWHG ⁇ IRU ⁇ PLQ.
- the reactions are initiated by DGGLQJ ⁇ O ⁇ RI ⁇ IOXRURJHQLF ⁇ SHSWLGHV ⁇ 0DF-APK-'QS ⁇ *HQ6FULSW ⁇ DW ⁇ 0 ⁇ RU ⁇ ZLWK ⁇ WZR- fold serial dilutions ranging frRP ⁇ WR ⁇ 0 ⁇ WR ⁇ GHWHUPLQH ⁇ WKH ⁇ NLQHWLF ⁇ FRQVWDQWV ⁇ IRU ⁇ hACE2 hydrolysis.
- the relative fluorescence units are read at excitation and HPLVVLRQ ⁇ ZDYHOHQJWKV ⁇ RI ⁇ DQG ⁇ QP ⁇ UHVSHFWLYHO ⁇ LQ ⁇ NLQHWLF ⁇ PRGH ⁇ DW ⁇ -min 30 LQWHUYDOV ⁇ IRU ⁇ K ⁇ %0* ⁇ /$%7(&+ ⁇ &/ARIOstar Plus 5.61).
- the intensities of RFU are converted to molarities according to standard substrate Mca-P-L-OH (GenScript).
- Mca-P-L-OH GeneScript
- the initial velocity conditions are limited to 1 ⁇ PLQ.
- HEK293T cells are SUHSDUHG ⁇ DQG ⁇ DGMXVWHG ⁇ WR ⁇ WKH ⁇ FRQFHQWUDWLRQ ⁇ RI ⁇ î ⁇ 5 FHOO ⁇ PO ⁇ PO ⁇ 20 of which are transferred LQWR ⁇ D ⁇ 7 ⁇ FHOO ⁇ FXOWXUH ⁇ IODVN ⁇ DQG ⁇ LQFXEDWHG ⁇ RYHUQLJKW ⁇ DW ⁇ & ⁇ LQ ⁇ an incubator conditioned with 5% CO2. The cells generally reach 70–90% confluence after overnight incubation. Thirty micrograms of DNA plasmid expressing the spike protein is transfected according to the user’s instruction manual of Lipofectamine 3000 (Invitrogen, L3000001).
- the transfected cells are subsequently infected with G ⁇ *- 25 VSV (VSV G-pseudotyped virus) aW ⁇ FRQFHQWUDWLRQV ⁇ RI ⁇ î ⁇ 5 TCID50/ml.
- VSV G-pseudotyped virus VSV G-pseudotyped virus
- aW ⁇ FRQFHQWUDWLRQV ⁇ RI ⁇ î ⁇ 5 TCID50/ml After being LQFXEDWHG ⁇ IRU ⁇ K ⁇ WKH ⁇ PHGLXP ⁇ is UHSODFHG ⁇ ZLWK ⁇ D ⁇ IUHVK ⁇ PHGLXP ⁇ DQG ⁇ LQFXEDWHG ⁇ IRU ⁇ K.
- the culture supernatants containing the pseudovirus are KDUYHVWHG ⁇ ILOWHUHG ⁇ 0 ⁇ SRUH ⁇ VL]H ⁇ DQG ⁇ VWRUHG ⁇ DW ⁇ &.
- TCID50 of pseudoviruses is determined as described previously.
- hACE2+ cells employed in assays described herein can, as appropriate, be either hTMPRSS2+ cells or hTMPRSS2- cells.
- Mice experiments 25 All animal experiments are carried out according to the relevant procedures and relevant ethical regulations regarding animal research. Briefly, the full cDNAs of hACE2 are knocked into the exon 2, the first coding exon, of the mAce2 gene located in GRC m38.p6 sites.
- hACE2 transgenic mice female, 30 30 weeks old
- Animals in the pre-exposure groups are LQMHFWHG ⁇ ZLWK ⁇ RU ⁇ PJ ⁇ NJ ⁇ antibody one day before the viral challenge.
- mice are administered ZLWK ⁇ RU ⁇ PJ ⁇ NJ ⁇ DQWLERG ⁇ RQH ⁇ GD ⁇ DIWHU ⁇ WKH ⁇ YLUDO ⁇ FKDOOHQJH. All mice are HXWKDQL]HG ⁇ RQ ⁇ WKH ⁇ ILIWK ⁇ GD ⁇ DIWHU ⁇ EHLQJ ⁇ FKDOOHQJHG ⁇ ZLWK ⁇ î ⁇ 5 TCID50 of SARS-CoV-2. 35
- the lung tissues from five mice in each group are SODFHG ⁇ LQWR ⁇ PO ⁇ RI ⁇ '0(0 ⁇ VHSDUDWHO ⁇ . 53
- viral RNAs are extracted by Magnetic Bead Extraction Kit ⁇ (PHU7KHU ⁇ 5( ⁇ DFFRUGLQJ ⁇ WR ⁇ WKH ⁇ PDQXIDFWXUHU ⁇ V ⁇ LQVWUXFWLRQV ⁇ DQG ⁇ HOXWHG ⁇ LQ ⁇ O ⁇ RI ⁇ elution buffer and used as the template for reverse transcription-polymerase chain reaction (RT-PCR).
- RT-PCR reverse transcription-polymerase chain reaction
- the pairs of primers are used to target ORF1ab gene: OFR1ab-F, 5 ⁇ -CCCTGTGGGTTTTACACTTAA- ⁇ DQG ⁇ 2)5 ⁇ DE-5 ⁇ -ACGATTGTGCATCAGCTGA- ⁇ 3UREH-25) ⁇ DE ⁇ -the FAM-CCGTCTGCGGTATGTGGAAAGGTTATGG-BHQ1- ⁇ .
- Five microliters of RNA is used to verify the RNA quantity by One Step PrimeScript RT- PCR Kit (Takara, RR064B) according to the manufacturer’s instructions.
- the amplification is SHUIRUPHG ⁇ DV ⁇ IROORZV ⁇ & ⁇ IRU ⁇ PLQ ⁇ & ⁇ IRU ⁇ V ⁇ IROORZHG ⁇ E ⁇ 10 F ⁇ FOHV ⁇ FRQVLVWLQJ ⁇ RI ⁇ & ⁇ IRU ⁇ V ⁇ & ⁇ IRU ⁇ V ⁇ DQG ⁇ D ⁇ GHIDXOW ⁇ PHOWLQJ-curve step in an Applied QuantStudio 5 Real-Time PCR System (QuantStudio Design and Analysis Software v1.5.1).
- the limit of detection in this RT-PCR program is 40 copies. When the detection is lower than 40 copies, the value is recorded as 20 copies. 15 Histopathology and pathology Mice necropsies are performed according to a standard protocol.
- the lung tissues of three mice in each group for histological examination are stored in 10% neutral-buffered formalin for 7 days, embedded in paraffin, sectioned, and stained with hematoxylin 20 before examination by light microscopy.
- Safety assessment using cynomolgus monkeys Purpose-bred cynomolgus monkeys (Macaca fascicularis) are obtained from licensed 25 vendors and undergo standard quarantine periods ( ⁇ 4 weeks) before initiation. During the study periods, animals are single-housed in primary enclosures according to the appropriate regulations. All experimental procedures (the management, sampling, and euthanasia) are conducted in appropriate facilities according to the appropriate regulations.
- Cynomolgus monkeys are DGPLQLVWHUHG ⁇ YLD ⁇ UHSHDWHG ⁇ LQWUDYHQRXV ⁇ LQIXVLRQ ⁇ RU ⁇ PJ ⁇ NJ ⁇ DW ⁇ RQFH ⁇ D ⁇ ZHHN ⁇ IRU ⁇ weeks).
- the animals in each group survived until the planned 35 euthanasia.
- the dosing period D22
- all animals are euthanized. 54
- Clinical signs of toxicity are subjectively determined following standard procedures. Blood samples for hematology and clinical chemistry are drawn pre-study, D7, D14, and D21. Comprehensive hematology evaluations included determinations of differential leukocyte count and indicators of erythrocyte mass (RBC count). Meanwhile, 5 serum chemistry analyses including the determination of serum enzyme activity are employed. Blood pressure measurements (systolic, diastolic, and mean blood pressure) are FRQGXFWHG ⁇ RQ ⁇ DQG ⁇ K ⁇ DIWHU ⁇ WKH ⁇ FRPSOHWLRQ ⁇ RI ⁇ LQIXVLRQ ⁇ RQ ⁇ ' ⁇ . Blood pressure (ecgAUTO v3.3.0.20).
- the amount of anesthetic is calculated based on the animal’s body weight.
- Anesthesia euthanasia is performed after femoral artery/venous release. 15 Statistical analysis Statistical significance between groups is determined by unpaired two-tailed t test.
- FIG. 4 shows a schematic diagram of an expression cassette for use in the subject rAAV vector encoding the present anti-hACE2 monoclonal antibody.
- the cassette has the following structure: 5’ITR—CAG—Antibody Heavy Chain—Furin F2A—Antibody Light Chain—SV40 polyA—3’ITR.
- cassette components include a CMV enhancer/chicken beta-actin promoter and intron (or CAG); an SV40 polyadenylation signal (or SV40 polyA); heavy and light chains of the antibody; and a furin F2A self-processing peptide cleavage site.
- the expression cassette is flanked by AAV serotype 2 inverted terminal repeats (ITR).
- ITR AAV serotype 2 inverted terminal repeats
- the furin cleavage sequence “RKRR” for the cellular protease furin is added for removal of amino acids left on the heavy chain C-terminus following F2A self-processing.
- the subject rAAV vectors possess introns, and in another embodiment, they do not.
- Example 8 – rAAV Production The subject rAAVs can be produced according to known methods.
- HEK-293 cells are transfected with a select rAAV vector plasmid and two helper plasmids to allow generation of infectious AAV particles.
- rAAV is purified by three sequential CsCl centrifugation steps. Vector genome number is assessed by Real-Time PCR, and the purity of the preparation is verified by electron microscopy and silver-stained SDS- 15 PAGE (Mueller, et al.).
- Example 9 Antibody Purification SE-UPLC was performed for H11B11-hIgG1(STR), H11B11-hIgG1(STR/YTE), 3E8-20 hIgG1(STR), and 3E8-hIgG1(STR/LS).
- H11B11-hIgG1(STR) and H11B11- hIgG1(STR/YTE) are both humanized antibodies.
- 3E8-hIgG1(STR) and 3E8- hIgG1(STR/LS) are both murine-human chimeric antibodies. All proteins were >96% monomer.
- Example 10 Octet Affinity Assays of Antibodies Against hACE2-His Antigen
- the four antibodies H11B11-hIgG1(STR), H11B11-hIgG1(STR/YTE), 3E8-hIgG1(STR), and 3E8-hIgG1(STR/LS) (“ligands”) were produced, and hACE2-His protein (“analyte”) 5 was commercially obtained. Analysis was performed using standard procedures.
- the antibody-loaded 20 sensors were dipped in serial dilutions of analyte (1:3 dilution, seven points from top concentration (240 nM)).
- Reference sample well (buffer) was used for data analysis.
- Kinetic constants were calculated using a monovalent binding model.
- the assay buffer used was PBS with 0.1% BSA, 0.02% Tween-20, pH 7.2.
- the regeneration buffer used was 10 mM glycine buffer, pH 1.7. 25
- the sensogram and kinetic constant results are as follows: 57 Example 11 - Octet FcRy and FcRn Binding for hlqGs
- An Fey receptor panel (including FcRn at pH 6.0) binding assessment was performed with Octet for two antibodies. This assessment shows whether the STR amino acid substitution present in the two antibodies tested abrogates FcRy binding, but not FcRn binding.
- H11 B11-hlgG1 (STR), 1.01 mg/ml, 146 kDa; and (ii) H11 B11 -hlgG1 (STR-YTE), 1.48 mg/ml, 146 kDa.
- a control IgG (7101 +7103) was also used.
- H11 B11- h!gG1 (STR) and H 11 B11 ⁇ h IgG 1 (STR/YTE) only bound to Human FcRn (pH 6.0), and the control IgG performed consistently within assay expectations.
- a summary of results for KD values is shown below. Note - “n.d.” (not determined) indicates that insufficient binding was observed (i.e. , response ⁇ 0.05 nm).
- Characterization Potency (i.e., IC50, IC90, and IC99) was determined for anti-ACE2 antibody inhibition of ACE2-biotin binding to SARS-CoV-2 spike or RBD variants, using plates coated with spike or RBD.
- H11B11-hIgG1(STR) abbreviated as “H11B11-hIgG1”
- H11B11-hIgG1(STR-YTE) abbreviated as “H11B11- hIgG1_YTE”
- a control antibody potent inhibitors of ACE2 binding to all spike and RBD constructs tested, with IC50s ranging from 70 pM to 22.98 nM for H11B11- 15 hIgG1(STR); 560 pM to 24.71 nM for H11B11-hIgG1(STR-YTE); and 2.29 nM to 22.05 nM for the control antibody.
- CNE means “could not estimate”, which occurs where the curve becomes too shallow and renders the IC99 calculation unreliable. 5 The following is an IC50, IC90, and IC99 (nM and ⁇ g/ml) summary table for anti-ACE2 monoclonal antibodies H11B11-hIgG1(STR), H11B11-hIgG1(STR-YTE), and control antibody. Note – “CNE” means “could not estimate.” 60
- Anti-ACE2 monoclonal antibodies H11B11-hIgG1(STR), H11B11-hIgG1(STR-YTE), 3E8-hIgG1(STR), and 3E8-hIgG1(STR/LS) were shown to be potent ACE2 binders, 5 with EC50s from 255 pM to 465 pM.
- the control antibody was also shown to be a potent ACE2 binder, with and EC50 of 2.013 nM.
- Spike protein and RBD from eight SARS-CoV-2 variants were also generally potent 10 ACE2 binders, except for Omicron [B.1.1.529] spike, which had an EC50 of 28 nM.
- the ACE2 binding potency for the other seven spike proteins and eight RBDs ranged from 527 pM to 6.257 nM.
- the following experiment measured the binding of anti-ACE2 monoclonal antibodies to 15 hACE2-biotin in terms of potency (EC50).
- ELISA plates were coated with hACE2-biotin (5 ⁇ J ⁇ PO).
- H11B11-hIgG1(STR), H11B11-hIgG1(STR-YTE), 3E8-hIgG1(STR), 3E8- hIgG1(STR/LS), and control antibody were added (starting at 3 ⁇ J ⁇ PO and going down three-fold, 8 pt). Binding was detected with anti-human IgG HRP or anti-mouse IgG HRP (for the control antibody). The EC50 values measured are shown below. 61
- hACE2-biotin was added (starting at 30 pg/ml and going down three-fold, 8 pt). Binding was detected with sAv-HRP. The ECso and ECso values measured are shown below.
- This example sets forth single amino acid point mutations of exemplary heavy chain CDR1 , CDR2, and CDR3 regions, and exemplary light chain CDR1 , CDR2, and CDR3 regions, envisioned for the present monoclonal antibody.
- These six exemplary CDR regions are those shown in Figure 5 for humanized 11 B11 VH (heavy chain) and humanized 11 B11 VK (light chain), as originally presented in Supplementary Figure 2 of Du, et al.
- the heavy chain CDR1 has the following amino acid seguence: GFTFIDYYMN.
- the heavy chain CDR2 has the following amino acid seguence: FIRNKANDYTTEYST.
- the heavy chain CDR3 has the following amino acid seguence: RHMYDDGFDF.
- the light chain CDR1 has the following amino acid seguence: ASSSVRYMH.
- the light chain CDR2 has the following amino acid sequence: LLIYDTSKLA.
- the light chain CDR3 has the following amino acid sequence: QQWSYNPLTF.
- the numbering for each CDR residue corresponds to the amino acid residue numbering in the variable region shown in Figure 5 for humanized 11 B11 VH or humanized 11 B11 VK, as applicable.
- the first heavy chain CDR1 residue, G is the 26th amino acid residue of the humanized 11 B11 VH heavy chain variable region shown in Figure 5. As such, it is referred to in this example as G26.
- amino acids used in this example are the following 20 naturally occurring amino acids: A, R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, and V. So, for each of the 10 amino acid residues in the heavy chain CDR1 (beginning with G26), there are 19 point mutations possible. For instance, a point mutation whereby V replaces G26 would be written as G26V. Examples of single point mutations are set forth below for heavy chain CDR1 , CDR2, and CDR3, and light chain CDR1 , CDR2, and CDR3.
- the point mutants envisioned are G26A, G26R, G26N, G26D, G26C, G26Q, G26E, G26H, G26I, G26L, G26K, G26M, G26F, G26P, G26S, G26T, G26W, G26Y, and G26V.
- the point mutants envisioned are F27A, F27R, F27N, F27D, F27C, F27Q, F27E, F27G, F27H, F27I, F27L, F27K, F27M, F27P, F27S, F27T, F27W, F27Y, and F27V.
- the point mutants envisioned are T28A, T28R, T28N, T28D, T28C, T28Q, T28E, T28G, T28H, T28I, T28L, T28K, T28M, T28F, T28P, T28S, T28W, T28Y, and T28V.
- the point mutants envisioned are F29A, F29R, F29N, F29D, F29C, F29Q, F29E, F29G, F29H, F29I, F29L, F29K, F29M, F29P, F29S, F29T, F29W, F29Y, and F29V.
- the point mutants envisioned are I30A, I30R, I30N, I30D, I30C, I30Q, I30E, I30G, I30H, I30L, I30K, I30M, I30F, I30P, I30S, I30T, I30W, I30Y, and I30V.
- the point mutants envisioned are D31A, D31 R, D31 N, D31 C, D31 Q, D31 E, D31 G, D31 H, D311, D31 L, D31 K, D31 M, D31 F, D31 P, D31S, D31T, D31W, D31Y, and D31V.
- the point mutants envisioned are Y32A, Y32R, Y32N, Y32D, Y32C, Y32Q, Y32E, Y32G, Y32H, Y32I, Y32L, Y32K, Y32M, Y32F, Y32P, Y32S, Y32T, Y32W, and Y32V.
- the point mutants envisioned are Y33A, Y33R, Y33N, Y33D, Y33C, Y33Q, Y33E, Y33G, Y33H, Y33I, Y33L, Y33K, Y33M, Y33F, Y33P, Y33S, Y33T, Y33W, and Y33V.
- the point mutants envisioned are M34A, M34R, M34N, M34D, M34C, M34Q, M34E, M34G, M34H, M34I, M34L, M34K, M34F, M34P, M34S, M34T, M34W, M34Y, and M34V.
- the point mutants envisioned are N35A, N35R, N35D, N35C, N35Q, N35E, N35G, N35H, N35I, N35L, N35K, N35M, N35F, N35P, N35S, N35T, N35W, N35Y, and N35V.
- the point mutants envisioned are F50A, F50R, F50N, F50D, F50C, F50Q, F50E, F50G, F50H, F50I, F50L, F50K, F50M, F50P, F50S, F50T, F50W, F50Y, and F50V.
- the point mutants envisioned are 151 A, 151 R, 151 N, 151 D, 151 C, 151 Q, 151 E, 151 G, 151 H, 151 L, 151 K, 151 M, 151 F, 151 P, 151 S, I51T, 151 W, 151 Y, and 151V.
- the point mutants envisioned are R52A, R52N, R52D, R52C, R52Q, R52E, R52G, R52H, R52I, R52L, R52K, R52M, R52F, R52P, R52S, R52T, R52W, R52Y, and R52V.
- the point mutants envisioned are N53A, N53R, N53D, N53C, N53Q, N53E, N53G, N53H, N53I, N53L, N53K, N53M, N53F, N53P, N53S, N53T, N53W, N53Y, and N53V.
- the point mutants envisioned are K54A, K54R, K54N, K54D, K54C, K54Q, K54E, K54G, K54H, K54I, K54L, K54M, K54F, K54P, K54S, K54T, K54W, K54Y, and K54V.
- the point mutants envisioned are A55R, A55N, A55D, A55C, A55Q, A55E, A55G, A55H, A55I, A55L, A55K, A55M, A55F, A55P, A55S, A55T, A55W, A55Y, and A55V.
- the point mutants envisioned are N56A, N56R, N56D, N56C, N56Q, N56E, N56G, N56H, N56I, N56L, N56K, N56M, N56F, N56P, N56S, N56T, N56W, N56Y, and N56V.
- the point mutants envisioned are D57A, D57R, D57N, D57C, D57Q, D57E, D57G, D57H, D57I, D57L, D57K, D57M, D57F, D57P, D57S, D57T, D57W, D57Y, and D57V.
- the point mutants envisioned are Y58A, Y58R, Y58N, Y58D, Y58C, Y58Q, Y58E, Y58G, Y58H, Y58I, Y58L, Y58K, Y58M, Y58F, Y58P, Y58S, Y58T, Y58W, and Y58V.
- the point mutants envisioned are T59A, T59R, T59N, T59D, T59C, T59Q, T59E, T59G, T59H, T59I, T59L, T59K, T59M, T59F, T59P, T59S, T59W, T59Y, and T59V.
- the point mutants envisioned are T60A, T60R, T60N, T60D, T60C, T60Q, T60E, T60G, T60H, T60I, T60L, T60K, T60M, T60F, T60P, T60S, T60W, T60Y, and T60V.
- the point mutants envisioned are E61A, E61 R, E61 N, E61 D, E61C, E61 Q, E61 E, E61 G, E61 H, E611, E61 L, E61 K, E61 M, E61 F, E61 P, E61S, E61T, E61W, E61Y, and E61V.
- the point mutants envisioned are Y62A, Y62R, Y62N, Y62D, Y62C, Y62Q, Y62E, Y62G, Y62H, Y62I, Y62L, Y62K, Y62M, Y62F, Y62P, Y62S, Y62T, Y62W, Y62Y, and Y62V.
- the point mutants envisioned are S63A, S63R, S63N, S63D, S63C, S63Q, S63E, S63G, S63H, S63I, S63L, S63K, S63M, S63F, S63P, S63S, S63T, S63W, S63Y, and S63V.
- the point mutants envisioned are T64A, T64R, T64N, T64D, T64C, T64Q, T64E, T64G, T64H, T64I, T64L, T64K, T64M, T64F, T64P, T64S, T64T, T64W, T64Y, and T64V.
- the point mutants envisioned are R93A, R93N, R93D, R93C, R93Q, R93E, R93G, R93H, R93I, R93L, R93K, R93M, R93F, R93P, R93S, R93T, R93W, R93Y, and R93V.
- the point mutants envisioned are H94A, H94R, H94N, H94D, H94C, H94Q, H94E, H94G, H94I, H94L, H94K, H94M, H94F, H94P, H94S, H94T, H94W, H94Y, and H94V.
- the point mutants envisioned are M95A, M95R, M95N, M95D, M95C, M95Q, M95E, M95G, M95H, M95I, M95L, M95K, M95F, M95P, M95S, M95T, M95W, M95Y, and M95V.
- the point mutants envisioned are Y96A, Y96R, Y96N, Y96D, Y96C, Y96Q, Y96E, Y96G, Y96H, Y96I, Y96L, Y96K, Y96M, Y96F, Y96P, Y96S, Y96T, Y96W, and Y96V.
- the point mutants envisioned are D97A, D97R, D97N, D97C, D97Q, D97E, D97G, D97H, D97I, D97L, D97K, D97M, D97F, D97P, D97S, D97T, D97W, D97Y, and D97V.
- the point mutants envisioned are D98A, D98R, D98N, D98C, D98Q, D98E, D98G, D98H, D98I, D98L, D98K, D98M, D98F, D98P, D98S, D98T, D98W, D98Y, and D98V.
- the point mutants envisioned are G99A, G99R, G99N, G99D, G99C, G99Q, G99E, G99H, G99I, G99L, G99K, G99M, G99F, G99P, G99S, G99T, G99W, G99Y, and G99V.
- the point mutants envisioned are F100A, F100R, F100N, F100D, F100C, F100Q, F100E, F100G, F100H, F100I, F100L, F100K, F100M, F100P, F100S, F100T, F100W, F100Y, and F100V.
- the point mutants envisioned are D101A, D101 R, D101 N, D101 C, D101 Q, D101 E, D101 G, D101 H, D101 I, D101 L, D101 K, D101 M, D101 F, D101 P, D101 S, D101T, D101W, D101Y, and D101V.
- the point mutants envisioned are F102A, F102R, F102N, F102D, F102C, F102Q, F102E, F102G, F102H, F102I, F102L, F102K, F102M, F102P, F102S, F102T, F102W, F102Y, and F102V.
- the point mutants envisioned are A25R, A25N, A25D, A25C, A25Q, A25E, A25G, A25H, A25I, A25L, A25K, A25M, A25F, A25P, A25S, A25T, A25W, A25Y, and A25V.
- the point mutants envisioned are S26A, S26R, S26N, S26D, S26C, S26Q, S26E, S26G, S26H, S26I, S26L, S26K, S26M, S26F, S26P, S26T, S26W, S26Y, and S26V.
- the point mutants envisioned are S27A, S27R, S27N, S27D, S27C, S27Q, S27E, S27G, S27H, S27I, S27L, S27K, S27M, S27F, S27P, S27T, S27W, S27Y, and S27V.
- the point mutants envisioned are S28A, S28R, S28N, S28D, S28C, S28Q, S28E, S28G, S28H, S28I, S28L, S28K, S28M, S28F, S28P, S28T, S28W, S28Y, and S28V.
- the point mutants envisioned are V29A, V29R, V29N, V29D, V29C, V29Q, V29E, V29G, V29H, V29I, V29L, V29K, V29M, V29F, V29P, V29S, V29T, V29W, and V29Y.
- the point mutants envisioned are R30A, R30N, R30D, R30C, R30Q, R30E, R30G, R30H, R30I, R30L, R30K, R30M, R30F, R30P, R30S, R30T, R30W, R30Y, and R30V.
- the point mutants envisioned are Y32A, Y32R, Y32N, Y32D, Y32C, Y32Q, Y32E, Y32G, Y32H, Y32I, Y32L, Y32K, Y32M, Y32F, Y32P, Y32S, Y32T, Y32W, and Y32V.
- the point mutants envisioned are M33A, M33R, M33N, M33D, M33C, M33Q, M33E, M33G, M33H, M33I, M33L, M33K, M33F, M33P, M33S, M33T, M33W, M33Y, and M33V.
- the point mutants envisioned are H34A, H34R, H34N, H34D, H34C, H34Q, H34E, H34G, H34I, H34L, H34K, H34M, H34F, H34P, H34S, H34T, H34W, H34Y, and H34V.
- L46A For light chain CDR2 (having the sequence LLIYDTSKLA), when the amino acid residue to be mutated is L46, the point mutants envisioned are L46A, L46R, L46N, L46D, L46C, L46Q, L46E, L46G, L46H, L46I, L46K, L46M, L46F, L46P, L46S, L46T, L46W, L46Y, and L46V.
- the point mutants envisioned are L47A, L47R, L47N, L47D, L47C, L47Q, L47E, L47G, L47H, L47I, L47K, L47M, L47F, L47P, L47S, L47T, L47W, L47Y, and L47V.
- the point mutants envisioned are I48A, I48R, I48N, I48D, I48C, I48Q, I48E, I48G, I48H, I48L, I48K, I48M, I48F, I48P, I48S, I48T, I48W, I48Y, and 148V.
- the point mutants envisioned are Y49A, Y49R, Y49N, Y49D, Y49C, Y49Q, Y49E, Y49G, Y49H, Y49I, Y49L, Y49K, Y49M, Y49F, Y49P, Y49S, Y49T, Y49W, and Y49V.
- the point mutants envisioned are D50A, D50R, D50N, D50C, D50Q, D50E, D50G, D50H, D50I, D50L, D50K, D50M, D50F, D50P, D50S, D50T, D50W, D50Y, and D50V.
- the point mutants envisioned are T51A, T51 R, T51 N, T51 D, T51 C, T51Q, T51 E, T51 G, T51 H, T51 I, T51 L, T51 K, T51 M, T51 F, T51 P, T51 S, T51W, T51Y, and T51V.
- the point mutants envisioned are S52A, S52R, S52N, S52D, S52C, S52Q, S52E, S52G, S52H, S52I, S52L, S52K, S52M, S52F, S52P, S52T, S52W, S52Y, and S52V.
- the point mutants envisioned are K53A, K53R, K53N, K53D, K53C, K53Q, K53E, K53G, K53H, K53I, K53L, K53M, K53F, K53P, K53S, K53T, K53W, K53Y, and K53V.
- the point mutants envisioned are L54A, L54R, L54N, L54D, L54C, L54Q, L54E, L54G, L54H, L54I, L54K, L54M, L54F, L54P, L54S, L54T, L54W, L54Y, and L54V.
- the point mutants envisioned are A55R, A55N, A55D, A55C, A55Q, A55E, A55G, A55H, A55I, A55L, A55K, A55M, A55F, A55P, A55S, A55T, A55W, A55Y, and A55V.
- the point mutants envisioned are Q89A, Q89R, Q89N, Q89D, Q89C, Q89E, Q89G, Q89H, Q89I, Q89L, Q89K, Q89M, Q89F, Q89P, Q89S, Q89T, Q89W, Q89Y, and Q89V.
- the point mutants envisioned are Q90A, Q90R, Q90N, Q90D, Q90C, Q90E, Q90G, Q90H, Q90I, Q90L, Q90K, Q90M, Q90F, Q90P, Q90S, Q90T, Q90W, Q90Y, and Q90V.
- the point mutants envisioned are W91A, W91 R, W91 N, W91 D, W91 C, W91 Q, W91 E, W91 G, W91 H, W911, W91 L, W91 K, W91 M, W91 F, W91 P, W91 S, W91T, W91Y, and W91V.
- the point mutants envisioned are S92A, S92R, S92N, S92D, S92C, S92Q, S92E, S92G, S92H, S92I, S92L, S92K, S92M, S92F, S92P, S92T, S92W, S92Y, and S92V.
- the point mutants envisioned are Y93A, Y93R, Y93N, Y93D, Y93C, Y93Q, Y93E, Y93G, Y93H, Y93I, Y93L, Y93K, Y93M, Y93F, Y93P, Y93S, Y93T, Y93W, and Y93V.
- the point mutants envisioned are N94A, N94R, N94D, N94C, N94Q, N94E, N94G, N94H, N94I, N94L, N94K, N94M, N94F, N94P, N94S, N94T, N94W, N94Y, and N94V.
- the point mutants envisioned are P95A, P95R, P95N, P95D, P95C, P95Q, P95E, P95G, P95H, P95I, P95L, P95K, P95M, P95F, P95S, P95T, P95W, P95Y, and P95V.
- the point mutants envisioned are L96A, L96R, L96N, L96D, L96C, L96Q, L96E, L96G, L96H, L96I, L96K, L96M, L96F, L96P, L96S, L96T, L96W, L96Y, and L96V.
- the point mutants envisioned are T97A, T97R, T97N, T97D, T97C, T97Q, T97E, T97G, T97H, T97I, T97L, T97K, T97M, T97F, T97P, T97S, T97W, T97Y, and T97V.
- the point mutants envisioned are F98A, F98R, F98N, F98D, F98C, F98Q, F98E, F98G, F98H, F98I, F98L, F98K, F98M, F98P, F98S, F98T, F98W, F98Y, and F98V.
- This example sets forth examples of double amino acid point mutations of an exemplary heavy chain CDR3 envisioned for the present monoclonal antibody.
- the heavy chain CDR3 has the following amino acid sequence: RHMYDDGFDF, wherein the numbering for each heavy chain CDR3 residue corresponds to the amino acid residue numbering in the heavy chain variable region shown in Figure 5.
- the first and third heavy chain CDR3 residues, i.e. , R and M are, respectively, the 93rd and 95th amino acid residues of the heavy chain variable region shown in Figure 5. As such, they are referred to in this example as R93 and M95.
- the amino acids used in this example are the following 20 naturally occurring amino acids: A, R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, and V.
- R93A/M95Q i.e. , the double point mutation wherein A replaces R93 and Q replaces M95
- Examples of double point mutations are set forth below. In each example, the double point mutation is expressed as a two- letter abbreviation. So, for example, the double point mutation R93A/M95Q would be expressed simply as AQ.
- the double point mutants envisioned are as follows:
- AA AR, AN, AD, AC, AQ, AE, AG, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, NA, NR, NN, ND, NC, NQ, NE, NG, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR, DN, DD, DC, DQ, DE, DG, DI, DL, DK, DM, DF, DP, DS, DT, DW, DY, DV, CA, CR, CN, CD, CC, CQ, CE, CG, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, QA, QR, QN, QD, QC, QQ, QE, QG, QI, QL, QK, QM, QF, QP, QS, QT, QW,
- the double point mutants envisioned are as follows:
- AA AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AF, AP, AS, AT, AW, AY, AV, NA, NR, NN, ND, NC, NQ, NE, NG, NH, Nl, NL, NK, NF, NP, NS, NT, NW, NY, NV, DA, DR, DN, DD, DC, DQ, DE, DG, DH, DI, DL, DK, DF, DP, DS, DT, DW, DY, DV, CA, CR, CN, CD, CC, CQ, CE, CG, CH, Cl, CL, CK, CF, CP, CS, CT, CW, CY, CV, QA, QR, QN, QD,
- the double point mutants envisioned are as follows:
- AA AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AV, NA,
- NR NN, ND, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NV, DA, DR,
- DN DD, DC, DQ, DE, DG, DH, DI, DL, DK, DM, DF, DP, DS, DT, DW, DV, CA, CR, CN,
- the double point mutants envisioned are as follows:
- AA AR, AN, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, NA, NR, NN, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR, DN, DC, DQ, DE, DG, DH, DI, DL, DK, DM, DF, DP, DS, DT, DW, DY, DV, CA, CR, CN, CC, CQ, CE, CG, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, QA, QR, QN, QC, QQ, QE, QG, QH, QI, QL, QK, QM, QF, QP, QS, QT, QW
- the double point mutants envisioned are as follows:
- AA AR, AN, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, NA, NR, NN, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR,
- the double point mutants envisioned are as follows:
- AA AR, AN, AD, AC, AQ, AE, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, NA, NR, NN, ND, NC, NQ, NE, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR,
- DN DD, DC, DQ, DE, DH, DI, DL, DK, DM, DF, DP, DS, DT, DW, DY, DV, CA, CR, CN, CD, CC, CQ, CE, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, QA, QR, QN,
- the double point mutants envisioned are as follows:
- AA AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AP, AS, AT, AW, AY, AV, NA,
- NR NN, ND, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NP, NS, NT, NW, NY, NV, DA, DR,
- DN DD, DC, DQ, DE, DG, DH, DI, DL, DK, DM, DP, DS, DT, DW, DY, DV, CA, CR, CN,
- the double point mutants envisioned are as follows:
- AA AR, AN, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, NA, NR, NN, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR,
- the double point mutants envisioned are as follows:
- AA AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AP, AS, AT, AW, AY, AV, NA,
- NR NN, ND, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NP, NS, NT, NW, NY, NV, DA, DR,
- DN DD, DC, DQ, DE, DG, DH, DI, DL, DK, DM, DP, DS, DT, DW, DY, DV, CA, CR, CN,
- the double point mutants envisioned are as follows:
- AA AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RD, RC, RQ, RE, RG, RH, Rl, RL, RK, RF, RP, RS, RT, RW, RY, RV, NA, NR,
- NN ND
- NC NQ
- NE NQ
- NE NG
- NH Nl
- NL NK
- NF NP
- NS NT
- NW NY
- NV DA
- DR DN
- the double point mutants envisioned are as follows:
- AA AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AV, RA, RR, RN, RD, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RV, NA, NR,
- NN ND
- NC NQ
- NE NQ
- NE NG
- NH Nl
- NL NK
- NM NF
- NP NP
- NS NT
- NW NV
- DA DR
- DN DN
- the double point mutants envisioned are as follows:
- AA AR, AN, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV, NA, NR,
- NN NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR, DN,
- FT FW, FY, FV, PA, PR, PN, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PF, PP, PS, PT, PW, PY, PV, SA, SR, SN, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SF, SP, SS, ST, SW, SY, SV, TA, TR, TN, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TF, TP, TS, TT, TW, TY, TV, WA, WR, WN, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WF, WP, WS, WT, WW, WY, WV, YA, YR, YN, YC, YQ, YE, YG, YH, Yl,
- AA AR, AN, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV, NA, NR,
- NN NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR, DN,
- the double point mutants envisioned are as follows:
- NN ND
- NC NQ
- NE NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR, DN,
- the double point mutants envisioned are as follows:
- AA AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AP, AS, AT, AW, AY, AV, RA, RR, RN, RD, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RP, RS, RT, RW, RY, RV, NA, NR,
- NN ND
- NC NQ
- NE NQ
- NE NG
- NH Nl
- NL NK
- NM NP
- NS NT
- NW NY
- NV DA
- DR DR
- the double point mutants envisioned are as follows: AA, AR, AN, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV, NA, NR,
- NN NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR, DN,
- the double point mutants envisioned are as follows:
- AA AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AP, AS, AT, AW, AY, AV, RA, RR, RN, RD, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RP, RS, RT, RW, RY, RV, NA, NR,
- NN ND
- NC NQ
- NE NQ
- NE NG
- NH Nl
- NL NK
- NM NP
- NS NT
- NW NY
- NV DA
- DR DR
- the double point mutants envisioned are as follows:
- AA AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AV, RA, RR, RN, RD, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RV, NA, NR,
- NN ND
- NC NQ
- NE NQ
- NE NG
- NH Nl
- NL NK
- NM NF
- NP NP
- NS NT
- NW NV
- DA DR
- DN DN
- the double point mutants envisioned are as follows:
- AA AR, AN, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV, NA, NR, NN, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR, DN, DC, DQ, DE, DG, DH, DI, DL, DK, DM, DF, DP, DS, DT, DW, DY, DV, CA, CR, CN, CC, CQ, CE, CG, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW
- the double point mutants envisioned are as follows:
- AA AR, AN, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV, NA, NR,
- NN NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR, DN,
- the double point mutants envisioned are as follows:
- NN ND
- NC NQ
- NE NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR, DN,
- the double point mutants envisioned are as follows:
- AA AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AP, AS, AT, AW, AY, AV, RA, RR, RN, RD, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RP, RS, RT, RW, RY, RV, NA, NR,
- NN ND
- NC NQ
- NE NQ
- NE NG
- NH Nl
- NL NK
- NM NP
- NS NT
- NW NY
- NV DA
- DR DR
- the double point mutants envisioned are as follows:
- AA AR, AN, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV, NA, NR,
- NN NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR, DN,
- AA AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AP, AS, AT, AW, AY, AV, RA, RR, RN, RD, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RP, RS, RT, RW, RY, RV, NA, NR,
- NN ND
- NC NQ
- NE NQ
- NE NG
- NH Nl
- NL NK
- NM NP
- NS NT
- NW NY
- NV DA
- DR DR
- the double point mutants envisioned are as follows:
- AA AR, AN, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV, NA, NR,
- NN NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR, DN,
- the double point mutants envisioned are as follows:
- AA AR, AN, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV, NA, NR,
- NN NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR, DN,
- NN ND
- NC NQ
- NE NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR, DN,
- the double point mutants envisioned are as follows:
- AA AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AP, AS, AT, AW, AY, AV, RA, RR, RN, RD, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RP, RS, RT, RW, RY, RV, NA, NR,
- NN ND
- NC NQ
- NE NQ
- NE NG
- NH Nl
- NL NK
- NM NP
- NS NT
- NW NY
- NV DA
- DR DR
- the double point mutants envisioned are as follows:
- AA AR, AN, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV, NA, NR,
- NN NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR, DN,
- FT FW, FY, FV, PA, PR, PN, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PF, PP, PS, PT, PW, PY, PV, SA, SR, SN, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SF, SP, SS, ST, SW, SY, SV, TA, TR, TN, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TF, TP, TS, TT, TW, TY, TV, WA, WR, WN, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WF, WP, WS, WT, WW, WY, WV, VA, VR, VN, VC, VQ, VE, VG, VH, VI, VL, VK, VM, VF,
- AA AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AP, AS, AT, AW, AY, AV, RA, RR, RN, RD, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RP, RS, RT, RW, RY, RV, NA, NR,
- NN ND
- NC NQ
- NE NQ
- NE NG
- NH Nl
- NL NK
- NM NP
- NS NT
- NW NY
- NV DA
- DR DR
- the double point mutants envisioned are as follows:
- AA AR, AN, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV, NA, NR, NN, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, CA, CR, CN, CC, CQ, CE, CG, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, QA, QR, QN, QC, QQ, QE, QG, QH, QI, QL, QK, QM, QF, QP, QS, QT, Q
- the double point mutants envisioned are as follows:
- AA AR, AN, AD, AC, AQ, AE, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RD, RC, RQ, RE, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV, NA, NR, NN, ND, NC, NQ, NE, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, CA, CR, CN, CD, CC, CQ, CE, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, QA, QR, QN, QD, QC, QQ, QE, QH, QI, QL, QK, QM, QF, QP, QS, QT, QW
- AA AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AP, AS, AT, AW, AY, AV, RA, RR, RN, RD, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RP, RS, RT, RW, RY, RV, NA, NR, NN, ND, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NP, NS, NT, NW, NY, NV, CA, CR, CN, CD, CC, CQ, CE, CG, CH, Cl, CL, CK, CM, CP, CS, CT, CW, CY, CV, QA, QR, QN, QD, QC, QQ, QE, QG, QH, QI, QL, QK, QM, QP, QS, QT, QW,
- the double point mutants envisioned are as follows:
- AA AR, AN, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV, NA, NR, NN, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, CA, CR, CN, CC, CQ, CE, CG, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, QA, QR, QN, QC, QQ, QE, QG, QH, QI, QL, QK, QM, QF, QP, QS, QT, Q
- the double point mutants envisioned are as follows:
- AA AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AP, AS, AT, AW, AY, AV, RA,
- RR RN, RD, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RP, RS, RT, RW, RY, RV, NA, NR,
- NN ND
- NC NQ
- NE NQ
- NE NG
- NH Nl
- NL NK
- NM NP
- NS NT
- NW NY
- NV CA
- CR CN
- AA AR, AN, AD, AC, AQ, AE, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RD, RC, RQ, RE, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV, NA, NR, NN, ND, NC, NQ, NE, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, CA, CR, CN, CD, CC, CQ, CE, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, QA, QR, QN, QD, QC, QQ, QE, QH, QI, QL, QK, QM, QF, QP, QS, QT, QW
- the double point mutants envisioned are as follows:
- AA AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AP, AS, AT, AW, AY, AV, RA, RR, RN, RD, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RP, RS, RT, RW, RY, RV, NA, NR,
- NN ND
- NC NQ
- NE NQ
- NE NG
- NH Nl
- NL NK
- NM NP
- NS NT
- NW NY
- NV CA
- CR CN
- the double point mutants envisioned are as follows:
- AA AR, AN, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV, NA, NR, NN, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, CA, CR, CN, CC, CQ, CE, CG, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, QA, QR, QN, QC, QQ, QE, QG, QH, QI, QL, QK, QM, QF, QP, QS, QT, Q
- AA AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AP, AS, AT, AW, AY, AV, RA, RR, RN, RD, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RP, RS, RT, RW, RY, RV, NA, NR, NN, ND, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NP, NS, NT, NW, NY, NV, CA, CR, CN, CD, CC, CQ, CE, CG, CH, Cl, CL, CK, CM, CP, CS, CT, CW, CY, CV, QA, QR, QN, QD, QC, QQ, QE, QG, QH, QI, QL, QK, QM, QP, QS, QT, QW,
- the double point mutants envisioned are as follows:
- AA AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AP, AS, AT, AW, AY, AV, RA, RR, RN, RD, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RP, RS, RT, RW, RY, RV, NA, NR,
- NN ND
- NC NQ
- NE NQ
- NE NG
- NH Nl
- NL NK
- NM NP
- NS NT
- NW NY
- NV DA
- DR DR
- the double point mutants envisioned are as follows:
- AA AR, AN, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV, NA, NR,
- NN NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR, DN,
- FT FW, FY, FV, PA, PR, PN, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PF, PP, PS, PT, PW, PY, PV, SA, SR, SN, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SF, SP, SS, ST, SW, SY, SV, TA, TR, TN, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TF, TP, TS, TT, TW, TY, TV, WA, WR, WN, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WF, WP, WS, WT, WW, WY, WV, YA, YR, YN, YC, YQ, YE, YG, YH, Yl,
- AA AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AP, AS, AT, AW, AY, AV, RA, RR, RN, RD, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RP, RS, RT, RW, RY, RV, NA, NR,
- NN ND
- NC NQ
- NE NQ
- NE NG
- NH Nl
- NL NK
- NM NP
- NS NT
- NW NY
- NV DA
- DR DR
- the double point mutants envisioned are as follows:
- AA AR, AN, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV, NA, NR,
- NN NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR, DN,
- the double point mutants envisioned are as follows:
- AA AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AP, AS, AT, AW, AY, AV, RA, RR, RN, RD, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RP, RS, RT, RW, RY, RV, NA, NR,
- NN ND
- NC NQ
- NE NQ
- NE NG
- NH Nl
- NL NK
- NM NP
- NS NT
- NW NY
- NV DA
- DR DR
- AA AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AP, AS, AT, AW, AY, AV, RA,
- RR RN, RD, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RP, RS, RT, RW, RY, RV, NA, NR,
- NN ND
- NC NQ
- NE NQ
- NE NG
- NH Nl
- NL NK
- NM NP
- NS NT
- NW NY
- NV CA
- CR CN
- Adeno-Associated Virus (AAV) Guide Addgene Catalog (https://www.addgene. org/viral-vectors/aav/aav-guide/).
- ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker, Signal Transduction and Targeted Therapy, 6, Article number: 315 (2021 ).
- ACE2 angiotensin receptor 2
- angiotensin receptors 1 and 2 Front. Pharmacol., 30 January 2015.
- AAV Adeno-Associated Virus
- TMPRSS2 a potential target for treatment of influenza virus and coronavirus infections, Biochimie 142 (2017) 1-10.
- TMPRSS2 isoform 1 activates respiratory viruses and is expressed in viral target cells, PLOS ONE September 17, 2015.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
This invention provides a monoclonal antibody that (i) specifically binds to the extracellular portion of human angiotensin converting enzyme 2 (hACE2); (ii) specifically inhibits binding of SARS-CoV-2 to the extracellular portion of hACE2; and (iii) does not significantly inhibit the ability of hACE2 to cleave angiotensin II and/or a synthetic MCA-based peptide. This invention also provides related recombinant AAV vectors, recombinant AAV particles, compositions, prophylactic and therapeutic methods, and kits.
Description
ACE2-TARGETED COMPOSITIONS AND METHODS FOR TREATING COOVID-19
This application claims the benefit of U.S. Application No. 63/379,019, filed October 11 , 2022, the contents of which are incorporated herein by reference.
Throughout this application, various publications are cited. The disclosure of these publications is hereby incorporated by reference into this application to describe more fully the state of the art to which this invention pertains.
Field of the Invention
The present invention relates to monoclonal antibodies and related engineered viruses useful for therapeutically and prophylactically addressing SARS-CoV-2 infection.
Background of the Invention
Since the beginning of the COVID-19 outbreak, there has been - and continues to be - an intensive worldwide effort to develop effective anti-SARS-CoV-2 therapeutics and prophylactics. To date, this nascent effort has yielded a few effective vaccines, but little success otherwise. For at least this reason, there is an urgent need for an effective way to treat and prevent SARS-CoV-2 infection.
Summary of the Invention
This invention provides a monoclonal antibody that (i) specifically binds to the extracellular portion of human angiotensin converting enzyme 2 (hACE2); (ii) specifically inhibits binding of SARS-CoV-2 to the extracellular portion of hACE2; and (iii) does not significantly inhibit the ability of hACE2 to cleave angiotensin II and/or a synthetic MCA-based peptide.
This invention also provides a monoclonal antibody comprising residues 21 through 230 of the light chain amino acid sequence set forth in Figure 6 and residues 25 through 471 of the heavy chain amino acid sequence set forth in Figure 7. This invention further provides a monoclonal antibody comprising residues 21 through 230 of the light
chain amino acid sequence set forth in Figure 6 and residues 25 through 471 of the heavy chain amino acid sequence set forth in Figure 8.
This invention also provides an isolated nucleic acid molecule encoding (i) the complete light chain, or a portion of the light chain, of the present monoclonal antibody, and/or (ii) the complete heavy chain, or a portion of the heavy chain, of the present monoclonal antibody. This invention further provides a recombinant vector comprising the present nucleic acid molecule operably linked to a promoter of RNA transcription. This invention still further provides a host vector system comprising one or more of the present vectors in a suitable host cell.
This invention further provides a composition comprising (i) the present monoclonal antibody, and (ii) a pharmaceutically acceptable carrier.
This invention still further provides a method for reducing the likelihood of a human subject’s becoming infected with SARS-CoV-2 comprising administering to the subject a prophylactically effective amount of the present monoclonal antibody. This invention also provides a method for treating a human subject who is infected with SARS-CoV-2 comprising administering to the subject a therapeutically effective amount of the present monoclonal antibody.
This invention provides (a) a recombinant AAV vector comprising a nucleic acid sequence encoding a heavy chain and/or a light chain of the present monoclonal antibody; (b) a recombinant AAV particle comprising the present recombinant AAV vector; and (c) a composition comprising (i) a plurality of the present AAV particles and (ii) a pharmaceutically acceptable carrier.
This invention provides (a) a method for reducing the likelihood of a human subject’s becoming infected with SARS-CoV-2 comprising administering to the subject a prophylactically effective number of the present AAV particles; and (b) a method for treating a human subject who is infected with SARS-CoV-2 comprising administering to the subject a therapeutically effective number of the present AAV particles.
Finally, this invention provides (a) a first kit comprising, in separate compartments, (i) a diluent and (ii) a suspension of the present monoclonal antibody; (b) a second kit
comprising, in separate compartments, (i) a diluent and (ii) the present monoclonal antibody in lyophilized form; and (c) a third kit comprising, in separate compartments, (i) a diluent and (ii) a suspension of a plurality of the present recombinant AAV particles.
Brief Description of the Figures
Figure 1
This figure sets forth the amino acid sequence of hACE2, as well as the nucleic acid sequence encoding it (Tipnis, et al.).
Figure 2
This figure sets forth the nucleotide and predicted amino acid sequence of human TMPRSS2 (GenBank Accession No. U75329). The potential initiation methionine codon and the translation stop codon are bold and underlined. The trapped sequences are underlined (for example the trapped sequence HMC26A01 extending from nucleotide 740 to 955). The different domains of the predicted polypeptide are dotted underlined (for example the SRCR domain extends from amino acid residue 148 to 242). The locations of the introns are shown with arrows. (Figure from, and text adapted from, Figure 1 of A. Paoloni-Giacobino, et al.)
Figure 3
This figure sets forth the characterization of SARS-CoV-2 RBD. It shows multiple sequence alignment of RBDs of SARS-CoV-2, SARS-CoV, and MERS-CoV spike (S) proteins. GenBank accession numbers are QHR63250.1 (SARS-CoV-2 S), AY278488.2 (SARS-CoV S), and AFS88936.1 (MERS-CoV S). Variable amino acid residues between SARS-CoV-2 and SARS-CoV are highlighted in dark grey (cyan), and conserved residues among SARS-CoV-2, SARS-CoV, and MERS-CoV are highlighted in light grey (yellow). Asterisks represent fully conserved residues, colons represent highly conserved residues, and periods represent lowly conserved residues. (Figure from, and text adapted from, Figure 1 (a) of Tai, et al.).
Figure 4
This figure shows a schematic diagram of an expression cassette for inclusion in an AAV-antibody vector.
Figure 5
This figure, taken from Du, et al., shows a humanization strategy for monoclonal antibody 11 B11 . Sequence alignments highlight the humanization strategy of murine 11 B11 , which strategy involves retaining all the CDRs and substituting the remaining amino acids with the corresponding residues of the human immunoglobulins. Human IGHV2-23*04, which exhibits high sequence identity to murine 11 B11 in the heavy chain, was selected as the humanization backbone for the H chain, while IGKV2-39*01 was selected as the humanization backbone for the L chain. Panel (a) shows the heavy chain sequences, and panel (b) shows the light chain sequences. This description is adapted from Du, et al.
Figure 6
This figure shows the amino acid sequence of a human kappa light chain (H11 B11- hKappa). This sequence includes a leader sequence (shown in red; residues 1-20, beginning with MET... and ending with ... STG) and the light chain sequence (residues 21-230, beginning with DIQ... and ending with ... GEC). The variable domain is shaded. The C-terminal lysine residue normally present in the wild-type light chain sequence is deleted here, although its inclusion is envisioned in one embodiment of this invention.
Figure 7
This figure shows the amino acid sequence of a human lgG1 (G1m17) heavy chain (H11 B11 -h IgG 1 (STR). This sequence includes a leader sequence (shown in red; residues 1-24, beginning with MDP... and ending with ... SYG) and the heavy chain sequence (residues 25-471 , beginning with EVQ... and ending with ... SPG). The variable domain is shaded. The constant domain sequence contains the mutation (L234S)(L235T)(G236R). The C-terminal lysine residue normally present in the wildtype heavy chain sequence is deleted here, although its inclusion is envisioned in one embodiment of this invention.
Figure 8
This figure shows the amino acid sequence of a human lgG1 (G1m17) heavy chain (H11 B11 -h IgG 1 (STR/YTE). This sequence includes a leader sequence (shown in red; residues 1-24, beginning with MDP... and ending with ... SYG) and the heavy chain sequence (residues 25-471 , beginning with EVQ... and ending with ... SPG). The variable domain is shaded. The constant domain sequence contains the mutation
(L234S)(L235T)(G236R)(M252Y)(S254T) (T256E). The C-terminal lysine residue normally present in the wild-type heavy chain sequence is deleted here, although its inclusion is envisioned in one embodiment of this invention.
Figure 9
This figure shows the human kappa light chain (H11 B11 -hKappa) amino acid sequence shown in Figure 6, along with the full-length DNA sequence (pLEV123-H11 B11 -hKappa) encoding it. The C-terminal lysine residue normally present in the wild-type light chain sequence is deleted here, as indicated by an asterisk.
Figure 10
This figure shows the human IgG 1 (G1 ml 7) heavy chain (H11 B11 -h IgG 1 (STR) amino acid sequence shown in Figure 7, along with the full-length DNA sequence (pLEV123- H11 B11 -h IgG 1 (STR)) encoding it. The C-terminal lysine residue normally present in the wild-type heavy chain sequence is deleted here, as indicated by an asterisk.
Figure 11
This figure shows the human IgG 1 (G1 ml 7) heavy chain (H11 B11 -h IgG 1 (STR/YTE) amino acid sequence shown in Figure 8, along with the full-length DNA sequence (pLEV123-H11 B11 -hlgG1 (STR/YTE)) encoding it. The C-terminal lysine residue normally present in the wild-type heavy chain sequence is deleted here, as indicated by an asterisk.
Figure 12
This figure shows the kappa light chain (3E8-hKappa) amino acid sequence, along with the full-length DNA sequence (pLEV123-hKappa) encoding it. The C-terminal lysine residue normally present in the wild-type light chain sequence is deleted here, as indicated by an asterisk.
Figure 13
This figure shows the lgG1 heavy chain (3E8-hlgG1 (STR)) amino acid sequence, along with the full-length DNA sequence (pLEV123-3E8-hlgG1 (STR)) encoding it. The C- terminal lysine residue normally present in the wild-type heavy chain sequence is deleted here, as indicated by an asterisk.
Figure 14
This figure shows the lgG1 heavy chain (3E8-hlgG1 (STR/LS)) amino acid sequence, along with the full-length DNA sequence (pLEV123-3E8-hlgG1 (STR/LS)) encoding it. The C-terminal lysine residue normally present in the wild-type heavy chain sequence is deleted here, as indicated by an asterisk.
Detailed Description of the Invention
This invention provides certain antibodies and monoclonal antibody-encoding recombinant viral vectors, related viral particles, and related methods for inhibiting and treating SARS-CoV-2-infection.
Definitions
In this application, certain terms are used which shall have the meanings set forth as follows.
As used herein, “administer”, with respect to monoclonal antibodies, means to deliver the antibodies to a subject’s body via any known method suitable for that purpose. Specific modes of administration include, without limitation, intravenous administration, intramuscular administration, intranasal administration, and subcutaneous administration. Similarly, as used herein, “administer”, with respect to recombinant viral particles, means to deliver the particles to a subject’s body via any known method suitable for that purpose. Specific modes of administration include, without limitation, intravenous administration, intramuscular administration, and subcutaneous administration.
In this invention, monoclonal antibodies can be formulated using one or more routinely used pharmaceutically acceptable carriers. Such carriers are well known to those skilled in the art. For example, injectable drug delivery systems include solutions containing salts (e.g., sodium chloride and sodium phosphate). In a specific embodiment, the injectable drug delivery system comprises monoclonal antibody (e.g., 100 mg, 200 mg, 300 mg, 400 mg, or 500 mg) in the form of a lyophilized powder in a multi-use vial, which is then reconstituted and diluted in, for example, 0.9% Sodium Chloride Injection, USP. In another specific embodiment, the injectable drug delivery
system comprises monoclonal antibody (e.g., 100 mg/50 ml, 200 mg/50 ml, 300 mg/50 ml, 400 mg/50 ml, or 500 mg/50 ml) in the form of a suspension in a single-use vial, which is then withdrawn and diluted in, for example, 0.9% Sodium Chloride Injection, USP. Injectable drug delivery systems also include suspensions, gels, microspheres and polymeric injectables, and can comprise excipients such as solubility-altering agents (e.g., ethanol, propylene glycol, and sucrose) and polymers (e.g., polycaprylactones and PLGAs).
In addition, in this invention, recombinant viral particles can be formulated using one or more routinely used pharmaceutically acceptable carriers. Such carriers are well known to those skilled in the art. For example, injectable drug delivery systems include solutions containing salts (e.g., sodium chloride and sodium phosphate) and surfactants (e.g., a poloxamer). In a specific embodiment, the injectable drug delivery system comprises an aqueous solution of sodium chloride (e.g., 180 mM), sodium phosphate (e.g., 10 mM), and a poloxamer (e.g., 0.001% Poloxamer 188). Injectable drug delivery systems also include suspensions, gels, microspheres and polymeric injectables, and can comprise excipients such as solubility-altering agents (e.g., ethanol, propylene glycol, and sucrose) and polymers (e.g., polycaprylactones and PLGAs).
As used herein, the term “antibody” includes, without limitation, (a) an immunoglobulin molecule comprising two heavy chains (i.e. , H chains, such as p, 5, y, a and s) and two light chains (i.e., L chains, such as A and K) and which recognizes an antigen; (b) polyclonal and monoclonal immunoglobulin molecules; (c) monovalent (e.g., Fab) and divalent fragments thereof, and (d) bispecific forms thereof. Immunoglobulin molecules may derive from any of the commonly known classes, including but not limited to IgA, secretory IgA, IgG and IgM. IgG subclasses are also well known to those in the art and include, but are not limited to, human lgG1 , lgG2, lgG3 and lgG4 (preferably, in this invention, lgG1 ). Antibodies can be both naturally occurring and non-naturally occurring. Furthermore, antibodies include chimeric antibodies, wholly synthetic antibodies, single chain antibodies (e.g., scFv), and fragments thereof. Antibodies may contain, for example, all or a portion of a constant region (e.g., an Fc region) and a variable region, or contain only a variable region (responsible for antigen binding). Antibodies may be human, humanized, chimeric, or nonhuman. Methods for designing and making human and humanized antibodies are well known (See, e.g., Chiu and
Gilliland; Lafleur, et al.). Antibodies include, without limitation, the present monoclonal antibodies as defined herein.
As used herein, “CDR1” shall mean complementarity-determining region 1 , which includes heavy chain CDR1 and light chain CDR1. “CDR2” shall mean complementarity-determining region 2, which includes heavy chain CDR2 and light chain CDR2. Finally, “CDR3” shall mean complementarity-determining region 3, which includes heavy chain CDR3 and light chain CDR3.
As used herein, “effector function”, with respect to an antibody, includes, without limitation, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement fixation.
As used herein, the present monoclonal antibody binds to an hACE2 “epitope” comprising a given amino acid residue if, for example, that residue directly contacts (e.g., via a hydrogen bond) at least one amino acid residue in the antibody’s paratope.
As used herein, a subject who has been “exposed” to SARS-CoV-2 includes, for example, a subject who experienced a high-risk event (e.g., one in which he/she came into contact with the bodily fluids of an infected human subject, such as by inhaling droplets of virus-containing saliva or touching a virus-containing surface). In one embodiment, this exposure occurs two weeks, one week, five days, four days, three days, two days, one day, six hours, two hours, one hour, or 30 minutes prior to receiving the subject prophylaxis.
As used herein, “human angiotensin converting enzyme 2”, also referred to herein as “hACE2”, shall mean (i) the protein having the amino acid sequence set forth in Figure 1 ; or (ii) a naturally occurring human variant thereof (e.g., the 121 T variant, the N33D variant, the D38E variant, and the K26R variant). In a preferred embodiment, hACE2 shall mean the protein having the amino acid sequence set forth in Figure 1 .
As used herein, a “human subject” can be of any age, gender, or state of co-morbidity. In one embodiment, the subject is male, and in another, the subject is female. In another embodiment, the subject is co-morbid (e.g., afflicted with diabetes, asthma, and/or heart disease). In a further embodiment, the subject is not co-morbid. In still
another embodiment, the subject is younger than 60 years old. In yet another embodiment, the subject is at least 60 years old, at least 65 years old, at least 70 years old, at least 75 years old, at least 80 years old, at least 85 years old, or at least 90 years old.
As used herein, “human TMPRSS2”, also referred to herein as “hTMPRSS2”, shall mean (i) the protein having the amino acid sequence set forth in Figure 2; or (ii) a naturally occurring human variant thereof. Human TMPRSS2 is also known in the art as epitheliasin, and as transmembrane protease, serine 2. hTMPRSS2 cleaves the SARS-CoV-2 S protein. Without wishing to be bound by any particular theory of hTMPRSS2 function, it is believed that hTMPRSS2 cleaves SARS-CoV-2 S protein at an “S1/S2” cleavage site (i.e., between amino acid residues R685 and S686) and an “S2”’ cleavage site (i.e., between amino acid residues R815 and S816). See, e.g., Coutard, et al.
As used herein, a subject is “infected” with a virus if the virus is present in the subject. Present in the subject includes, without limitation, present in at least some cells in the subject, and/or present in at least some extracellular fluid in the subject. In one embodiment, the virus present in the subject’s cells is replicating. A subject who is exposed to a virus may or may not become infected with it.
Heavy chain modifications that “inhibit half antibody formation” in lgG4 are described, for example, in C. Dumet, et al. They include, without limitation, the following, with numbering according to the Ell Index: (i) S228P; (ii) the mutation combination S228P/R409K; and (iii) K447del and the mutation combination S228P/K447del. Related heavy chain modifications that solve the heavy chain-mispairing problem include, for example, the “knobs-into-holes” (kih) modifications described in M. Godar, et al., and WO/1996/027011.
As used herein, a “long serum half-life”, with respect to a monoclonal antibody, is a serum half-life of at least five days (preferably as measured in vivo in a human, but which may also be measured, for example, in mice, rats, rabbits, and monkeys (e.g., rhesus monkeys, cynamolgous macaques, and marmosets)). In a preferred embodiment, a monoclonal antibody has a long serum half-life if its half-life is at least 15 days, at least 20 days, at least 25 days, at least 30 days, at least 35 days, at least
40 days, at least 45 days, at least 50 days, at least 55 days, at least 60 days, at least 65 days, at least 70 days, at least 75 days, at least 80 days, at least 85 days, at least 90 days, at least 95 days, or at least 100 days. In another preferred embodiment, a monoclonal antibody has a long serum half-life if its half-life is from 15 days to 20 days, from 20 days to 25 days, from 25 days to 30 days, from 30 days to 35 days, from 35 days to 40 days, from 40 days to 45 days, from 45 days to 50 days, from 50 days to 55 days, from 55 days to 60 days, from 60 days to 65 days, from 65 days to 70 days, from 70 days to 75 days, from 75 days to 80 days, from 80 days to 85 days, from 85 days to 90 days, from 90 days to 95 days, from 95 days to 100 days, or over 100 days. Examples of IgG heavy chain modifications that increase half-life relative to corresponding wild-type IgG heavy chains (such as those that increase antibody binding to FcRn) are described in C. Dumet, et al. and G.J. Robbie, et al. They include, without limitation, the following, with numbering according to the Ell Index: (i) point mutations at position 252, 254, 256, 309, 311 , 433, 434, and/or 436, including the “YTE” mutation combination M252Y/S254T/T256E (U.S. Patent No. 7,083,784); (ii) the “LS” mutation combination M428L/N434S (WG/2009/086320); (iii) the “QL” mutation combination T250Q/M428L; and (iv) the mutation combinations M428L/V308F and Q311V/N434S.
As used herein, a monoclonal antibody having a “low effector function” includes, without limitation, (i) a monoclonal antibody that has no effector function (e.g., by virtue of having no Fc domain), and (ii) a monoclonal antibody that has a moiety (e.g., a modified Fc domain) possessing an effector function lower than that of a wild-type IgG 1 antibody. Monoclonal antibodies having a low effector function include, for example, a monoclonal lgG4 antibody (e.g., a monoclonal lgG4 antibody having heavy chains engineered to reduce effector function relative to wild-type lgG4 heavy chains). An example of an IgG 1 heavy chain modification that lowers effector function relative to wild-type lgG1 heavy chains is the L234A/L235A/P329G (LALA-PG) modification described in Ferarri, et al., with numbering according to the EU Index. Another example of an IgG 1 heavy chain modification that lowers effector function relative to wild-type lgG1 heavy chains is the L234A/L235A (LALA) modification, with numbering according to the EU Index. Examples of lgG4 heavy chain modifications that lower effector function relative to wild-type lgG4 heavy chains are described in C. Dumet, et al. They include, without limitation, the following, with numbering according to the EU Index: (i) L235E (WO/1994/028027); (ii) L235A, F234A,
and G237A (WO/1994/029351 and WO/1995/026403); (iii) D265A (U.S. Patent No. 7,332,581 ); (iv) L328 substitution, A330R, and F243L (WQ/2004/029207); (v) lgG2/lgG4 format wherein lgG2 (up to T260) is joined to lgG4 (WG/2005/007809); (vi) F243A/V264A combination (WO/2011/149999); (vii) E233P/F234A/L235A/ G236del/G237A combination (WO/2017/079369); and (viii) S228P/L235E combination. Examples of such lgG4 heavy chain modifications are also described in T. Schlothauer, et al., and include, without limitation, S228P/L235E/P329G (SPLE P329G), with numbering according to the EU Index. Further examples of IgG 1 heavy chain modifications that lower effector function relative to wild-type lgG1 heavy chains are described in I. Wilkinson, et al. They include, without limitation, the following, with numbering according to the EU Index: (i) L234S/L235T/G236R (STR); (ii) L234G/L235S/G236R (GSR); (iii) L234S/L235V/G236R (SVR); (iv) L234T/L235Q/G236R (TQR); and (v) L234T/L235T/G236R (TTR).
As used herein, the “normal function” of hACE2 includes, without limitation, at least one of the following: (i) the ability to convert angiotensin II to angiotensin-(1-7) (i.e., by enzymatically cleaving the C-terminal phenylalanine residue from angiotensin II to form angiotensin-(1-7)); (ii) the ability to cleave [des-Arg]-bradykinin (also known as [des- Arg9]-bradykinin); (iii) the ability to hydrolyze A[3-43 to yield A[3-42; (iv) the ability to convert angiotensin I to angiotensin-(1-9); (v) the ability to cleave neurotensin; (vi) the ability to cleave kinetensin; (vii) the ability to cleave a synthetic MCA-based peptide; (viii) the ability to cleave apelin-13; and (ix) the ability to cleave dynorphin A 1-13. In one embodiment, the normal function of hACE2 means (i) the ability to convert angiotensin II to angiotensin-(1-7); (ii) the ability to cleave [des-Arg]-bradykinin; (iii) the ability to hydrolyze A[3-43 to yield A[3-42; (iv) the ability to convert angiotensin I to angiotensin-(1-9); (v) the ability to cleave neurotensin; (vi) the ability to cleave kinetensin; (vii) the ability to cleave a synthetic MCA-based peptide; (viii) the ability to cleave apelin-13; and (ix) the ability to cleave dynorphin A 1-13. In a preferred embodiment, the normal function of hACE2 means the ability to convert angiotensin II to angiotensin-(1-7). By way of example, hACE2 activity can be measured using angiotensin II as a substrate to yield angiotensin-(1-7) according to known methods using known reagents, as described in the examples below. hACE2 activity can also be measured using a synthetic MCA-based peptide (e.g., a Mc-Ala/Dnp fluorescence resonance energy transfer (FRET) peptide that yields Mc-Ala upon cleavage by
hACE2) according to known methods using known reagents, as described in the examples below.
As used herein, a “prophylactically effective amount” of the present monoclonal antibodies includes, without limitation, (i) 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, 1 g, 2 g, 3 g, 4 g, 5 g, 6 g, 7 g, 8 g, 9 g, or 10 g; (ii) 5 mg to 20 mg, 20 mg to 50 mg, 50 mg to 100 mg, 100 mg to 200 mg, 200 mg to 300 mg, 300 mg to 400 mg, 400 mg to 500 mg, 500 mg to 1 g, 1 g to 2 g, 2 g to 5 g, or 5 g to 10 g; (iii) 1 mg/kg, 2 mg/kg, 3 mg/kg,
4 mg/kg, 5 mg/kg, 6 mg/kg, 7 mg/kg, 8 mg/kg, 9 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg, 25 mg/kg, 30 mg/kg, 35 mg/kg, 40 mg/kg, 45 mg/kg, 50 mg/kg, 60 mg/kg, 70 mg/kg, 80 mg/kg, 90 mg/kg, 100 mg/kg, 125 mg/kg, 150 mg/kg, 175 mg/kg, or 200 mg/kg; or (iv) 1 mg/kg to 10 mg/kg, 10 mg/kg to 20 mg/kg, 20 mg/kg to 30 mg/kg, 30 mg/kg to 40 mg/kg, 40 mg/kg to 50 mg/kg, 50 mg/kg to 100 mg/kg, 75 mg/kg to 125 mg/kg, 100 mg/kg to 150 mg/kg, or 150 mg/kg to 200 mg/kg. In the preferred embodiment, the prophylactically effective amount of monoclonal antibodies is administered as a single, one-time-only dose. In another embodiment, the prophylactically effective amount of monoclonal antibodies is administered as two or more doses over a period of days, weeks, or months (e.g., twice daily for one or two weeks; once daily for one or two weeks; every other day for two weeks; three times per week for two weeks; twice per week for two weeks; once per week for two weeks; twice with the administrations separated by two weeks; once per month; once every two months; once every three months; once every four months; twice per year; or once per year).
As used herein, a “prophylactically effective amount” of the present recombinant viral particles (e.g., recombinant AAV particles) includes, without limitation, (i) from 1 x 1010 to 5 x 1010 particles (also referred to as “viral genomes” or “vg”) per kg of body weight, from 5 x 1010 to 1 x 1011 particles I kg, from 1 x 1011 to 5 x 1011 particles I kg, from 5 x 1011 to 1 x 1012 particles I kg, from 1 x 1012 to 5 x 1012 particles I kg, from 5 x 1012 to 1 x 1013 particles I kg, from 1 x 1013 to 5 x 1013 particles I kg, or from 5 x 1013 to 1 x 1014 particles I kg; or (ii) 1 x 101° particles / kg, 5 x 101° particles / kg, 1 x 1011 particles I kg,
5 x 1011 particles / kg, 1 x 1012 particles / kg, 5 x 1012 particles / kg, 1 x 1013 particles I kg, 5 x 1013 particles I kg, or 1 x 1014 particles / kg, 5 x 1014 particles I kg, or 1 x 1015 particles / kg. In the preferred embodiment, the prophylactically effective amount of
viral particles is administered as a single, one-time-only dose. In another embodiment, the prophylactically effective amount of viral particles is administered as two or more doses over a period of months or years.
As used herein, a “recombinant AAV (adeno-associated virus) particle”, also referred to as “rAAV particle”, includes, without limitation, an AAV capsid protein (e.g., VP1 , VP2 and/or VP3) and a vector comprising a nucleic acid encoding an exogenous protein (e.g., an antibody heavy chain) situated between a pair of AAV inverted terminal repeats in a manner permitting the AAV particle to infect a target cell. Preferably, the recombinant AAV particle is incapable of replication within its target cell. The AAV serotype may be any AAV serotype suitable for use in gene therapy, such as AAV1 , AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAVrhIO, AAV11 , AAV12, LK01 , LK02 or LK03.
As used herein, “reducing the likelihood” of a human subject’s becoming infected with a virus includes, without limitation, reducing such likelihood by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 99%. Preferably, reducing the likelihood of a human subject’s becoming infected with a virus means preventing the subject from becoming infected with it. Similarly, “reducing the likelihood” of a human subject’s becoming symptomatic of a viral infection includes, without limitation, reducing such likelihood by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 99%. Preferably, reducing the likelihood of a human subject’s becoming symptomatic of a viral infection means preventing the subject from becoming symptomatic. “Reducing the likelihood” of a human subject’s developing long COVID includes, without limitation, reducing such likelihood by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 99%.
As used herein, “SARS-CoV-2” includes, without limitation, the following variants: Wuhan-1 ; F338L; A348T; N354D; N354K; V367F; R408I; Q409E; Q414E; G446V; L452R; K458N; K458R; I468T; A475V; T478I; V483A; V483I; E484K; N501Y; Y508H; H519P; H519Q; A520S; V615L; P1263L; D614G+69-70del; D614G+A262S; D614G+V341 I; D614G+Q321 L; D614G+K417N; D614G+N439K; D614G+Y453F;
D614G+S477N; D614G+F486L; Delta; Omicron [B.1.1.529]; BA.2; BA.2.12.1 ; BA.2.75; BA.4; and BA.5.
As used herein, a monoclonal antibody does not “significantly inhibit the ability of hACE2 to cleave” a substrate if (i) it inhibits the ability of intact hACE2 (i.e. , full-length hACE2 that includes the extracellular portion, transmembrane portion, and intracellular portion) to cleave the substrate by less than 90%, and/or (ii) it inhibits the ability of the extracellular portion of hACE2 (e.g., recombinant soluble hACE2) to cleave the substrate by less than 90%. In one embodiment, a monoclonal antibody does not significantly inhibit the ability of hACE2 to cleave a substrate if it inhibits the ability of intact hACE2 to cleave the substrate by less than 90%. In another embodiment, a monoclonal antibody does not significantly inhibit the ability of hACE2 to cleave a substrate if it inhibits the ability of the extracellular portion of hACE2 to cleave the substrate by less than 90%. Preferably, a monoclonal antibody does not significantly inhibit the ability of hACE2 (i.e., intact hACE2 and/or its extracellular portion) to cleave a substrate if it inhibits that ability by less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, or less than 1 %. By way of example, a monoclonal antibody does not significantly inhibit the ability of hACE2 (i.e., intact hACE2 and/or its extracellular portion) to cleave angiotensin II if it inhibits that ability by less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, or less than 1 %. By way of further example, a monoclonal antibody does not significantly inhibit the ability of hACE2 (i.e., intact hACE2 and/or its extracellular portion) to cleave des-Arg-bradykinin if it inhibits that ability by less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, or less than 1%. By way of further example, a monoclonal antibody does not significantly inhibit the ability of hACE2 (i.e., intact hACE2 and/or its extracellular portion) to cleave neurotensin if it inhibits that ability by less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, or less than 1 %. By way of further example, a monoclonal antibody does not significantly inhibit the ability of hACE2 (i.e., intact hACE2 and/or its extracellular portion) to cleave kinetensin if it inhibits that ability by less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, or less than 1 %. By way of further example, a
monoclonal antibody does not significantly inhibit the ability of hACE2 (i.e. , intact hACE2 and/or its extracellular portion) to cleave a synthetic MCA-based peptide (preferably Mca-APK(Dnp)) if it inhibits that ability by less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, or less than 1 %. By way of further example, a monoclonal antibody does not significantly inhibit the ability of hACE2 (i.e., intact hACE2 and/or its extracellular portion) to cleave apelin-13 if it inhibits that ability by less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, or less than 1 %. By way of further example, a monoclonal antibody does not significantly inhibit the ability of hACE2 (i.e., intact hACE2 and/or its extracellular portion) to cleave dynorphin A 1-13 if it inhibits that ability by less than 90%, less than 80%, less than 70%, less than 60%, less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, or less than 1 %.
As used herein, a monoclonal antibody “specifically binds” to the extracellular portion of hACE2 if it does at least one of the following: (i) binds to the extracellular portion of hACE2 with an affinity greater than that with which it binds to any other human cell surface protein; or (ii) binds to the extracellular portion of hACE2 with an affinity of at least 500 pM. Preferably, a monoclonal antibody specifically binds to the extracellular portion of hACE2 if it performs both of items (i) and (ii) above. In a preferred embodiment, the monoclonal antibody binds to hACE2 (i.e., to its extracellular portion) with an affinity of at least 100 pM, at least 10 pM, at least 1 pM, at least 500 nM, at least 300 nM, at least 200 nM, at least 100 nM, at least 50 nM, at least 20 nM, at least 10 nM, at least 5 nM, at least 1 nM, at least 0.5 nM, at least 0.1 nM, at least 0.05 nM, or at least 0.01 nM. In a preferred embodiment, the present monoclonal antibody binds to hACE2 with an affinity greater than that with which SARS-CoV-2 RBD binds to hACE2.
As used herein, a monoclonal antibody “specifically inhibits” binding of SARS-CoV-2 to the extracellular portion of hACE2 if it does at least one of the following: (i) reduces such binding more than it reduces the binding of SARS-CoV-2 to any other human cell surface protein; or (ii) reduces such binding by a factor of at least two. Preferably, a monoclonal antibody specifically inhibits binding of SARS-CoV-2 to the extracellular portion of hACE2 if it performs both of items (i) and (ii) above. In a preferred embodiment, the monoclonal antibody reduces binding of SARS-CoV-2 to the
extracellular portion of hACE2 by a factor of at least 10, at least 20, at least 50, at least 100, at least 1 ,000, at least 10,000, at least 100,000, or at least 1 ,000,000.
As used herein, a monoclonal antibody “specifically inhibits” binding of the SARS-CoV- 2 S1 protein receptor binding domain fragment, also referred to as the RBD (e.g., the protein consisting of S amino acid residues 331 to 524) to the extracellular portion of hACE2 if it does at least one of the following: (i) reduces such binding more than it reduces the binding of SARS-CoV-2 S1 protein receptor binding domain fragment to any other human cell surface protein; or (ii) reduces such binding by a factor of at least two. Preferably, a monoclonal antibody specifically inhibits binding of SARS-CoV-2 S1 protein receptor binding domain fragment to the extracellular portion of hACE2 if it performs both of items (i) and (ii) above. In a preferred embodiment, the monoclonal antibody reduces binding of SARS-CoV-2 S1 protein receptor binding domain fragment to the extracellular portion of hACE2 by a factor of at least 10, at least 20, at least 50, at least 100, at least 1 ,000, at least 10,000, at least 100,000, or at least 1 ,000,000.
As used herein, a monoclonal antibody “specifically inhibits” the entry of SARS-CoV-2 into hACE27hTMPRSS2+ human cells if it does at least one of the following: (i) reduces such entry more than it reduces the entry of SARS-CoV-2 into hACE27hTMPRSS2_ human cells; or (ii) reduces such entry by a factor of at least two. Preferably, a monoclonal antibody specifically inhibits the entry of SARS-CoV-2 into hACE27hTMPRSS2+ human cells if it performs both of items (i) and (ii) above. In a preferred embodiment, the monoclonal antibody reduces the entry of SARS-CoV-2 into hACE27hTMPRSS2+ human cells by a factor of at least 10, at least 20, at least 50, at least 100, at least 1 ,000, at least 10,000, at least 100,000, or at least 1 ,000,000.
As used herein, a monoclonal antibody “specifically inhibits” the entry into hACE27hTMPRSS2+ human cells of a pseudovirus (e.g., a replication-defective SARS- CoV-2 pseudovirus) bearing SARS-CoV-2 S protein if it does at least one of the following: (i) reduces such entry more than it reduces the entry into hACE2_ /hTMPRSS2_ human cells of a pseudovirus bearing SARS-CoV-2 S protein; or (ii) reduces such entry by a factor of at least two. Preferably, a monoclonal antibody specifically inhibits the entry into hACE27hTMPRSS2+ human cells of a pseudovirus bearing SARS-CoV-2 S protein if it performs both of items (i) and (ii) above. In a preferred embodiment, the monoclonal antibody reduces the entry into
hACE27hTMPRSS2+ human cells of a pseudovirus bearing SARS-CoV-2 S protein by a factor of at least 10, at least 20, at least 50, at least 100, at least 1 ,000, at least 10,000, at least 100,000, or at least 1 ,000,000.
As used herein, the term “subject” includes, without limitation, a mammal such as a human, a non-human primate, a dog, a cat, a horse, a sheep, a goat, a cow, a rabbit, a pig, a hamster, a rat and a mouse. The present methods are envisioned for these non- human embodiments, mutatis mutandis, as they are for human subjects in this invention.
As used herein, a human subject is “symptomatic” of a SARS-CoV-2 infection if the subject shows one or more symptoms known to appear in a SARS-CoV-2-infected human subject after a suitable incubation period. Such symptoms include, without limitation, detectable SARS-CoV-2 in the subject, and those symptoms shown by patients afflicted with COVID-19. COVID-19-related symptoms include, without limitation, fever, cough, shortness of breath, persistent pain or pressure in the chest, new confusion or inability to arouse, and/or bluish lips or face. Such symptoms also include, without limitation, those symptoms shown by patients afflicted with “long COVID”, also known as long COVID-19, post-COVID-19 syndrome, post- COVID conditions, long-haul COVID-19, and post acute sequelae of SARS COV-2 infection (PASC). Long COVID involves a variety of new, returning, or ongoing symptoms that patients experience more than four weeks after getting COVID-19. In some patients, long COVID lasts months or years or causes disability. Symptoms of long COVID include fatigue, symptoms that get worse after physical or mental effort, fever, and respiratory symptoms (e.g., difficulty breathing or shortness of breath and cough).
As used herein, a “synthetic MCA-based peptide” is a peptide having affixed at one end an MCA (i.e. , (7-methoxycoumarin-4-yl)acetyl) moiety and having affixed at the other end a fluorescence-quenching moiety (e.g., 2,4-dinitrophenyl, which is also referred to as DNP or Dnp). Upon its enzymatic cleavage (e.g., by hACE2), the MCA-containing portion of the cleaved peptide is freed from the portion containing the fluorescencequenching moiety. This, in turn, results in the now unquenched MCA-containing portion emitting a greater detectable fluorescent signal. As such, synthetic MCA-based peptides cleavable by hACE2 can serve as substrates permitting facile fluorescence-
based measurement of hACE2 activity and its inhibition. In one embodiment, the synthetic MCA-based peptide comprises the consensus sequence Pro-X<i -3 residues)- ProHydrophobic Residue (e.g., MCA-Pro-X<i -3 residues)- Pro-Hydrophobic Residue-DNP), whereby hACE2 cleaves between the proline and the hydrophobic residue. In another embodiment, the synthetic MCA-based peptide is MCA-YVADAPK-DNP (also referred to as Mca-YVADAPK(Dnp)). In a preferred embodiment, the synthetic MCA-based peptide is MCA-APK-DNP (also referred to as Mca-APK(Dnp)). In another preferred embodiment, the synthetic MCA-based peptide is the Mc-Ala/Dnp fluorescence resonance energy transfer (FRET) peptide used in the SensoLyte® 390 ACE2 Activity Assay Kit *Fluorimetric* (Anaspec) described below. In yet another preferred embodiment, the synthetic MCA-based peptide is the ACE2 Substrate used in the Angiotensin II Converting Enzyme (ACE2) Activity Assay Kit (Fluorometric) (BioVision) described below.
As used herein, a “therapeutically effective amount” of the present monoclonal antibodies includes, without limitation, (i) 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 350 mg, 400 mg, 450 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, 1 g, 2 g, 3 g, 4 g, 5 g, 6 g, 7 g, 8 g, 9 g, or 10 g; (ii) 5 mg to 20 mg, 20 mg to 50 mg, 50 mg to 100 mg, 100 mg to 200 mg, 200 mg to 300 mg, 300 mg to 400 mg, 400 mg to 500 mg, 500 mg to 1 g, 1 g to 2 g, 2 g to 5 g, or 5 g to 10 g; (iii) 1 mg/kg, 2 mg/kg, 3 mg/kg, 4 mg/kg, 5 mg/kg, 6 mg/kg, 7 mg/kg, 8 mg/kg, 9 mg/kg, 10 mg/kg, 15 mg/kg, 20 mg/kg, 25 mg/kg, 30 mg/kg, 35 mg/kg, 40 mg/kg, 45 mg/kg, 50 mg/kg, 60 mg/kg, 70 mg/kg, 80 mg/kg, 90 mg/kg, 100 mg/kg, 125 mg/kg, 150 mg/kg, 175 mg/kg, or 200 mg/kg; or (iv) 1 mg/kg to 10 mg/kg, 10 mg/kg to 20 mg/kg, 20 mg/kg to 30 mg/kg, 30 mg/kg to 40 mg/kg, 40 mg/kg to 50 mg/kg, 50 mg/kg to 100 mg/kg, 75 mg/kg to 125 mg/kg, 100 mg/kg to 150 mg/kg, or 150 mg/kg to 200 mg/kg. In the preferred embodiment, the therapeutically effective amount of monoclonal antibodies is administered as a single, one-time-only dose. In another embodiment, the therapeutically effective amount of monoclonal antibodies is administered as two or more doses over a period of days, weeks, or months (e.g., twice daily for one or two weeks; once daily for one or two weeks; every other day for two weeks; three times per week for two weeks; twice per week for two weeks; once per week for two weeks; twice with the administrations separated by two weeks; once per month; once every two months; once every three months; once every four months; twice per year; or once per year).
As used herein, a “therapeutically effective amount” of the subject recombinant viral particles (e.g., recombinant AAV particles) includes, without limitation, (i) from 1 x 1O10 to 5 x 1O10 particles (also referred to as “viral genomes” or “vg”) per kg of body weight, from 5 x 1O10 to 1 x 1011 particles I kg, from 1 x 1011 to 5 x 1011 particles I kg, from 5 x 1011 to 1 x 1012 particles I kg, from 1 x 1012 to 5 x 1012 particles I kg, from 5 x 1012 to 1 x 1013 particles I kg, from 1 x 1013 to 5 x 1013 particles I kg, or from 5 x 1013 to 1 x 1014 particles I kg; or (ii) 1 x 1010 particles / kg, 5 x 1010 particles / kg, 1 x 1011 particles I kg, 5 x 1011 particles / kg, 1 x 1012 particles / kg, 5 x 1012 particles / kg, 1 x 1013 particles I kg, 5 x 1013 particles I kg, or 1 x 1014 particles / kg, 5 x 1014 particles I kg, or 1 x 1015 particles I kg. In the preferred embodiment, the therapeutically effective amount of viral particles is administered as a single, one-time-only dose. In another embodiment, the therapeutically effective amount of viral particles is administered as two or more doses over a period of months or years.
As used herein, “treating” a subject afflicted with a disorder (e.g., a subject infected with SARS-CoV-2 and symptomatic of that infection) includes, without limitation, (i) slowing, stopping, or reversing the progression of one or more of the disorder’s symptoms, (ii) slowing, stopping or reversing the progression of the disorder underlying such symptoms, (iii) reducing or eliminating the likelihood of the symptoms’ recurrence, and/or (iv) slowing the progression of, lowering or eliminating the disorder. In the preferred embodiment, treating a subject afflicted with a disorder includes (i) reversing the progression of one or more of the disorder’s symptoms, (ii) reversing the progression of the disorder underlying such symptoms, (iii) preventing the symptoms’ recurrence, and/or (iv) eliminating the disorder. For a subject infected with SARS-CoV- 2 but not symptomatic of that infection, “treating” the subject also includes, without limitation, reducing the likelihood of the subject’s becoming symptomatic of the infection, and preferably, preventing the subject from becoming symptomatic of the infection. For a subject infected with SARS-CoV-2 and symptomatic of that infection, “treating” the subject also includes, without limitation, reducing the likelihood of the subject’s developing long COVID, and preferably, preventing the subject from developing long COVID. For a subject infected with SARS-CoV-2 and symptomatic of long COVID, “treating” the subject also includes, without limitation, eliminating the symptoms of long COVID.
Embodiments of the Invention
This invention provides certain anti-hACE2 monoclonal antibodies. It also provides recombinant viral particles (preferably recombinant AAV particles) that, when introduced into a subject, cause the long-term expression of those antibodies. These antibodies and viral particles permit prophylaxis and therapy for SARS-CoV-2 infection. The recently published reference of Du, et al., provides in vivo evidence that an anti- hACE2 monoclonal antibody can be used to prevent and treat SARS-CoV-2 infection. The present recombinant viruses can be any ones suitable for viral-mediated gene therapy including, without limitation, AAV, adenovirus, alphavirus, herpesvirus, retrovirus/lentivirus, or vaccinia virus.
Specifically, this invention provides a monoclonal antibody that (i) specifically binds to the extracellular portion of human angiotensin converting enzyme 2 (hACE2); (ii) specifically inhibits binding of SARS-CoV-2 to the extracellular portion of hACE2 (e.g., binding via the SARS-CoV-2 S1 protein receptor binding domain); and (iii) does not significantly inhibit the ability of hACE2 to cleave angiotensin II and/or a synthetic MCA- based peptide.
This invention also provides a monoclonal antibody that (i) specifically binds to the extracellular portion of human angiotensin converting enzyme 2 (hACE2); (ii) specifically inhibits binding of SARS-CoV-2 to the extracellular portion of hACE2 (e.g., via the SARS-CoV-2 S1 protein receptor binding domain); (iii) specifically inhibits binding of the SARS-CoV-2 S1 protein receptor binding domain fragment (e.g., the protein consisting of S amino acid residues 331 to 524) to the extracellular portion of hACE2; (iv) specifically inhibits the entry of SARS-CoV-2 into hACE2+/hTMPRSS2+ human cells; (v) specifically inhibits the entry into hACE27hTMPRSS2+ human cells of a pseudovirus (e.g., a replication-defective SARS-CoV-2 pseudovirus) bearing SARS- CoV-2 S protein; and (vi) does not significantly inhibit the ability of hACE2 to cleave angiotensin II and/or a synthetic MCA-based peptide.
This invention further provides a monoclonal antibody that (i) specifically binds to the extracellular portion of human angiotensin converting enzyme 2 (hACE2); (ii) specifically inhibits binding of SARS-CoV-2 to the extracellular portion of hACE2 (e.g., via the SARS-CoV-2 S1 protein receptor binding domain); (iii) specifically inhibits
binding of the SARS-CoV-2 S1 protein receptor binding domain fragment (e.g., the protein consisting of S amino acid residues 331 to 524) to the extracellular portion of hACE2; (iv) specifically inhibits the entry of SARS-CoV-2 into hACE2+/hTMPRSS2+ human cells; and (v) does not significantly inhibit the ability of hACE2 to cleave angiotensin II and/or a synthetic MCA-based peptide.
This invention still further provides a monoclonal antibody that (i) specifically binds to the extracellular portion of human angiotensin converting enzyme 2 (hACE2); (ii) specifically inhibits binding of SARS-CoV-2 to the extracellular portion of hACE2 (e.g., via the SARS-CoV-2 S1 protein receptor binding domain); (iii) specifically inhibits binding of the SARS-CoV-2 S1 protein receptor binding domain fragment (e.g., the protein consisting of S amino acid residues 331 to 524) to the extracellular portion of hACE2; (iv) specifically inhibits the entry into hACE27hTMPRSS2+ human cells of a pseudovirus (e.g., a replication-defective SARS-CoV-2 pseudovirus) bearing SARS- CoV-2 S protein; and (v) does not significantly inhibit the ability of hACE2 to cleave angiotensin II and/or a synthetic MCA-based peptide.
This invention also provides a monoclonal antibody that (i) specifically binds to the extracellular portion of human angiotensin converting enzyme 2 (hACE2); (ii) specifically inhibits binding of SARS-CoV-2 to the extracellular portion of hACE2 (e.g., via the SARS-CoV-2 S1 protein receptor binding domain); (iii) specifically inhibits the entry of SARS-CoV-2 into hACE27hTMPRSS2+ human cells; and (iv) does not significantly inhibit the ability of hACE2 to cleave angiotensin II and/or a synthetic MCA- based peptide.
This invention further provides a monoclonal antibody that (i) specifically binds to the extracellular portion of human angiotensin converting enzyme 2 (hACE2); (ii) specifically inhibits binding of the SARS-CoV-2 S1 protein receptor binding domain fragment (e.g., the protein consisting of S amino acid residues 331 to 524) to the extracellular portion of hACE2; (iii) specifically inhibits the entry into hACE27hTMPRSS2+ human cells of a pseudovirus (e.g., a replication-defective SARS- CoV-2 pseudovirus) bearing SARS-CoV-2 S protein; and (iv) does not significantly inhibit the ability of hACE2 to cleave angiotensin II and/or a synthetic MCA-based peptide.
The above six monoclonal antibodies are referred to herein, collectively and individually, as the present monoclonal antibody. SARS-CoV-2 pseudoviruses and methods of making and using them are known, as are SARS-CoV-2 S1 protein receptor binding domain (RBD) fragments. See, e.g., Shang, et al., and Hoffman, et al. (Cell 2020).
In a preferred embodiment, the present monoclonal antibody does not significantly inhibit the ability of hACE2 to cleave angiotensin II (i.e. , to convert angiotensin II to angiotensin-(1-7). This inhibition can be measured according to the methods in the examples section below. A specific example of this embodiment of the invention is a monoclonal antibody that (i) binds to the extracellular portion of hACE2 with an affinity of 50 nM; (ii) reduces binding of SARS-CoV-2 to the extracellular portion of hACE2 by a factor of 100,000; and (iii) inhibits by 20% the ability of hACE2 to cleave angiotensin II.
In a second embodiment, the present monoclonal antibody does not significantly inhibit the ability of hACE2 to cleave des-Arg-bradykinin. This inhibition can be measured according to the methods in the examples section below. A specific example of this embodiment of the invention is a monoclonal antibody that (i) binds to the extracellular portion of hACE2 with an affinity of 50 nM; (ii) reduces binding of SARS-CoV-2 to the extracellular portion of hACE2 by a factor of 100,000; and (iii) inhibits by 20% the ability of hACE2 to cleave des-Arg-bradykinin.
In a third embodiment, the present monoclonal antibody does not significantly inhibit the ability of hACE2 to cleave neurotensin. This inhibition can be measured according to the methods in the examples section below. A specific example of this embodiment of the invention is a monoclonal antibody that (i) binds to the extracellular portion of hACE2 with an affinity of 50 nM; (ii) reduces binding of SARS-CoV-2 to the extracellular portion of hACE2 by a factor of 100,000; and (iii) inhibits by 20% the ability of hACE2 to cleave neurotensin.
In a fourth embodiment, the present monoclonal antibody does not significantly inhibit the ability of hACE2 to cleave kinetensin. This inhibition can be measured according to the methods in the examples section below. A specific example of this embodiment of the invention is a monoclonal antibody that (i) binds to the extracellular portion of hACE2 with an affinity of 50 nM; (ii) reduces binding of SARS-CoV-2 to the extracellular
portion of hACE2 by a factor of 100,000; and (iii) inhibits by 20% the ability of hACE2 to cleave kinetensin.
In a fifth embodiment, the present monoclonal antibody does not significantly inhibit the ability of hACE2 to cleave a synthetic MCA-based peptide. This inhibition can be measured according to the methods in the examples section below. A specific example of this embodiment of the invention is a monoclonal antibody that (i) binds to the extracellular portion of hACE2 with an affinity of 50 nM; (ii) reduces binding of SARS- CoV-2 to the extracellular portion of hACE2 by a factor of 100,000; and (iii) inhibits by 20% the ability of hACE2 to cleave a synthetic MCA-based peptide (preferably Mca- APK(Dnp), which is also referred to as Mac-APK-Dnp). As shown in the examples below, these peptides can be used to measure the inhibition of hACE2 carboxypeptidase activity.
In a sixth embodiment, the present monoclonal antibody does not significantly inhibit the ability of hACE2 to cleave apelin-13. This inhibition can be measured according to the methods in the examples section below. A specific example of this embodiment of the invention is a monoclonal antibody that (i) binds to the extracellular portion of hACE2 with an affinity of 50 nM; (ii) reduces binding of SARS-CoV-2 to the extracellular portion of hACE2 by a factor of 100,000; and (iii) inhibits by 20% the ability of hACE2 to cleave apelin-13.
In a seventh embodiment, the present monoclonal antibody does not significantly inhibit the ability of hACE2 to cleave dynorphin A 1-13. This inhibition can be measured according to the methods in the examples section below. A specific example of this embodiment of the invention is a monoclonal antibody that (i) binds to the extracellular portion of hACE2 with an affinity of 50 nM; (ii) reduces binding of SARS-CoV-2 to the extracellular portion of hACE2 by a factor of 100,000; and (iii) inhibits by 20% the ability of hACE2 to cleave dynorphin A 1-13.
In another preferred embodiment of the invention, the present monoclonal antibody binds to an epitope that does not include hACE2 amino acid residues required for normal function. So, in one embodiment, the present monoclonal antibody does not specifically bind to an epitope on hACE2 comprising an amino acid residue selected from the group consisting of Arg273, His345, Pro346, His374, Glu375, His378, Glu402,
His505, and Tyr515. The following embodiments are exemplary, (i) The present monoclonal antibody does not specifically bind to an epitope on hACE2 comprising Arg273. (ii) The present monoclonal antibody does not specifically bind to an epitope on hACE2 comprising His345. (iii) The present monoclonal antibody does not specifically bind to an epitope on hACE2 comprising Pro346. (iv) The present monoclonal antibody does not specifically bind to an epitope on hACE2 comprising His374. (v) The present monoclonal antibody does not specifically bind to an epitope on hACE2 comprising Glu375. (vi) The present monoclonal antibody does not specifically bind to an epitope on hACE2 comprising His378. (vii) The present monoclonal antibody does not specifically bind to an epitope on hACE2 comprising Glu402. (viii) The present monoclonal antibody does not specifically bind to an epitope on hACE2 comprising His505. (ix) The present monoclonal antibody does not specifically bind to an epitope on hACE2 comprising Tyr515.
In another embodiment, the present monoclonal antibody does not specifically bind to an epitope on hACE2 comprising an amino acid residue selected from the group consisting of residues 290 to 397 and residues 417 to 430. The following embodiments are exemplary, (i) The present monoclonal antibody does not specifically bind to an epitope on hACE2 comprising an amino acid residue within residues 290 to 397. (ii) The present monoclonal antibody does not specifically bind to an epitope on hACE2 comprising an amino acid residue within residues 417 to 430.
In a further embodiment, the present monoclonal antibody does not specifically bind to an epitope on hACE2 comprising an amino acid residue selected from the group consisting of residues 103 to 289, residues 398 to 416, and residues 431 to 615. The following embodiments are exemplary, (i) The present monoclonal antibody does not specifically bind to an epitope on hACE2 comprising an amino acid residue within residues 103 to 289. (ii) The present monoclonal antibody does not specifically bind to an epitope on hACE2 comprising an amino acid residue within residues 398 to 416. (iii) The present monoclonal antibody does not specifically bind to an epitope on hACE2 comprising an amino acid residue within residues 431 to 615.
In a further embodiment, the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue selected from the group consisting of residues 1-18, residues 417-430, and residues 616-740. The following embodiments
are exemplary, (i) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 1-5. (ii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 5-10. (iii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 10-15. (iv) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 15-18. (v) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 417-420. (vi) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 420-425. (vii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 425-430. (viii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 616-620. (ix) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 620-625. (x) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 625-630. (xi) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 630-635. (xii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 635-640. (xiii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 640-645. (xiv) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 645-650. (xv) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 650-655. (xvi) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 655-660. (xvii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 660-665. (xviii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 665-670. (xix) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 670-675. (xx) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 675-680. (xxi) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 680-685. (xxii)
The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 685-690. (xxiii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 690-695. (xxiv) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 695-700. (xxv) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 700-705. (xxvi) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 705-710. (xxvii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 710-715. (xviii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 715-720. (xxix) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 720-725. (xxx) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 725-730. (xxxi) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 730-735. (xxxii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 735-740.
In a further embodiment, the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue selected from the group consisting of residues 19-416. The following embodiments are exemplary, (i) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 19-25. (ii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 26-30. (iii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 31-35. (iv) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 36-40. (v) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 41-45. (vi) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 46-50. (vii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 51-55. (viii) The present monoclonal antibody specifically binds to an epitope
on hACE2 comprising an amino acid residue within residues 56-60. (ix) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 61-65. (x) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 66-70. (xi) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 71-75. (xii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 76-80. (xiii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 81-85. (xiv) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 86-90. (xv) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 91-95. (xvi) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 96-100. (xvii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 101-105. (xviii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 106-110. (xix) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 111-115. (xx) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 116-120. (xxi) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 121-125. (xxii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 126-130. (xxiii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 131-135. (xxiv) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 136-140. (xxv) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 141-145. (xxvi) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 146-150. (xxvii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 151-155. (xxviii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 156-160. (xxix) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising
an amino acid residue within residues 161-165. (xxx) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 166-170. (xxxi) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 171-175. (xxxii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 176-180. (xxxiii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 181-185. (xxxiv) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 186-190. (xxxv) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 191-195. (xxxvi) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 196-200. (xxxvii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 201-205. (xxxviii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 206-210. (xxxix) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 211-215. (xl) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 216-220. (xli) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 221-225. (xlii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 226-230. (xliii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 231-235. (xliv) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 236-240. (xlv) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 241-245. (xlvi) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 246-250. (xlvii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 251-255. (xlviii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 256-260. (xlix) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 261-265. (I) The present monoclonal antibody specifically binds to an epitope
on hACE2 comprising an amino acid residue within residues 266-270. (li) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 271-275. (lii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 276- 280. (liii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 281-285. (liv) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 286-290. (Iv) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 291- 295. (Ivi) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 296-300. (Ivii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 301-305. (Iviii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 306-310. (lix) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 311-315. (lx) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 316-320. (Ixi) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 321-325. (Ixii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 326-330. (Ixiii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 331-335. (Ixiv) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 336-340. (Ixv) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 341-345. (Ixvi) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 346-350. (Ixvii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 351-355. (Ixviii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 356-360. (Ixix) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 361-365. (Ixx) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 366-370. (Ixxi) The present monoclonal antibody specifically binds to an
epitope on hACE2 comprising an amino acid residue within residues 371-375. (Ixxii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 376-380. (Ixxiii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 381-385. (Ixxiv) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 386-390. (Ixxv) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 391-395. (Ixxvi) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 396-400. (Ixxvii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 401-405. (Ixxviii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 406-410. (Ixxix) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 411-416.
In a further embodiment, the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue selected from the group consisting of residues 431-615. The following embodiments are exemplary, (i) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 431-435. (ii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 436- 440. (iii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 441-445. (iv) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 446-450. (v) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 451- 455. (vi) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 456-460. (vii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 461-465. (viii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 466-470. (ix) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 471-475. (x) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an
amino acid residue within residues 476-480. (xi) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 481-485. (xii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 486-490. (xiii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 491-495. (xiv) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 496-500. (xv) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 501-505. (xvi) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 506-510. (xvii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 511-515. (xviii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 516-520. (xix) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 521-525. (xx) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 526-530. (xxi) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 531-535. (xxii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 536-540. (xxiii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 541-545. (xxiv) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 546-550. (xxv) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 551-555. (xxvi) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 556-560. (xxvii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 561-565. (xxviii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 566-570. (xxix) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 571-575. (xxx) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 576-580. (xxxi) The present monoclonal antibody specifically binds to an
epitope on hACE2 comprising an amino acid residue within residues 581-585. (xxxii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 586-590. (xxxiii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 591-595. (xxxiv) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 596-600. (xxxv) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 601-605. (xxxvi) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 606-610. (xxxvii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue within residues 611-615.
In a further embodiment, the present monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue selected from the group consisting of Ser19, Gln24, Ala25, Thr27, Phe28, Lys31 , His34, Glu35, Glu37, Asp38, Tyr41 , Gln42, Leu45, Leu79, Met82, Tyr83, Gln325, Glu329, Asn330, Lys353, Gly354, Asp355, and Arg357. The following embodiments are exemplary, (i) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Seri 9. (ii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Gln24. (iii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Ala25. (iv) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Thr27. (v) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Phe28. (vi) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Lys31 . (vii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue His34. (viii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Glu35. (ix) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Glu37. (x) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Asp38. (xi) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Tyr41 . (xii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Gln42. (xiii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Leu45. (xiv) The present monoclonal antibody specifically binds to an epitope
on hACE2 comprising residue Leu79. (xv) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Met82. (xvi) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Tyr83. (xvii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Gln325. (xviii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Glu329. (xix) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Asn330. (xx) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Lys353. (xxi) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Gly354. (xxii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Asp355. (xxiii) The present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Arg357. In a preferred embodiment, the present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Lys31 . In another preferred embodiment, the present monoclonal antibody specifically binds to an epitope on hACE2 comprising residue Lys353. In yet another preferred embodiment, the present monoclonal antibody specifically binds to an epitope on hACE2 comprising the amino acid residues Gln24, Ala25, Thr27, Phe28, Lys31 , Leu79, Met82, and Tyr83.
Preferably, the present monoclonal antibody comprises the heavy and light chain variable regions identified, respectively, as humanized 11 B11 VH and humanized 11 B11 VK, and set forth in Figure 5 below (taken from Supplementary Figure 2 of Du, et al.). These variable regions include heavy chain CDR1 (GFTFIDYYMN), CDR2 (FIRNKANDYTTEYST), and CDR3 (RHMYDDGFDF), and light chain CDR1 (ASSSVRYMH), CDR2 (LLIYDTSKLA), and CDR3 (QQWSYNPLTF). In a preferred embodiment, the present monoclonal antibody comprises the heavy chain CDR1 having the amino acid sequence GFTFIDYYMN. In another preferred embodiment, the present monoclonal antibody comprises the heavy chain CDR2 having the amino acid sequence FIRNKANDYTTEYST. In another preferred embodiment, the present monoclonal antibody comprises the heavy chain CDR3 having the amino acid sequence RHMYDDGFDF. In another preferred embodiment, the present monoclonal antibody comprises the light chain CDR1 having the amino acid sequence ASSSVRYMH. In another preferred embodiment, the present monoclonal antibody comprises the light chain CDR2 having the amino acid sequence LLIYDTSKLA. In
another preferred embodiment, the present monoclonal antibody comprises the light chain CDR3 having the amino acid sequence QQWSYNPLTF. In a further preferred embodiment, the present monoclonal antibody comprises the heavy chain CDR1 having the amino acid sequence GFTFIDYYMN, the heavy chain CDR2 having the amino acid sequence FIRNKANDYTTEYST, the heavy chain CDR3 having the amino acid sequence RHMYDDGFDF, the light chain CDR1 having the amino acid sequence ASSSVRYMH, the light chain CDR2 having the amino acid sequence LLIYDTSKLA, and the light chain CDR3 having the amino acid sequence QQWSYNPLTF. The following additional embodiments are envisioned, and are exemplified in Examples 13 and 14 below, (i) The present monoclonal antibody comprises a point mutant of the heavy chain CDR1 . (ii) The present monoclonal antibody comprises a point mutant of the heavy chain CDR2. (iii) The present monoclonal antibody comprises a point mutant of the heavy chain CDR3. (iv) The present monoclonal antibody comprises a point mutant of the light chain CDR1 . (v) The present monoclonal antibody comprises a point mutant of the light chain CDR2. (vi) The present monoclonal antibody comprises a point mutant of the light chain CDR3.
In yet a further embodiment, the present monoclonal antibody comprises a heavy chain CDR3 comprising an amino acid sequence selected from the group consisting of (i) CAKDRGYSSSWYGGFDYW; (ii) CARHTWWKGAGFFDHW; (iii) CARGTRFLEWSLPLDVW; (iv) CATTENPNPRW; (v) CATTEDPYPRW; (vi) CARASPNTGWHFDHW; (vii) CATTMNPNPRW; (viii) CAAIAYEEGVYR-WDW; and (ix) RHMYDDGFDF. The following embodiments are exemplary, (i) The present monoclonal antibody comprises a heavy chain CDR3 comprising the amino acid sequence CAKDRGYSSSWYGGFDYW. (ii) The present monoclonal antibody comprises a heavy chain CDR3 comprising the amino acid sequence CARHTWWKGAGF-FDHW. (iii) The present monoclonal antibody comprises a heavy chain CDR3 comprising the amino acid sequence CARGTRFLEWSLPLDVW. (iv) The present monoclonal antibody comprises a heavy chain CDR3 comprising the amino acid sequence CATTENPNPRW. (v) The present monoclonal antibody comprises a heavy chain CDR3 comprising the amino acid sequence CATTEDP-YPRW. (vi) The present monoclonal antibody comprises a heavy chain CDR3 comprising the amino acid sequence CARASPNTGWHFDHW. (vii) The present monoclonal antibody comprises a heavy chain CDR3 comprising the amino acid sequence
CATTMNPNPRW. (viii) The present monoclonal antibody comprises a heavy chain CDR3 comprising the amino acid sequence CAAIAYEEGVYRWDW.
In yet a further embodiment, the present monoclonal antibody comprises one or more of (i) a heavy chain CDR1 comprising the amino acid sequence GFTFIDYYMN; (ii) a heavy chain CDR2 comprising the amino acid sequence FIRNKANDYTTEYST; (iii) a heavy chain CDR3 comprising the amino acid sequence RHMYDDGFDF; (iv) a light chain CDR1 comprising the amino acid sequence ASSSVRYMH; (v) a light chain CDR2 comprising the amino acid sequence LLIYDTSKLA; and (vi) a light chain CDR3 comprising the amino acid sequence QQWSYNPLTF. Preferably, the present monoclonal antibody comprises (i) a heavy chain CDR1 comprising the amino acid sequence GFTFIDYYMN; (ii) a heavy chain CDR2 comprising the amino acid sequence FIRNKANDYTTEYST; (iii) a heavy chain CDR3 comprising the amino acid sequence RHMYDDGFDF; (iv) a light chain CDR1 comprising the amino acid sequence ASSSVRYMH; (v) a light chain CDR2 comprising the amino acid sequence LLIYDTSKLA; and (vi) a light chain CDR3 comprising the amino acid sequence QQWSYNPLTF.
In yet a further embodiment, the present monoclonal antibody comprises one or more of (i) a heavy chain CDR1 comprising a heavy chain CDR1 amino acid sequence set forth in Table 1 ; (ii) a heavy chain CDR2 comprising a heavy chain CDR2 amino acid sequence set forth in Table 1 ; (iii) a heavy chain CDR3 comprising a heavy chain CDR3 amino acid sequence set forth in Table 1 ; (iv) a light chain CDR1 comprising a light chain CDR1 amino acid sequence set forth in Table 2; (v) a light chain CDR2 comprising a light chain CDR2 amino acid sequence set forth in Table 2; and (vi) a light chain CDR3 comprising a light chain CDR3 amino acid sequence set forth in Table 2. Preferably, the present monoclonal antibody comprises the heavy and light chain CDR sequences of antibody “05B04”, namely, (i) the 05B04 heavy chain CDR1 , CDR2, and CDR3 amino acid sequences set forth in Table 1 , and (ii) the 05B04 light chain CDR1 , CDR2, and CDR3 amino acid sequences set forth in Table 2. (Tables 1 and 2 are taken from Zhang, et al.)
In a preferred embodiment, the present monoclonal antibody is a humanized monoclonal antibody, and preferably a human monoclonal antibody.
In a first preferred embodiment, the present monoclonal antibody has a low effector function. In a second preferred embodiment, the present monoclonal antibody has a long serum half-life. In a third preferred embodiment, the present monoclonal antibody is an lgG1 antibody. In a fourth preferred embodiment, the present monoclonal antibody comprises a heavy chain modification that inhibits half antibody formation. In a fifth preferred embodiment, the present monoclonal antibody (i) has a low effector function; (ii) has a long serum half-life; (iii) is an lgG4 antibody; and (iv) comprises a heavy chain modification that inhibits half antibody formation.
In a further preferred embodiment, the present monoclonal antibody is an antigenbinding fragment or a single chain antibody.
The following eight embodiments of the present monoclonal antibody are exemplary. In a first embodiment of the invention, the present monoclonal antibody is a humanized or human lgG4 antibody that (i) has the serum half-life-extending mutation combination M252Y/S254T/T256E (YTE) (with numbering according to the Ell Index); (ii) has the half antibody formation-inhibiting mutation S228P or K447del, or the mutation combination S228P/K447del (with numbering according to the Ell Index); and (iii) has the effector function-lowering L235E mutation (with numbering according to the Ell Index).
In a second embodiment of the invention, the present monoclonal antibody is a humanized or human lgG4 antibody that (i) has the serum half-life-extending mutation combination M252Y/S254T/T256E (YTE) (with numbering according to the Ell Index);
(ii) has the half antibody formation-inhibiting mutation S228P or K447del, or the mutation combination S228P/K447del (with numbering according to the Ell Index); and
(iii) has one or more of the effector function-lowering mutations L235A, F234A, and G237A (with numbering according to the Ell Index).
In a third embodiment of the invention, the present monoclonal antibody is a humanized or human lgG4 antibody that (i) has the serum half-life-extending mutation combination M252Y/S254T/T256E (YTE) (with numbering according to the Ell Index); (ii) has the half antibody formation-inhibiting mutation S228P or K447del, or the mutation combination S228P/K447del (with numbering according to the Ell Index); and (iii) has
the effector function-lowering D265A mutation (with numbering according to the Ell Index).
In a fourth embodiment of the invention, the present monoclonal antibody is a humanized or human lgG4 antibody that (i) has the serum half-life-extending mutation combination M252Y/S254T/T256E (YTE) (with numbering according to the Ell Index);
(ii) has the half antibody formation-inhibiting mutation S228P or K447del, or the mutation combination S228P/K447del (with numbering according to the Ell Index); and
(iii) has one or more of the effector function-lowering mutations A330R, F243L, and an L328 substitution (with numbering according to the Ell Index).
In a fifth embodiment of the invention, the present monoclonal antibody is a humanized or human lgG4 antibody that (i) has the serum half-life-extending mutation combination M252Y/S254T/T256E (YTE) (with numbering according to the Ell Index); (ii) has the half antibody formation-inhibiting mutation S228P or K447del, or the mutation combination S228P/K447del (with numbering according to the Ell Index); and (iii) has the effector function-lowering lgG2/lgG4 format wherein lgG2 (up to T260) is joined to lgG4 (with numbering according to the Ell Index).
In a sixth embodiment of the invention, the present monoclonal antibody is a humanized or human lgG4 antibody that (i) has the serum half-life-extending mutation combination M252Y/S254T/T256E (YTE) (with numbering according to the Ell Index);
(ii) has the half antibody formation-inhibiting mutation S228P or K447del, or the mutation combination S228P/K447del (with numbering according to the Ell Index); and
(iii) has the effector function-lowering F243AA/264A mutation combination (with numbering according to the Ell Index).
In a seventh embodiment of the invention, the present monoclonal antibody is a humanized or human lgG4 antibody that (i) has the serum half-life-extending mutation combination M252Y/S254T/T256E (YTE) (with numbering according to the Ell Index);
(ii) has the half antibody formation-inhibiting mutation S228P or K447del, or the mutation combination S228P/K447del (with numbering according to the Ell Index); and
(iii) has the effector function-lowering E233P/F234A/L235A/G236del/G237A mutation combination (with numbering according to the Ell Index).
In an eighth embodiment of the invention, the present monoclonal antibody is a humanized or human lgG4 antibody that (i) has the serum half-life-extending mutation combination M252Y/S254T/T256E (YTE) (with numbering according to the Ell Index);
(ii) has the half antibody formation-inhibiting mutation S228P or K447del, or the mutation combination S228P/K447del (with numbering according to the Ell Index); and
(iii) has the effector function-lowering S228P/L235E mutation combination (with numbering according to the Ell Index).
In a preferred embodiment of each of the above eight embodiments, the present monoclonal antibody has a “knobs-into-holes” (kih) modification to prevent heavy chain mispairing. In another preferred embodiment of each of the above eight embodiments, the present monoclonal antibody comprises two distinct heavy chains and two identical light chains. In a further preferred embodiment of each of the above eight embodiments wherein the antibody comprises two distinct heavy chains and two identical light chains, one of the heavy chains contains a chimeric Fc form that ablates binding to Protein A via the contact region. This technology, known as FcAAdp, is described in M. Godar, et al., and A.D. Tustian, et al.
The following additional two embodiments of the present monoclonal antibody are exemplary. In a first embodiment of the invention, the present monoclonal antibody is a humanized lgG4 antibody that (i) has the serum half-life-extending mutation combination M252Y/S254T/T256E (YTE) (with numbering according to the Ell Index);
(ii) has the half antibody formation-inhibiting mutation S228P or K447del, or the mutation combination S228P/K447del (with numbering according to the Ell Index); and
(iii) has an effector function-lowering mutation, mutation combination, or alteration, selected from the group consisting of L235E, L235A, F234A, G237A, D265A, A330R, F243L, L328 substitution, F243AA/264A, E233P/F234A/L235A/G236del/ G237A, S228P/L235E, and an lgG2/lgG4 format wherein lgG2 (up to T260) is joined to lgG4 (with numbering according to the Ell Index).
In a second embodiment of the invention, the present monoclonal antibody is a human lgG4 antibody that (i) has the serum half-life-extending mutation combination M252Y/S254T/T256E (YTE) (with numbering according to the Ell Index); (ii) has the half antibody formation-inhibiting mutation S228P or K447del, or the mutation combination S228P/K447del (with numbering according to the Ell Index); and (iii) has
an effector function-lowering mutation, mutation combination, or alteration, selected from the group consisting of L235E, L235A, F234A, G237A, D265A, A330R, F243L, L328 substitution, F243AA/264A, E233P/F234A/L235A/G236del/G237A, S228P/L235E, and an lgG2/lgG4 format wherein lgG2 (up to T260) is joined to lgG4 (with numbering according to the Ell Index).
In a preferred embodiment of each of the above two embodiments, the present monoclonal antibody has a “knobs-into-holes” (kih) modification to prevent heavy chain mispairing. In another preferred embodiment of each of the above two embodiments, the present monoclonal antibody comprises two distinct heavy chains and two identical light chains. In a further preferred embodiment of each of the above two embodiments wherein the antibody comprises two distinct heavy chains and two identical light chains, one of the heavy chains contains a chimeric Fc form that ablates binding to Protein A via the contact region (i.e. , FcAAdp technology).
This invention further provides a monoclonal antibody comprising residues 21 through 230 of the light chain amino acid sequence set forth in Figure 6 and residues 25 through 471 of the heavy chain amino acid sequence set forth in Figure 7. This invention still further provides a monoclonal antibody comprising residues 21 through 230 of the light chain amino acid sequence set forth in Figure 6 and residues 25 through 471 of the heavy chain amino acid sequence set forth in Figure 8. These two monoclonal antibodies are included in the term “present monoclonal antibody” as used herein, wherever applicable.
This invention further provides the monoclonal antibody designated 3E8-hlgG1(STR) having the heavy and light chain amino acid sequences as defined herein, and 3E8- hlgG1 (STR/LS) having the heavy and light chain amino acid sequences as defined herein. This invention still further provides the monoclonal antibody disclosed in F.
Zhang, et al., and designated 05B04, wherein the antibody comprises the heavy chain modification (i) L234S/L235T/G236R (STR) or (ii) L234S/L235T/G236R/M252Y/S254T/T256E (STR/YTE). These monoclonal antibodies are included in the term “present monoclonal antibody” as used herein, wherever applicable.
This invention provides an isolated nucleic acid molecule encoding (i) the complete light chain, or a portion of the light chain, of the present monoclonal antibody, and/or (ii) the complete heavy chain, or a portion of the heavy chain, of the present monoclonal antibody. In one embodiment, the present nucleic acid molecule is a DNA molecule, for example, a cDNA molecule.
This invention further provides a recombinant vector, for example a plasmid or a viral vector, comprising the present nucleic acid molecule operably linked to a promoter of RNA transcription.
This invention still further provides a host vector system comprising one or more of the present vectors in a suitable host cell (e.g., a bacterial cell, an insect cell, a yeast cell, or a mammalian cell such as a hybridoma cell (See, e.g., Chiu and Gilliland; Kohler and Milstein)).
This invention provides a composition comprising (i) the present monoclonal antibody, and (ii) a pharmaceutically acceptable carrier.
This invention also provides a method for reducing the likelihood of a human subject’s becoming infected with SARS-CoV-2 comprising administering to the subject a prophylactically effective amount of the present monoclonal antibody. In a preferred embodiment of this method, the subject has been exposed to SARS-CoV-2. In another preferred embodiment of this method, the present monoclonal antibody does not exhibit significant toxicity in a cynomolgus monkey when administered at a prophylactically effective amount. As an example, when administered at a prophylactically effective amount to a cynomolgus monkey, the present monoclonal antibody does not cause more than a 15% fluctuation in blood pressure or in the number of white blood cells, red blood cells, monocytes, or lymphocytes. Methods for determining toxicity in cynomolgus monkeys are presented in the examples below.
This invention further provides a method for treating a human subject who is infected with SARS-CoV-2 comprising administering to the subject a therapeutically effective amount of the present monoclonal antibody. In one embodiment of this method, the subject is symptomatic of a SARS-CoV-2 infection. In another embodiment, the subject is asymptomatic of a SARS-CoV-2 infection. In another preferred embodiment of this
method, the present monoclonal antibody does not exhibit significant toxicity in a cynomolgus monkey when administered at a therapeutically effective amount. As an example, when administered at a therapeutically effective amount to a cynomolgus monkey, the present monoclonal antibody does not cause more than a 15% fluctuation in blood pressure or in the number of white blood cells, red blood cells, monocytes, or lymphocytes.
This invention provides a recombinant AAV vector comprising a nucleic acid sequence encoding a heavy chain and/or a light chain of the present monoclonal antibody.
In connection with the subject vectors, a nucleic acid sequence “encoding” a protein (e.g., an antibody heavy chain) encodes it operably (i.e. , in a manner permitting its expression in a cell infected by a viral particle comprising the vector that contains the nucleic acid sequence). Additionally, the recombinant viral vectors of this invention are not limited to any particular configuration with respect to the exogenous protein-coding sequences. For example, in one embodiment of the subject recombinant AAV vector, a “one vector” approach is used wherein a singular recombinant AAV vector includes nucleic acid sequences encoding both heavy and light antibody chains. In another embodiment, a “two vector” approach is used wherein one recombinant AAV vector includes a nucleic acid sequence encoding the heavy antibody chain, and a second recombinant AAV vector includes a nucleic acid sequence encoding the light antibody chain (See, e.g., S.P. Fuchs, et al. (2016)).
This invention further provides a recombinant AAV particle comprising the present recombinant AAV vector and an AAV capsid protein.
This invention also provides a composition comprising (i) a plurality of the present AAV particles and (ii) a pharmaceutically acceptable carrier.
This invention provides a method for reducing the likelihood of a human subject’s becoming infected with SARS-CoV-2 comprising administering to the subject a prophylactically effective number of the present AAV particles.
In one embodiment of the present prophylactic method, the subject has been exposed to SARS-CoV-2. In another embodiment, the subject has not been exposed to SARS- CoV-2.
This invention provides a method for treating a human subject who is infected with SARS-CoV-2 comprising administering to the subject a therapeutically effective number of the present AAV particles.
In one embodiment of the present therapeutic method, the subject is symptomatic of a SARS-CoV-2 infection. In another embodiment, the subject is asymptomatic of a SARS-CoV-2 infection.
This invention further provides a kit comprising, in separate compartments, (a) a diluent and (b) the present monoclonal antibody either as a suspension or in lyophilized form.
Finally, this invention provides a kit comprising, in separate compartments, (a) a diluent and (b) a suspension of a plurality of the present recombinant AAV particles. In one example, the subject kit comprises (i) a single-dose vial containing a concentrated solution of the subject particles (also measured as viral genomes) in a suitable solution (e.g., a solution of sterile water, sodium chloride, sodium phosphate, and Poloxamer 188) and (ii) one or more vials of suitable diluent (e.g., a solution of sterile water, sodium chloride, sodium phosphate, and Poloxamer 188).
The present vectors, particles, and methods are envisioned for suitable recombinant non-AW viruses (e.g., lentivirus, adenovirus, alphavirus, herpesvirus, or vaccinia virus), mutatis mutandis, as they are for recombinant AAV viruses in this invention.
The present monoclonal antibodies, compositions, vectors, particles, and methods are envisioned for the prophylaxis and treatment of all SARS-CoV viruses other than SARS-CoV-2 (e.g., SARS-CoV), mutatis mutandis, as they are for the prophylaxis and treatment of SARS-CoV-2 in this invention.
This invention will be better understood by reference to the examples which follow, but those skilled in the art will readily appreciate that the specific examples detailed are
only illustrative of the invention as described more fully in the claims which follow thereafter.
Examples
Example 1 - BioVision Assay Kit for ACE2 Function
BioVision, Inc. sells the Angiotensin II Converting Enzyme (ACE2) Activity Assay Kit (Fluorometric) (https://www.biovision.com/angiotensin-ii-converting-enzyrne-ace2- activity-assay-kit-fluorometric.html). This kit can be used to measure the degree to which an antibody inhibits the ability of hACE2 to cleave angiotensin II.
BioVision provides the following background information regarding its test kit, which has been edited here. Angiotensin II converting enzyme (ACE2), a zinc-based metalloprotease, is part of the renin-angiotensin system (RAS) that controls the regulation of blood pressure by cleaving the C-terminal amino acid residue of Angiotensin II to convert it into Angiotensin 1-7. ACE2 is a receptor of human coronaviruses, such as SARS and HCoV-NL63. It is expressed on the vascular endothelial cells of lung, kidney, and heart. ACE2 is a potential therapeutic target for cardiovascular and coronavirus-induced diseases. BioVision’s kit will aid research in this field. It utilizes the ability of an active ACE2 to cleave a synthetic MCA-based peptide substrate to release a free fluorophore. The released MCA can be easily quantified using a fluorescence microplate reader. BioVision also provides an ACE2- specific inhibitor that can differentiate the ACE2 activity from other proteolytic activity. This kit can detect as low as 0.4 mil, is simple, and can be used in a high- throughput format.
BioVision’s kit has the following specifications: (i) Cat # - K897-100; (ii) Size - 100 assays; (iii) Detection Method - Fluorometric (Ex/Em = 320/420 nm); (iv) Species Reactivity - Mammalian; (v) Applications - Detection of ACE2 activity in tissue/cell lysates and enzyme preparations; (vi) Features & Benefits - Simple one-step reaction I Takes only 1-2 hrs I Non-radiometric fluorescent detection I HTP adaptable; (vii) Kit Components - ACE2 Assay Buffer / ACE2 Dilution Buffer, and ACE2 Lysis Buffer / ACE2 Positive Control, ACE2 Substrate, ACE2 Inhibitor (22 mM), and MCA-Standard (1 mM); (viii) Storage Conditions - -20°C; and (ix) Shipping Conditions - Gel Pack.
Example 2 - SensoLyte Assay Kit for ACE2 Function
Anaspec sells the SensoLyte® 390 ACE2 Activity Assay Kit *Fluorimetric* (“SensoLyte kit”) (https://www.anaspec.com/products/product.asp7ick43987). This kit can be used to measure the degree to which an antibody inhibits the ability of hACE2 to cleave angiotensin II.
Anaspec provides the following information regarding its SensoLyte test kit, which has been edited here. The kit provides a convenient assay for high throughput screening of ACE2 enzyme inhibitors and inducers using a Mc-Ala/Dnp fluorescence resonance energy transfer (FRET) peptide. In the FRET peptide, Dnp quenches the fluorescence of Mc-Ala. Upon cleavage into two separate fragments by ACE2, the fluorescence of Mc-Ala is recovered, and can be monitored at excitation/emission = 330/390 nm. This assay can detect the activity of sub-nanogram levels of ACE2. Assays are performed in a convenient 96-well microplate format.
The Sensolyte kit also has the following specifications: (i) Cat # - AS-72086; (ii) Size - 100 assays; (iii) Storage Conditions - -20°C.
Example 3 - Angiotensin Il-Based Mass Spectrometry Assay for hACE2 Function
This method (the “mass spectrometry assay”) can be used to quantitatively measure hACE2 activity using mass spectrometry. In particular, it can be used to measure the degree to which an antibody inhibits the ability of hACE2 to cleave angiotensin II, as well as other substrates. The method is adapted from the ACE2 assay described in Donoghue, et al.
Enzymatic reactions are performed in 15 pl. To each tube at room temperature is added 10 pl of buffer (10 mmol/l Tris, pH 7.0) with or without hACE2. The hACE2 used in this method is recombinant soluble hACE2 prepared according to Donoghue, et al. Five microliters of purified angiotensin II (Sigma) are added to each tube for a final concentration of 5 pmol/l. (This mass spectrometry assay can also employ peptide substrates other than angiotensin II (e.g., des-Arg-bradykinin, neurotensin, kinetensin, apelin-13, and dynorphin A 1-13).) Lisinopril or captopril (Sigma) is added to some reactions at final concentrations of 6.6 pmol/l. Neither lisinopril nor captopril inhibits
hACE2 activity, and these compounds are thus useful as controls to ensure that the angiotensin II cleavage measured is due to hACE2 activity. For reactions and control experiments, the tubes are incubated at 37°C for 30 minutes. A portion (1 pl) of each reaction is quenched by the addition of 1 pl of a low-pH MALDI matrix compound (10 g/L a-cyano-4 hydroxycinnamic acid in a 1 :1 mixture of acetonitrile and water). One microliter of the resulting solution is applied to the surface of a MALDI plate. The plate is then air-dried and inserted into the sample introduction port of the Voyager Elite biospectrometry MALDI time-of-flight (TOF) mass spectrometer (PerSeptive Biosystems). The resulting signal is digitized at a frequency of 1 GHz and accumulated for 64 scans. Purified conditioned medium from empty vector transfections is used to control individual experiments for variability in extent of substrate conversion to product. For tandem mass spectrometry sequencing, a hybrid quadrupole time-of-flight mass spectrometer (Q-TOF-MS) (Micromass UK Limited) equipped with an orthogonal electrospray source (Z-spray) is used. The quadrupole is set up to pass precursor ions of selected m/z to the hexapole collision cell (Q2), and product ion spectra are acquired with the TOF analyzer. Argon is introduced into the Q2 with a collision energy of 35 eV and cone energy of 25 V.
Example 4 - Angiotensin Il-Based HPLC Assay for hACE2 Function
This method (the “HPLC assay”) can be used to quantitatively measure hACE2 activity using HPLC. In particular, it can be used to measure the degree to which an antibody inhibits the ability of hACE2 to cleave angiotensin II, as well as other substrates. The method is adapted from the “ACEH” assay described in Tipnis, et al.
Protein and Enzymatic Assays. Protein concentrations are determined using the bicinchoninic acid assay (Smith, et al.) with bovine serum albumin as a standard. Assays for hACE2 activity are carried out in a total volume of 100 pl, containing 100 mM Tris-HCI, pH 7.4, 20 pg of protein and 100 pM angiotensin II as a substrate. (This HPLC assay can also employ peptide substrates other than angiotensin II (e.g., des- Arg-bradykinin, neurotensin, and kinetensin, apelin-13, and dynorphin A 1-13).) Where appropriate, inhibitors are added to give final concentrations of 10 pM lisinopril, 10 pM captopril, 10 pM enalaprilat, 100 pM benzyl succinate, or 10 mM EDTA. EDTA inhibits hACE2 activity, but none of lisinopril, captopril, enalaprilat, and benzyl succinate (a carboxypeptidase A inhibitor) inhibits hACE2 activity. These compounds are thus
useful as controls to ensure that the angiotensin II cleavage measured is due to hACE2 activity. Reactions are carried out at 37°C, for 2 hours and stopped by heating to 100°C for 5 minutes followed by centrifugation at 11 ,600 x g for 10 minutes.
Carboxypeptidase A assays are carried out at room temperature for 30 minutes, using 0.1 units of enzyme per assay.
HPLC Analysis of Cleavage Products. Peptide hydrolysis products are separated using reverse-phase HPLC (pBondapak C-18 reverse phase column, Waters) with a UV detector set at 214 nm. All separations are carried out at room temperature, with a flow rate of 1 .5 ml/min. Mobile phase A consists of 0.08% (v/v) phosphoric acid and mobile phase B consists of 40% (v/v) acetonitrile in 0.08% (v/v) phosphoric acid. A linear solvent gradient of 11 % B to 100% B over 15 minutes with five minutes at final conditions, and eight minute re-equilibration is used. The product from angiotensin II is collected and analyzed by matrix-assisted laser desorption ionization/time-of-flight mass spectrometry.
Example 5 - Measuring Interaction of Soluble RBD Protein with Soluble hACE2
In a preferred embodiment of this invention, measuring the interaction of soluble RBD protein (a proxy for SARS-CoV-2) with soluble hACE2 (a proxy for the extracellular portion of hACE2) can be used to indirectly measure (i) the binding of a monoclonal antibody to the extracellular portion of hACE2, and (ii) a monoclonal antibody’s ability to inhibit binding of SARS-CoV-2 to the extracellular portion of hACE2.
The following method for analyzing hACE2-binding inhibition is taken from Suryadevara, et al. Wells of 384-well microtiter plates are coated with 1 pg/mL purified recombinant SARS-CoV-2 S2Pecto protein at 4°C overnight. Plates are blocked with 2% non-fat dry milk and 2% normal goat serum in DPBS-T for 1 hour. For screening assays, purified monoclonal antibodies are diluted two-fold in blocking buffer starting from 10 pg/mL in triplicate, added to the wells (20 pL per well) and incubated for 1 hour at ambient temperature. Recombinant hACE2 with a C-terminal Flag tag peptide is added to wells at 2 pg/mL in a 5 pL per well volume (final 0.4 pg/mL concentration of hACE2) without washing of antibody and then incubated for 40 minutes at ambient temperature. Plates are washed and bound hACE2 is detected using HRP-conjugated anti-Flag antibody (Sigma-Aldrich, cat. A8592, lot SLBV3799, 1 :5,000 dilution) and TMB
substrate. ACE2 binding without antibody serves as a control. The signal obtained for binding of the human ACE2 in the presence of each dilution of tested antibody is expressed as a percentage of the human ACE2 binding without antibody after subtracting the background signal. For dose-response assays, serial dilutions of purified monoclonal antibodies are applied to the wells in triplicate, and monoclonal antibody binding is detected as detailed above. IC50 values for inhibition by monoclonal antibody of S2Pecto protein binding to human ACE2 are determined after log transformation of antibody concentration using sigmoidal dose-response nonlinear regression analysis.
The reagents used in this example can be made according to this reference and/or purchased commercially (e.g., from LakePharma, Inc., Worcester, MA). In addition, related kits are commercially available. For example, (i) a SARS-CoV-2 Spike-ACE2 Interaction Inhibitor Screening Assay Kit is available from Cayman Chemical (Ann Arbor, Ml); and (ii) a SARS-CoV-2 Spike:ACE2 Inhibitor Screening Assay Kit, an ACE2 Inhibitor Screening Assay Kit, and a Spike RBD (SARS-CoV-2) : ACE2 Inhibitor Screening Assay Kit are all available from BPS Bioscience (San Diego, CA).
Example 6 - Supplemental Antibody Generation and Testing Methods
In a preferred embodiment of this invention, the present monoclonal antibody’s hACE2- binding ability, hACE2 carboxypeptidase-inhibiting ability, virus-neutralizing ability, and toxicity can be determined using the following methods taken from Du, et al.
Cell lines and viruses
HEK293T (ATCC, CRL-3216), HEK293T-ACE2 (SinoBiological, OEC001 ), Vero E6 (ATCC, CRL-1586), and LLC-MK2 (ATCC, CRL-7) cells are cultured at 37 °C under 5% CO2 in Dulbecco’s modified Eagle’s medium (DMEM) (HyClone, South Logan, UT) supplemented with 10% fetal bovine serum (FBS) (Gibco, Carlsbad, CA, USA).
SARS-CoV-2 virus (BetaCoV/Wuhan/IVDC-HB-01/2020, GISAID accession ID: EPI JSL 402119) is used. Vero E6 cells are applied to the reproduction of SARS-CoV- 2 stocks. The HCoV-NL63 strain is used. LLC-MK2 cells are applied to the reproduction of HCoV-NL63 stocks.
Generation of ACE2-blocking monoclonal antibodies To generate murine anti-hACE2 antibodies, BALB/c mice receive hACE2 (19–615) soluble antigens in a prime-boost immunization regimen with a 4-week interval. Using 5 hybridoma technology, one obtains a number of mouse anti-hACE2 cell clones. After screening hybridoma supernatants, several clones of the monoclonal antibodies that block HEK293T-hACE2 cell infection with SARS-CoV and SARS-CoV-2 spike pseudotyped virus are identified. The antibody clone exhibiting the best inhibitory activity against pseudotyped virus infection (top antibody) is identified. The sequences 10 of the variable regions of the top antibody are obtained through rapid amplification of complementary DNA (cDNA) ends amplification. Plasmid construction 15 The coding sequences of SARS-CoV-RBD (residues 306–527, accession number: NC_004718), SARS-CoV-2-RBD (residues 319–541, accession number EPI_ISL_402119), hACE2 (residues 19–615, accession number BAJ21180), and hACE2 variants (S19P, I21T, K26R, N33D, and D38E) fused with N-terminal native signal peptides and C-terminal 6× His tag are, respectively, cloned into the pCAGGS 20 expression vector (Addgene) using the EcoRI and XhoI restriction sites. The signal peptides and variable regions of antibody are synthesized (GenScript) and fused with the coding sequences for the human IgG4 and kappa light chain constant region into the pCAGGS vectors. The pEGFP-N1-hACE2 plasmid is constructed by cloning the coding region of hACE2 into pEGFP-N1 using restriction enzymes XhoI and SmaI. To 25 express minimal glycosylated ACE2, a coding sequence of residues 19–615 is synthesized (GenScript) and cloned into pFastBac1 vector (Invitrogen), with an N- terminal gp67 signal peptide and a C-terminal 6×His tag. Protein expression and purification 30 To prepare the proteins of ACE2 (19–615), SARS-CoV-RBD, and SARS-CoV-2-RBD, HEK293T cells are transiently transfected with expressing plasmids containing the coding sequence for the indicated proteins. After 3 days, the supernatant is collected and soluble protein is purified by Ni affinity chromatograph\^XVLQJ^D^+LV7UDS^+3^^ௗPO^ 35 column (GE Healthcare). The samples are then further purified via size-exclusion 49
chromatography with a Superdex 200 column (GE Healthcare) in a buffer composed of ^^ௗP0^7ULV-+&O^^S+^^^^^^DQG^^^^ௗP0^1D&O. Preparation of the full-length protein is achieved by transfection of plasmids into HEK293T cells. The protein is purified from the culture supernatants using a HiTrap Protein A HP column (GE Healthcare) and 5 subsequently purified via the above size-exclusion chromatography. For crystal screenings, the peptidase domain of human ACE2 (19–615) with a C- terminal 6×His tag is expressed using the baculovirus–insect cell system. The baculovirus is generated and amplified using the Sf21 insect cells (Invitrogen, B82101), 10 and Hi5 insect cells (Invitrogen, B85502) are used for protein expression. The conditioned medium is FROOHFWHG^^^ௗK^SRVW^LQIHFWLRQ^DQG^H[FKDQJHG^LQWR^WKH^ELQGLQJ^ EXIIHU^^^^ௗP0^+(3(6^^S+^^^^^^DQG^^^^ௗP0^1D&O^. The ACE2 (19–615) and antibody- Fab proteins are purified as described above for HEK293T cell-derived ACE2 (19–615). To obtain the complex between ACE2 and antibody-Fab, purified ACE2 and antibody- 15 Fab are incubated together, passed through a Superdex 200 increase 10/300 gel filtration column (GE Healthcare), and eluted using the binding buffer. Flow cytometry assay 20 To test the activity of antibodies to block the binding between ACE2 and SARS-CoV- RBD, or SARS-CoV-2-RBD. HEK293T cells are transiently transfected with pEGFP- N1-ACE2 plasmids. $IWHU^^^ௗK^^^^îௗ^^5 cells are FROOHFWHG^DQG^LQFXEDWHG^ZLWK^^^ௗ^J^PO^ antibody SURWHLQ^RU^LVRW\SH^,J*^DW^^^ௗ^&^IRU^^^ௗPLQ^^IROORZHG^E\^LQFXEDWLRQ^ZLWK^ ^^^ௗQJ^PO^5%'^SURWHLQV^DW^^^ௗ^&^IRU^DQRWKHU^^^ௗPLQ. After washing three times, the25 cells are incubated with APC-conjugated anti-His antibody (1:200, Miltenyi Biotec, 130- 119-782) for DQRWKHU^^^ௗPLQ. Then, the cells and data are collected and analyzed using flow cytometry (BD FACS Canto™ II, BD FACSDiva Software v8.0.3, and FlowJo 7.6.1). To test whether the antibody has any impact on the cell-surface expression of hACE2,30 HEK293T-hACE2 cells are LQFXEDWHG^ZLWK^GLIIHUHQW^FRQFHQWUDWLRQV^^^^ௗ^J^PO^RU^ZLWK^ five-IROG^VHULDO^GLOXWLRQV^UDQJLQJ^IURP^^^ௗ^J^PO^WR^^^^^ௗQJ^PO^^RI^DQWLERG\ DW^^^ௗ^&^LQ^ '0(0^ZLWK^^^^^)%6^IRU^^^RU^^^ௗK. Then, the cells are washed with FACS buffer (phosphate-bufferHG^VDOLQH^^3%6^^^^^^ERYLQH^VHUXP^DOEXPLQ^^DQG^^ௗP0^('7$^^DQG^ LQFXEDWHG^ZLWK^^^ௗ^J^PO^DQWLERG\^RU^LVRW\SH^,J*^DW^^ௗ^&^IRU^^^ௗPLQ. After washing three35 times, cells are incubated with Alexa FluorTM488 goat anti-KXPDQ^,J*^^+ௗ^ௗ/^^DQWLERG\^ 50
(1:200, Invitrogen, $^^^^^^^DW^^ௗ^&^IRU^DQRWKHU^^^ௗPLQ. Then, the cells are washed WZLFH^DQG^UHVXVSHQGHG^LQ^^^^ௗ^O^)$&6^EXIIHU^IRU^IORZ^F\WRPHWU\^DQDO\VLV^^%HFNPDQ^ CytoFLEX S, Beckman CytExpert 2.3.0.84, and FlowJo 7.6.1). 5 Surface plasmon resonance The interaction between antibody and hACE2 is monitored by SPR using a BIAcore 8K (GE Healthcare) carried out in single-cycle mode with protein A biosensor chip (GE Healthcare). All the measurements are SHUIRUPHG^LQ^WKH^EXIIHU^FRQVLVWLQJ^RI^^^ௗP0^10 Na2HPO4, ^ௗP0^.+2PO4^^^^^ௗP0^1D&O^^^^^ௗP0^.&O^^S+^^^^^^DQG^^^^^^^^Y^Y^^7ZHHQ- 20. The antibody protein is captured on the chip at ~1000 response units. Then, JUDGLHQW^FRQFHQWUDWLRQV^RI^$&(^^SURWHLQ^^IURP^^^^^WR^^^^^ௗQ0 with two-fold dilutions) flowed over the chip surface and the real-time response is recorded. After each cycle, the sensor is UHJHQHUDWHG^ZLWK^^^ௗP0^*O\-HCl (pH 1.5). The raw data and affinities are 15 collected and calculated using a 1:1 fitting model with BIAevaluation software (GE +HDOWKFDUH^^%LDFRUH^^ௗ.^&RQWURO^6RIWZDUH^^^^^^^^^^^^^^DQG^%LDFRUH^,QVLJKW^(YDOXDWLRQ^ 1.0.5.11069). hACE2 carboxypeptidase activity measurement 20 Enzymatic reactions are performed in black microtiter plates at ambient temperature ^^^ௗ^&^. 7R^HDFK^ZHOO^^^^ௗ^O^RI^^^^ௗ^J^PO^K$&(^^^^^–615) protein in PBS is added, respectively. 7KHQ^^^^ௗ^O antibody at various final concentrations of 100, 200, and ^^^ௗ^J^PO^RU^K$&(^^LQKLELWRr (MLN-4760, Sigma, 5.30616) at a final concentration of 25 ^^ௗ^0^are DGGHG^WR^ZHOOV^DQG^LQFXEDWHG^IRU^^^ௗPLQ. The reactions are initiated by DGGLQJ^^^ௗ^O^RI^IOXRURJHQLF^SHSWLGHV^^0DF-APK-'QS^^^*HQ6FULSW^^DW^^^ௗ^0^RU^ZLWK^WZR- fold serial dilutions ranging frRP^^^^WR^^^^^^^ௗ^0^WR^GHWHUPLQH^WKH^NLQHWLF^FRQVWDQWV^IRU^ hACE2 hydrolysis. The relative fluorescence units (RFUs) are read at excitation and HPLVVLRQ^ZDYHOHQJWKV^RI^^^^^DQG^^^^ௗQP^^UHVSHFWLYHO\^^LQ^NLQHWLF^PRGH^DW^^-min 30 LQWHUYDOV^IRU^^ௗK^^%0*^/$%7(&+^^&/ARIOstar Plus 5.61). To calculate the specific activity of hACE2, the intensities of RFU are converted to molarities according to standard substrate Mca-P-L-OH (GenScript). To obtain the kinetic constants, the initial velocity conditions are limited to 1^ௗPLQ. Initial velocities are plotted versus substrate concentration and fit to the Michaelis–Menten equation vௗ ௗVmax[S]/(Kmௗ^ௗ>S]) using 35 GraphPad Prism software (version 6.0). Turnover numbers (kcat) are calculated from 51
the equation kcatௗ ௗVmax/[E], XVLQJ^WKH^K$&(^^PROHFXODU^PDVV^RI^^^ௗN'D^DQG^DVVXPLQJ^ the enzyme sample to be essentially pure and fully active. Generation of pseudoviruses 5 pcDNA3.1.S2 recombinant plasmid (GenBank: MT_613044), constructed by inserting the codon-optimized S gene of SARS-CoV-2 (GenBank: MN_908947) into pcDNA3.1, is used as the template to generate the plasmid with mutagenesis in the S gene. Following the procedure of circular PCR, 15–20 nucleotides before and after the target 10 mutation site are selected as forward primers, while the reverse complementary sequences are selected as reverse primers. Following site-directed mutagenesis PCR, the template chain is digested using DpnI restriction endonuclease (NEB, R0176S). Afterward, the PCR product is directly used to transform Escherichia coli '+^Į- competent cells (Vazyme, C502-02) and single clones are selected and then 15 sequenced. The SARS-CoV and SARS-CoV-2 pseudoviruses are produced using the VSV pseudovirus system as described previously. In brief, on the day before transfection, HEK293T cells are SUHSDUHG^DQG^DGMXVWHG^WR^WKH^FRQFHQWUDWLRQ^RI^^ௗîௗ^^5 FHOO^PO^^^^ௗPO^20 of which are transferred LQWR^D^7^^^FHOO^FXOWXUH^IODVN^DQG^LQFXEDWHG^RYHUQLJKW^DW^^^ௗ^&^LQ^ an incubator conditioned with 5% CO2. The cells generally reach 70–90% confluence after overnight incubation. Thirty micrograms of DNA plasmid expressing the spike protein is transfected according to the user’s instruction manual of Lipofectamine 3000 (Invitrogen, L3000001). The transfected cells are subsequently infected with Gכǻ*- 25 VSV (VSV G-pseudotyped virus) aW^FRQFHQWUDWLRQV^RI^^ௗîௗ^^5 TCID50/ml. After being LQFXEDWHG^IRU^^ௗK^^WKH^PHGLXP^is UHSODFHG^ZLWK^D^IUHVK^PHGLXP^DQG^LQFXEDWHG^IRU^^^ௗK. The culture supernatants containing the pseudovirus are KDUYHVWHG^^ILOWHUHG^^^^^^ௗ^0^ SRUH^VL]H^^^DQG^VWRUHG^DW^í^^ௗ^&. TCID50 of pseudoviruses is determined as described previously. 30 Neutralization assay For pseudovirus neutralization assay, 104 HEK293T-hACE2 cells per well are seeded into 96-well plates (Corning) before infection. Fifty-five microliters of three- or five-fold35 serially diluted antibody ^IURP^^^ௗ^J^PO^^are added to cells. $IWHU^LQFXEDWLRQ^DW^^^ௗ^&^IRU^ 52
^ௗK^^^^^ௗîௗ^^4 TCID50 of SARS-CoV-2 pseudovirus LQ^^^ௗ^O^are added in mixtures and VXEVHTXHQWO\^LQFXEDWHG^IRU^^^ௗK. 7UDQVIHU^FHOO^O\VDWHV^^^^ௗ^O^ZHOO^^are placed into luminometer plates (Microfluor 96-well plates). $GG^OXFLIHUDVH^VXEVWUDWH^^^^ௗ^O^ZHOO^^is included in a luciferase assay system. The infectivity is determined by measuring the 5 bioluminescence (Promega, GLoMax 1.9.3). For live neutralization assay, 104 Vero E6 cells per well are seeded in 96-well plates (Corning) before infection. Fifty microliters of two-fold serially diluted antibody (from ^^ௗ^J^PO^^is added to Vero E6 cells with eight replicates. $IWHU^LQFXEDWLRQ^DW^^^ௗ^&^IRU^ 10 ^ௗK^^^^^^7&,'^^^RI^6$56-CoV-^^LQ^^^ௗ^O^is added to cells. In parallel, 104 LLC-MK2 cells per well are seeded in 96-well plates (Corning) before infection. Fifty microliters of two-fold serially diluted antibody ^IURP^^^^ௗ^J^PO^^is added to the cells with eight replicates. $IWHU^LQFXEDWLRQ^DW^^^ௗ^&^IRU^^ௗK^^^^^7&,'^^^RI^+&R9-1/^^^LQ^^^ௗ^O^is added to the mixtures. Then, mixtures are VXEVHTXHQWO\^LQFXEDWHG^DW^^^ௗ^&^IRU^^^GD\V. Cells 15 infected with or without the virus are applied as positive or negative controls. CPE in each well is observed and recorded on the third day. A virus back titration is performed to assess the correct virus titer used in each experiment. All experiments followed the standard operating procedures (SOPs) of the approved Biosafety Level-3 facility. 20 It is noted that the hACE2+ cells employed in assays described herein can, as appropriate, be either hTMPRSS2+ cells or hTMPRSS2- cells. Mice experiments 25 All animal experiments are carried out according to the relevant procedures and relevant ethical regulations regarding animal research. Briefly, the full cDNAs of hACE2 are knocked into the exon 2, the first coding exon, of the mAce2 gene located in GRC m38.p6 sites. hACE2 transgenic mice (female, 30 30 weeks old) are divided into five groups including eight mice in the placebo group injected with PBS. Animals in the pre-exposure groups are LQMHFWHG^ZLWK^^^RU^^^ௗPJ^NJ^ antibody one day before the viral challenge. In the post-exposure groups, the mice are administered ZLWK^^^RU^^^ௗPJ^NJ^DQWLERG\^RQH^GD\^DIWHU^WKH^YLUDO^FKDOOHQJH. All mice are HXWKDQL]HG^RQ^WKH^ILIWK^GD\^DIWHU^EHLQJ^FKDOOHQJHG^ZLWK^^ௗîௗ^^5 TCID50 of SARS-CoV-2. 35 The lung tissues from five mice in each group are SODFHG^LQWR^^ௗPO^RI^'0(0^VHSDUDWHO\. 53
After homogenization, viral RNAs are extracted by Magnetic Bead Extraction Kit ^(PHU7KHU^^5(^^^^DFFRUGLQJ^WR^WKH^PDQXIDFWXUHU¶V^LQVWUXFWLRQV^DQG^HOXWHG^LQ^^^ௗ^O^RI^ elution buffer and used as the template for reverse transcription-polymerase chain reaction (RT-PCR). The pairs of primers are used to target ORF1ab gene: OFR1ab-F, 5 ^ƍ-CCCTGTGGGTTTTACACTTAA-^ƍ^DQG^2)5^DE-5^^^ƍ-ACGATTGTGCATCAGCTGA- ^ƍ^^3UREH-25)^DE^^ƍ-the FAM-CCGTCTGCGGTATGTGGAAAGGTTATGG-BHQ1-^ƍ. Five microliters of RNA is used to verify the RNA quantity by One Step PrimeScript RT- PCR Kit (Takara, RR064B) according to the manufacturer’s instructions. The amplification is SHUIRUPHG^DV^IROORZV^^^^ௗ^&^IRU^^ௗPLQ^^^^ௗ^&^IRU^^^ௗV^^IROORZHG^E\^^^^ 10 F\FOHV^FRQVLVWLQJ^RI^^^ௗ^&^IRU^^ௗV^^^^ௗ^&^IRU^^^ௗV^^DQG^D^GHIDXOW^PHOWLQJ-curve step in an Applied QuantStudio 5 Real-Time PCR System (QuantStudio Design and Analysis Software v1.5.1). The limit of detection in this RT-PCR program is 40 copies. When the detection is lower than 40 copies, the value is recorded as 20 copies. 15 Histopathology and pathology Mice necropsies are performed according to a standard protocol. The lung tissues of three mice in each group for histological examination are stored in 10% neutral-buffered formalin for 7 days, embedded in paraffin, sectioned, and stained with hematoxylin 20 before examination by light microscopy. Safety assessment using cynomolgus monkeys Purpose-bred cynomolgus monkeys (Macaca fascicularis) are obtained from licensed 25 vendors and undergo standard quarantine periods (~4 weeks) before initiation. During the study periods, animals are single-housed in primary enclosures according to the appropriate regulations. All experimental procedures (the management, sampling, and euthanasia) are conducted in appropriate facilities according to the appropriate regulations. 30 A total of four male cynomolgus monkeys (3 years old) are selected and randomly divided into two groups according to body weight. Cynomolgus monkeys are DGPLQLVWHUHG^YLD^UHSHDWHG^LQWUDYHQRXV^LQIXVLRQ^^^^^RU^^^^ௗPJ^NJ^DW^RQFH^D^ZHHN^IRU^^^ weeks). During the study, the animals in each group survived until the planned 35 euthanasia. At the end of the dosing period (D22), all animals are euthanized. 54
Clinical signs of toxicity are subjectively determined following standard procedures. Blood samples for hematology and clinical chemistry are drawn pre-study, D7, D14, and D21. Comprehensive hematology evaluations included determinations of differential leukocyte count and indicators of erythrocyte mass (RBC count). Meanwhile, 5 serum chemistry analyses including the determination of serum enzyme activity are employed. Blood pressure measurements (systolic, diastolic, and mean blood pressure) are FRQGXFWHG^RQ^^^^^^^^^^^^^^^^DQG^^^^ௗK^DIWHU^WKH^FRPSOHWLRQ^RI^LQIXVLRQ^RQ^'^. Blood pressure (ecgAUTO v3.3.0.20). 10 According to the American Veterinary Medical Association principle, the amount of anesthetic is calculated based on the animal’s body weight. At the end of the dosing period (D22), the animals are LQWUDPXVFXODUO\^LQMHFWHG^ZLWK^^ௗPJ^NJ^=ROHWLO^^^^^9LUEDF^^ FRPELQHG^ZLWK^^ௗPJ^NJ^6XPLDQ[LQ^,,^^'XQKXD^6KHQJGD^$QLPDO^&R^, Ltd). Anesthesia euthanasia is performed after femoral artery/venous release. 15 Statistical analysis Statistical significance between groups is determined by unpaired two-tailed t test. For the inhibition and neutralization experiments, IC50 and ND50 are calculated with the log 20 (inhibitor) versus response–variable slope in GraphPad Prism 6.0. Enzyme kinetics (Km and Vmax) of ACE2 is fit with Michaelis–Menten in GraphPad Prism 6.0. Example 7 – Antibody Expression Cassettes 25 Figure 4 shows a schematic diagram of an expression cassette for use in the subject rAAV vector encoding the present anti-hACE2 monoclonal antibody. The cassette has the following structure: 5’ITR—CAG—Antibody Heavy Chain—Furin F2A—Antibody Light Chain—SV40 polyA—3’ITR. 30 These cassette components include a CMV enhancer/chicken beta-actin promoter and intron (or CAG); an SV40 polyadenylation signal (or SV40 polyA); heavy and light chains of the antibody; and a furin F2A self-processing peptide cleavage site. The expression cassette is flanked by AAV serotype 2 inverted terminal repeats (ITR). In the cassette-containing bicistronic single-stranded AAV (ssAAV) vector, both the heavy35 and light chains are expressed from one open reading frame using a F2A self- 55
processing peptide from FMD. The furin cleavage sequence “RKRR” for the cellular protease furin is added for removal of amino acids left on the heavy chain C-terminus following F2A self-processing. In one embodiment of this invention, the subject rAAV vectors possess introns, and in another embodiment, they do not. Abbreviations: CMV, 5 cytomegalovirus; SV40, simian virus 40; and FMD, foot-in-mouth disease virus. Example 8 – rAAV Production The subject rAAVs can be produced according to known methods. For instance, in one 10 such method, HEK-293 cells are transfected with a select rAAV vector plasmid and two helper plasmids to allow generation of infectious AAV particles. After harvesting transfected cells and cell culture supernatant, rAAV is purified by three sequential CsCl centrifugation steps. Vector genome number is assessed by Real-Time PCR, and the purity of the preparation is verified by electron microscopy and silver-stained SDS- 15 PAGE (Mueller, et al.). Example 9 – Antibody Purification SE-UPLC was performed for H11B11-hIgG1(STR), H11B11-hIgG1(STR/YTE), 3E8-20 hIgG1(STR), and 3E8-hIgG1(STR/LS). H11B11-hIgG1(STR) and H11B11- hIgG1(STR/YTE) are both humanized antibodies. 3E8-hIgG1(STR) and 3E8- hIgG1(STR/LS) are both murine-human chimeric antibodies. All proteins were >96% monomer. 25 The preliminary yields for H11B11-hIgG1(STR) and H11B11-hIgG1(STR/YTE) were ~3.8 mg and ~4.1 mg, respectively, and they were 96.8% and 96.7% monomer, respectively. The final yields for 3E8-hIgG1(STR) and 3E8-hIgG1(STR/LS) were 4.95 mg and 5.28 mg, respectively, and they were 100% and 99.2% monomer, respectively. 30 Intact mass QC by mass spectrometry was performed, and the measured molecular weights for the IgGs were within the expected range for all four antibodies. 56
Example 10 – Octet Affinity Assays of Antibodies Against hACE2-His Antigen The four antibodies H11B11-hIgG1(STR), H11B11-hIgG1(STR/YTE), 3E8-hIgG1(STR), and 3E8-hIgG1(STR/LS) (“ligands”) were produced, and hACE2-His protein (“analyte”) 5 was commercially obtained. Analysis was performed using standard procedures. The following amounts of ligand and analyte were used: (i) H11B11-hIgG1(STR) - 1.01 mg/ml; (ii) H11B11-hIgG1(STR/YTE) - 1.48 mg/ml; (iii) 3E8-hIgG1(STR) - 1.38 mg/ml; (iv) 3E8-hIgG1(STR/LS) - 1.41 mg/ml; and (v) hACE2-His protein - 0.54 mg/ml. 10 The results of this analysis were as follows. Association rates ranged from 1.12E+05 to 1.44E+05 M-1s-1. Slow dissociation rates beyond the limit of Octet using standard conditions (i.e., 1.0E-05 s-1) were observed. Because association rates exceeded the limits of detection, estimated KD values based on the full dose response could only be estimated at less than 100 pM under the current conditions. Based on curve fitting of15 binding solely at 80 nM hACE2 HIS, the affinity of 3E8-hIgG1(STR) and 3E8- hIgG1(STR/LS) was estimated as 213 pM and 482 pM, respectively. Binding experiments were performed on Octet HTX at 30 °C. Antibodies were loaded onto anti-human IgG Fc capture(AHC) sensors at 5 ^g/ml. The antibody-loaded 20 sensors were dipped in serial dilutions of analyte (1:3 dilution, seven points from top concentration (240 nM)). Reference sample well (buffer) was used for data analysis. Kinetic constants were calculated using a monovalent binding model. The assay buffer used was PBS with 0.1% BSA, 0.02% Tween-20, pH 7.2. The regeneration buffer used was 10 mM glycine buffer, pH 1.7. 25 The sensogram and kinetic constant results are as follows:
57
Example 11 - Octet FcRy and FcRn Binding for hlqGs
An Fey receptor panel (including FcRn at pH 6.0) binding assessment was performed with Octet for two antibodies. This assessment shows whether the STR amino acid substitution present in the two antibodies tested abrogates FcRy binding, but not FcRn binding.
The following antibodies were used: (i) H11 B11-hlgG1(STR), 1.01 mg/ml, 146 kDa; and (ii) H11 B11 -hlgG1 (STR-YTE), 1.48 mg/ml, 146 kDa. A control IgG (7101 +7103) was also used.
The binding analysis against the FcyR panel (pH 7.2) and FcRn (pH 6.0) employed the following: Human FcyRI; Human FcyRIIA; Human FcyRIIB; Human FcyRIIIA-F158; Human FcyRIIIA-V158; Human FcyRIIIB; and Human FcRn (pH 6.0). H11 B11- h!gG1 (STR) and H 11 B11 ~h IgG 1 (STR/YTE) only bound to Human FcRn (pH 6.0), and the control IgG performed consistently within assay expectations. A summary of results for KD values is shown below. Note - “n.d.” (not determined) indicates that insufficient binding was observed (i.e. , response < 0.05 nm).
Binding experiments were performed on Octet HTX at 25 °C. FcRn or Fey receptors were loaded onto anti-penta His (HIS1 K) sensors. Loaded sensors were dipped into serial dilutions of protein samples (300 nM start, 1 :3 dilution, seven points). Reference sample well (buffer) was used for data analysis. Kinetic constants were calculated using a monovalent (1 :1 ) binding model. Results are shown below.
5
Characterization Potency (i.e., IC50, IC90, and IC99) was determined for anti-ACE2 antibody inhibition of ACE2-biotin binding to SARS-CoV-2 spike or RBD variants, using plates coated with spike or RBD. 10 The results show that anti-ACE2 monoclonal antibodies H11B11-hIgG1(STR) (abbreviated as “H11B11-hIgG1”), H11B11-hIgG1(STR-YTE) (abbreviated as “H11B11- hIgG1_YTE”), and a control antibody are potent inhibitors of ACE2 binding to all spike and RBD constructs tested, with IC50s ranging from 70 pM to 22.98 nM for H11B11- 15 hIgG1(STR); 560 pM to 24.71 nM for H11B11-hIgG1(STR-YTE); and 2.29 nM to 22.05 nM for the control antibody. The results also show that neither 3E8-hIgG1(STR) (abbreviated as “3E8-hIgG1”) nor 3E8-hIgG1(STR/LS) (abbreviated as “3E8- hIgG1_LS”) inhibits ACE2 binding to any of the tested spike or RBD constructs. 20 The following is an IC50, IC90, and IC99 summary table for anti-ACE2 monoclonal antibodies H11B11-hIgG1(STR), H11B11-hIgG1(STR-YTE), and control antibody. 59
Note – “CNE” means “could not estimate”, which occurs where the curve becomes too shallow and renders the IC99 calculation unreliable.
5 The following is an IC50, IC90, and IC99 (nM and ^g/ml) summary table for anti-ACE2 monoclonal antibodies H11B11-hIgG1(STR), H11B11-hIgG1(STR-YTE), and control antibody. Note – “CNE” means “could not estimate.”
60
Anti-ACE2 monoclonal antibodies H11B11-hIgG1(STR), H11B11-hIgG1(STR-YTE), 3E8-hIgG1(STR), and 3E8-hIgG1(STR/LS) were shown to be potent ACE2 binders, 5 with EC50s from 255 pM to 465 pM. The control antibody was also shown to be a potent ACE2 binder, with and EC50 of 2.013 nM. Spike protein and RBD from eight SARS-CoV-2 variants (i.e., WT, Delta, Omicron [B.1.1.529], BA.2, BA.2.12.1, BA.2.75, BA.4, and BA.5) were also generally potent 10 ACE2 binders, except for Omicron [B.1.1.529] spike, which had an EC50 of 28 nM. The ACE2 binding potency for the other seven spike proteins and eight RBDs ranged from 527 pM to 6.257 nM. The following experiment measured the binding of anti-ACE2 monoclonal antibodies to 15 hACE2-biotin in terms of potency (EC50). ELISA plates were coated with hACE2-biotin (5 ^J^PO). H11B11-hIgG1(STR), H11B11-hIgG1(STR-YTE), 3E8-hIgG1(STR), 3E8- hIgG1(STR/LS), and control antibody were added (starting at 3 ^J^PO and going down three-fold, 8 pt). Binding was detected with anti-human IgG HRP or anti-mouse IgG HRP (for the control antibody). The EC50 values measured are shown below. 61
The following experiment measured the binding of hACE2-biotin to spike/RBD proteins in terms of potency (ECso/ECso). ELISA plates were coated with Spike protein or RBD from eight SARS-CoV-2 variants (i.e., WT, Delta, Omicron [B.1.1.529], BA.2, BA.2.12.1 , BA.2.75, BA.4, and BA.5) at 5 pg/ml. hACE2-biotin was added (starting at 30 pg/ml and going down three-fold, 8 pt). Binding was detected with sAv-HRP. The ECso and ECso values measured are shown below.
Example 13 - Heavy and Light Chain CDR Single Point Mutation Embodiments
This example sets forth single amino acid point mutations of exemplary heavy chain CDR1 , CDR2, and CDR3 regions, and exemplary light chain CDR1 , CDR2, and CDR3 regions, envisioned for the present monoclonal antibody. These six exemplary CDR regions are those shown in Figure 5 for humanized 11 B11 VH (heavy chain) and humanized 11 B11 VK (light chain), as originally presented in Supplementary Figure 2 of Du, et al. The heavy chain CDR1 has the following amino acid seguence: GFTFIDYYMN. The heavy chain CDR2 has the following amino acid seguence: FIRNKANDYTTEYST. The heavy chain CDR3 has the following amino acid seguence: RHMYDDGFDF. The light chain CDR1 has the following amino acid seguence:
ASSSVRYMH. The light chain CDR2 has the following amino acid sequence: LLIYDTSKLA. The light chain CDR3 has the following amino acid sequence: QQWSYNPLTF. For the purpose of this Example, the numbering for each CDR residue corresponds to the amino acid residue numbering in the variable region shown in Figure 5 for humanized 11 B11 VH or humanized 11 B11 VK, as applicable. So, the first heavy chain CDR1 residue, G, is the 26th amino acid residue of the humanized 11 B11 VH heavy chain variable region shown in Figure 5. As such, it is referred to in this example as G26. Moreover, the amino acids used in this example are the following 20 naturally occurring amino acids: A, R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, and V. So, for each of the 10 amino acid residues in the heavy chain CDR1 (beginning with G26), there are 19 point mutations possible. For instance, a point mutation whereby V replaces G26 would be written as G26V. Examples of single point mutations are set forth below for heavy chain CDR1 , CDR2, and CDR3, and light chain CDR1 , CDR2, and CDR3.
For heavy chain CDR1 (having the sequence GFTFIDYYMN), when the amino acid residue to be mutated is G26, the point mutants envisioned are G26A, G26R, G26N, G26D, G26C, G26Q, G26E, G26H, G26I, G26L, G26K, G26M, G26F, G26P, G26S, G26T, G26W, G26Y, and G26V. When the amino acid residue to be mutated is F27, the point mutants envisioned are F27A, F27R, F27N, F27D, F27C, F27Q, F27E, F27G, F27H, F27I, F27L, F27K, F27M, F27P, F27S, F27T, F27W, F27Y, and F27V. When the amino acid residue to be mutated is T28, the point mutants envisioned are T28A, T28R, T28N, T28D, T28C, T28Q, T28E, T28G, T28H, T28I, T28L, T28K, T28M, T28F, T28P, T28S, T28W, T28Y, and T28V. When the amino acid residue to be mutated is F29, the point mutants envisioned are F29A, F29R, F29N, F29D, F29C, F29Q, F29E, F29G, F29H, F29I, F29L, F29K, F29M, F29P, F29S, F29T, F29W, F29Y, and F29V. When the amino acid residue to be mutated is I30, the point mutants envisioned are I30A, I30R, I30N, I30D, I30C, I30Q, I30E, I30G, I30H, I30L, I30K, I30M, I30F, I30P, I30S, I30T, I30W, I30Y, and I30V. When the amino acid residue to be mutated is D31 , the point mutants envisioned are D31A, D31 R, D31 N, D31 C, D31 Q, D31 E, D31 G, D31 H, D311, D31 L, D31 K, D31 M, D31 F, D31 P, D31S, D31T, D31W, D31Y, and D31V. When the amino acid residue to be mutated is Y32, the point mutants envisioned are Y32A, Y32R, Y32N, Y32D, Y32C, Y32Q, Y32E, Y32G, Y32H, Y32I, Y32L, Y32K, Y32M, Y32F, Y32P, Y32S, Y32T, Y32W, and Y32V. When the amino acid residue to be mutated is Y33, the point mutants envisioned are Y33A, Y33R, Y33N, Y33D, Y33C,
Y33Q, Y33E, Y33G, Y33H, Y33I, Y33L, Y33K, Y33M, Y33F, Y33P, Y33S, Y33T, Y33W, and Y33V. When the amino acid residue to be mutated is M34, the point mutants envisioned are M34A, M34R, M34N, M34D, M34C, M34Q, M34E, M34G, M34H, M34I, M34L, M34K, M34F, M34P, M34S, M34T, M34W, M34Y, and M34V. When the amino acid residue to be mutated is N35, the point mutants envisioned are N35A, N35R, N35D, N35C, N35Q, N35E, N35G, N35H, N35I, N35L, N35K, N35M, N35F, N35P, N35S, N35T, N35W, N35Y, and N35V.
For heavy chain CDR2 (having the sequence FIRNKANDYTTEYST), when the amino acid residue to be mutated is F50, the point mutants envisioned are F50A, F50R, F50N, F50D, F50C, F50Q, F50E, F50G, F50H, F50I, F50L, F50K, F50M, F50P, F50S, F50T, F50W, F50Y, and F50V. When the amino acid residue to be mutated is 151 , the point mutants envisioned are 151 A, 151 R, 151 N, 151 D, 151 C, 151 Q, 151 E, 151 G, 151 H, 151 L, 151 K, 151 M, 151 F, 151 P, 151 S, I51T, 151 W, 151 Y, and 151V. When the amino acid residue to be mutated is R52, the point mutants envisioned are R52A, R52N, R52D, R52C, R52Q, R52E, R52G, R52H, R52I, R52L, R52K, R52M, R52F, R52P, R52S, R52T, R52W, R52Y, and R52V. When the amino acid residue to be mutated is N53, the point mutants envisioned are N53A, N53R, N53D, N53C, N53Q, N53E, N53G, N53H, N53I, N53L, N53K, N53M, N53F, N53P, N53S, N53T, N53W, N53Y, and N53V. When the amino acid residue to be mutated is K54, the point mutants envisioned are K54A, K54R, K54N, K54D, K54C, K54Q, K54E, K54G, K54H, K54I, K54L, K54M, K54F, K54P, K54S, K54T, K54W, K54Y, and K54V. When the amino acid residue to be mutated is A55, the point mutants envisioned are A55R, A55N, A55D, A55C, A55Q, A55E, A55G, A55H, A55I, A55L, A55K, A55M, A55F, A55P, A55S, A55T, A55W, A55Y, and A55V. When the amino acid residue to be mutated is N56, the point mutants envisioned are N56A, N56R, N56D, N56C, N56Q, N56E, N56G, N56H, N56I, N56L, N56K, N56M, N56F, N56P, N56S, N56T, N56W, N56Y, and N56V. When the amino acid residue to be mutated is D57, the point mutants envisioned are D57A, D57R, D57N, D57C, D57Q, D57E, D57G, D57H, D57I, D57L, D57K, D57M, D57F, D57P, D57S, D57T, D57W, D57Y, and D57V. When the amino acid residue to be mutated is Y58, the point mutants envisioned are Y58A, Y58R, Y58N, Y58D, Y58C, Y58Q, Y58E, Y58G, Y58H, Y58I, Y58L, Y58K, Y58M, Y58F, Y58P, Y58S, Y58T, Y58W, and Y58V. When the amino acid residue to be mutated is T59, the point mutants envisioned are T59A, T59R, T59N, T59D, T59C, T59Q, T59E, T59G, T59H, T59I, T59L, T59K, T59M, T59F, T59P, T59S, T59W, T59Y, and T59V. When the amino acid residue to be
mutated is T60, the point mutants envisioned are T60A, T60R, T60N, T60D, T60C, T60Q, T60E, T60G, T60H, T60I, T60L, T60K, T60M, T60F, T60P, T60S, T60W, T60Y, and T60V. When the amino acid residue to be mutated is E61 , the point mutants envisioned are E61A, E61 R, E61 N, E61 D, E61C, E61 Q, E61 E, E61 G, E61 H, E611, E61 L, E61 K, E61 M, E61 F, E61 P, E61S, E61T, E61W, E61Y, and E61V. When the amino acid residue to be mutated is Y62, the point mutants envisioned are Y62A, Y62R, Y62N, Y62D, Y62C, Y62Q, Y62E, Y62G, Y62H, Y62I, Y62L, Y62K, Y62M, Y62F, Y62P, Y62S, Y62T, Y62W, Y62Y, and Y62V. When the amino acid residue to be mutated is S63, the point mutants envisioned are S63A, S63R, S63N, S63D, S63C, S63Q, S63E, S63G, S63H, S63I, S63L, S63K, S63M, S63F, S63P, S63S, S63T, S63W, S63Y, and S63V. When the amino acid residue to be mutated is T64, the point mutants envisioned are T64A, T64R, T64N, T64D, T64C, T64Q, T64E, T64G, T64H, T64I, T64L, T64K, T64M, T64F, T64P, T64S, T64T, T64W, T64Y, and T64V.
For heavy chain CDR3 (having the sequence RHMYDDGFDF), when the amino acid residue to be mutated is R93, the point mutants envisioned are R93A, R93N, R93D, R93C, R93Q, R93E, R93G, R93H, R93I, R93L, R93K, R93M, R93F, R93P, R93S, R93T, R93W, R93Y, and R93V. When the amino acid residue to be mutated is H94, the point mutants envisioned are H94A, H94R, H94N, H94D, H94C, H94Q, H94E, H94G, H94I, H94L, H94K, H94M, H94F, H94P, H94S, H94T, H94W, H94Y, and H94V. When the amino acid residue to be mutated is M95, the point mutants envisioned are M95A, M95R, M95N, M95D, M95C, M95Q, M95E, M95G, M95H, M95I, M95L, M95K, M95F, M95P, M95S, M95T, M95W, M95Y, and M95V. When the amino acid residue to be mutated is Y96, the point mutants envisioned are Y96A, Y96R, Y96N, Y96D, Y96C, Y96Q, Y96E, Y96G, Y96H, Y96I, Y96L, Y96K, Y96M, Y96F, Y96P, Y96S, Y96T, Y96W, and Y96V. When the amino acid residue to be mutated is D97, the point mutants envisioned are D97A, D97R, D97N, D97C, D97Q, D97E, D97G, D97H, D97I, D97L, D97K, D97M, D97F, D97P, D97S, D97T, D97W, D97Y, and D97V. When the amino acid residue to be mutated is D98, the point mutants envisioned are D98A, D98R, D98N, D98C, D98Q, D98E, D98G, D98H, D98I, D98L, D98K, D98M, D98F, D98P, D98S, D98T, D98W, D98Y, and D98V. When the amino acid residue to be mutated is G99, the point mutants envisioned are G99A, G99R, G99N, G99D, G99C, G99Q, G99E, G99H, G99I, G99L, G99K, G99M, G99F, G99P, G99S, G99T, G99W, G99Y, and G99V. When the amino acid residue to be mutated is F100, the point mutants envisioned are F100A, F100R, F100N, F100D, F100C, F100Q, F100E, F100G, F100H, F100I, F100L,
F100K, F100M, F100P, F100S, F100T, F100W, F100Y, and F100V. When the amino acid residue to be mutated is D101 , the point mutants envisioned are D101A, D101 R, D101 N, D101 C, D101 Q, D101 E, D101 G, D101 H, D101 I, D101 L, D101 K, D101 M, D101 F, D101 P, D101 S, D101T, D101W, D101Y, and D101V. When the amino acid residue to be mutated is F102, the point mutants envisioned are F102A, F102R, F102N, F102D, F102C, F102Q, F102E, F102G, F102H, F102I, F102L, F102K, F102M, F102P, F102S, F102T, F102W, F102Y, and F102V.
For light chain CDR1 (having the sequence ASSSVRYMH, wherein R30 is immediately followed by Y32), when the amino acid residue to be mutated is A25, the point mutants envisioned are A25R, A25N, A25D, A25C, A25Q, A25E, A25G, A25H, A25I, A25L, A25K, A25M, A25F, A25P, A25S, A25T, A25W, A25Y, and A25V. When the amino acid residue to be mutated is S26, the point mutants envisioned are S26A, S26R, S26N, S26D, S26C, S26Q, S26E, S26G, S26H, S26I, S26L, S26K, S26M, S26F, S26P, S26T, S26W, S26Y, and S26V. When the amino acid residue to be mutated is S27, the point mutants envisioned are S27A, S27R, S27N, S27D, S27C, S27Q, S27E, S27G, S27H, S27I, S27L, S27K, S27M, S27F, S27P, S27T, S27W, S27Y, and S27V. When the amino acid residue to be mutated is S28, the point mutants envisioned are S28A, S28R, S28N, S28D, S28C, S28Q, S28E, S28G, S28H, S28I, S28L, S28K, S28M, S28F, S28P, S28T, S28W, S28Y, and S28V. When the amino acid residue to be mutated is V29, the point mutants envisioned are V29A, V29R, V29N, V29D, V29C, V29Q, V29E, V29G, V29H, V29I, V29L, V29K, V29M, V29F, V29P, V29S, V29T, V29W, and V29Y. When the amino acid residue to be mutated is R30, the point mutants envisioned are R30A, R30N, R30D, R30C, R30Q, R30E, R30G, R30H, R30I, R30L, R30K, R30M, R30F, R30P, R30S, R30T, R30W, R30Y, and R30V. When the amino acid residue to be mutated is Y32, the point mutants envisioned are Y32A, Y32R, Y32N, Y32D, Y32C, Y32Q, Y32E, Y32G, Y32H, Y32I, Y32L, Y32K, Y32M, Y32F, Y32P, Y32S, Y32T, Y32W, and Y32V. When the amino acid residue to be mutated is M33, the point mutants envisioned are M33A, M33R, M33N, M33D, M33C, M33Q, M33E, M33G, M33H, M33I, M33L, M33K, M33F, M33P, M33S, M33T, M33W, M33Y, and M33V. When the amino acid residue to be mutated is H34, the point mutants envisioned are H34A, H34R, H34N, H34D, H34C, H34Q, H34E, H34G, H34I, H34L, H34K, H34M, H34F, H34P, H34S, H34T, H34W, H34Y, and H34V.
For light chain CDR2 (having the sequence LLIYDTSKLA), when the amino acid residue to be mutated is L46, the point mutants envisioned are L46A, L46R, L46N, L46D, L46C, L46Q, L46E, L46G, L46H, L46I, L46K, L46M, L46F, L46P, L46S, L46T, L46W, L46Y, and L46V. When the amino acid residue to be mutated is L47, the point mutants envisioned are L47A, L47R, L47N, L47D, L47C, L47Q, L47E, L47G, L47H, L47I, L47K, L47M, L47F, L47P, L47S, L47T, L47W, L47Y, and L47V. When the amino acid residue to be mutated is 148, the point mutants envisioned are I48A, I48R, I48N, I48D, I48C, I48Q, I48E, I48G, I48H, I48L, I48K, I48M, I48F, I48P, I48S, I48T, I48W, I48Y, and 148V. When the amino acid residue to be mutated is Y49, the point mutants envisioned are Y49A, Y49R, Y49N, Y49D, Y49C, Y49Q, Y49E, Y49G, Y49H, Y49I, Y49L, Y49K, Y49M, Y49F, Y49P, Y49S, Y49T, Y49W, and Y49V. When the amino acid residue to be mutated is D50, the point mutants envisioned are D50A, D50R, D50N, D50C, D50Q, D50E, D50G, D50H, D50I, D50L, D50K, D50M, D50F, D50P, D50S, D50T, D50W, D50Y, and D50V. When the amino acid residue to be mutated is T51 , the point mutants envisioned are T51A, T51 R, T51 N, T51 D, T51 C, T51Q, T51 E, T51 G, T51 H, T51 I, T51 L, T51 K, T51 M, T51 F, T51 P, T51 S, T51W, T51Y, and T51V. When the amino acid residue to be mutated is S52, the point mutants envisioned are S52A, S52R, S52N, S52D, S52C, S52Q, S52E, S52G, S52H, S52I, S52L, S52K, S52M, S52F, S52P, S52T, S52W, S52Y, and S52V. When the amino acid residue to be mutated is K53, the point mutants envisioned are K53A, K53R, K53N, K53D, K53C, K53Q, K53E, K53G, K53H, K53I, K53L, K53M, K53F, K53P, K53S, K53T, K53W, K53Y, and K53V. When the amino acid residue to be mutated is L54, the point mutants envisioned are L54A, L54R, L54N, L54D, L54C, L54Q, L54E, L54G, L54H, L54I, L54K, L54M, L54F, L54P, L54S, L54T, L54W, L54Y, and L54V. When the amino acid residue to be mutated is A55, the point mutants envisioned are A55R, A55N, A55D, A55C, A55Q, A55E, A55G, A55H, A55I, A55L, A55K, A55M, A55F, A55P, A55S, A55T, A55W, A55Y, and A55V.
For light chain CDR3 (having the sequence QQWSYNPLTF), when the amino acid residue to be mutated is Q89, the point mutants envisioned are Q89A, Q89R, Q89N, Q89D, Q89C, Q89E, Q89G, Q89H, Q89I, Q89L, Q89K, Q89M, Q89F, Q89P, Q89S, Q89T, Q89W, Q89Y, and Q89V. When the amino acid residue to be mutated is Q90, the point mutants envisioned are Q90A, Q90R, Q90N, Q90D, Q90C, Q90E, Q90G, Q90H, Q90I, Q90L, Q90K, Q90M, Q90F, Q90P, Q90S, Q90T, Q90W, Q90Y, and Q90V. When the amino acid residue to be mutated is W91 , the point mutants envisioned are
W91A, W91 R, W91 N, W91 D, W91 C, W91 Q, W91 E, W91 G, W91 H, W911, W91 L, W91 K, W91 M, W91 F, W91 P, W91 S, W91T, W91Y, and W91V. When the amino acid residue to be mutated is S92, the point mutants envisioned are S92A, S92R, S92N, S92D, S92C, S92Q, S92E, S92G, S92H, S92I, S92L, S92K, S92M, S92F, S92P, S92T, S92W, S92Y, and S92V. When the amino acid residue to be mutated is Y93, the point mutants envisioned are Y93A, Y93R, Y93N, Y93D, Y93C, Y93Q, Y93E, Y93G, Y93H, Y93I, Y93L, Y93K, Y93M, Y93F, Y93P, Y93S, Y93T, Y93W, and Y93V. When the amino acid residue to be mutated is N94, the point mutants envisioned are N94A, N94R, N94D, N94C, N94Q, N94E, N94G, N94H, N94I, N94L, N94K, N94M, N94F, N94P, N94S, N94T, N94W, N94Y, and N94V. When the amino acid residue to be mutated is P95, the point mutants envisioned are P95A, P95R, P95N, P95D, P95C, P95Q, P95E, P95G, P95H, P95I, P95L, P95K, P95M, P95F, P95S, P95T, P95W, P95Y, and P95V. When the amino acid residue to be mutated is L96, the point mutants envisioned are L96A, L96R, L96N, L96D, L96C, L96Q, L96E, L96G, L96H, L96I, L96K, L96M, L96F, L96P, L96S, L96T, L96W, L96Y, and L96V. When the amino acid residue to be mutated is T97, the point mutants envisioned are T97A, T97R, T97N, T97D, T97C, T97Q, T97E, T97G, T97H, T97I, T97L, T97K, T97M, T97F, T97P, T97S, T97W, T97Y, and T97V. When the amino acid residue to be mutated is F98, the point mutants envisioned are F98A, F98R, F98N, F98D, F98C, F98Q, F98E, F98G, F98H, F98I, F98L, F98K, F98M, F98P, F98S, F98T, F98W, F98Y, and F98V.
Example 14 - Heavy Chain CDR3 Double Point Mutation Embodiments
This example sets forth examples of double amino acid point mutations of an exemplary heavy chain CDR3 envisioned for the present monoclonal antibody. Again, the heavy chain CDR3 has the following amino acid sequence: RHMYDDGFDF, wherein the numbering for each heavy chain CDR3 residue corresponds to the amino acid residue numbering in the heavy chain variable region shown in Figure 5. So, for example, the first and third heavy chain CDR3 residues, i.e. , R and M, are, respectively, the 93rd and 95th amino acid residues of the heavy chain variable region shown in Figure 5. As such, they are referred to in this example as R93 and M95. As in Example 13, the amino acids used in this example are the following 20 naturally occurring amino acids: A, R, N, D, C, Q, E, G, H, I, L, K, M, F, P, S, T, W, Y, and V. And again, for each of the 10 amino acid residues in the heavy chain CDR3 (beginning with R93), there are 19 single point mutations possible. For each double point mutation,
however, there are far more permutations possible. For example, R93A/M95Q (i.e. , the double point mutation wherein A replaces R93 and Q replaces M95) would constitute one of the many double point mutations possible. Examples of double point mutations are set forth below. In each example, the double point mutation is expressed as a two- letter abbreviation. So, for example, the double point mutation R93A/M95Q would be expressed simply as AQ.
When the first and second amino acid residues to be mutated are R93 and H94, the double point mutants envisioned are as follows:
AA, AR, AN, AD, AC, AQ, AE, AG, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, NA, NR, NN, ND, NC, NQ, NE, NG, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR, DN, DD, DC, DQ, DE, DG, DI, DL, DK, DM, DF, DP, DS, DT, DW, DY, DV, CA, CR, CN, CD, CC, CQ, CE, CG, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, QA, QR, QN, QD, QC, QQ, QE, QG, QI, QL, QK, QM, QF, QP, QS, QT, QW, QY, QV, EA, ER, EN, ED, EC, EQ, EE, EG, El, EL, EK, EM, EF, EP, ES, ET, EW, EY, EV, GA, GR, GN, GD, GC, GQ, GE, GG, Gl, GL, GK, GM, GF, GP, GS, GT, GW, GY, GV, HA, HR, HN, HD, HC, HQ, HE, HG, HI, HL, HK, HM, HF, HP, HS, HT, HW, HY, HV, IA, IR, IN, ID, IC, IQ, IE, IG, II, IL, IK, IM, IF, IP, IS, IT, IW, IY, IV, LA, LR, LN, LD, LC, LQ, LE, LG, LI, LL, LK, LM, LF, LP, LS, LT, LW, LY, LV, KA, KR, KN, KD, KC, KQ, KE, KG, KI, KL, KK, KM, KF, KP, KS, KT, KW, KY, KV, MA, MR, MN, MD, MC, MQ, ME, MG, Ml, ML, MK, MM, MF, MP, MS, MT, MW, MY, MV, FA, FR, FN, FD, FC, FQ, FE, FG, Fl, FL, FK, FM, FF, FP, FS, FT, FW, FY, FV, PA, PR, PN, PD, PC, PQ, PE, PG, PI, PL, PK, PM, PF, PP, PS, PT, PW, PY, PV, SA, SR, SN, SD, SC, SQ, SE, SG, SI, SL, SK, SM, SF, SP, SS, ST, SW, SY, SV, TA, TR, TN, TD, TC, TQ, TE, TG, Tl, TL, TK, TM, TF, TP, TS, TT, TW, TY, TV, WA, WR, WN, WD, WC, WQ, WE, WG, Wl, WL, WK, WM, WF, WP, WS, WT, WW, WY, WV, YA, YR, YN, YD, YC, YQ, YE, YG, Yl, YL, YK, YM, YF, YP, YS, YT, YW, YY, YV, VA, VR, VN, VD, VC, VQ, VE, VG, VI, VL, VK, VM, VF, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are R93 and M95, the double point mutants envisioned are as follows:
AA, AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AF, AP, AS, AT, AW, AY, AV, NA, NR, NN, ND, NC, NQ, NE, NG, NH, Nl, NL, NK, NF, NP, NS, NT, NW, NY, NV, DA, DR,
DN, DD, DC, DQ, DE, DG, DH, DI, DL, DK, DF, DP, DS, DT, DW, DY, DV, CA, CR, CN, CD, CC, CQ, CE, CG, CH, Cl, CL, CK, CF, CP, CS, CT, CW, CY, CV, QA, QR, QN, QD,
QC, QQ, QE, QG, QH, QI, QL, QK, QF, QP, QS, QT, QW, QY, QV, EA, ER, EN, ED,
EC, EQ, EE, EG, EH, El, EL, EK, EF, EP, ES, ET, EW, EY, EV, GA, GR, GN, GD, GC, GQ, GE, GG, GH, Gl, GL, GK, GF, GP, GS, GT, GW, GY, GV, HA, HR, HN, HD, HC, HQ, HE, HG, HH, HI, HL, HK, HF, HP, HS, HT, HW, HY, HV, IA, IR, IN, ID, IC, IQ, IE, IG, IH, II, IL, IK, IF, IP, IS, IT, IW, IY, IV, LA, LR, LN, LD, LC, LQ, LE, LG, LH, LI, LL, LK, LF, LP, LS, LT, LW, LY, LV, KA, KR, KN, KD, KC, KQ, KE, KG, KH, KI, KL, KK, KF, KP, KS, KT, KW, KY, KV, MA, MR, MN, MD, MC, MQ, ME, MG, MH, Ml, ML, MK, MF, MP, MS, MT, MW, MY, MV, FA, FR, FN, FD, FC, FQ, FE, FG, FH, Fl, FL, FK, FF, FP, FS, FT, FW, FY, FV, PA, PR, PN, PD, PC, PQ, PE, PG, PH, PI, PL, PK, PF, PP, PS, PT, PW, PY, PV, SA, SR, SN, SD, SC, SQ, SE, SG, SH, SI, SL, SK, SF, SP, SS, ST, SW, SY, SV, TA, TR, TN, TD, TC, TQ, TE, TG, TH, Tl, TL, TK, TF, TP, TS, TT, TW, TY, TV, WA, WR, WN, WD, WC, WQ, WE, WG, WH, Wl, WL, WK, WF, WP, WS, WT, WW, WY, WV, YA, YR, YN, YD, YC, YQ, YE, YG, YH, Yl, YL, YK, YF, YP, YS, YT, YW, YY, YV, VA, VR, VN, VD, VC, VQ, VE, VG, VH, VI, VL, VK, VF, VP, VS, VT, VW, VY, and VV.
When the first and second amino acid residues to be mutated are R93 and Y96, the double point mutants envisioned are as follows:
AA, AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AV, NA,
NR, NN, ND, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NV, DA, DR,
DN, DD, DC, DQ, DE, DG, DH, DI, DL, DK, DM, DF, DP, DS, DT, DW, DV, CA, CR, CN,
CD, CC, CQ, CE, CG, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CV, QA, QR, QN,
QD, QC, QQ, QE, QG, QH, QI, QL, QK, QM, QF, QP, QS, QT, QW, QV, EA, ER, EN, ED, EC, EQ, EE, EG, EH, El, EL, EK, EM, EF, EP, ES, ET, EW, EV, GA, GR, GN, GD, GC, GQ, GE, GG, GH, Gl, GL, GK, GM, GF, GP, GS, GT, GW, GV, HA, HR, HN, HD, HC, HQ, HE, HG, HH, HI, HL, HK, HM, HF, HP, HS, HT, HW, HV, IA, IR, IN, ID, IC, IQ, IE, IG, IH, II, IL, IK, IM, IF, IP, IS, IT, IW, IV, LA, LR, LN, LD, LC, LQ, LE, LG, LH, LI, LL, LK, LM, LF, LP, LS, LT, LW, LV, KA, KR, KN, KD, KC, KQ, KE, KG, KH, KI, KL, KK, KM, KF, KP, KS, KT, KW, KV, MA, MR, MN, MD, MC, MQ, ME, MG, MH, Ml, ML, MK, MM, MF, MP, MS, MT, MW, MV, FA, FR, FN, FD, FC, FQ, FE, FG, FH, Fl, FL, FK, FM, FF, FP, FS, FT, FW, FV, PA, PR, PN, PD, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PF, PP, PS, PT, PW, PV, SA, SR, SN, SD, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SF, SP, SS, ST, SW, SV, TA, TR, TN, TD, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TF, TP, TS, TT, TW,
TV, WA, WR, WN, WD, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WF, WP, WS, WT, WW, WV, YA, YR, YN, YD, YC, YQ, YE, YG, YH, Yl, YL, YK, YM, YF, YP, YS, YT, YW, YV, VA, VR, VN, VD, VC, VQ, VE, VG, VH, VI, VL, VK, VM, VF, VP, VS, VT, VW, and W.
When the first and second amino acid residues to be mutated are R93 and D97, the double point mutants envisioned are as follows:
AA, AR, AN, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, NA, NR, NN, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR, DN, DC, DQ, DE, DG, DH, DI, DL, DK, DM, DF, DP, DS, DT, DW, DY, DV, CA, CR, CN, CC, CQ, CE, CG, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, QA, QR, QN, QC, QQ, QE, QG, QH, QI, QL, QK, QM, QF, QP, QS, QT, QW, QY, QV, EA, ER, EN,
EC, EQ, EE, EG, EH, El, EL, EK, EM, EF, EP, ES, ET, EW, EY, EV, GA, GR, GN, GC, GQ, GE, GG, GH, Gl, GL, GK, GM, GF, GP, GS, GT, GW, GY, GV, HA, HR, HN, HC, HQ, HE, HG, HH, HI, HL, HK, HM, HF, HP, HS, HT, HW, HY, HV, IA, IR, IN, IC, IQ, IE, IG, IH, II, IL, IK, IM, IF, IP, IS, IT, IW, IY, IV, LA, LR, LN, LC, LQ, LE, LG, LH, LI, LL, LK, LM, LF, LP, LS, LT, LW, LY, LV, KA, KR, KN, KC, KQ, KE, KG, KH, KI, KL, KK, KM, KF, KP, KS, KT, KW, KY, KV, MA, MR, MN, MC, MQ, ME, MG, MH, Ml, ML, MK, MM, MF, MP, MS, MT, MW, MY, MV, FA, FR, FN, FC, FQ, FE, FG, FH, Fl, FL, FK, FM, FF, FP, FS, FT, FW, FY, FV, PA, PR, PN, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PF, PP, PS, PT, PW, PY, PV, SA, SR, SN, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SF, SP, SS, ST, SW, SY, SV, TA, TR, TN, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TF, TP, TS, TT, TW, TY, TV, WA, WR, WN, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WF, WP, WS, WT, WW, WY, WV, YA, YR, YN, YC, YQ, YE, YG, YH, Yl, YL, YK, YM, YF, YP, YS, YT, YW, YY, YV, VA, VR, VN, VC, VQ, VE, VG, VH, VI, VL, VK, VM, VF, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are R93 and D98, the double point mutants envisioned are as follows:
AA, AR, AN, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, NA, NR, NN, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR,
DN, DC, DQ, DE, DG, DH, DI, DL, DK, DM, DF, DP, DS, DT, DW, DY, DV, CA, CR, CN, CC, CQ, CE, CG, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, QA, QR, QN,
QC, QQ, QE, QG, QH, QI, QL, QK, QM, QF, QP, QS, QT, QW, QY, QV, EA, ER, EN,
EC, EQ, EE, EG, EH, El, EL, EK, EM, EF, EP, ES, ET, EW, EY, EV, GA, GR, GN, GC, GQ, GE, GG, GH, Gl, GL, GK, GM, GF, GP, GS, GT, GW, GY, GV, HA, HR, HN, HC, HQ, HE, HG, HH, HI, HL, HK, HM, HF, HP, HS, HT, HW, HY, HV, IA, IR, IN, IC, IQ, IE, IG, IH, II, IL, IK, IM, IF, IP, IS, IT, IW, IY, IV, LA, LR, LN, LC, LQ, LE, LG, LH, LI, LL, LK, LM, LF, LP, LS, LT, LW, LY, LV, KA, KR, KN, KC, KQ, KE, KG, KH, KI, KL, KK, KM, KF, KP, KS, KT, KW, KY, KV, MA, MR, MN, MC, MQ, ME, MG, MH, Ml, ML, MK, MM, MF, MP, MS, MT, MW, MY, MV, FA, FR, FN, FC, FQ, FE, FG, FH, Fl, FL, FK, FM, FF, FP, FS, FT, FW, FY, FV, PA, PR, PN, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PF, PP, PS, PT, PW, PY, PV, SA, SR, SN, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SF, SP, SS, ST, SW, SY, SV, TA, TR, TN, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TF, TP, TS, TT, TW, TY, TV, WA, WR, WN, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WF, WP, WS, WT, WW, WY, WV, YA, YR, YN, YC, YQ, YE, YG, YH, Yl, YL, YK, YM, YF, YP, YS, YT, YW, YY, YV, VA, VR, VN, VC, VQ, VE, VG, VH, VI, VL, VK, VM, VF, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are R93 and G99, the double point mutants envisioned are as follows:
AA, AR, AN, AD, AC, AQ, AE, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, NA, NR, NN, ND, NC, NQ, NE, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR,
DN, DD, DC, DQ, DE, DH, DI, DL, DK, DM, DF, DP, DS, DT, DW, DY, DV, CA, CR, CN, CD, CC, CQ, CE, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, QA, QR, QN,
QD, QC, QQ, QE, QH, QI, QL, QK, QM, QF, QP, QS, QT, QW, QY, QV, EA, ER, EN, ED, EC, EQ, EE, EH, El, EL, EK, EM, EF, EP, ES, ET, EW, EY, EV, GA, GR, GN, GD, GC, GQ, GE, GH, Gl, GL, GK, GM, GF, GP, GS, GT, GW, GY, GV, HA, HR, HN, HD, HC, HQ, HE, HH, HI, HL, HK, HM, HF, HP, HS, HT, HW, HY, HV, IA, IR, IN, ID, IC, IQ, IE, IH, II, IL, IK, IM, IF, IP, IS, IT, IW, IY, IV, LA, LR, LN, LD, LC, LQ, LE, LH, LI, LL, LK, LM, LF, LP, LS, LT, LW, LY, LV, KA, KR, KN, KD, KC, KQ, KE, KH, KI, KL, KK, KM, KF, KP, KS, KT, KW, KY, KV, MA, MR, MN, MD, MC, MQ, ME, MH, Ml, ML, MK, MM, MF, MP, MS, MT, MW, MY, MV, FA, FR, FN, FD, FC, FQ, FE, FH, Fl, FL, FK, FM, FF, FP, FS, FT, FW, FY, FV, PA, PR, PN, PD, PC, PQ, PE, PH, PI, PL, PK, PM, PF, PP, PS, PT, PW, PY, PV, SA, SR, SN, SD, SC, SQ, SE, SH, SI, SL, SK, SM, SF, SP, SS, ST, SW, SY, SV, TA, TR, TN, TD, TC, TQ, TE, TH, Tl, TL, TK, TM, TF, TP, TS, TT, TW, TY, TV, WA, WR, WN, WD, WC, WQ, WE, WH, Wl, WL, WK, WM, WF, WP, WS, WT, WW,
WY, VW, YA, YR, YN, YD, YC, YQ, YE, YH, Yl, YL, YK, YM, YF, YP, YS, YT, YW, YY, YV, VA, VR, VN, VD, VC, VQ, VE, VH, VI, VL, VK, VM, VF, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are R93 and F100, the double point mutants envisioned are as follows:
AA, AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AP, AS, AT, AW, AY, AV, NA,
NR, NN, ND, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NP, NS, NT, NW, NY, NV, DA, DR,
DN, DD, DC, DQ, DE, DG, DH, DI, DL, DK, DM, DP, DS, DT, DW, DY, DV, CA, CR, CN,
CD, CC, CQ, CE, CG, CH, Cl, CL, CK, CM, CP, CS, CT, CW, CY, CV, QA, QR, QN,
QD, QC, QQ, QE, QG, QH, QI, QL, QK, QM, QP, QS, QT, QW, QY, QV, EA, ER, EN, ED, EC, EQ, EE, EG, EH, El, EL, EK, EM, EP, ES, ET, EW, EY, EV, GA, GR, GN, GD, GC, GQ, GE, GG, GH, Gl, GL, GK, GM, GP, GS, GT, GW, GY, GV, HA, HR, HN, HD, HC, HQ, HE, HG, HH, HI, HL, HK, HM, HP, HS, HT, HW, HY, HV, IA, IR, IN, ID, IC, IQ, IE, IG, IH, II, IL, IK, IM, IP, IS, IT, IW, IY, IV, LA, LR, LN, LD, LC, LQ, LE, LG, LH, LI, LL, LK, LM, LP, LS, LT, LW, LY, LV, KA, KR, KN, KD, KC, KQ, KE, KG, KH, KI, KL, KK, KM, KP, KS, KT, KW, KY, KV, MA, MR, MN, MD, MC, MQ, ME, MG, MH, Ml, ML, MK, MM, MP, MS, MT, MW, MY, MV, FA, FR, FN, FD, FC, FQ, FE, FG, FH, Fl, FL, FK, FM, FP, FS, FT, FW, FY, FV, PA, PR, PN, PD, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PP, PS, PT, PW, PY, PV, SA, SR, SN, SD, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SP, SS, ST, SW, SY, SV, TA, TR, TN, TD, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TP, TS, TT, TW, TY, TV, WA, WR, WN, WD, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WP, WS, WT, WW, WY, VW, YA, YR, YN, YD, YC, YQ, YE, YG, YH, Yl, YL, YK, YM, YP, YS, YT, YW, YY, YV, VA, VR, VN, VD, VC, VQ, VE, VG, VH, VI, VL, VK, VM, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are R93 and D101 , the double point mutants envisioned are as follows:
AA, AR, AN, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, NA, NR, NN, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR,
DN, DC, DQ, DE, DG, DH, DI, DL, DK, DM, DF, DP, DS, DT, DW, DY, DV, CA, CR, CN,
CC, CQ, CE, CG, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, QA, QR, QN,
QC, QQ, QE, QG, QH, QI, QL, QK, QM, QF, QP, QS, QT, QW, QY, QV, EA, ER, EN,
EC, EQ, EE, EG, EH, El, EL, EK, EM, EF, EP, ES, ET, EW, EY, EV, GA, GR, GN, GC, GQ, GE, GG, GH, Gl, GL, GK, GM, GF, GP, GS, GT, GW, GY, GV, HA, HR, HN, HC, HQ, HE, HG, HH, HI, HL, HK, HM, HF, HP, HS, HT, HW, HY, HV, IA, IR, IN, IC, IQ, IE, IG, IH, II, IL, IK, IM, IF, IP, IS, IT, IW, IY, IV, LA, LR, LN, LC, LQ, LE, LG, LH, LI, LL, LK, LM, LF, LP, LS, LT, LW, LY, LV, KA, KR, KN, KC, KQ, KE, KG, KH, KI, KL, KK, KM, KF, KP, KS, KT, KW, KY, KV, MA, MR, MN, MC, MQ, ME, MG, MH, Ml, ML, MK, MM, MF, MP, MS, MT, MW, MY, MV, FA, FR, FN, FC, FQ, FE, FG, FH, Fl, FL, FK, FM, FF, FP, FS, FT, FW, FY, FV, PA, PR, PN, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PF, PP, PS, PT, PW, PY, PV, SA, SR, SN, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SF, SP, SS, ST, SW, SY, SV, TA, TR, TN, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TF, TP, TS, TT, TW, TY, TV, WA, WR, WN, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WF, WP, WS, WT, WW, WY, WV, YA, YR, YN, YC, YQ, YE, YG, YH, Yl, YL, YK, YM, YF, YP, YS, YT, YW, YY, YV, VA, VR, VN, VC, VQ, VE, VG, VH, VI, VL, VK, VM, VF, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are R93 and F102, the double point mutants envisioned are as follows:
AA, AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AP, AS, AT, AW, AY, AV, NA,
NR, NN, ND, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NP, NS, NT, NW, NY, NV, DA, DR,
DN, DD, DC, DQ, DE, DG, DH, DI, DL, DK, DM, DP, DS, DT, DW, DY, DV, CA, CR, CN,
CD, CC, CQ, CE, CG, CH, Cl, CL, CK, CM, CP, CS, CT, CW, CY, CV, QA, QR, QN,
QD, QC, QQ, QE, QG, QH, QI, QL, QK, QM, QP, QS, QT, QW, QY, QV, EA, ER, EN, ED, EC, EQ, EE, EG, EH, El, EL, EK, EM, EP, ES, ET, EW, EY, EV, GA, GR, GN, GD, GC, GQ, GE, GG, GH, Gl, GL, GK, GM, GP, GS, GT, GW, GY, GV, HA, HR, HN, HD, HC, HQ, HE, HG, HH, HI, HL, HK, HM, HP, HS, HT, HW, HY, HV, IA, IR, IN, ID, IC, IQ, IE, IG, IH, II, IL, IK, IM, IP, IS, IT, IW, IY, IV, LA, LR, LN, LD, LC, LQ, LE, LG, LH, LI, LL, LK, LM, LP, LS, LT, LW, LY, LV, KA, KR, KN, KD, KC, KQ, KE, KG, KH, KI, KL, KK, KM, KP, KS, KT, KW, KY, KV, MA, MR, MN, MD, MC, MQ, ME, MG, MH, Ml, ML, MK, MM, MP, MS, MT, MW, MY, MV, FA, FR, FN, FD, FC, FQ, FE, FG, FH, Fl, FL, FK, FM, FP, FS, FT, FW, FY, FV, PA, PR, PN, PD, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PP, PS, PT, PW, PY, PV, SA, SR, SN, SD, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SP, SS, ST, SW, SY, SV, TA, TR, TN, TD, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TP, TS, TT, TW, TY, TV, WA, WR, WN, WD, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WP, WS, WT, WW, WY, WV, YA, YR, YN, YD, YC, YQ, YE, YG, YH, Yl, YL, YK, YM, YP, YS, YT, YW, YY,
YV, VA, VR, VN, VD, VC, VQ, VE, VG, VH, VI, VL, VK, VM, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are H94 and M95, the double point mutants envisioned are as follows:
AA, AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RD, RC, RQ, RE, RG, RH, Rl, RL, RK, RF, RP, RS, RT, RW, RY, RV, NA, NR,
NN, ND, NC, NQ, NE, NG, NH, Nl, NL, NK, NF, NP, NS, NT, NW, NY, NV, DA, DR, DN,
DD, DC, DQ, DE, DG, DH, DI, DL, DK, DF, DP, DS, DT, DW, DY, DV, CA, CR, CN, CD,
CC, CQ, CE, CG, CH, Cl, CL, CK, CF, CP, CS, CT, CW, CY, CV, QA, QR, QN, QD,
QC, QQ, QE, QG, QH, QI, QL, QK, QF, QP, QS, QT, QW, QY, QV, EA, ER, EN, ED, EC, EQ, EE, EG, EH, El, EL, EK, EF, EP, ES, ET, EW, EY, EV, GA, GR, GN, GD, GC, GQ, GE, GG, GH, Gl, GL, GK, GF, GP, GS, GT, GW, GY, GV, IA, IR, IN, ID, IC, IQ, IE, IG, IH, II, IL, IK, IF, IP, IS, IT, IW, IY, IV, LA, LR, LN, LD, LC, LQ, LE, LG, LH, LI, LL, LK, LF, LP, LS, LT, LW, LY, LV, KA, KR, KN, KD, KC, KQ, KE, KG, KH, KI, KL, KK, KF, KP, KS, KT, KW, KY, KV, MA, MR, MN, MD, MC, MQ, ME, MG, MH, Ml, ML, MK, MF, MP, MS, MT, MW, MY, MV, FA, FR, FN, FD, FC, FQ, FE, FG, FH, Fl, FL, FK, FF, FP, FS, FT, FW, FY, FV, PA, PR, PN, PD, PC, PQ, PE, PG, PH, PI, PL, PK, PF, PP, PS, PT, PW, PY, PV, SA, SR, SN, SD, SC, SQ, SE, SG, SH, SI, SL, SK, SF, SP, SS, ST, SW, SY, SV, TA, TR, TN, TD, TC, TQ, TE, TG, TH, Tl, TL, TK, TF, TP, TS, TT, TW, TY, TV, WA, WR, WN, WD, WC, WQ, WE, WG, WH, Wl, WL, WK, WF, WP, WS, WT, WW, WY, WV, YA, YR, YN, YD, YC, YQ, YE, YG, YH, Yl, YL, YK, YF, YP, YS, YT, YW, YY, YV, VA, VR, VN, VD, VC, VQ, VE, VG, VH, VI, VL, VK, VF, VP, VS, VT, VW, VY, and VV.
When the first and second amino acid residues to be mutated are H94 and Y96, the double point mutants envisioned are as follows:
AA, AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AV, RA, RR, RN, RD, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RV, NA, NR,
NN, ND, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NV, DA, DR, DN,
DD, DC, DQ, DE, DG, DH, DI, DL, DK, DM, DF, DP, DS, DT, DW, DV, CA, CR, CN, CD,
CC, CQ, CE, CG, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CV, QA, QR, QN, QD,
QC, QQ, QE, QG, QH, QI, QL, QK, QM, QF, QP, QS, QT, QW, QV, EA, ER, EN, ED, EC, EQ, EE, EG, EH, El, EL, EK, EM, EF, EP, ES, ET, EW, EV, GA, GR, GN, GD, GC,
GQ, GE, GG, GH, Gl, GL, GK, GM, GF, GP, GS, GT, GW, GV, IA, IR, IN, ID, IC, IQ, IE,
IG, IH, II, IL, IK, IM, IF, IP, IS, IT, IW, IV, LA, LR, LN, LD, LC, LQ, LE, LG, LH, LI, LL, LK, LM, LF, LP, LS, LT, LW, LV, KA, KR, KN, KD, KC, KQ, KE, KG, KH, KI, KL, KK, KM, KF, KP, KS, KT, KW, KV, MA, MR, MN, MD, MC, MQ, ME, MG, MH, Ml, ML, MK, MM, MF, MP, MS, MT, MW, MV, FA, FR, FN, FD, FC, FQ, FE, FG, FH, Fl, FL, FK, FM, FF, FP,
FS, FT, FW, FV, PA, PR, PN, PD, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PF, PP, PS, PT, PW, PV, SA, SR, SN, SD, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SF, SP, SS, ST, SW, SV, TA, TR, TN, TD, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TF, TP, TS, TT, TW, TV, WA, WR, WN, WD, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WF, WP, WS, WT, WW, WV, YA, YR, YN, YD, YC, YQ, YE, YG, YH, Yl, YL, YK, YM, YF, YP, YS, YT, YW, YV, VA, VR, VN, VD, VC, VQ, VE, VG, VH, VI, VL, VK, VM, VF, VP, VS, VT, VW, and W.
When the first and second amino acid residues to be mutated are H94 and D97, the double point mutants envisioned are as follows:
AA, AR, AN, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV, NA, NR,
NN, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR, DN,
DC, DQ, DE, DG, DH, DI, DL, DK, DM, DF, DP, DS, DT, DW, DY, DV, CA, CR, CN, CC,
CQ, CE, CG, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, QA, QR, QN, QC,
QQ, QE, QG, QH, QI, QL, QK, QM, QF, QP, QS, QT, QW, QY, QV, EA, ER, EN, EC, EQ, EE, EG, EH, El, EL, EK, EM, EF, EP, ES, ET, EW, EY, EV, GA, GR, GN, GC, GQ, GE, GG, GH, Gl, GL, GK, GM, GF, GP, GS, GT, GW, GY, GV, IA, IR, IN, IC, IQ, IE, IG,
IH, II, IL, IK, IM, IF, IP, IS, IT, IW, IY, IV, LA, LR, LN, LC, LQ, LE, LG, LH, LI, LL, LK, LM, LF, LP, LS, LT, LW, LY, LV, KA, KR, KN, KC, KQ, KE, KG, KH, KI, KL, KK, KM, KF, KP, KS, KT, KW, KY, KV, MA, MR, MN, MC, MQ, ME, MG, MH, Ml, ML, MK, MM, MF, MP, MS, MT, MW, MY, MV, FA, FR, FN, FC, FQ, FE, FG, FH, Fl, FL, FK, FM, FF, FP, FS,
FT, FW, FY, FV, PA, PR, PN, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PF, PP, PS, PT, PW, PY, PV, SA, SR, SN, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SF, SP, SS, ST, SW, SY, SV, TA, TR, TN, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TF, TP, TS, TT, TW, TY, TV, WA, WR, WN, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WF, WP, WS, WT, WW, WY, WV, YA, YR, YN, YC, YQ, YE, YG, YH, Yl, YL, YK, YM, YF, YP, YS, YT, YW, YY, YV, VA, VR, VN, VC, VQ, VE, VG, VH, VI, VL, VK, VM, VF, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are H94 and D98, the double point mutants envisioned are as follows:
AA, AR, AN, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV, NA, NR,
NN, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR, DN,
DC, DQ, DE, DG, DH, DI, DL, DK, DM, DF, DP, DS, DT, DW, DY, DV, CA, CR, CN, CC,
CQ, CE, CG, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, QA, QR, QN, QC,
QQ, QE, QG, QH, QI, QL, QK, QM, QF, QP, QS, QT, QW, QY, QV, EA, ER, EN, EC, EQ, EE, EG, EH, El, EL, EK, EM, EF, EP, ES, ET, EW, EY, EV, GA, GR, GN, GC, GQ, GE, GG, GH, Gl, GL, GK, GM, GF, GP, GS, GT, GW, GY, GV, IA, IR, IN, IC, IQ, IE, IG, IH, II, IL, IK, IM, IF, IP, IS, IT, IW, IY, IV, LA, LR, LN, LC, LQ, LE, LG, LH, LI, LL, LK, LM, LF, LP, LS, LT, LW, LY, LV, KA, KR, KN, KC, KQ, KE, KG, KH, KI, KL, KK, KM, KF, KP, KS, KT, KW, KY, KV, MA, MR, MN, MC, MQ, ME, MG, MH, Ml, ML, MK, MM, MF, MP, MS, MT, MW, MY, MV, FA, FR, FN, FC, FQ, FE, FG, FH, Fl, FL, FK, FM, FF, FP, FS, FT, FW, FY, FV, PA, PR, PN, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PF, PP, PS, PT, PW, PY, PV, SA, SR, SN, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SF, SP, SS, ST, SW, SY, SV, TA, TR, TN, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TF, TP, TS, TT, TW, TY, TV, WA, WR, WN, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WF, WP, WS, WT, WW, WY, WV, YA, YR, YN, YC, YQ, YE, YG, YH, Yl, YL, YK, YM, YF, YP, YS, YT, YW, YY, YV, VA, VR, VN, VC, VQ, VE, VG, VH, VI, VL, VK, VM, VF, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are H94 and G99, the double point mutants envisioned are as follows:
AA, AR, AN, AD, AC, AQ, AE, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RD, RC, RQ, RE, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV, NA, NR,
NN, ND, NC, NQ, NE, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR, DN,
DD, DC, DQ, DE, DH, DI, DL, DK, DM, DF, DP, DS, DT, DW, DY, DV, CA, CR, CN, CD,
CC, CQ, CE, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, QA, QR, QN, QD,
QC, QQ, QE, QH, QI, QL, QK, QM, QF, QP, QS, QT, QW, QY, QV, EA, ER, EN, ED, EC, EQ, EE, EH, El, EL, EK, EM, EF, EP, ES, ET, EW, EY, EV, GA, GR, GN, GD, GC, GQ, GE, GH, Gl, GL, GK, GM, GF, GP, GS, GT, GW, GY, GV, IA, IR, IN, ID, IC, IQ, IE, IH, II, IL, IK, IM, IF, IP, IS, IT, IW, IY, IV, LA, LR, LN, LD, LC, LQ, LE, LH, LI, LL, LK, LM, LF, LP, LS, LT, LW, LY, LV, KA, KR, KN, KD, KC, KQ, KE, KH, KI, KL, KK, KM, KF, KP,
KS, KT, KW, KY, KV, MA, MR, MN, MD, MC, MQ, ME, MH, Ml, ML, MK, MM, MF, MP, MS, MT, MW, MY, MV, FA, FR, FN, FD, FC, FQ, FE, FH, Fl, FL, FK, FM, FF, FP, FS, FT, FW, FY, FV, PA, PR, PN, PD, PC, PQ, PE, PH, PI, PL, PK, PM, PF, PP, PS, PT, PW, PY, PV, SA, SR, SN, SD, SC, SQ, SE, SH, SI, SL, SK, SM, SF, SP, SS, ST, SW, SY, SV, TA, TR, TN, TD, TC, TQ, TE, TH, Tl, TL, TK, TM, TF, TP, TS, TT, TW, TY, TV, WA, WR, WN, WD, WC, WQ, WE, WH, Wl, WL, WK, WM, WF, WP, WS, WT, WW, WY, WV, YA, YR, YN, YD, YC, YQ, YE, YH, Yl, YL, YK, YM, YF, YP, YS, YT, YW, YY, YV,
VA, VR, VN, VD, VC, VQ, VE, VH, VI, VL, VK, VM, VF, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are H94 and F100, the double point mutants envisioned are as follows:
AA, AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AP, AS, AT, AW, AY, AV, RA, RR, RN, RD, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RP, RS, RT, RW, RY, RV, NA, NR,
NN, ND, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NP, NS, NT, NW, NY, NV, DA, DR, DN,
DD, DC, DQ, DE, DG, DH, DI, DL, DK, DM, DP, DS, DT, DW, DY, DV, CA, CR, CN, CD,
CC, CQ, CE, CG, CH, Cl, CL, CK, CM, CP, CS, CT, CW, CY, CV, QA, QR, QN, QD,
QC, QQ, QE, QG, QH, QI, QL, QK, QM, QP, QS, QT, QW, QY, QV, EA, ER, EN, ED, EC, EQ, EE, EG, EH, El, EL, EK, EM, EP, ES, ET, EW, EY, EV, GA, GR, GN, GD, GC, GQ, GE, GG, GH, Gl, GL, GK, GM, GP, GS, GT, GW, GY, GV, IA, IR, IN, ID, IC, IQ, IE, IG, IH, II, IL, IK, IM, IP, IS, IT, IW, IY, IV, LA, LR, LN, LD, LC, LQ, LE, LG, LH, LI, LL, LK, LM, LP, LS, LT, LW, LY, LV, KA, KR, KN, KD, KC, KQ, KE, KG, KH, KI, KL, KK, KM, KP, KS, KT, KW, KY, KV, MA, MR, MN, MD, MC, MQ, ME, MG, MH, Ml, ML, MK, MM, MP, MS, MT, MW, MY, MV, FA, FR, FN, FD, FC, FQ, FE, FG, FH, Fl, FL, FK, FM, FP, FS, FT, FW, FY, FV, PA, PR, PN, PD, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PP, PS, PT, PW, PY, PV, SA, SR, SN, SD, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SP, SS, ST, SW, SY, SV, TA, TR, TN, TD, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TP, TS, TT, TW, TY,
TV, WA, WR, WN, WD, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WP, WS, WT, WW, WY, WV, YA, YR, YN, YD, YC, YQ, YE, YG, YH, Yl, YL, YK, YM, YP, YS, YT, YW, YY, YV, VA, VR, VN, VD, VC, VQ, VE, VG, VH, VI, VL, VK, VM, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are H94 and D101 , the double point mutants envisioned are as follows:
AA, AR, AN, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV, NA, NR,
NN, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR, DN,
DC, DQ, DE, DG, DH, DI, DL, DK, DM, DF, DP, DS, DT, DW, DY, DV, CA, CR, CN, CC,
CQ, CE, CG, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, QA, QR, QN, QC,
QQ, QE, QG, QH, QI, QL, QK, QM, QF, QP, QS, QT, QW, QY, QV, EA, ER, EN, EC, EQ, EE, EG, EH, El, EL, EK, EM, EF, EP, ES, ET, EW, EY, EV, GA, GR, GN, GC, GQ, GE, GG, GH, Gl, GL, GK, GM, GF, GP, GS, GT, GW, GY, GV, IA, IR, IN, IC, IQ, IE, IG, IH, II, IL, IK, IM, IF, IP, IS, IT, IW, IY, IV, LA, LR, LN, LC, LQ, LE, LG, LH, LI, LL, LK, LM, LF, LP, LS, LT, LW, LY, LV, KA, KR, KN, KC, KQ, KE, KG, KH, KI, KL, KK, KM, KF, KP, KS, KT, KW, KY, KV, MA, MR, MN, MC, MQ, ME, MG, MH, Ml, ML, MK, MM, MF, MP, MS, MT, MW, MY, MV, FA, FR, FN, FC, FQ, FE, FG, FH, Fl, FL, FK, FM, FF, FP, FS, FT, FW, FY, FV, PA, PR, PN, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PF, PP, PS, PT, PW, PY, PV, SA, SR, SN, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SF, SP, SS, ST, SW, SY, SV, TA, TR, TN, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TF, TP, TS, TT, TW, TY, TV, WA, WR, WN, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WF, WP, WS, WT, WW, WY, WV, YA, YR, YN, YC, YQ, YE, YG, YH, Yl, YL, YK, YM, YF, YP, YS, YT, YW, YY, YV, VA, VR, VN, VC, VQ, VE, VG, VH, VI, VL, VK, VM, VF, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are H94 and F102, the double point mutants envisioned are as follows:
AA, AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AP, AS, AT, AW, AY, AV, RA, RR, RN, RD, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RP, RS, RT, RW, RY, RV, NA, NR,
NN, ND, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NP, NS, NT, NW, NY, NV, DA, DR, DN,
DD, DC, DQ, DE, DG, DH, DI, DL, DK, DM, DP, DS, DT, DW, DY, DV, CA, CR, CN, CD,
CC, CQ, CE, CG, CH, Cl, CL, CK, CM, CP, CS, CT, CW, CY, CV, QA, QR, QN, QD,
QC, QQ, QE, QG, QH, QI, QL, QK, QM, QP, QS, QT, QW, QY, QV, EA, ER, EN, ED, EC, EQ, EE, EG, EH, El, EL, EK, EM, EP, ES, ET, EW, EY, EV, GA, GR, GN, GD, GC, GQ, GE, GG, GH, Gl, GL, GK, GM, GP, GS, GT, GW, GY, GV, IA, IR, IN, ID, IC, IQ, IE, IG, IH, II, IL, IK, IM, IP, IS, IT, IW, IY, IV, LA, LR, LN, LD, LC, LQ, LE, LG, LH, LI, LL, LK, LM, LP, LS, LT, LW, LY, LV, KA, KR, KN, KD, KC, KQ, KE, KG, KH, KI, KL, KK, KM, KP, KS, KT, KW, KY, KV, MA, MR, MN, MD, MC, MQ, ME, MG, MH, Ml, ML, MK, MM, MP, MS, MT, MW, MY, MV, FA, FR, FN, FD, FC, FQ, FE, FG, FH, Fl, FL, FK, FM, FP, FS, FT, FW, FY, FV, PA, PR, PN, PD, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PP, PS,
PT, PW, PY, PV, SA, SR, SN, SD, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SP, SS, ST, SW, SY, SV, TA, TR, TN, TD, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TP, TS, TT, TW, TY, TV, WA, WR, WN, WD, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WP, WS, WT, WW, WY, WV, YA, YR, YN, YD, YC, YQ, YE, YG, YH, Yl, YL, YK, YM, YP, YS, YT, YW, YY, YV, VA, VR, VN, VD, VC, VQ, VE, VG, VH, VI, VL, VK, VM, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are M95 and Y96, the double point mutants envisioned are as follows:
AA, AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AV, RA, RR, RN, RD, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RV, NA, NR,
NN, ND, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NV, DA, DR, DN,
DD, DC, DQ, DE, DG, DH, DI, DL, DK, DM, DF, DP, DS, DT, DW, DV, CA, CR, CN, CD,
CC, CQ, CE, CG, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CV, QA, QR, QN, QD,
QC, QQ, QE, QG, QH, QI, QL, QK, QM, QF, QP, QS, QT, QW, QV, EA, ER, EN, ED, EC, EQ, EE, EG, EH, El, EL, EK, EM, EF, EP, ES, ET, EW, EV, GA, GR, GN, GD, GC, GQ, GE, GG, GH, Gl, GL, GK, GM, GF, GP, GS, GT, GW, GV, HA, HR, HN, HD, HC, HQ, HE, HG, HH, HI, HL, HK, HM, HF, HP, HS, HT, HW, HV, IA, IR, IN, ID, IC, IQ, IE, IG, IH, II, IL, IK, IM, IF, IP, IS, IT, IW, IV, LA, LR, LN, LD, LC, LQ, LE, LG, LH, LI, LL, LK, LM, LF, LP, LS, LT, LW, LV, KA, KR, KN, KD, KC, KQ, KE, KG, KH, KI, KL, KK, KM, KF, KP, KS, KT, KW, KV, FA, FR, FN, FD, FC, FQ, FE, FG, FH, Fl, FL, FK, FM, FF, FP, FS, FT, FW, FV, PA, PR, PN, PD, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PF, PP, PS, PT, PW, PV, SA, SR, SN, SD, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SF, SP, SS, ST, SW, SV, TA, TR, TN, TD, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TF, TP, TS, TT, TW, TV, WA, WR, WN, WD, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WF, WP, WS, WT, WW, WV, YA, YR, YN, YD, YC, YQ, YE, YG, YH, Yl, YL, YK, YM, YF, YP, YS, YT, YW, YV, VA, VR, VN, VD, VC, VQ, VE, VG, VH, VI, VL, VK, VM, VF, VP, VS, VT, VW, and W.
When the first and second amino acid residues to be mutated are M95 and D97, the double point mutants envisioned are as follows:
AA, AR, AN, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV, NA, NR, NN, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR, DN,
DC, DQ, DE, DG, DH, DI, DL, DK, DM, DF, DP, DS, DT, DW, DY, DV, CA, CR, CN, CC, CQ, CE, CG, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, QA, QR, QN, QC, QQ, QE, QG, QH, QI, QL, QK, QM, QF, QP, QS, QT, QW, QY, QV, EA, ER, EN, EC, EQ, EE, EG, EH, El, EL, EK, EM, EF, EP, ES, ET, EW, EY, EV, GA, GR, GN, GC, GQ, GE, GG, GH, Gl, GL, GK, GM, GF, GP, GS, GT, GW, GY, GV, HA, HR, HN, HC, HQ, HE, HG, HH, HI, HL, HK, HM, HF, HP, HS, HT, HW, HY, HV, IA, IR, IN, IC, IQ, IE, IG, IH, II, IL, IK, IM, IF, IP, IS, IT, IW, IY, IV, LA, LR, LN, LC, LQ, LE, LG, LH, LI, LL, LK, LM, LF, LP, LS, LT, LW, LY, LV, KA, KR, KN, KC, KQ, KE, KG, KH, KI, KL, KK, KM, KF, KP, KS, KT, KW, KY, KV, FA, FR, FN, FC, FQ, FE, FG, FH, Fl, FL, FK, FM, FF, FP, FS, FT, FW, FY, FV, PA, PR, PN, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PF, PP, PS, PT, PW, PY, PV, SA, SR, SN, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SF, SP, SS, ST, SW, SY, SV, TA, TR, TN, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TF, TP, TS, TT, TW, TY, TV, WA, WR, WN, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WF, WP, WS, WT, WW, WY, WV, YA, YR, YN, YC, YQ, YE, YG, YH, Yl, YL, YK, YM, YF, YP, YS, YT, YW, YY, YV, VA, VR, VN, VC, VQ, VE, VG, VH, VI, VL, VK, VM, VF, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are M95 and D98, the double point mutants envisioned are as follows:
AA, AR, AN, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV, NA, NR,
NN, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR, DN,
DC, DQ, DE, DG, DH, DI, DL, DK, DM, DF, DP, DS, DT, DW, DY, DV, CA, CR, CN, CC,
CQ, CE, CG, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, QA, QR, QN, QC,
QQ, QE, QG, QH, QI, QL, QK, QM, QF, QP, QS, QT, QW, QY, QV, EA, ER, EN, EC, EQ, EE, EG, EH, El, EL, EK, EM, EF, EP, ES, ET, EW, EY, EV, GA, GR, GN, GC, GQ, GE, GG, GH, Gl, GL, GK, GM, GF, GP, GS, GT, GW, GY, GV, HA, HR, HN, HC, HQ, HE, HG, HH, HI, HL, HK, HM, HF, HP, HS, HT, HW, HY, HV, IA, IR, IN, IC, IQ, IE, IG, IH, II, IL, IK, IM, IF, IP, IS, IT, IW, IY, IV, LA, LR, LN, LC, LQ, LE, LG, LH, LI, LL, LK, LM, LF, LP, LS, LT, LW, LY, LV, KA, KR, KN, KC, KQ, KE, KG, KH, KI, KL, KK, KM, KF, KP, KS, KT, KW, KY, KV, FA, FR, FN, FC, FQ, FE, FG, FH, Fl, FL, FK, FM, FF, FP, FS, FT, FW, FY, FV, PA, PR, PN, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PF, PP, PS, PT, PW, PY, PV, SA, SR, SN, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SF, SP, SS, ST, SW, SY, SV, TA, TR, TN, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TF, TP, TS, TT, TW, TY, TV, WA, WR, WN, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WF, WP, WS, WT, WW, WY, WV,
YA, YR, YN, YC, YQ, YE, YG, YH, Yl, YL, YK, YM, YF, YP, YS, YT, YW, YY, YV, VA, VR, VN, VC, VQ, VE, VG, VH, VI, VL, VK, VM, VF, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are M95 and G99, the double point mutants envisioned are as follows:
AA, AR, AN, AD, AC, AQ, AE, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RD, RC, RQ, RE, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV, NA, NR,
NN, ND, NC, NQ, NE, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR, DN,
DD, DC, DQ, DE, DH, DI, DL, DK, DM, DF, DP, DS, DT, DW, DY, DV, CA, CR, CN, CD,
CC, CQ, CE, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, QA, QR, QN, QD,
QC, QQ, QE, QH, QI, QL, QK, QM, QF, QP, QS, QT, QW, QY, QV, EA, ER, EN, ED, EC, EQ, EE, EH, El, EL, EK, EM, EF, EP, ES, ET, EW, EY, EV, GA, GR, GN, GD, GC, GQ, GE, GH, Gl, GL, GK, GM, GF, GP, GS, GT, GW, GY, GV, HA, HR, HN, HD, HC,
HQ, HE, HH, HI, HL, HK, HM, HF, HP, HS, HT, HW, HY, HV, IA, IR, IN, ID, IC, IQ, IE,
IH, II, IL, IK, IM, IF, IP, IS, IT, IW, IY, IV, LA, LR, LN, LD, LC, LQ, LE, LH, LI, LL, LK, LM, LF, LP, LS, LT, LW, LY, LV, KA, KR, KN, KD, KC, KQ, KE, KH, KI, KL, KK, KM, KF, KP, KS, KT, KW, KY, KV, FA, FR, FN, FD, FC, FQ, FE, FH, Fl, FL, FK, FM, FF, FP, FS, FT, FW, FY, FV, PA, PR, PN, PD, PC, PQ, PE, PH, PI, PL, PK, PM, PF, PP, PS, PT, PW, PY, PV, SA, SR, SN, SD, SC, SQ, SE, SH, SI, SL, SK, SM, SF, SP, SS, ST, SW, SY, SV, TA, TR, TN, TD, TC, TQ, TE, TH, Tl, TL, TK, TM, TF, TP, TS, TT, TW, TY, TV, WA, WR, WN, WD, WC, WQ, WE, WH, Wl, WL, WK, WM, WF, WP, WS, WT, WW, WY, WV, YA, YR, YN, YD, YC, YQ, YE, YH, Yl, YL, YK, YM, YF, YP, YS, YT, YW, YY, YV, VA, VR, VN, VD, VC, VQ, VE, VH, VI, VL, VK, VM, VF, VP, VS, VT, VW, VY, and VV.
When the first and second amino acid residues to be mutated are M95 and F100, the double point mutants envisioned are as follows:
AA, AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AP, AS, AT, AW, AY, AV, RA, RR, RN, RD, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RP, RS, RT, RW, RY, RV, NA, NR,
NN, ND, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NP, NS, NT, NW, NY, NV, DA, DR, DN,
DD, DC, DQ, DE, DG, DH, DI, DL, DK, DM, DP, DS, DT, DW, DY, DV, CA, CR, CN, CD,
CC, CQ, CE, CG, CH, Cl, CL, CK, CM, CP, CS, CT, CW, CY, CV, QA, QR, QN, QD,
QC, QQ, QE, QG, QH, QI, QL, QK, QM, QP, QS, QT, QW, QY, QV, EA, ER, EN, ED, EC, EQ, EE, EG, EH, El, EL, EK, EM, EP, ES, ET, EW, EY, EV, GA, GR, GN, GD, GC,
GQ, GE, GG, GH, Gl, GL, GK, GM, GP, GS, GT, GW, GY, GV, HA, HR, HN, HD, HC, HQ, HE, HG, HH, HI, HL, HK, HM, HP, HS, HT, HW, HY, HV, IA, IR, IN, ID, IC, IQ, IE,
IG, IH, II, IL, IK, IM, IP, IS, IT, IW, IY, IV, LA, LR, LN, LD, LC, LQ, LE, LG, LH, LI, LL, LK, LM, LP, LS, LT, LW, LY, LV, KA, KR, KN, KD, KC, KQ, KE, KG, KH, KI, KL, KK, KM, KP, KS, KT, KW, KY, KV, FA, FR, FN, FD, FC, FQ, FE, FG, FH, Fl, FL, FK, FM, FP, FS, FT, FW, FY, FV, PA, PR, PN, PD, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PP, PS, PT, PW, PY, PV, SA, SR, SN, SD, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SP, SS, ST, SW, SY, SV, TA, TR, TN, TD, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TP, TS, TT, TW, TY, TV, WA, WR, WN, WD, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WP, WS, WT, WW, WY, WV, YA, YR, YN, YD, YC, YQ, YE, YG, YH, Yl, YL, YK, YM, YP, YS, YT, YW, YY, YV, VA, VR, VN, VD, VC, VQ, VE, VG, VH, VI, VL, VK, VM, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are M95 and D101 , the double point mutants envisioned are as follows:
AA, AR, AN, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV, NA, NR,
NN, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR, DN,
DC, DQ, DE, DG, DH, DI, DL, DK, DM, DF, DP, DS, DT, DW, DY, DV, CA, CR, CN, CC,
CQ, CE, CG, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, QA, QR, QN, QC,
QQ, QE, QG, QH, QI, QL, QK, QM, QF, QP, QS, QT, QW, QY, QV, EA, ER, EN, EC, EQ, EE, EG, EH, El, EL, EK, EM, EF, EP, ES, ET, EW, EY, EV, GA, GR, GN, GC, GQ, GE, GG, GH, Gl, GL, GK, GM, GF, GP, GS, GT, GW, GY, GV, HA, HR, HN, HC, HQ, HE, HG, HH, HI, HL, HK, HM, HF, HP, HS, HT, HW, HY, HV, IA, IR, IN, IC, IQ, IE, IG,
IH, II, IL, IK, IM, IF, IP, IS, IT, IW, IY, IV, LA, LR, LN, LC, LQ, LE, LG, LH, LI, LL, LK, LM, LF, LP, LS, LT, LW, LY, LV, KA, KR, KN, KC, KQ, KE, KG, KH, KI, KL, KK, KM, KF, KP, KS, KT, KW, KY, KV, FA, FR, FN, FC, FQ, FE, FG, FH, Fl, FL, FK, FM, FF, FP, FS, FT, FW, FY, FV, PA, PR, PN, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PF, PP, PS, PT, PW, PY, PV, SA, SR, SN, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SF, SP, SS, ST, SW, SY, SV, TA, TR, TN, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TF, TP, TS, TT, TW, TY, TV, WA, WR, WN, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WF, WP, WS, WT, WW, WY, WV, YA, YR, YN, YC, YQ, YE, YG, YH, Yl, YL, YK, YM, YF, YP, YS, YT, YW, YY, YV, VA, VR, VN, VC, VQ, VE, VG, VH, VI, VL, VK, VM, VF, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are M95 and F102, the double point mutants envisioned are as follows:
AA, AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AP, AS, AT, AW, AY, AV, RA, RR, RN, RD, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RP, RS, RT, RW, RY, RV, NA, NR,
NN, ND, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NP, NS, NT, NW, NY, NV, DA, DR, DN,
DD, DC, DQ, DE, DG, DH, DI, DL, DK, DM, DP, DS, DT, DW, DY, DV, CA, CR, CN, CD,
CC, CQ, CE, CG, CH, Cl, CL, CK, CM, CP, CS, CT, CW, CY, CV, QA, QR, QN, QD,
QC, QQ, QE, QG, QH, QI, QL, QK, QM, QP, QS, QT, QW, QY, QV, EA, ER, EN, ED, EC, EQ, EE, EG, EH, El, EL, EK, EM, EP, ES, ET, EW, EY, EV, GA, GR, GN, GD, GC, GQ, GE, GG, GH, Gl, GL, GK, GM, GP, GS, GT, GW, GY, GV, HA, HR, HN, HD, HC, HQ, HE, HG, HH, HI, HL, HK, HM, HP, HS, HT, HW, HY, HV, IA, IR, IN, ID, IC, IQ, IE, IG, IH, II, IL, IK, IM, IP, IS, IT, IW, IY, IV, LA, LR, LN, LD, LC, LQ, LE, LG, LH, LI, LL, LK, LM, LP, LS, LT, LW, LY, LV, KA, KR, KN, KD, KC, KQ, KE, KG, KH, KI, KL, KK, KM, KP, KS, KT, KW, KY, KV, FA, FR, FN, FD, FC, FQ, FE, FG, FH, Fl, FL, FK, FM, FP, FS, FT, FW, FY, FV, PA, PR, PN, PD, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PP, PS, PT, PW, PY, PV, SA, SR, SN, SD, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SP, SS, ST, SW, SY, SV, TA, TR, TN, TD, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TP, TS, TT, TW, TY, TV, WA, WR, WN, WD, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WP, WS, WT, WW, WY, WV, YA, YR, YN, YD, YC, YQ, YE, YG, YH, Yl, YL, YK, YM, YP, YS, YT, YW, YY, YV, VA, VR, VN, VD, VC, VQ, VE, VG, VH, VI, VL, VK, VM, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are Y96 and D97, the double point mutants envisioned are as follows:
AA, AR, AN, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV, NA, NR,
NN, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR, DN,
DC, DQ, DE, DG, DH, DI, DL, DK, DM, DF, DP, DS, DT, DW, DY, DV, CA, CR, CN, CC,
CQ, CE, CG, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, QA, QR, QN, QC,
QQ, QE, QG, QH, QI, QL, QK, QM, QF, QP, QS, QT, QW, QY, QV, EA, ER, EN, EC, EQ, EE, EG, EH, El, EL, EK, EM, EF, EP, ES, ET, EW, EY, EV, GA, GR, GN, GC, GQ, GE, GG, GH, Gl, GL, GK, GM, GF, GP, GS, GT, GW, GY, GV, HA, HR, HN, HC, HQ, HE, HG, HH, HI, HL, HK, HM, HF, HP, HS, HT, HW, HY, HV, IA, IR, IN, IC, IQ, IE, IG,
IH, II, IL, IK, IM, IF, IP, IS, IT, IW, IY, IV, LA, LR, LN, LC, LQ, LE, LG, LH, LI, LL, LK, LM, LF, LP, LS, LT, LW, LY, LV, KA, KR, KN, KC, KQ, KE, KG, KH, KI, KL, KK, KM, KF, KP, KS, KT, KW, KY, KV, MA, MR, MN, MC, MQ, ME, MG, MH, Ml, ML, MK, MM, MF, MP, MS, MT, MW, MY, MV, FA, FR, FN, FC, FQ, FE, FG, FH, Fl, FL, FK, FM, FF, FP, FS, FT, FW, FY, FV, PA, PR, PN, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PF, PP, PS, PT, PW, PY, PV, SA, SR, SN, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SF, SP, SS, ST, SW, SY, SV, TA, TR, TN, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TF, TP, TS, TT, TW, TY, TV, WA, WR, WN, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WF, WP, WS, WT, WW, WY, WV, VA, VR, VN, VC, VQ, VE, VG, VH, VI, VL, VK, VM, VF, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are Y96 and D98, the double point mutants envisioned are as follows:
AA, AR, AN, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV, NA, NR,
NN, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR, DN,
DC, DQ, DE, DG, DH, DI, DL, DK, DM, DF, DP, DS, DT, DW, DY, DV, CA, CR, CN, CC,
CQ, CE, CG, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, QA, QR, QN, QC,
QQ, QE, QG, QH, QI, QL, QK, QM, QF, QP, QS, QT, QW, QY, QV, EA, ER, EN, EC, EQ, EE, EG, EH, El, EL, EK, EM, EF, EP, ES, ET, EW, EY, EV, GA, GR, GN, GC, GQ, GE, GG, GH, Gl, GL, GK, GM, GF, GP, GS, GT, GW, GY, GV, HA, HR, HN, HC, HQ, HE, HG, HH, HI, HL, HK, HM, HF, HP, HS, HT, HW, HY, HV, IA, IR, IN, IC, IQ, IE, IG, IH, II, IL, IK, IM, IF, IP, IS, IT, IW, IY, IV, LA, LR, LN, LC, LQ, LE, LG, LH, LI, LL, LK, LM, LF, LP, LS, LT, LW, LY, LV, KA, KR, KN, KC, KQ, KE, KG, KH, KI, KL, KK, KM, KF, KP, KS, KT, KW, KY, KV, MA, MR, MN, MC, MQ, ME, MG, MH, Ml, ML, MK, MM, MF, MP, MS, MT, MW, MY, MV, FA, FR, FN, FC, FQ, FE, FG, FH, Fl, FL, FK, FM, FF, FP, FS, FT, FW, FY, FV, PA, PR, PN, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PF, PP, PS, PT, PW, PY, PV, SA, SR, SN, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SF, SP, SS, ST, SW, SY, SV, TA, TR, TN, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TF, TP, TS, TT, TW, TY, TV, WA, WR, WN, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WF, WP, WS, WT, WW, WY, WV, VA, VR, VN, VC, VQ, VE, VG, VH, VI, VL, VK, VM, VF, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are Y96 and G99, the double point mutants envisioned are as follows:
AA, AR, AN, AD, AC, AQ, AE, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RD, RC, RQ, RE, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV, NA, NR,
NN, ND, NC, NQ, NE, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR, DN,
DD, DC, DQ, DE, DH, DI, DL, DK, DM, DF, DP, DS, DT, DW, DY, DV, CA, CR, CN, CD,
CC, CQ, CE, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, QA, QR, QN, QD,
QC, QQ, QE, QH, QI, QL, QK, QM, QF, QP, QS, QT, QW, QY, QV, EA, ER, EN, ED, EC, EQ, EE, EH, El, EL, EK, EM, EF, EP, ES, ET, EW, EY, EV, GA, GR, GN, GD, GC, GQ, GE, GH, Gl, GL, GK, GM, GF, GP, GS, GT, GW, GY, GV, HA, HR, HN, HD, HC,
HQ, HE, HH, HI, HL, HK, HM, HF, HP, HS, HT, HW, HY, HV, IA, IR, IN, ID, IC, IQ, IE,
IH, II, IL, IK, IM, IF, IP, IS, IT, IW, IY, IV, LA, LR, LN, LD, LC, LQ, LE, LH, LI, LL, LK, LM, LF, LP, LS, LT, LW, LY, LV, KA, KR, KN, KD, KC, KQ, KE, KH, KI, KL, KK, KM, KF, KP, KS, KT, KW, KY, KV, MA, MR, MN, MD, MC, MQ, ME, MH, Ml, ML, MK, MM, MF, MP, MS, MT, MW, MY, MV, FA, FR, FN, FD, FC, FQ, FE, FH, Fl, FL, FK, FM, FF, FP, FS, FT, FW, FY, FV, PA, PR, PN, PD, PC, PQ, PE, PH, PI, PL, PK, PM, PF, PP, PS, PT, PW, PY, PV, SA, SR, SN, SD, SC, SQ, SE, SH, SI, SL, SK, SM, SF, SP, SS, ST, SW, SY, SV, TA, TR, TN, TD, TC, TQ, TE, TH, Tl, TL, TK, TM, TF, TP, TS, TT, TW, TY, TV, WA, WR, WN, WD, WC, WQ, WE, WH, Wl, WL, WK, WM, WF, WP, WS, WT, WW, WY, WV, VA, VR, VN, VD, VC, VQ, VE, VH, VI, VL, VK, VM, VF, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are Y96 and F100, the double point mutants envisioned are as follows:
AA, AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AP, AS, AT, AW, AY, AV, RA, RR, RN, RD, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RP, RS, RT, RW, RY, RV, NA, NR,
NN, ND, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NP, NS, NT, NW, NY, NV, DA, DR, DN,
DD, DC, DQ, DE, DG, DH, DI, DL, DK, DM, DP, DS, DT, DW, DY, DV, CA, CR, CN, CD,
CC, CQ, CE, CG, CH, Cl, CL, CK, CM, CP, CS, CT, CW, CY, CV, QA, QR, QN, QD,
QC, QQ, QE, QG, QH, QI, QL, QK, QM, QP, QS, QT, QW, QY, QV, EA, ER, EN, ED, EC, EQ, EE, EG, EH, El, EL, EK, EM, EP, ES, ET, EW, EY, EV, GA, GR, GN, GD, GC, GQ, GE, GG, GH, Gl, GL, GK, GM, GP, GS, GT, GW, GY, GV, HA, HR, HN, HD, HC, HQ, HE, HG, HH, HI, HL, HK, HM, HP, HS, HT, HW, HY, HV, IA, IR, IN, ID, IC, IQ, IE,
IG, IH, II, IL, IK, IM, IP, IS, IT, IW, IY, IV, LA, LR, LN, LD, LC, LQ, LE, LG, LH, LI, LL, LK, LM, LP, LS, LT, LW, LY, LV, KA, KR, KN, KD, KC, KQ, KE, KG, KH, KI, KL, KK, KM, KP, KS, KT, KW, KY, KV, MA, MR, MN, MD, MC, MQ, ME, MG, MH, Ml, ML, MK, MM, MP, MS, MT, MW, MY, MV, FA, FR, FN, FD, FC, FQ, FE, FG, FH, Fl, FL, FK, FM, FP,
FS, FT, FW, FY, FV, PA, PR, PN, PD, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PP, PS, PT, PW, PY, PV, SA, SR, SN, SD, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SP, SS, ST, SW, SY, SV, TA, TR, TN, TD, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TP, TS, TT, TW, TY, TV, WA, WR, WN, WD, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WP, WS, WT, WW, WY, WV, VA, VR, VN, VD, VC, VQ, VE, VG, VH, VI, VL, VK, VM, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are Y96 and D101 , the double point mutants envisioned are as follows:
AA, AR, AN, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV, NA, NR,
NN, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR, DN,
DC, DQ, DE, DG, DH, DI, DL, DK, DM, DF, DP, DS, DT, DW, DY, DV, CA, CR, CN, CC,
CQ, CE, CG, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, QA, QR, QN, QC,
QQ, QE, QG, QH, QI, QL, QK, QM, QF, QP, QS, QT, QW, QY, QV, EA, ER, EN, EC, EQ, EE, EG, EH, El, EL, EK, EM, EF, EP, ES, ET, EW, EY, EV, GA, GR, GN, GC, GQ, GE, GG, GH, Gl, GL, GK, GM, GF, GP, GS, GT, GW, GY, GV, HA, HR, HN, HC, HQ, HE, HG, HH, HI, HL, HK, HM, HF, HP, HS, HT, HW, HY, HV, IA, IR, IN, IC, IQ, IE, IG,
IH, II, IL, IK, IM, IF, IP, IS, IT, IW, IY, IV, LA, LR, LN, LC, LQ, LE, LG, LH, LI, LL, LK, LM, LF, LP, LS, LT, LW, LY, LV, KA, KR, KN, KC, KQ, KE, KG, KH, KI, KL, KK, KM, KF, KP, KS, KT, KW, KY, KV, MA, MR, MN, MC, MQ, ME, MG, MH, Ml, ML, MK, MM, MF, MP, MS, MT, MW, MY, MV, FA, FR, FN, FC, FQ, FE, FG, FH, Fl, FL, FK, FM, FF, FP, FS,
FT, FW, FY, FV, PA, PR, PN, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PF, PP, PS, PT, PW, PY, PV, SA, SR, SN, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SF, SP, SS, ST, SW, SY, SV, TA, TR, TN, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TF, TP, TS, TT, TW, TY, TV, WA, WR, WN, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WF, WP, WS, WT, WW, WY, WV, VA, VR, VN, VC, VQ, VE, VG, VH, VI, VL, VK, VM, VF, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are Y96 and F102, the double point mutants envisioned are as follows:
AA, AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AP, AS, AT, AW, AY, AV, RA, RR, RN, RD, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RP, RS, RT, RW, RY, RV, NA, NR,
NN, ND, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NP, NS, NT, NW, NY, NV, DA, DR, DN,
DD, DC, DQ, DE, DG, DH, DI, DL, DK, DM, DP, DS, DT, DW, DY, DV, CA, CR, CN, CD,
CC, CQ, CE, CG, CH, Cl, CL, CK, CM, CP, CS, CT, CW, CY, CV, QA, QR, QN, QD,
QC, QQ, QE, QG, QH, QI, QL, QK, QM, QP, QS, QT, QW, QY, QV, EA, ER, EN, ED, EC, EQ, EE, EG, EH, El, EL, EK, EM, EP, ES, ET, EW, EY, EV, GA, GR, GN, GD, GC, GQ, GE, GG, GH, Gl, GL, GK, GM, GP, GS, GT, GW, GY, GV, HA, HR, HN, HD, HC, HQ, HE, HG, HH, HI, HL, HK, HM, HP, HS, HT, HW, HY, HV, IA, IR, IN, ID, IC, IQ, IE, IG, IH, II, IL, IK, IM, IP, IS, IT, IW, IY, IV, LA, LR, LN, LD, LC, LQ, LE, LG, LH, LI, LL, LK, LM, LP, LS, LT, LW, LY, LV, KA, KR, KN, KD, KC, KQ, KE, KG, KH, KI, KL, KK, KM, KP, KS, KT, KW, KY, KV, MA, MR, MN, MD, MC, MQ, ME, MG, MH, Ml, ML, MK, MM, MP, MS, MT, MW, MY, MV, FA, FR, FN, FD, FC, FQ, FE, FG, FH, Fl, FL, FK, FM, FP, FS, FT, FW, FY, FV, PA, PR, PN, PD, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PP, PS, PT, PW, PY, PV, SA, SR, SN, SD, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SP, SS, ST, SW, SY, SV, TA, TR, TN, TD, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TP, TS, TT, TW, TY, TV, WA, WR, WN, WD, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WP, WS, WT, WW, WY, WV, VA, VR, VN, VD, VC, VQ, VE, VG, VH, VI, VL, VK, VM, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are D97 and D98, the double point mutants envisioned are as follows:
AA, AR, AN, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV, NA, NR, NN, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, CA, CR, CN, CC, CQ, CE, CG, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, QA, QR, QN, QC, QQ, QE, QG, QH, QI, QL, QK, QM, QF, QP, QS, QT, QW, QY, QV, EA, ER, EN, EC, EQ, EE, EG, EH, El, EL, EK, EM, EF, EP, ES, ET, EW, EY, EV, GA, GR, GN, GC, GQ, GE, GG, GH, Gl, GL, GK, GM, GF, GP, GS, GT, GW, GY, GV, HA, HR, HN, HC, HQ, HE, HG, HH, HI, HL, HK, HM, HF, HP, HS, HT, HW, HY, HV, IA, IR, IN, IC, IQ, IE, IG, IH, II, IL, IK, IM, IF, IP, IS, IT, IW, IY, IV, LA, LR, LN, LC, LQ, LE, LG, LH, LI, LL, LK,
LM, LF, LP, LS, LT, LW, LY, LV, KA, KR, KN, KC, KQ, KE, KG, KH, KI, KL, KK, KM, KF, KP, KS, KT, KW, KY, KV, MA, MR, MN, MC, MQ, ME, MG, MH, Ml, ML, MK, MM, MF, MP, MS, MT, MW, MY, MV, FA, FR, FN, FC, FQ, FE, FG, FH, Fl, FL, FK, FM, FF, FP, FS, FT, FW, FY, FV, PA, PR, PN, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PF, PP, PS, PT, PW, PY, PV, SA, SR, SN, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SF, SP, SS, ST, SW, SY, SV, TA, TR, TN, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TF, TP, TS, TT, TW, TY, TV, WA, WR, WN, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WF, WP, WS, WT, WW, WY, WV, YA, YR, YN, YC, YQ, YE, YG, YH, Yl, YL, YK, YM, YF, YP, YS, YT, YW, YY, YV, VA, VR, VN, VC, VQ, VE, VG, VH, VI, VL, VK, VM, VF, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are D97 and G99, the double point mutants envisioned are as follows:
AA, AR, AN, AD, AC, AQ, AE, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RD, RC, RQ, RE, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV, NA, NR, NN, ND, NC, NQ, NE, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, CA, CR, CN, CD, CC, CQ, CE, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, QA, QR, QN, QD, QC, QQ, QE, QH, QI, QL, QK, QM, QF, QP, QS, QT, QW, QY, QV, EA, ER, EN, ED, EC, EQ, EE, EH, El, EL, EK, EM, EF, EP, ES, ET, EW, EY, EV, GA, GR, GN, GD, GC, GQ, GE, GH, Gl, GL, GK, GM, GF, GP, GS, GT, GW, GY, GV, HA, HR, HN, HD, HC, HQ, HE, HH, HI, HL, HK, HM, HF, HP, HS, HT, HW, HY, HV, IA, IR, IN, ID, IC, IQ, IE, IH, II, IL, IK, IM, IF, IP, IS, IT, IW, IY, IV, LA, LR, LN, LD, LC, LQ, LE, LH, LI, LL, LK, LM, LF, LP, LS, LT, LW, LY, LV, KA, KR, KN, KD, KC, KQ, KE, KH, KI, KL, KK, KM, KF, KP, KS, KT, KW, KY, KV, MA, MR, MN, MD, MC, MQ, ME, MH, Ml, ML, MK, MM, MF, MP, MS, MT, MW, MY, MV, FA, FR, FN, FD, FC, FQ, FE, FH, Fl, FL, FK, FM, FF, FP, FS, FT, FW, FY, FV, PA, PR, PN, PD, PC, PQ, PE, PH, PI, PL, PK, PM, PF, PP, PS, PT, PW, PY, PV, SA, SR, SN, SD, SC, SQ, SE, SH, SI, SL, SK, SM, SF, SP, SS, ST, SW, SY, SV, TA, TR, TN, TD, TC, TQ, TE, TH, Tl, TL, TK, TM, TF, TP, TS, TT, TW, TY, TV, WA, WR, WN, WD, WC, WQ, WE, WH, Wl, WL, WK, WM, WF, WP, WS, WT, WW, WY, WV, YA, YR, YN, YD, YC, YQ, YE, YH, Yl, YL, YK, YM, YF, YP, YS, YT, YW, YY, YV, VA, VR, VN, VD, VC, VQ, VE, VH, VI, VL, VK, VM, VF, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are D97 and F100, the double point mutants envisioned are as follows:
AA, AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AP, AS, AT, AW, AY, AV, RA, RR, RN, RD, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RP, RS, RT, RW, RY, RV, NA, NR, NN, ND, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NP, NS, NT, NW, NY, NV, CA, CR, CN, CD, CC, CQ, CE, CG, CH, Cl, CL, CK, CM, CP, CS, CT, CW, CY, CV, QA, QR, QN, QD, QC, QQ, QE, QG, QH, QI, QL, QK, QM, QP, QS, QT, QW, QY, QV, EA, ER, EN, ED, EC, EQ, EE, EG, EH, El, EL, EK, EM, EP, ES, ET, EW, EY, EV, GA, GR, GN, GD, GC, GQ, GE, GG, GH, Gl, GL, GK, GM, GP, GS, GT, GW, GY, GV, HA, HR, HN, HD, HC, HQ, HE, HG, HH, HI, HL, HK, HM, HP, HS, HT, HW, HY, HV, IA, IR, IN, ID, IC, IQ, IE, IG, IH, II, IL, IK, IM, IP, IS, IT, IW, IY, IV, LA, LR, LN, LD, LC, LQ, LE, LG, LH, LI, LL, LK, LM, LP, LS, LT, LW, LY, LV, KA, KR, KN, KD, KC, KQ, KE, KG, KH, KI, KL, KK, KM, KP, KS, KT, KW, KY, KV, MA, MR, MN, MD, MC, MQ, ME, MG, MH, Ml, ML, MK, MM, MP, MS, MT, MW, MY, MV, FA, FR, FN, FD, FC, FQ, FE, FG, FH, Fl, FL, FK, FM, FP, FS, FT, FW, FY, FV, PA, PR, PN, PD, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PP, PS, PT, PW, PY, PV, SA, SR, SN, SD, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SP, SS, ST, SW, SY, SV, TA, TR, TN, TD, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TP, TS, TT, TW, TY, TV, WA, WR, WN, WD, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WP, WS, WT, WW, WY, WV, YA, YR, YN, YD, YC, YQ, YE, YG, YH, Yl, YL, YK, YM, YP, YS, YT, YW, YY, YV, VA, VR, VN, VD, VC, VQ, VE, VG, VH, VI, VL, VK, VM, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are D97 and D101 , the double point mutants envisioned are as follows:
AA, AR, AN, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV, NA, NR, NN, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, CA, CR, CN, CC, CQ, CE, CG, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, QA, QR, QN, QC, QQ, QE, QG, QH, QI, QL, QK, QM, QF, QP, QS, QT, QW, QY, QV, EA, ER, EN, EC, EQ, EE, EG, EH, El, EL, EK, EM, EF, EP, ES, ET, EW, EY, EV, GA, GR, GN, GC, GQ, GE, GG, GH, Gl, GL, GK, GM, GF, GP, GS, GT, GW, GY, GV, HA, HR, HN, HC, HQ, HE, HG, HH, HI, HL, HK, HM, HF, HP, HS, HT, HW, HY, HV, IA, IR, IN, IC, IQ, IE, IG, IH, II, IL, IK, IM, IF, IP, IS, IT, IW, IY, IV, LA, LR, LN, LC, LQ, LE, LG, LH, LI, LL, LK,
LM, LF, LP, LS, LT, LW, LY, LV, KA, KR, KN, KC, KQ, KE, KG, KH, KI, KL, KK, KM, KF, KP, KS, KT, KW, KY, KV, MA, MR, MN, MC, MQ, ME, MG, MH, Ml, ML, MK, MM, MF, MP, MS, MT, MW, MY, MV, FA, FR, FN, FC, FQ, FE, FG, FH, Fl, FL, FK, FM, FF, FP, FS, FT, FW, FY, FV, PA, PR, PN, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PF, PP, PS, PT, PW, PY, PV, SA, SR, SN, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SF, SP, SS, ST, SW, SY, SV, TA, TR, TN, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TF, TP, TS, TT, TW, TY, TV, WA, WR, WN, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WF, WP, WS, WT, WW, WY, WV, YA, YR, YN, YC, YQ, YE, YG, YH, Yl, YL, YK, YM, YF, YP, YS, YT, YW, YY, YV, VA, VR, VN, VC, VQ, VE, VG, VH, VI, VL, VK, VM, VF, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are D97 and F102, the double point mutants envisioned are as follows:
AA, AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AP, AS, AT, AW, AY, AV, RA,
RR, RN, RD, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RP, RS, RT, RW, RY, RV, NA, NR,
NN, ND, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NP, NS, NT, NW, NY, NV, CA, CR, CN,
CD, CC, CQ, CE, CG, CH, Cl, CL, CK, CM, CP, CS, CT, CW, CY, CV, QA, QR, QN,
QD, QC, QQ, QE, QG, QH, QI, QL, QK, QM, QP, QS, QT, QW, QY, QV, EA, ER, EN, ED, EC, EQ, EE, EG, EH, El, EL, EK, EM, EP, ES, ET, EW, EY, EV, GA, GR, GN, GD, GC, GQ, GE, GG, GH, Gl, GL, GK, GM, GP, GS, GT, GW, GY, GV, HA, HR, HN, HD, HC, HQ, HE, HG, HH, HI, HL, HK, HM, HP, HS, HT, HW, HY, HV, IA, IR, IN, ID, IC, IQ, IE, IG, IH, II, IL, IK, IM, IP, IS, IT, IW, IY, IV, LA, LR, LN, LD, LC, LQ, LE, LG, LH, LI, LL, LK, LM, LP, LS, LT, LW, LY, LV, KA, KR, KN, KD, KC, KQ, KE, KG, KH, KI, KL, KK, KM, KP, KS, KT, KW, KY, KV, MA, MR, MN, MD, MC, MQ, ME, MG, MH, Ml, ML, MK, MM, MP, MS, MT, MW, MY, MV, FA, FR, FN, FD, FC, FQ, FE, FG, FH, Fl, FL, FK, FM, FP, FS, FT, FW, FY, FV, PA, PR, PN, PD, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PP, PS, PT, PW, PY, PV, SA, SR, SN, SD, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SP, SS, ST, SW, SY, SV, TA, TR, TN, TD, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TP, TS, TT, TW, TY, TV, WA, WR, WN, WD, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WP, WS, WT, WW, WY, WV, YA, YR, YN, YD, YC, YQ, YE, YG, YH, Yl, YL, YK, YM, YP, YS, YT, YW, YY, YV, VA, VR, VN, VD, VC, VQ, VE, VG, VH, VI, VL, VK, VM, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are D98 and G99, the double point mutants envisioned are as follows:
AA, AR, AN, AD, AC, AQ, AE, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RD, RC, RQ, RE, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV, NA, NR, NN, ND, NC, NQ, NE, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, CA, CR, CN, CD, CC, CQ, CE, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, QA, QR, QN, QD, QC, QQ, QE, QH, QI, QL, QK, QM, QF, QP, QS, QT, QW, QY, QV, EA, ER, EN, ED, EC, EQ, EE, EH, El, EL, EK, EM, EF, EP, ES, ET, EW, EY, EV, GA, GR, GN, GD, GC, GQ, GE, GH, Gl, GL, GK, GM, GF, GP, GS, GT, GW, GY, GV, HA, HR, HN, HD, HC, HQ, HE, HH, HI, HL, HK, HM, HF, HP, HS, HT, HW, HY, HV, IA, IR, IN, ID, IC, IQ, IE, IH, II, IL, IK, IM, IF, IP, IS, IT, IW, IY, IV, LA, LR, LN, LD, LC, LQ, LE, LH, LI, LL, LK, LM, LF, LP, LS, LT, LW, LY, LV, KA, KR, KN, KD, KC, KQ, KE, KH, KI, KL, KK, KM, KF, KP, KS, KT, KW, KY, KV, MA, MR, MN, MD, MC, MQ, ME, MH, Ml, ML, MK, MM, MF, MP, MS, MT, MW, MY, MV, FA, FR, FN, FD, FC, FQ, FE, FH, Fl, FL, FK, FM, FF, FP, FS, FT, FW, FY, FV, PA, PR, PN, PD, PC, PQ, PE, PH, PI, PL, PK, PM, PF, PP, PS, PT, PW, PY, PV, SA, SR, SN, SD, SC, SQ, SE, SH, SI, SL, SK, SM, SF, SP, SS, ST, SW, SY, SV, TA, TR, TN, TD, TC, TQ, TE, TH, Tl, TL, TK, TM, TF, TP, TS, TT, TW, TY, TV, WA, WR, WN, WD, WC, WQ, WE, WH, Wl, WL, WK, WM, WF, WP, WS, WT, WW, WY, WV, YA, YR, YN, YD, YC, YQ, YE, YH, Yl, YL, YK, YM, YF, YP, YS, YT, YW, YY, YV, VA, VR, VN, VD, VC, VQ, VE, VH, VI, VL, VK, VM, VF, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are D98 and F100, the double point mutants envisioned are as follows:
AA, AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AP, AS, AT, AW, AY, AV, RA, RR, RN, RD, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RP, RS, RT, RW, RY, RV, NA, NR,
NN, ND, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NP, NS, NT, NW, NY, NV, CA, CR, CN,
CD, CC, CQ, CE, CG, CH, Cl, CL, CK, CM, CP, CS, CT, CW, CY, CV, QA, QR, QN,
QD, QC, QQ, QE, QG, QH, QI, QL, QK, QM, QP, QS, QT, QW, QY, QV, EA, ER, EN, ED, EC, EQ, EE, EG, EH, El, EL, EK, EM, EP, ES, ET, EW, EY, EV, GA, GR, GN, GD, GC, GQ, GE, GG, GH, Gl, GL, GK, GM, GP, GS, GT, GW, GY, GV, HA, HR, HN, HD, HC, HQ, HE, HG, HH, HI, HL, HK, HM, HP, HS, HT, HW, HY, HV, IA, IR, IN, ID, IC, IQ, IE, IG, IH, II, IL, IK, IM, IP, IS, IT, IW, IY, IV, LA, LR, LN, LD, LC, LQ, LE, LG, LH, LI, LL,
LK, LM, LP, LS, LT, LW, LY, LV, KA, KR, KN, KD, KC, KQ, KE, KG, KH, KI, KL, KK, KM, KP, KS, KT, KW, KY, KV, MA, MR, MN, MD, MC, MQ, ME, MG, MH, Ml, ML, MK, MM, MP, MS, MT, MW, MY, MV, FA, FR, FN, FD, FC, FQ, FE, FG, FH, Fl, FL, FK, FM, FP, FS, FT, FW, FY, FV, PA, PR, PN, PD, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PP, PS, PT, PW, PY, PV, SA, SR, SN, SD, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SP, SS, ST, SW, SY, SV, TA, TR, TN, TD, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TP, TS, TT, TW, TY, TV, WA, WR, WN, WD, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WP, WS, WT, WW, WY, WV, YA, YR, YN, YD, YC, YQ, YE, YG, YH, Yl, YL, YK, YM, YP, YS, YT, YW, YY, YV, VA, VR, VN, VD, VC, VQ, VE, VG, VH, VI, VL, VK, VM, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are D98 and D101 , the double point mutants envisioned are as follows:
AA, AR, AN, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV, NA, NR, NN, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, CA, CR, CN, CC, CQ, CE, CG, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, QA, QR, QN, QC, QQ, QE, QG, QH, QI, QL, QK, QM, QF, QP, QS, QT, QW, QY, QV, EA, ER, EN, EC, EQ, EE, EG, EH, El, EL, EK, EM, EF, EP, ES, ET, EW, EY, EV, GA, GR, GN, GC, GQ, GE, GG, GH, Gl, GL, GK, GM, GF, GP, GS, GT, GW, GY, GV, HA, HR, HN, HC, HQ, HE, HG, HH, HI, HL, HK, HM, HF, HP, HS, HT, HW, HY, HV, IA, IR, IN, IC, IQ, IE, IG, IH, II, IL, IK, IM, IF, IP, IS, IT, IW, IY, IV, LA, LR, LN, LC, LQ, LE, LG, LH, LI, LL, LK, LM, LF, LP, LS, LT, LW, LY, LV, KA, KR, KN, KC, KQ, KE, KG, KH, KI, KL, KK, KM, KF, KP, KS, KT, KW, KY, KV, MA, MR, MN, MC, MQ, ME, MG, MH, Ml, ML, MK, MM, MF, MP, MS, MT, MW, MY, MV, FA, FR, FN, FC, FQ, FE, FG, FH, Fl, FL, FK, FM, FF, FP, FS, FT, FW, FY, FV, PA, PR, PN, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PF, PP, PS, PT, PW, PY, PV, SA, SR, SN, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SF, SP, SS, ST, SW, SY, SV, TA, TR, TN, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TF, TP, TS, TT, TW, TY, TV, WA, WR, WN, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WF, WP, WS, WT, WW, WY, WV, YA, YR, YN, YC, YQ, YE, YG, YH, Yl, YL, YK, YM, YF, YP, YS, YT, YW, YY, YV, VA, VR, VN, VC, VQ, VE, VG, VH, VI, VL, VK, VM, VF, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are D98 and F102, the double point mutants envisioned are as follows:
AA, AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AP, AS, AT, AW, AY, AV, RA, RR, RN, RD, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RP, RS, RT, RW, RY, RV, NA, NR, NN, ND, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NP, NS, NT, NW, NY, NV, CA, CR, CN, CD, CC, CQ, CE, CG, CH, Cl, CL, CK, CM, CP, CS, CT, CW, CY, CV, QA, QR, QN, QD, QC, QQ, QE, QG, QH, QI, QL, QK, QM, QP, QS, QT, QW, QY, QV, EA, ER, EN, ED, EC, EQ, EE, EG, EH, El, EL, EK, EM, EP, ES, ET, EW, EY, EV, GA, GR, GN, GD, GC, GQ, GE, GG, GH, Gl, GL, GK, GM, GP, GS, GT, GW, GY, GV, HA, HR, HN, HD, HC, HQ, HE, HG, HH, HI, HL, HK, HM, HP, HS, HT, HW, HY, HV, IA, IR, IN, ID, IC, IQ, IE, IG, IH, II, IL, IK, IM, IP, IS, IT, IW, IY, IV, LA, LR, LN, LD, LC, LQ, LE, LG, LH, LI, LL, LK, LM, LP, LS, LT, LW, LY, LV, KA, KR, KN, KD, KC, KQ, KE, KG, KH, KI, KL, KK, KM, KP, KS, KT, KW, KY, KV, MA, MR, MN, MD, MC, MQ, ME, MG, MH, Ml, ML, MK, MM, MP, MS, MT, MW, MY, MV, FA, FR, FN, FD, FC, FQ, FE, FG, FH, Fl, FL, FK, FM, FP, FS, FT, FW, FY, FV, PA, PR, PN, PD, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PP, PS, PT, PW, PY, PV, SA, SR, SN, SD, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SP, SS, ST, SW, SY, SV, TA, TR, TN, TD, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TP, TS, TT, TW, TY, TV, WA, WR, WN, WD, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WP, WS, WT, WW, WY, WV, YA, YR, YN, YD, YC, YQ, YE, YG, YH, Yl, YL, YK, YM, YP, YS, YT, YW, YY, YV, VA, VR, VN, VD, VC, VQ, VE, VG, VH, VI, VL, VK, VM, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are G99 and F100, the double point mutants envisioned are as follows:
AA, AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AP, AS, AT, AW, AY, AV, RA, RR, RN, RD, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RP, RS, RT, RW, RY, RV, NA, NR,
NN, ND, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NP, NS, NT, NW, NY, NV, DA, DR, DN,
DD, DC, DQ, DE, DG, DH, DI, DL, DK, DM, DP, DS, DT, DW, DY, DV, CA, CR, CN, CD,
CC, CQ, CE, CG, CH, Cl, CL, CK, CM, CP, CS, CT, CW, CY, CV, QA, QR, QN, QD,
QC, QQ, QE, QG, QH, QI, QL, QK, QM, QP, QS, QT, QW, QY, QV, EA, ER, EN, ED, EC, EQ, EE, EG, EH, El, EL, EK, EM, EP, ES, ET, EW, EY, EV, HA, HR, HN, HD, HC, HQ, HE, HG, HH, HI, HL, HK, HM, HP, HS, HT, HW, HY, HV, IA, IR, IN, ID, IC, IQ, IE, IG, IH, II, IL, IK, IM, IP, IS, IT, IW, IY, IV, LA, LR, LN, LD, LC, LQ, LE, LG, LH, LI, LL,
LK, LM, LP, LS, LT, LW, LY, LV, KA, KR, KN, KD, KC, KQ, KE, KG, KH, KI, KL, KK, KM, KP, KS, KT, KW, KY, KV, MA, MR, MN, MD, MC, MQ, ME, MG, MH, Ml, ML, MK, MM, MP, MS, MT, MW, MY, MV, FA, FR, FN, FD, FC, FQ, FE, FG, FH, Fl, FL, FK, FM, FP,
FS, FT, FW, FY, FV, PA, PR, PN, PD, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PP, PS, PT, PW, PY, PV, SA, SR, SN, SD, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SP, SS, ST, SW, SY, SV, TA, TR, TN, TD, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TP, TS, TT, TW, TY, TV, WA, WR, WN, WD, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WP, WS, WT, WW, WY, WV, YA, YR, YN, YD, YC, YQ, YE, YG, YH, Yl, YL, YK, YM, YP, YS, YT, YW, YY, YV, VA, VR, VN, VD, VC, VQ, VE, VG, VH, VI, VL, VK, VM, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are G99 and D101 , the double point mutants envisioned are as follows:
AA, AR, AN, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV, NA, NR,
NN, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR, DN,
DC, DQ, DE, DG, DH, DI, DL, DK, DM, DF, DP, DS, DT, DW, DY, DV, CA, CR, CN, CC,
CQ, CE, CG, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, QA, QR, QN, QC,
QQ, QE, QG, QH, QI, QL, QK, QM, QF, QP, QS, QT, QW, QY, QV, EA, ER, EN, EC, EQ, EE, EG, EH, El, EL, EK, EM, EF, EP, ES, ET, EW, EY, EV, HA, HR, HN, HC, HQ, HE, HG, HH, HI, HL, HK, HM, HF, HP, HS, HT, HW, HY, HV, IA, IR, IN, IC, IQ, IE, IG, IH, II, IL, IK, IM, IF, IP, IS, IT, IW, IY, IV, LA, LR, LN, LC, LQ, LE, LG, LH, LI, LL, LK, LM, LF, LP, LS, LT, LW, LY, LV, KA, KR, KN, KC, KQ, KE, KG, KH, KI, KL, KK, KM, KF, KP, KS, KT, KW, KY, KV, MA, MR, MN, MC, MQ, ME, MG, MH, Ml, ML, MK, MM, MF, MP, MS, MT, MW, MY, MV, FA, FR, FN, FC, FQ, FE, FG, FH, Fl, FL, FK, FM, FF, FP, FS,
FT, FW, FY, FV, PA, PR, PN, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PF, PP, PS, PT, PW, PY, PV, SA, SR, SN, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SF, SP, SS, ST, SW, SY, SV, TA, TR, TN, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TF, TP, TS, TT, TW, TY, TV, WA, WR, WN, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WF, WP, WS, WT, WW, WY, WV, YA, YR, YN, YC, YQ, YE, YG, YH, Yl, YL, YK, YM, YF, YP, YS, YT, YW, YY, YV, VA, VR, VN, VC, VQ, VE, VG, VH, VI, VL, VK, VM, VF, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are G99 and F102, the double point mutants envisioned are as follows:
AA, AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AP, AS, AT, AW, AY, AV, RA, RR, RN, RD, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RP, RS, RT, RW, RY, RV, NA, NR,
NN, ND, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NP, NS, NT, NW, NY, NV, DA, DR, DN,
DD, DC, DQ, DE, DG, DH, DI, DL, DK, DM, DP, DS, DT, DW, DY, DV, CA, CR, CN, CD,
CC, CQ, CE, CG, CH, Cl, CL, CK, CM, CP, CS, CT, CW, CY, CV, QA, QR, QN, QD,
QC, QQ, QE, QG, QH, QI, QL, QK, QM, QP, QS, QT, QW, QY, QV, EA, ER, EN, ED, EC, EQ, EE, EG, EH, El, EL, EK, EM, EP, ES, ET, EW, EY, EV, HA, HR, HN, HD, HC, HQ, HE, HG, HH, HI, HL, HK, HM, HP, HS, HT, HW, HY, HV, IA, IR, IN, ID, IC, IQ, IE, IG, IH, II, IL, IK, IM, IP, IS, IT, IW, IY, IV, LA, LR, LN, LD, LC, LQ, LE, LG, LH, LI, LL, LK, LM, LP, LS, LT, LW, LY, LV, KA, KR, KN, KD, KC, KQ, KE, KG, KH, KI, KL, KK, KM, KP, KS, KT, KW, KY, KV, MA, MR, MN, MD, MC, MQ, ME, MG, MH, Ml, ML, MK, MM, MP, MS, MT, MW, MY, MV, FA, FR, FN, FD, FC, FQ, FE, FG, FH, Fl, FL, FK, FM, FP, FS, FT, FW, FY, FV, PA, PR, PN, PD, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PP, PS, PT, PW, PY, PV, SA, SR, SN, SD, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SP, SS, ST, SW, SY, SV, TA, TR, TN, TD, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TP, TS, TT, TW, TY, TV, WA, WR, WN, WD, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WP, WS, WT, WW, WY, WV, YA, YR, YN, YD, YC, YQ, YE, YG, YH, Yl, YL, YK, YM, YP, YS, YT, YW, YY, YV, VA, VR, VN, VD, VC, VQ, VE, VG, VH, VI, VL, VK, VM, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are F100 and D101 , the double point mutants envisioned are as follows:
AA, AR, AN, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AF, AP, AS, AT, AW, AY, AV, RA, RR, RN, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RF, RP, RS, RT, RW, RY, RV, NA, NR,
NN, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NF, NP, NS, NT, NW, NY, NV, DA, DR, DN,
DC, DQ, DE, DG, DH, DI, DL, DK, DM, DF, DP, DS, DT, DW, DY, DV, CA, CR, CN, CC,
CQ, CE, CG, CH, Cl, CL, CK, CM, CF, CP, CS, CT, CW, CY, CV, QA, QR, QN, QC,
QQ, QE, QG, QH, QI, QL, QK, QM, QF, QP, QS, QT, QW, QY, QV, EA, ER, EN, EC, EQ, EE, EG, EH, El, EL, EK, EM, EF, EP, ES, ET, EW, EY, EV, GA, GR, GN, GC, GQ, GE, GG, GH, Gl, GL, GK, GM, GF, GP, GS, GT, GW, GY, GV, HA, HR, HN, HC, HQ, HE, HG, HH, HI, HL, HK, HM, HF, HP, HS, HT, HW, HY, HV, IA, IR, IN, IC, IQ, IE, IG,
IH, II, IL, IK, IM, IF, IP, IS, IT, IW, IY, IV, LA, LR, LN, LC, LQ, LE, LG, LH, LI, LL, LK, LM, LF, LP, LS, LT, LW, LY, LV, KA, KR, KN, KC, KQ, KE, KG, KH, KI, KL, KK, KM, KF, KP, KS, KT, KW, KY, KV, MA, MR, MN, MC, MQ, ME, MG, MH, Ml, ML, MK, MM, MF, MP, MS, MT, MW, MY, MV, PA, PR, PN, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PF, PP, PS, PT, PW, PY, PV, SA, SR, SN, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SF, SP, SS, ST, SW, SY, SV, TA, TR, TN, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TF, TP, TS, TT, TW, TY, TV, WA, WR, WN, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WF, WP, WS, WT, WW, WY, WV, YA, YR, YN, YC, YQ, YE, YG, YH, Yl, YL, YK, YM, YF, YP, YS, YT, YW, YY, YV, VA, VR, VN, VC, VQ, VE, VG, VH, VI, VL, VK, VM, VF, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are F100 and F102, the double point mutants envisioned are as follows:
AA, AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AP, AS, AT, AW, AY, AV, RA, RR, RN, RD, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RP, RS, RT, RW, RY, RV, NA, NR,
NN, ND, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NP, NS, NT, NW, NY, NV, DA, DR, DN,
DD, DC, DQ, DE, DG, DH, DI, DL, DK, DM, DP, DS, DT, DW, DY, DV, CA, CR, CN, CD,
CC, CQ, CE, CG, CH, Cl, CL, CK, CM, CP, CS, CT, CW, CY, CV, QA, QR, QN, QD,
QC, QQ, QE, QG, QH, QI, QL, QK, QM, QP, QS, QT, QW, QY, QV, EA, ER, EN, ED, EC, EQ, EE, EG, EH, El, EL, EK, EM, EP, ES, ET, EW, EY, EV, GA, GR, GN, GD, GC, GQ, GE, GG, GH, Gl, GL, GK, GM, GP, GS, GT, GW, GY, GV, HA, HR, HN, HD, HC, HQ, HE, HG, HH, HI, HL, HK, HM, HP, HS, HT, HW, HY, HV, IA, IR, IN, ID, IC, IQ, IE, IG, IH, II, IL, IK, IM, IP, IS, IT, IW, IY, IV, LA, LR, LN, LD, LC, LQ, LE, LG, LH, LI, LL, LK, LM, LP, LS, LT, LW, LY, LV, KA, KR, KN, KD, KC, KQ, KE, KG, KH, KI, KL, KK, KM, KP, KS, KT, KW, KY, KV, MA, MR, MN, MD, MC, MQ, ME, MG, MH, Ml, ML, MK, MM, MP, MS, MT, MW, MY, MV, PA, PR, PN, PD, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PP, PS, PT, PW, PY, PV, SA, SR, SN, SD, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SP, SS, ST, SW, SY, SV, TA, TR, TN, TD, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TP, TS, TT, TW, TY, TV, WA, WR, WN, WD, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WP, WS, WT, WW, WY, WV, YA, YR, YN, YD, YC, YQ, YE, YG, YH, Yl, YL, YK, YM, YP, YS, YT, YW, YY, YV, VA, VR, VN, VD, VC, VQ, VE, VG, VH, VI, VL, VK, VM, VP, VS, VT, VW, VY, and W.
When the first and second amino acid residues to be mutated are D101 and F102, the double point mutants envisioned are as follows:
AA, AR, AN, AD, AC, AQ, AE, AG, AH, Al, AL, AK, AM, AP, AS, AT, AW, AY, AV, RA,
RR, RN, RD, RC, RQ, RE, RG, RH, Rl, RL, RK, RM, RP, RS, RT, RW, RY, RV, NA, NR,
NN, ND, NC, NQ, NE, NG, NH, Nl, NL, NK, NM, NP, NS, NT, NW, NY, NV, CA, CR, CN,
CD, CC, CQ, CE, CG, CH, Cl, CL, CK, CM, CP, CS, CT, CW, CY, CV, QA, QR, QN,
QD, QC, QQ, QE, QG, QH, QI, QL, QK, QM, QP, QS, QT, QW, QY, QV, EA, ER, EN, ED, EC, EQ, EE, EG, EH, El, EL, EK, EM, EP, ES, ET, EW, EY, EV, GA, GR, GN, GD, GC, GQ, GE, GG, GH, Gl, GL, GK, GM, GP, GS, GT, GW, GY, GV, HA, HR, HN, HD, HC, HQ, HE, HG, HH, HI, HL, HK, HM, HP, HS, HT, HW, HY, HV, IA, IR, IN, ID, IC, IQ, IE, IG, IH, II, IL, IK, IM, IP, IS, IT, IW, IY, IV, LA, LR, LN, LD, LC, LQ, LE, LG, LH, LI, LL, LK, LM, LP, LS, LT, LW, LY, LV, KA, KR, KN, KD, KC, KQ, KE, KG, KH, KI, KL, KK, KM, KP, KS, KT, KW, KY, KV, MA, MR, MN, MD, MC, MQ, ME, MG, MH, Ml, ML, MK, MM, MP, MS, MT, MW, MY, MV, FA, FR, FN, FD, FC, FQ, FE, FG, FH, Fl, FL, FK, FM, FP, FS, FT, FW, FY, FV, PA, PR, PN, PD, PC, PQ, PE, PG, PH, PI, PL, PK, PM, PP, PS, PT, PW, PY, PV, SA, SR, SN, SD, SC, SQ, SE, SG, SH, SI, SL, SK, SM, SP, SS, ST, SW, SY, SV, TA, TR, TN, TD, TC, TQ, TE, TG, TH, Tl, TL, TK, TM, TP, TS, TT, TW, TY, TV, WA, WR, WN, WD, WC, WQ, WE, WG, WH, Wl, WL, WK, WM, WP, WS, WT, WW, WY, WV, YA, YR, YN, YD, YC, YQ, YE, YG, YH, Yl, YL, YK, YM, YP, YS, YT, YW, YY, YV, VA, VR, VN, VD, VC, VQ, VE, VG, VH, VI, VL, VK, VM, VP, VS, VT, VW, VY, and W.
References
P. Maddon, et al., U.S. Patent No. 6,451 ,313.
W. Dall’Acqua, et al., U.S. Patent No. 7,083,784.
W. Olson, et al., U.S. Patent No. 7,122,185.
L. Presta, et al., U.S. Patent No. 7,332,581.
V.M. Litwin, et al., U.S. Patent No. 7,345,153.
R.S. Mclvor, et al., U.S. Patent No. 9,827,295.
P. Hotez, et al., U.S. Patent Application No. 20160376321.
D. Ballon, et al., U.S. Patent Publication No. 20170067028.
G. Buchliss, et al., U.S. Patent Publication No. 20190038724.
J. Zhou, et al., U.S. Patent Publication No. 20190078099.
M. Gasmi, et al., U.S. Patent Publication No. 20190160187.
J. A. Bluestone, et al., International Publication No. WO/1994/028027.
S.A. Morgan, et al., International Publication No. WO/1994/029351 .
R.J. Owens, et al., International Publication No. WO/1995/026403.
P.J. Carter, et al., International Publication No. WO/1996/027011.
G.A. Lazar, et al., International Publication No. WO/2004/029207.
R.P. Rother, et al., International Publication No. WO/2005/007809.
A. Chamberlain, et al., International Publication No. WO/2009/086320.
T.A. Stadheim, et al., International Publication No. WO/2011/149999.
H. Zhou, International Publication No. WO/2017/079369.
Adeno-Associated Virus (AAV) Guide, Addgene Catalog (https://www.addgene. org/viral-vectors/aav/aav-guide/).
Amicus, Thermo Fisher’s Brammer Bio Partner on Gene Therapy Manufacturing, Genetic Engineering & Biotechnology News, July 2, 2019.
T.M. Antalis, et al., Membrane-anchored serine proteases in health and disease, Progress in Molecular Biology and Translational Science, Vol. 99 (2011 ).
M. Bolles, et al., A double inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge, J. of Virology, Dec. 2011 , 12201 - 12215.
E.M. Bouricha, et al., In silico analysis of ACE2 orthologues to predict animal host range with high susceptibility to SARS-CoV-2, 3 Biotech, 10, Article number: 483 (2020).
D.A. Brindley, et al., Emerging Platform Bioprocesses for Viral Vectors and Gene Therapies, Bioprocess International, April 18, 2016.
U. Brinkmann and R.E. Kontermann, The making of bispecific antibodies, mAbs, Vol. 9, 2:182-212 (2017).
T.H. Bugge, et al., Type II transmembrane serine proteases, J. Biol. Chem., 284(35): 23177-23181 (2009).
D.R. Burton and L.M. Walker, Rational Vaccine Design in the Time of COVID-19, Cell Host & Microbe, 27:695-698, May 13, 2020.
E. Callaway, The Race for Coronavirus Vaccines, Nature 580:576-77 (April 30, 2020).
Cai, et al., C-terminal lysine processing of human immunoglobulin G2 heavy chain in vivo, Biotechnol. Bioeng., 2011 Feb;108(2):404-12.
J.R. Cantor, et al., Therapeutic enzyme deimmunization by combinatorial T-cell epitope removal using neutral drift, Proc Natl Acad Sci USA, 2011 Jan 25; 108(4): 1272-1277.
W.H. Chen, et al., The SARS-CoV-2 Vaccine Pipeline: an Overview, Curr. Tropical Med. Reports, Springer Nature Switzerland AG (2020).
Y. Chen, et al., ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker, Signal Transduction and Targeted Therapy, 6, Article number: 315 (2021 ).
J.R. Chevillet, et al., Identification and characterization of small-molecule inhibitors of hepsin, Mol. Cancer The 2008 October; 7(10): 3343-3351.
F. Chiappelli, 2019-nCoV - Toward a 4th Generation Vaccine, Bioinformation 16(2):139- 144 (2020).
M.L. Chiu and G.L. Gilliland, Engineering antibody therapeutics, Current Opinion in Structural Biology 2016, 38: 163-173.
S.Y. Choi, et al., Type II transmembrane serine proteases in cancer and viral infections, Trends in Mol. Med. 15(7): 303-312 (2009).
T.-W. Chun, et al., Durable Control of HIV Infection in the Absence of Antiretroviral Therapy: Opportunities and Obstacles, JAMA. 2019;322(1 ): 27-28.
N.E. Clarke and A. J. Turner, Angiotensin-Converting Enzyme 2: The First Decade, Inti. J. of Hypertension, Volume 2012, Article ID 307315, pp. 1 -12.
D. Clayton, et al., Structural determinants for binding to angiotensin converting enzyme
2 (ACE2) and angiotensin receptors 1 and 2, Front. Pharmacol., 30 January 2015.
C.M. Coleman, et al., Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice, Vaccine 32 (2014) 3169-3174.
B. Coutard, et al., The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade, Antiviral Research 176 (2020) 104742.
M.C. Crank, et al., A proof of concept for structure-based vaccine design targeting RSV in humans, Science 365, 505-509 (2019).
S. Daya and K.l. Berns, Gene Therapy Using Adeno-Associated Virus Vectors, Clinical Microbiology Reviews, Oct. 2008, Vol. 21 , No. 4, p. 583-593.
C.E. Deal and A.B. Balazs, Vectored Antibody Gene Delivery for the Prevention or Treatment of HIV Infection, Curr Opin HIV AIDS. 2015 May;10(3): 190-197.
M.S. Diamond and T.C. Pierson, The Challenges of Vaccine Development against a New Virus during a Pandemic, Cell Host & Microbe, 27, May 13, 2020.
M. Donoghue, et al., A Novel Angiotensin-Converting Enzyme-Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9, Circulation Res., September 1 , 2000.
L.M. Drouin and M. Agbandje-McKenna, Adeno-associated virus structural biology as a tool in vector development, Future Virol. 2013 Dec; 8(12): 1183-1199.
Y. Du, et al., A broadly neutralizing humanized ACE2-targeting antibody against SARS- CoV-2 variants. Nat Commun 12, 5000 (2021 ) (https://doi.org/10.1038/ s41467-021- 25331 -x), including Supplemental Information (https://static- content.springer.com/esm/art%3A10.1038%2Fs41467-021 -25331 -x/Media Objects/41467_2021_25331_MOESM1_ESM.pdf).
C. Dumet, et al., Insights into the IgG heavy chain engineering patent landscape as applied to lgG4 antibody development, mAbs, Vol. 11 , 8:1341 -1350 (2019).
M. Ferarri, et al., Characterization of a novel ACE2-based therapeutic with enhanced rather than reduced activity against SARS-CoV-2 variants, J. of Virology, vol. 95, issue 19, October 2021.
S.P. Fuchs, et al., Recombinant AAV Vectors for Enhanced Expression of Authentic IgG, PLOS 0NE \ DOI: 10.1371/journal.pone.0158009, pp. 1-19, June 22, 2016.
S.P. Fuchs, et al., Liver-directed but not muscle-directed AAV-antibody gene transfer limits humoral immune responses in rhesus monkeys, Mol. Therapy: Methods & Clin. Dev., 16:94-102 (March 2020).
M.R. Gardner, AAV-delivered eCD4-lg protects rhesus macaques from high-dose SIVmac239 challenges, Sci. Transl. Med. 11 , eaau5409 (July 24, 2019).
M.R. Gardner, et al., Anti-Drug Antibody Responses Impair Prophylaxis Mediated by AAV-Delivered HIV-1 Broadly Neutralizing Antibodies, Molecular Therapy, Vol. 27, No. 3, 650-660 (March 2019).
M. Godar, et al., Therapeutic bispecific antibody formats: A patent applications review (1994-2017), Expert Opinion on Therapeutic Patents, Vol. 28, 3:251-276 (2018).
K. Gopinath, et al., Screening of Natural Products Targeting SARS-CoV-2-ACE2 Receptor Interface - A MixMD Based HTVS Pipeline, (2020) Front. Chem. 8:589769.
Y-R Guo, et al., The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status, Military Medical Res. (2020) 7:11.
J.L. Guy, et al., Identification of critical active-site residues in angiotensin-converting enzyme 2 (ACE2) by site-directed mutagenesis, FEBS Journal, 272 (2005) 3512-3520.
N. Halama, et al., Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients, 2016, Cancer Cell 29, 587-601 .
I. Hamming, et al., Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis, J. of Pathology, 2004, 203:631-637.
Y. Han and P. Kral, Computational Design of ACE2-Based Peptide Inhibitors of SARS- CoV-2, ACS Nano 2020, 14, 4, 5143-5147, April 14, 2020.
M. Hoffmann, et al., SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell, 181 :1-10 (2020).
M. Hoffmann, et al., A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells, Molecular Cell, 78:1-6 (2020).
M. Hoffman, et al., SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies, Cell 11954 (2021 ).
K. Hollevoet and P. J. Declerck, State of play and clinical prospects of antibody gene transfer, J Transl Med (2017) 15: 131.
D. Hu, et al., Effective Optimization of Antibody Affinity by Phage Display Integrated with High-Throughput DNA Synthesis and Sequencing Technologies, PLOS ONE | DOI:10.1371/journal.pone.0129125 June 5, 2015.
Y. Huang, et al., Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19, Acta Pharmacologica Sinica, volume 41 , pages 1141-1149 (2020).
Human Monoclonal Antibodies for Human ACE2, Twist Biopharma (2020).
C. J. Hutchings, A review of antibody-based therapeutics targeting G protein-coupled receptors: an update, Expert Opinion on Biological Therapy, 1744-7682 (online) (April 8, 2020).
C. Jackson, et al., Mechanism of SARS-CoV-2 entry into cells, Nature Reviews, October 5, 2021 .
Jefferis and M.-P. Lefranc, Human immunoglobulin allotypes, MAbs. 2009 Jul-Aug; 1 (4): 332-338.
R. Jefferys, HIV vaccine update: the “Miami macaque” as proof of-concept breakthrough? i-base, January 22, 2018. (http://i-base.info/htb/date/2018/01/22).
S. Jiang, et al., SARS Vaccine Development, Emerging Infectious Diseases, 11 (7): 1016-1020 (2005).
S. Jiang, et al., Roadmap to developing a recombinant coronavirus S protein receptorbinding domain vaccine for severe acute respiratory syndrome, Expert Review of Vaccines, 11 (12); 1405-1413 (2012).
S. Jiang, et al., An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies, Emerging Microbes & Infections, 9:275-277 (2020).
B. Ju, et al., Potent human neutralizing antibodies elicited by SARS-CoV-2 infection, bioRxiv doi: https://doi.org/10.1101/2020.03.21.990770.
J. Kaiser, Boys with a rare muscle disease are breathing on their own, thanks to gene therapy, May 2, 2019, Science.
Y. Kazama, et al., Hepsin, a putative membrane-associated serine protease, activates human factor VII and initiates a pathway of blood coagulation on the cell surface leading to thrombin formation, J. Biol. Chem., 1995, 270(1 ): 66-72.
A. Keener, The genetic shortcut to antibody drugs, Nature 564, S16-S17 (2018).
B. Kelley, Developing therapeutic monoclonal antibodies at pandemic pace, Nature Biotechnology, April 21 , 2020, doi: https://www.nature.com/articles/ s41587-020-0512- 5.
T. Kitazawa, et al., A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model, Nature Medicine, Vol. 18, No. 10, 1570- 1574 (Oct. 2012).
P.-A. Koenig, et al., Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape, Science 12, Feb 2021 : Vol. 371 , Issue 6530, eabe6230.
G. Kohler and C. Milstein, Continuous cultures of fused cells secreting antibody of predefined specificity, Nature 1975, 256:495-497.
T. Koschubs, et al., Allosteric antibody inhibition of human hepsin protease, Biochem J. (2012) 442:483-494.
M.A. Kotterman and D.V. Schaffer, Engineering adeno-associated viruses for clinical gene therapy, Nature Reviews Genetics | AOP, published online 20 May 2014; doi:10.1038/nrg3742.
B. Lafleur, et al., Production of human or humanized antibodies in mice, Methods Mol. Biol. 2012, 901 :149-159.
C.S. Lee, et al., Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine, Genes & Diseases (2017) 4, 43-63.
R.A. Liberatore and D.D. Ho, The Miami Monkey: A Sunny Alternative to the Berlin Patient, Immunity Previews, Volume 50, Issue 3, P537-539, March 19, 2019.
C. Li and RJ Samulski, Engineering adeno-associated virus vectors for gene therapy, Nature Reviews, 21 :255-272 (April 2020).
F. Li, et al., Structure of SARS coronavirus spike receptor-binding domain complexed with receptor, Science, 309:1864-1868 (2005).
F. Li, Receptor recognition and cross-species infections of SARS coronavirus, Antiviral Res., Oct. 2013, 100(1).
W. Li, et al., Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2, The EMBO J., (2005) 24:1634-1643.
C.C. Lim, et al., Cognizance of Molecular Methods for the Generation of Mutagenic Phage Display Antibody Libraries for Affinity Maturation, int. J. Mol. Sci., 2019 Apr; 20(8): 1861.
J. Luan, et al., Spike protein recognition of mammalian ACE2 predicts the host range and an optimized ACE2 for SARS-CoV-2 infection, Vol. 526, Issue 1 , May 21 , 2020, pp. 165-169.
N. Lurie, et al., Developing Covid-19 Vaccines at Pandemic Speed, l\l. Engl. J. Med., Perspective (April 2020).
S. Lytras, et al., The animal origin of SARS-CoV-2, Science, 10.1126/science. abh0117 (2021).
J.M. Martinez-Navio, et al., Adeno-Associated Virus Delivery of Anti-HIV Monoclonal Antibodies Can Drive Long-Term Virologic Suppression, Immunity, 50:567-575 (2019).
J.M. Martinez-Navio, et al., Long-Term Delivery of an Anti-SIV Monoclonal Antibody With AAV, Frontiers in Immunology, March 2020, Vol. 11 , Article 449.
S. Matsuyama, et al., Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells, PNAS, March 31 , 2020 117(13): 7001-7003.
K. McKeage, Ravulizumab: First Global Approval, Drugs (2019), 79:347-52.
A.D. Melin, et al., Comparative ACE2 variation and primate COVID-19 risk, Communications Biology, Volume 3, Article number 641 (2020).
T. Meng, et al., The insert sequence in SARS-CoV-2 enhances spike protein cleavage by TMPRSS, bioRxiv doi: https://www.biorxiv.org/content/10.1101/ 2020.02.08.926006v3.
J.K. Millet and G.R. Whittaker, Host cell proteases: critical determinants of coronavirus tropism and pathogenesis, Virus Res. 202 (2015) 120-134.
C. Mueller, et al., (2012). Production and discovery of novel recombinant adeno- associated viral vectors. Curr. Protoc. Microbiol. Chapter 14, Unit 14D.1.
S. Nagataa and I. Pastanb, Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics, Adv Drug Deliv Rev. 2009 September 30; 61(11 ): 977-985.
M.F. Naso, Adeno-Associated Virus (AAV) as a Vector for Gene Therapy, BioDrugs (2017) 31 :317-334.
D.S. Ojala, et al., Adeno-Associated Virus Vectors and Neurological Gene Therapy, The Neuroscientist, February 20, 2014.
V. Padilla-Sanchez, SARS-CoV-2 Structural Analysis of Receptor Binding Domain New Variants from United Kingdom and South Africa, Research Ideas and Outcomes 7, e62936, January 15, 2021.
S.K. Panda, et al., ACE-2-Derived Biomimetic Peptides for the Inhibition of Spike Protein of SARS-CoV-2, J. Proteome Res. 2021 , 20, 2, 1296-1303, January 20, 2021.
L.C. Paoletti and RC Kennedy, Neutralizing antibody induced in mice by novel glycoconjugates of Human Immunodeficiency Virus Type 1 gp120 and env2-3, J. of Infectious Diseases, 2002; 186:1597-1602.
A. Paoloni-Giacobino, et al., Cloning of the TEMPRSS2 gene, which encodes a novel serine protease with transmembrane, LDLRA, and SRCR domains and maps to 21q22.3, Genomics 44:309-320 (1997).
A.B. Patel and A. Verma, COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: What is the evidence? JAMA, March 24, 2020.
Z. Payandeh, et al., Design of an engineered ACE2 as a novel therapeutic against COVID-19, Journal of Theoretical Biology, Volume 505, 21 November 2020, 110425.
A. Pena, Gene Therapy for Hemophilia A, SB-525, Showing Continued Benefits in Trial Data Update, Hemophelia News Today, June 26, 2019.
A. Philippidis, Virus Supply Vexes Gene Therapy Developers, CMOs, Genetic Engineering & Biotechnology News, December 14, 2017.
M. Poglitsch, et al., Recombinant expression and characterization of human and murine ACE2: Species-specific activation of the alternative renin-angiotensin-system, Inti. J. of Hypertension, Volume 2012, Article ID 428950, pp. 1-8.
T.R.D.J. Radstake, et al., Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis, Ann Rheum Dis 2009;68:1739-1745.
G.J. Robbie, et al., A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults, Antimicrobial Agents and Chemotherapy, Dec. 2013, Vol. 57, No. 12, pp. 6147-6143.
R.A.S. Santos, et al., The ACE2 I Angiotensin-(1-7) I MAS Axis of the Renin- Angiotensin System: Focus on Angiotensin-(1-7), Physiol. Rev. 98:505-553 (2018).
A. Sato, “Synthetic DNA technologies enable fast and responsive SARS-CoV-2 antibody discovery and optimization”, Twist Biopharma, July 7, 2020, Webinar (https://www.youtube.com/watch?v=ceHCqy8UsXU).
Z.E. Sauna, et al., Evaluating and Mitigating the Immunogenicity of Therapeutic Proteins, Trends in Biotechnology, October 2018, Vol. 36, No. 10.
T. Schlothauer, et al., Novel human lgG1 and lgG4 Fc-engineered antibodies with completely abolished immune effector functions, Protein Engineering, Design & Selection, 2016, vol. 29, no. 10, pp. 457-466.
M. Schoof, et al., An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike, Science Dec 18, 2020: Vol. 370, Issue 6523, pp. 1473-1479.
J. Shang, et al., Structural basis of receptor recognition by SARS-CoV-2, Nature, pages 1-19, March 30, 2020.
L.W. Shen, et al., TMPRSS2: a potential target for treatment of influenza virus and coronavirus infections, Biochimie 142 (2017) 1-10.
D. Sheridan, et al., Design and preclinical characterization of ALXN1210: A novel anti- 05 antibody with extended duration of action, PLOS One, April 12, 2018.
K. Shirato, et al., Middle East Respiratory Syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2, J. of Virology, 87(23): 12552-12561 (December 2013).
A. Shulla, et al., A transmembrane serine protease is linked to the severe acute respiratory syndrome coronavirus receptor and activates virus entry, J. of Virology, 85(2): 873-882 (January 2011 ).
J.-P. Silva, et al., The S228P Mutation Prevents in Vivo and in Vitro lgG4 Fab-arm Exchange as Demonstrated using a Combination of Novel Quantitative Immunoassays and Physiological Matrix Preparation, J. Biol. Chem., 2015 Feb 27; 290(9): 5462-5469.
S.K. Singh, et al., CCR5/CCL5 axis interaction promotes migratory and invasiveness of pancreatic cancer cells, Scientific Reports, Nature, (2018) 8:1323.
P.K. Smith, et al., Measurement of protein using bicinchoninic acid, Anal. Biochem. 150:76-85 (1985). no
P. Sullivan, FDA approves world's most expensive drug at $2.1 M, The Hill, May 24, 2019.
J. Sun, et al., COVID-19: epidemiology, evolution, and cross-disciplinary perspectives, Trends in Mol. Med., 2020, doi: http://www.cell.com/trends/ molecular- medicine/retrieve/pii/S1471491420300654?_returnURL= https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS147149142030065 4%3Fshowall%3Dtrue.
P. Supasa, et al., Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera, Cell 11896 (2021 ).
N. Suryadevara, et al., Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein, 2021 , Cell, 184:1- 16.
F.V. Suurs, et al., A review of bispecific antibodies and antibody constructs in oncology and clinical challenges, Pharmacology & Therapeutics 201 (2019) 103-119.
W. Tai, et al., Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine, Cellular & Mol. Immun., March 19, 2020.
S.H. Tam, et al., Functional, Biophysical, and Structural Characterization of Human lgG1 and lgG4 Fc Variants with Ablated Immune Functionality, Antibodies 2017, 6, 12.
P. Tamamis and C.A. Floudas, Elucidating a Key Anti-HIV-1 and Cancer-Associated Axis: The Structure of CCL5 (Rantes) in Complex with CCR5, Scientific Reports, Nature, (2014) 4:5447.
C.-W. Tan, et al., Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-lmmunized SARS-CoV-1 Survivors, N. Engl. J. Med., August 18, 2021.
X. Tian, et al., Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody, Emerging Microbes & Infections, 9:382-385 (2020).
S.R. Tipnis, et al., A Human Homolog of Angiotensin-converting Enzyme, J. Biol. Chem., 2000 Oct. 27; 275(43): 33238-43.
A. J. Turner, et al., ACE2: from vasopeptidase to SARS virus receptor, Trends in Pharm. Sci, 25(6): 291-294 (2004).
M. Vaduganathan, et al., Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19, l\l. Engl. J. Med., Special Report (April 2020).
L. Vangelista and S. Vento, The Expanding Therapeutic Perspective of CCR5 Blockade, Front Immunol. 2017; 8:1981.
C. Vickers, et al., Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase, J. Biol. Chem., 2002 April 26; 277(17): 14838-43.
Viral Vectors, Gene Therapy Net (http://www.genetherapynet.com/viral-vectors.html).
A.C. Walls, et al., Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein, bioRxiv doi: https://doi.org/10.1101/2020.02.19.956581.
Y. Wan, et al., Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry, J. of Virology, Vol. 94, Issue 5, e02015-19 (March 2020).
N. Wang, et al., Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses, Frontiers in Microbiology, 11 : 298 (2020).
I. Wilkinson, et al., Fc-engineered antibodies with immune effector functions completely abolished, PLoS ONE 16(12): e0260954. https://doi.org/10.1371/ journal.pone.0260954.
S.K. Wong, et al., A 193-amino acid fragment of the SARS Coronavirus S Protein efficiently binds Angiotensin-converting Enzyme 2, J. Biol. Chem., 279(5): 3197-3201 (2004).
D. Wrapp, et al., Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation, Science, 367, 1260-1263 (2020).
D. Wrapp, et al., Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies, Cell 181 :1 -12 (May 28, 2020).
Y. Wu, et al., A non-competing pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2, Science, 10.1126/Science.abc2241 (2020).
S. Xia, et al., Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein, Cellular & Mol. Immunol., February 2020.
C. Xu, et al., Conformational dynamics of SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM, Science Advances Jan 1 , 2021 : Vol. 7, no. 1 , eabe5575.
J. A. Xuan, et al., Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture, Cancer Res. 2006, 66(7): 3611 -3619.
X. Yang, et al., Comprehensive Analysis of the Therapeutic lgG4 Antibody Pembrolizumab: Hinge Modification Blocks Half Molecule Exchange In Vitro and In Vivo, J Pharm Sci, 104:4002-4014, August 26, 2015, https://doi.org/10.1002/jps.24620.
F. Zhang, et al., Human anti-ACE2 monoclonal antibodies as pan-sarbecovirus prophylactic agents, bioRxiv preprint doi: https://doi.org/10.1101/ 2022.08.24.505169.
H. Zhang, et al., Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target, Intensive Care Medicine, 46:586-590 (2020).
J. Zhang, et al., Structure of SARS-CoV-2 spike protein, Cur Opinion in Virology 2021 , 50:173-182.
Zhou, ACE2 and TMPRSS2 are expressed on the human ocular surface, suggesting susceptibility to SARS-CoV-2 infection, bioRxiv, doi: https://www.biorxiv.org/contentZ10.1101 /2020.05.09.086165v1 .
P. Zmora, et al., TMPRSS2 isoform 1 activates respiratory viruses and is expressed in viral target cells, PLOS ONE September 17, 2015.
A. Zumla, et al., Coronaviruses - drug discovery and therapeutic options, Nature Reviews: Drug Discovery, Vol. 15, May 2016, 327-347.
Claims
1. A monoclonal antibody that (i) specifically binds to the extracellular portion of human angiotensin converting enzyme 2 (hACE2); (ii) specifically inhibits binding of SARS-CoV-2 to the extracellular portion of hACE2; and (iii) does not significantly inhibit the ability of hACE2 to cleave angiotensin II and/or a synthetic MCA-based peptide.
2. The monoclonal antibody of claim 1 , wherein the monoclonal antibody does not significantly inhibit the ability of hACE2 to cleave angiotensin II.
3. The monoclonal antibody of claim 1 , wherein the monoclonal antibody does not significantly inhibit the ability of hACE2 to cleave a synthetic MCA-based peptide.
4. The monoclonal antibody of any of claims 1-3, wherein the monoclonal antibody does not specifically bind to an epitope on hACE2 comprising an amino acid residue selected from the group consisting of Arg273, His345, Pro346, His374, Glu375, His378, Glu402, His505, and Tyr515.
5. The monoclonal antibody of any of claims 1-3, wherein the monoclonal antibody does not specifically bind to an epitope on hACE2 comprising an amino acid residue selected from the group consisting of residues 290 to 397 and residues 417 to 430.
6. The monoclonal antibody of any of claims 1-3, wherein the monoclonal antibody does not specifically bind to an epitope on hACE2 comprising an amino acid residue selected from the group consisting of residues 103 to 289, residues 398 to 416, and residues 431 to 615.
7. The monoclonal antibody of any of claims 1-3, wherein the monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue selected from the group consisting of Ser19, Gln24, Ala25, Thr27, Phe28, Lys31 , His34, Glu35, Glu37, Asp38, Tyr41 , Gln42, Leu45, Leu79, Met82, Tyr83, Gln325, Glu329, Asn330, Lys353, Gly354, Asp355, and Arg357.
The monoclonal antibody of any of claims 1-3, wherein the monoclonal antibody specifically binds to an epitope on hACE2 comprising an amino acid residue selected from the group consisting of Gln24, Ala25, Thr27, Phe28, Lys31 , Leu79, Met82, and Tyr83. The monoclonal antibody of any of claims 1-3, wherein the monoclonal antibody comprises (i) a heavy chain CDR1 comprising the amino acid sequence GFTFIDYYMN; (ii) a heavy chain CDR2 comprising the amino acid sequence FIRNKANDYTTEYST; (iii) a heavy chain CDR3 comprising the amino acid sequence RHMYDDGFDF; (iv) a light chain CDR1 comprising the amino acid sequence ASSSVRYMH; (v) a light chain CDR2 comprising the amino acid sequence LLIYDTSKLA; and (vi) a light chain CDR3 comprising the amino acid sequence QQWSYNPLTF. The monoclonal antibody of any of claims 1-9, wherein the monoclonal antibody is a humanized monoclonal antibody. The monoclonal antibody of any of claims 1-9, wherein the monoclonal antibody is a human monoclonal antibody. The monoclonal antibody of any of claims 1-11 , wherein the antibody is an antigen-binding fragment or a single chain antibody. A monoclonal antibody comprising residues 21 through 230 of the light chain amino acid sequence set forth in Figure 6 and residues 25 through 471 of the heavy chain amino acid sequence set forth in Figure 7. A monoclonal antibody comprising residues 21 through 230 of the light chain amino acid sequence set forth in Figure 6 and residues 25 through 471 of the heavy chain amino acid sequence set forth in Figure 8. An isolated nucleic acid molecule encoding (i) the light chain of the monoclonal antibody of any of claims 1 -14, and/or (ii) the heavy chain of the monoclonal antibody of any of claims 1 -14.
A recombinant vector comprising the nucleotide sequence of the nucleic acid molecule of claim 15 operably linked to a promoter of RNA transcription. A composition comprising (i) the monoclonal antibody of any of claims 1-14, and (ii) a pharmaceutically acceptable carrier. A method for reducing the likelihood of a human subject’s becoming infected with SARS-CoV-2 comprising administering to the subject a prophylactically effective amount of the monoclonal antibody of any of claims 1-14. The method of claim 18, wherein the subject has been exposed to SARS-CoV-2. A method for treating a human subject who is infected with SARS-CoV-2 comprising administering to the subject a therapeutically effective amount of the monoclonal antibody of any of claims 1 -14. The method of claim 20, wherein the subject is symptomatic of a SARS-CoV-2 infection. The method of claim 20, wherein the subject is asymptomatic of a SARS-CoV-2 infection. A recombinant AAV vector comprising a nucleic acid sequence encoding a heavy chain and/or a light chain of the monoclonal antibody of any of claims 1- 14. The recombinant AAV vector of claim 23, wherein the nucleic acid sequence encodes a heavy chain and a light chain. A recombinant AAV particle comprising the recombinant AAV vector of claim 23 or 24. A composition comprising (i) a plurality of the AAV particles of claim 25 and (ii) a pharmaceutically acceptable carrier.
A method for reducing the likelihood of a human subject’s becoming infected with SARS-CoV-2 comprising administering to the subject a prophylactically effective number of the AAV particles of claim 25. The method of claim 27, wherein the subject has been exposed to SARS-CoV-2. A method for treating a human subject who is infected with SARS-CoV-2 comprising administering to the subject a therapeutically effective number of the AAV particles of claim 25. The method of claim 29, wherein the subject is symptomatic of a SARS-CoV-2 infection. The method of claim 29, wherein the subject is asymptomatic of a SARS-CoV-2 infection. A kit comprising, in separate compartments, (a) a diluent and (b) a suspension of the monoclonal antibody of any of claims 1 -14. A kit comprising, in separate compartments, (a) a diluent and (b) the monoclonal antibody of any of claims 1-14 in lyophilized form. A kit comprising, in separate compartments, (a) a diluent and (b) a suspension of a plurality of the recombinant AAV particles of claim 25.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263379019P | 2022-10-11 | 2022-10-11 | |
US63/379,019 | 2022-10-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2024081602A2 true WO2024081602A2 (en) | 2024-04-18 |
WO2024081602A3 WO2024081602A3 (en) | 2024-05-16 |
Family
ID=90670273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/076403 WO2024081602A2 (en) | 2022-10-11 | 2023-10-10 | Ace2-targeted compositions and methods for treating co0vid-19 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024081602A2 (en) |
-
2023
- 2023-10-10 WO PCT/US2023/076403 patent/WO2024081602A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2024081602A3 (en) | 2024-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220056153A1 (en) | ACE2-Targeted Compositions and Methods for Treating COVID-19 | |
AU2021268361A1 (en) | Antibodies against SARS-CoV-2 | |
US20240059757A1 (en) | Antibodies against sars-cov-2 and methods of using the same | |
WO2021203053A1 (en) | Immunotherapy targeting a conserved region in sars coronaviruses | |
EP4214229A1 (en) | Coronavirus antibodies and uses thereof | |
US20230374116A1 (en) | Single domain antibodies that target sars-cov-2 | |
EP4251279A1 (en) | Antibodies that bind to multiple betacoronaviruses | |
CA3194162A1 (en) | Antibodies against sars-cov-2 | |
WO2022204202A1 (en) | Antibodies that bind to multiple sarbecoviruses | |
WO2024081602A2 (en) | Ace2-targeted compositions and methods for treating co0vid-19 | |
US20220056154A1 (en) | Bispecific Antibody Compositions and Methods for Treating COVID-19 | |
US11242379B2 (en) | Monoclonal antibodies and cocktails for treatment of Ebola infections | |
US20230220088A1 (en) | Anti-CCR5 Monoclonal Antibody-Based Compositions and Methods | |
Brady | Investigating the contribution of Fc function to effective antibody-based HIV prevention | |
WO2023034866A1 (en) | Antibody therapies for sars-cov-2 infection in pediatric subjects | |
CA3206022A1 (en) | Ace2-receptor ectodomain fusion molecules and uses thereof | |
AU2021369409A1 (en) | Anti-sars-cov-2 antigen antibodies and related compositions and methods | |
EP3583122A1 (en) | Monoclonal antibodies and cocktails for treatment of ebola infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23878119 Country of ref document: EP Kind code of ref document: A2 |